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Ovarian cancer is the 6th most common cancer to affect UK women and has the worst 
prognosis of any gynaecological cancer. Most women are not diagnosed until the disease is 
advanced, which leads to poor outcomes. Earlier ovarian cancer diagnosis has the potential 
to improve these outcomes. Cancer antigen 125 (CA125) is recommended by the National 
Institute for Health and Care Excellence (NICE) as the first line test for ovarian cancer in 
symptomatic women presenting to primary care in England. However, the performance of 
CA125 in this setting is unknown. The overarching aim of this thesis was to determine the 
diagnostic performance of CA125 for the detection of ovarian cancer when used in primary 
care, and to develop and evaluate novel approaches to improve its performance and clinical 
utility. 
 
Key methods  
I used routinely collected primary care and cancer registry data from 50,780 women who 
underwent CA125 testing in England between 1st May 2011 – 31st December 2014. First, I 
performed a diagnostic accuracy study, calculating the performance of CA125 within the 
cohort, at the national cut-off (≥35 U/ml), for the detection of ovarian cancer. Diagnostic 
accuracy metrics were also calculated for other types of cancer and all cancer types combined 
(secondary study outcomes). I used logistic regression to estimate the probability of ovarian 
cancer at specific CA125 levels (1-1000 U/ml) for women of different ages. CA125 levels 
equating to a 3% ovarian cancer probability (the “risk threshold” at which NICE advocates 
urgent specialist cancer investigation) were identified. Next, I examined the associations 
between CA125 test result and time from testing to diagnosis, tumour type and cancer stage, 
in those women with ovarian cancer. Finally, I developed and internally validated ovarian 
cancer diagnostic prediction models (of varying complexity) in a sub-group of women with a 
relevant symptom recorded prior to CA125 testing (n=29,962). To inform the development of 





CA125 had a sensitivity of 77%, a specificity of 94% and a Positive Predictive Value (PPV) of 
10% for ovarian cancer at the national cut-off (≥35 U/ml). The PPV for all cancers combined 
was 21% overall, and 33% in women ≥50 years of age. 20% of women ≥50 years with a raised 
CA125 level, but no ovarian cancer, had another type of cancer. A CA125 value of 53 U/ml 
equated to a 3% probability of ovarian cancer overall, but this varied markedly by age (40-
year-old: 104 U/ml, 70-year-old: 32 U/ml). Women with a ‘normal’ CA125 (<35 U/ml) prior to 
ovarian cancer diagnosis took twice as long to be diagnosed as those with an ‘abnormal’ 
CA125, but more frequently had indolent tumour types and were more likely to be diagnosed 
at an early stage. An ovarian cancer prediction model, incorporating patient age and CA125 
level, outperformed CA125 alone. This model showed excellent discrimination on internal 
validation (AUC: 0.94). Including symptoms, baseline risk factors and other routine blood tests 
did not improve model performance. 
 
Conclusions 
My findings demonstrate that CA125 is a useful test for ovarian cancer detection in primary 
care. They also indicate that clinicians should consider other types of cancer in women with 
high CA125 levels, especially if ovarian cancer has been excluded, in order to prevent 
diagnostic delay. The models presented in this thesis will allow patients and clinicians to 
determine the estimated probability of ovarian cancer at any given CA125 level and age. This 
information could inform individual patient decisions on the need for further investigation. If 
incorporated into the diagnostic pathway, the models would enable patients to be referred 
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Chapter 1. Introduction 
 
 
1.1 Thesis aim and objectives  
The overarching aim of this thesis was to evaluate the diagnostic performance of the serum 
biomarker Cancer Antigen 125 (CA125) for the detection of ovarian cancer when used in 
primary care and to develop and evaluate novel approaches to improve its performance and 
clinical utility. CA125 is first and foremost an ovarian cancer test and I have primarily focused 
on its role in ovarian cancer detection in this thesis. However, given reports that CA125 can 
be elevated in other types of cancer, I also sought to examine its accuracy for cancer as a 
whole (all forms) and to explore its utility in the detection of non-ovarian cancer types when 
used in primary care.  
 
In line with this aim, I set out a series of specific objectives: 
 
i) To evaluate the diagnostic accuracy of CA125 for a) ovarian cancer, b) non-ovarian 
cancers and c) all cancers combined, when used in English primary care. 
ii) To explore variations in the diagnostic accuracy of CA125 by patient age. 
iii) To explore the association between CA125 level and estimated probability of a) 
ovarian cancer and b) all cancers combined, in women undergoing CA125 testing 
in English primary care. 
iv) To identify the CA125 level at which a 3% probability of a) ovarian cancer and b) 
all cancers combined is reached in women undergoing CA125 testing in English 
primary care. 
v) To explore variations in estimated cancer probability by age and determine the 
CA125 level at which a 3% probability of a) ovarian cancer and b) all cancers 
combined is reached in different ages. 
vi) To examine the association of pre-diagnostic primary care CA125 result with time 
between testing and diagnosis, tumour morphology and disease stage in ovarian 
cancer. 
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vii) To perform a systematic review to identify published symptom predicated tools 
for ovarian cancer detection and to compare these tools in terms of a) included 
variables and b) diagnostic accuracy. 
viii) To develop and internally validate an ovarian cancer diagnostic prediction model 
incorporating symptoms, test results (including CA125), and risk factors. 
ix) To explore the potential diagnostic implications of implementing ‘action 
thresholds’, based on prediction model derived estimated ovarian cancer 
probabilities, within primary care. 
 
1.2 Thesis structure  
This thesis consists of 7 chapters. In Chapter 1 (Sections 1.3-1.10), I introduce the topic of 
ovarian cancer detection and outline the rationale for this thesis. In Chapter 2, I detail the 
data sources used in this thesis and describe the initial preparation of data. In Chapters 3, 4, 
5 and 6 I present four separate research studies, each designed to address specific thesis 
objectives. These chapters follow the standard format of a research paper with Introduction, 
Methods, Results, Discussion and Conclusion sections. In Chapter 7, I bring together the key 
research findings, consider their implications for clinical practice, and outline future research 
plans which build on this thesis. 
 
Chapter 1: Introduction 
In Sections 1.3 – 1.10 of Chapter 1, I provide essential background information on ovarian 
cancer and its diagnosis and set out the rational for this thesis.  
 
As background to this thesis I discuss the epidemiology of ovarian cancer and go on to 
describe the different types of ovarian cancer that can occur. I then consider current 
approaches to ovarian cancer detection. This includes the presentation of a systematic review 
of international guidelines on ovarian cancer detection, which I undertook to inform and 
direct the rest of my doctoral research. I go on to discuss the CA125 test and its role in cancer 
detection in detail. I summarise relevant literature and highlight gaps in current 
understanding of CA125 test performance. I conclude this chapter by drawing on the 
information presented to set out the rational for the research included within this thesis. 
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Chapter 2: Data sources and data preparation 
To conduct all primary research studies included in this thesis (Chapters 3, 4 and 6) I used a 
single dataset, consisting of data from four routinely collected sources. In this chapter, I 
provide an overview of these data sources and describe the regulatory approval obtained in 
order to use them. I go on to define the baseline patient cohort. This directly formed the study 
cohort for Chapter 3 and subsets of patients were selected from this baseline cohort for the 
research presented in Chapters 4 and 6. Finally, I describe the steps taken to prepare the 
baseline cohort and several key variables used across multiple thesis studies.  
 
Chapter 3: The diagnostic performance of CA125 for the detection of cancer in primary care: 
a population-based cohort study (Objectives i-v) 
This chapter focuses on the diagnostic accuracy of CA125 in primary care and explores how 
the probability of cancer changes with CA125 level and patient age. I present a population-
based cohort study, which includes two principle types of analysis. First, I report measures of 
CA125 diagnostic accuracy, which were calculated after applying the conventional threshold 
(≥35 U/ml), for ovarian cancer, non-ovarian cancers and all types of cancer. Second, I report 
the results of logistic regression analyses which were used to estimate the probability of 
cancer based on CA125 level and age. Based on these analyses, I detail the CA125 levels 
equating to a 3% probability of cancer – the National Institute for Health and Care Excellence 
(NICE) ‘risk threshold’ for urgent cancer referral. To conclude Chapter 3, I consider the key 
study findings within the context of the literature and explore their potential implications. 
This chapter addresses thesis Objectives i-v. 
 
Chapter 4: Associations between primary care CA125 test result with test-diagnosis interval 
and stage in ovarian cancer (Objective vi) 
This chapter focuses on potential reasons for, and implications of, false negative CA125 
results in primary care. I present the results of a cohort study in which I explored the 
association of primary care pre-diagnostic CA125 test results (‘normal’ or ‘abnormal’) with 
time between testing and diagnosis (test-diagnosis interval) and stage at diagnosis in ovarian 
cancer patients. Within this chapter I also examine the types of ovarian tumour which occur 
in women with normal and abnormal CA125 results. Thesis Objective vi is addressed in this 
chapter.  
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Chapter 5: Symptom based tools for ovarian cancer detection: a systematic review 
(Objective vii) 
In this chapter, I present a systematic review designed to address thesis Objective vii. I 
describe the systematic identification of studies which have developed or validated ovarian 
cancer diagnostic tools containing symptom variables. The variables included in these tools 
are summarised and the diagnostic accuracy of tools compared. I used the results of this 
review to directly inform the development of a multivariable prediction model in Chapter 6. 
 
Chapter 6: The development and internal validation of ovarian cancer diagnostic prediction 
models for use in symptomatic women in primary care (Objectives viii and ix) 
In this chapter, I describe the development and internal validation of two multivariable 
diagnostic prediction models for ovarian cancer, derived using routinely collected primary 
care data. In this work, I incorporated patient variables associated with ovarian cancer risk 
(identified in Chapter 6 and from other literature sources) alongside CA125, with the aim 
improving diagnostic accuracy. I present model diagnostic performance metrics and compare 
them with those of CA125 alone. In addition, I explore the potential implications of using 
various model derived thresholds (instead of the conventional CA125 cut-off) on the number 
of ovarian cancers detected in women undergoing CA125 testing in English primary care. 
Thesis objectives viii and ix are addressed within this chapter. 
 
Chapter 7: Discussion 
In the final chapter, I summarise my research findings and consider how they could help 
improve cancer diagnostic pathways. I discuss planned research, intended to build on this 
thesis and address remaining unanswered questions.  
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1.3 Ovarian cancer epidemiology 
1.3.1 Ovarian cancer incidence 
In 2020, an estimated 313,959 women were diagnosed with ovarian cancer worldwide.1 The 
2020 Global Cancer Observatory (GLOBOCAN) project estimated that ovarian cancer 
accounted for 3.4% of new female cancer cases.1 It is the 6th most commonly diagnosed type 
of cancer in women in the United Kingdom (UK) with 7,309 new diagnoses made in 2017.2 In 
that year, the age standardised ovarian cancer incidence rate in the UK was 22 per 100,000 
females.2* There has been a gradual decline in ovarian cancer incidence in recent years in high 
income countries.3 In the UK, the age standardised incidence rate was around 5% lower 
during 2015-2017 than 2005-2007.2  The reasons for this decline are not fully understood, but 
a reduction in the use of hormone replacement therapy (a risk factor) and the long term 
effects of higher oral contraceptive medication uptake (a protective factor) are likely to have 
contributed.4   
 
Ovarian cancer predominantly affects older women (Figure 1.1). Between 2015-2017, more 
than 80% of UK diagnoses were made in women aged 50 years or older and more than a 
quarter in women aged 75 years or older.5 Incidence rates increase with age, peaking in 
women aged 75-79 years (72 per 100,000 women), before declining.  
 
Differences in incidence rates have been noted between ethnic groups in several countries, 
including the United States and the UK.6,7 The most recent comparison from England (which 
utilised cancer registry data from 2002-2006) reported that age standardised incidence rates 
were higher in white women than in other ethnic groups (Black: 7-12 per 100,000; Asian: 9-
16 per 100,000; White: 17-18 per 100,00).7†    
 
 
                                                        
* Age standardisation performed using European Standard Population data.337 
† Ranges provided reflect different ways of handling missing ethnicity data in the study analysis.  
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Figure 1.1. Ovarian cancer (C56-C57.4), Average Number of New Cases per Year and Age-
Specific Incidence Rates per 100,000 Females, UK, 2015-2017.  
Source: CRUK.org/cancerstats5 
 
1.3.2 Stage at diagnosis 
The majority of women with ovarian cancer are diagnosed at an advanced stage. Of women 
diagnosed in England between 2010-2014, for whom staging data was available, 42% had 
stage I or II disease (often considered collectively as ‘early stage’) and 58% had stage III or IV 
disease (often considered collectively as ‘late stage’) (Figure 1.2).8  Recent data from the 
International Cancer Benchmarking Project (ICBP) found only minor differences in ovarian 
cancer stage distribution between seven high income countries including the UK.9‡ A greater 
proportion of ovarian cancers are detected at a late stage in the UK than other types of 
gynaecological cancer such as endometrial and cervical cancer.10,11   
                                                        
‡ ICBP applied a different definition of ovarian cancer to the one used in this thesis (detailed in in Section 
1.4.4) as they excluded Borderline tumours from their analyses. 
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1.3.3 Mortality and survival 
In 2020, an estimated 207,252 women died from ovarian cancer worldwide.1 Within the UK, 
the disease is the 6th most common cause of cancer death in women, accounting for over 
4,000 deaths annually.12 The prognosis for women diagnosed with ovarian cancer has 
improved markedly in recent decades. Women diagnosed with ovarian cancer in 2000-2001 
in England and Wales had an estimated age standardised 5-year net survival of 38%.13 By 
2010-2011 this had increased to 46%. However, recent evidence from the ICBP indicates that 
UK age standardised net survival (3-year) is lower than four (Australia, Canada, Denmark, 
Norway) of the six other high-income countries included in the ICBP comparative analyses.8 
The reasons for the variation in survival between the countries remain unclear. However, 
differences in patient healthcare beliefs, health seeking behaviours, access to diagnostic 
investigations, willingness of GPs to perform cancer investigations, national diagnostic 
pathways and approaches to, and availability of, cancer treatment, have all been suggested 





















Ovarian cancer survival falls dramatically with increasing stage at diagnosis, with estimated 
UK 5-year net survivals in England of 93% for stage I, 68% for stage II, 27% for stage III and 
13% for stage IV disease.16 
 
1.3.4 Risk and protective factors 
In addition to age and ethnicity, a number of genetic and environmental factors influence 
ovarian cancer risk.  
 
Inherited genetic susceptibilities are responsible for an estimated 5-15% of ovarian 
malignancies, with germline mutations in the breast cancer genes (BRCA1 and BRCA2) 
accounting for the majority of these cancers.17–19  The average cumulative risk of ovarian 
cancer by age 70 is estimated at 39-59% in BRCA1 mutation carriers and 11-17% in BRCA2 
mutation carriers.20,21 By contrast, the estimated lifetime risk of ovarian cancer in UK women 
(born after 1960) has been estimated at 2%.22 Women with Lynch syndrome, an autosomal 
dominant cancer predisposition syndrome resulting from germline mutations in DNA 
mismatch repair genes, are at increased risk of ovarian cancer in addition to a range of other 
malignancies including colorectal and endometrial cancer.23 A retrospective cohort study 
estimated that the lifetime risk of ovarian cancer in women with Lynch associated mutations 
was 7%.24  Risk of ovarian cancer is greater in women with family history of breast or ovarian 
cancers, with risk increasing if multiple first degree relatives are affected at a young age or at 
multiple sites.25–27 In addition to germline BRCA and Lynch associated mutations, a wide 
variety of other genetic mutations and shared environmental factors also contribute to 
increased familial risk.26 
 
Hormonal and reproductive factors affect ovarian cancer risk. Factors which contribute to a 
greater number of lifetime ovulatory cycles are associated with an increased risk of ovarian 
cancer while those which result in episodes of anovulation are associated with a decreased 
risk. For example, epidemiological studies indicate that early menarche and late menopause 
are associated with an increased risk of ovarian cancer,25,28,29 whereas higher parity and use 
of combined oral contraceptives are associated with a decreased risk of ovarian cancer.30–32 
A meta-analysis of 45 epidemiological studies found that the relative risk in women taking 
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combined oral contraceptive medication for 15 years or more (versus never users) was 0.42 
(95% confidence intervals [CI]: 0.36–0.49).30  
 
In contrast to oral contraceptive use, use of hormone replacement therapy is associated with 
an increased risk of ovarian cancer. A meta-analysis, which included individual datasets from 
52 studies, reported that the relative risk for current users (versus never users) was 1.43 (95% 
CI 1.31–1.56).33  The study also found that risk decreased with length of time from treatment 
cessation, but was still elevated for specific types of ovarian cancer at 10 years post-cessation.  
 
Epidemiological studies have reported positive associations between a variety of other 
factors and ovarian cancer risk, including greater body fatness,34–37 greater adult attained 
height,36–38 and asbestos exposure.39 Smoking is associated with an increased risk of some 
specific types of ovarian cancer.40 A link between talc exposure and ovarian cancer is 
controversial. The International Agency for Research on Cancer (IARC), which is part of the 
World Health Organisation (WHO), currently lists perineal talc use as a possible carcinogen 
(within the ‘limited evidence’ category).41 However, a recent pooled analysis, which included 
over a quarter of a million women, did not identify a significant association between genital 
talc exposure with ovarian cancer risk.42   
 
1.4 Tumour types 
Rather than a single disease, the term ovarian cancer encompasses a heterogeneous group 
of diseases that occur in the same anatomical region but differ in their cells of origin, clinical 
behaviour, treatment and prognosis. Understanding of the pathogenesis of ovarian cancer 
has improved dramatically over the last two decades, which has led to changes in how the 
disease is defined. In this section, I provide an overview of the different types of ovarian 
cancer and give the operational definition of ovarian cancer I use throughout this thesis. 
 
1.4.1 Histological classification 
Ovarian cancers can be broadly classified, on the basis of tissue of origin, into three principal 
categories: epithelial, germ cell and sex-cord stromal (Figure 1.3). Other tumour types exist, 




The proportion of ovarian cancers which fall into each category varies internationally, but the 
epithelial tumour type is consistently responsible for the vast majority of ovarian cancers.43 
In England, epithelial cancers account for more than 90% of all ovarian malignancies and are 
responsible for the majority of ovarian cancer-associated mortality.44 They can be classified 
into four principal categories based on cell type (Figure 1.3). The serous histo-type is sub-
divided on the basis of tumour grade into low grade serous (LGS) and high grade serous (HGS). 
HGS is the most common type of ovarian cancer, accounting for around 70% of epithelial 
ovarian malignancies.45  
 
 
Figure 1.3. Ovarian cancer tumour types.  
 
Malignant sex-cord stromal and germ cell tumours collectively account for under 5% of 
ovarian cancers diagnosed in England.46 While epithelial malignancies usually occur in women 
over the age of fifty years, sex-cord stromal and germ cell cancers occur most commonly in 
younger women (<35 years of age), frequently affecting women in their late teens and early 
twenties.46 The prognosis for women with these rare types of tumour is much better than for 
those with epithelial cancers. Even if diagnosed at an advanced stage, more than 75% of 
women with germ cell cancer are cured.47  
 
1.4.2 Borderline tumours 
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Borderline is a type of tumour virtually unknown outside of the ovary. Borderline tumours 
are epithelial in origin and exhibit morphology and behaviour which lies between that of 
benign tumours (which cannot invade surrounding tissue and metastasise to other parts of 
the body) and overtly malignant/invasive tumours (which can invade surrounding tissue and 
metastasise to other parts of the body). In fact, when they were originally described in 1929, 
they were termed “semi-malignant” tumours.48 Although borderline tumours do not 
penetrate and destroy surrounding tissue, they can exhibit weak invasive behaviour (termed 
micro-invasion).49 At diagnosis, most are localised to the ovary (82%) with the remainder 
having spread to other sites within the abdomen and pelvis (distant metastases are rare).49 
Borderline tumours are treated surgically, but can recur (<10%), and approximately 5% 
transform into low grade serous cancer.49,50 They principally affect women under the age of 
45 years of age and account for 14% of all ovarian malignancies in England.46 
 
Until the 3rd edition of the WHO International Classification of Diseases for Oncology (ICD-O3) 
was published in 2013, borderline tumours were included alongside other malignant tumours 
(which I hereafter refer to as invasive tumours for clarity) under the heading of “Malignant 
neoplasm of the ovary” (C56).51 They are now categorised as “neoplasm of uncertain 
behaviour” (D39.1). Borderline tumours are staged in the same way using the same staging 
system as invasive tumours.52  
 
Published early detection studies have varied as to whether they have included borderline 
tumours in their ovarian cancer outcome definition. Some, including the large UK 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), have included borderline 
tumours.53,54 However, as survival for women with borderline tumours is good, even in late 
stage disease, many other studies have excluded borderline tumours and focussed only on 
invasive cancers.3,53,55  
 
Ultimately, histological specimens are required to distinguish early invasive tumours from 
borderline tumours and both types of tumour are managed surgically.56 Women presenting 
symptomatically to their GP due to the presence of either a borderline tumour or an invasive 
tumour should be referred urgently for specialist assessment and treatment.57 Given this, I 
have included borderline tumours in my definition of ovarian cancer within this thesis.  
 12 
1.4.3 ‘Ovarian’ cancer: a misnomer? 
All types of tumour discussed above were once thought to originate from the ovary and 
cancers of the fallopian tube were considered extremely rare. However, research conducted 
over the last two decades has provided compelling evidence that most (if not all) HGS 
epithelial ovarian cancers arise from the distal lining of fallopian tubes rather than from the 
lining of the ovary.55,58–63 Some of the earliest evidence came from studies conducted in 
women undergoing risk reducing surgery (bilateral salpingo-oophorectomy) due to germline 
mutations in the BRCA genes. In these women, occult epithelial cancers were much more 
common in the fallopian tubes than in the ovaries in pathological specimens.60,61 Non-invasive 
lesions, known as serous tubal intraepithelial carcinomas (STICs), were also identified in the 
fallopian tubes and genetic studies have since confirmed that STIC lesions are a precursor of 
HGS ovarian cancer.62 Studies of pathological surgical specimens have also identified STIC 
lesions in around 60% of women with sporadic (i.e. non-germline BRCA associated) HGS 
ovarian cancers.63 
 
A hallmark of ovarian and fallopian epithelial cancers is early spread to the peritoneum. 
Occasionally, epithelial cancers (most commonly HGS) are found to affect the peritoneum but 
not the ovary or fallopian tube. These are classified as primary peritoneal cancer.51 
 
Regardless of where these cancers arise – ovary, fallopian tube or peritoneum – they behave 
and are managed clinically in the same way. A single classification system, published by the 
Fédération Internationale de Gynécologie et d'Obstétrique (FIGO), is now widely used to 
stage cancers arising from these three sites.52 Although recording of the primary site is 
encouraged during staging, this is often not possible as the cancer usually envelops ovarian 
and fallopian tube structures or is disseminated at surgery. Cancers of ovarian, fallopian and 
peritoneal origin are now usually included together in clinical trials and epidemiological 
studies.9,64 These cancers are often referred to collectively in the literature as ovarian 
cancer.55,65 For simplicity, I have adopted this approach throughout my thesis. 
 
1.4.4 Ovarian cancer: operational definition 
Within this thesis I define ovarian cancer as:  
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A tumour of borderline or invasive behaviour arising from the ovary, fallopian tube or 
peritoneum.  
 
This broad definition is in line with national guidelines on ovarian cancer detection and initial 
management in England.65  
 
1.5 Ovarian cancer detection 
1.5.1 Early detection 
The diagnosis of cancers earlier in their disease course is generally seen as key to improving 
patient outcomes including survival.66,67 It is an important area for policy makers, with the 
recently published National Health Service (NHS) England long term plan setting the goal of 
detecting 75% of cancers at an early stage (I and II) by 2028.68 It is clear that women diagnosed 
with earlier stage ovarian cancer have better survival than those diagnosed with later stage 
disease, both in the short (1-year) and longer term (5 and 10-years).69 A key prognostic factor 
in later stage ovarian cancer (III and IV) is whether all gross tumour can be removed at surgery 
(complete cytoreduction).70 Even in patients with the same stage disease, complete 
cytoreduction is associated with improved survival.70–72 Clinicians and researchers have 
suggested that the detection of less bulky ovarian cancer, which is more amenable to 
complete surgical resection, could help improve patient outcomes including survival even if a 
stage shift is not achieved.55 A lower proportion of women with stage IV disease (38%) 
undergo surgery in the UK than women with stage II-III disease (71%).73 This may be due to 
patient choice (after consideration of the low cure rate in advanced disease), or a clinical 
decision based on the low chance of complete cytoreduction or the poor performance status 
associated with advanced ovarian cancer. Even in advanced stage ovarian cancer, detection 
of less bulky and debilitating disease may allow more women to undergo treatment with 
curative intent.74  
 
1.5.2 Timely detection 
Given the association between earlier stage at diagnosis and higher survival rates, it would 
seem reasonable to assume that the shorter the time between a patient first presenting to 
their GP with symptoms and being diagnosed (the diagnostic interval) the better the 
outcomes. However, the relationship between diagnostic interval and cancer outcomes is 
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complex. For example, a retrospective analysis of the healthcare records of 601 Canadian 
women with epithelial ovarian cancer reported that the median diagnostic interval was 35 
days longer in women with stage I-II disease than in women with stage III-IV disease.75 This 
may be because cancer patients with advanced disease have more severe symptoms and are 
sicker at presentation and therefore experience an expedited diagnosis (sometimes called the 
‘sick quick’ phenomenon).76 A questionnaire based study (n=560), performed as part of the 
ICBP, found that the odds of being diagnosed with advanced ovarian cancer increased with 
longer primary care interval (time between symptomatic presentation in primary care and 
referral) up to around 50 days then decreased, although the relationship was not statistically 
significant.77 A retrospective interview-based cohort study of 1,381 Australian women with 
ovarian cancer found no association between time from symptom onset to diagnosis and 
survival.78 However, observational studies which examine associations between diagnostic 
interval and survival can be affected by the waiting time paradox (in which patients diagnosed 
quickly have poor outcomes).79 A recent study by Round et al reported that, for the four most 
common cancers (ovarian cancer was not examined), there was an association between 
higher use of the urgent suspected cancer referral pathway by GP practices, early stage 
diagnosis (except for colorectal cancer) and lower mortality.80 This provides some support for 
the assumption that prompt investigation and treatment of cancer patients could improve 
outcomes.  
 
By contrast, there is little direct evidence that more timely diagnosis has an effect on 
outcomes in symptomatic ovarian cancer. The Diagnosing Ovarian cancer Early (DOvE) pilot 
study in Canada found that women diagnosed using a proactive symptom triggered testing 
initiative (in which women with relevant symptoms are encouraged to self-refer for a series 
of tests) had lower volume and more resectable disease than those diagnosed via the usual 
care route.55 However, numbers were small (11 ovarian cancers were diagnosed via the 
proactive screening route). The definitive study results are still awaited.  
 
Prompt diagnosis can have psychosocial patient benefits. A Danish retrospective 
questionnaire study, which included 188 women with ovarian cancer, found that longer time 
between symptom onset and diagnosis was associated with lower patient satisfaction and 
some measures of quality of life.81  
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A recent retrospective study, which utilised routinely collected primary care data, reported 
that the median diagnostic interval in the UK (excluding Scotland) was 56 days.82 A quarter of 
these women had a diagnostic interval of 133 days or more.82 Data from the 2010 National 
Cancer Patient Experience Survey in England indicates that a third of women had three or 
more pre-referral primary care consultations relating to possible symptoms of ovarian cancer 
prior to ovarian cancer diagnosis.83 In the English National Cancer Diagnosis Audit, of women 
diagnosed with ovarian cancer in 2014, GP practices reported that some kind of avoidable 
delay in diagnosis (due to patient, clinician or system factors) had occurred in just under a 
third of women with ovarian cancer.84 This was the third highest proportion for any of the 20 
cancer sites examined. While ovarian cancer is a challenging disease to detect (as discussed 
in subsequent sections), this indicates that there may be opportunities to expedite diagnosis 
and that this may be beneficial. 
 
1.5.3 Approaches: screening vs symptomatic detection 
A significant effort has been made over the last 30 years to develop approaches to detect 
ovarian cancer as early as possible. Large randomised controlled screening trials of 
asymptomatic women have been performed in Japan, the United States and the UK.53,85,86 To 
date, none of these have demonstrated a long-term survival benefit. However, the final long-
term follow-up results from the largest of these trials (UKCTOCS) are awaited and are 
expected to be published later in 2021.  
 
In the absence of screening programs, the majority of women are diagnosed following 
symptomatic presentation.78,87 In countries such as the UK, where GPs play a gatekeeping 
role, the majority of patients are diagnosed following a symptomatic presentation in primary 
care.87,88 
   
1.5.4 Symptomatic presentations 
Case control studies, predominantly conducted in the United States and the UK, have 
demonstrated that a number of symptoms occur much more commonly in women with 
ovarian cancer (prior to diagnosis) than in controls.89 These studies were ground-breaking as 
ovarian cancer had often been perceived as the ‘silent-killer’, an unhelpful label which is still 
used by the media today.90  
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In a case-control study by Hamilton et al, which utilised GP records from England, odds ratios 
for relevant symptoms were similar for those subsequently diagnosed with early (stage I and 
II) and late (III and IV) disease.91 In a case control study by Goff et al, performed in the United 
States using patient survey data, symptoms were reported with equal frequency in those with 
early and late stage disease, although numbers with early stage cancers were small.92 A 
retrospective cohort study in the United States, in which 622 women with ovarian cancer 
were interviewed about the symptoms they experienced prior to their diagnosis, found that 
women commonly reported experiencing symptoms in both early and late stage disease.93 
However, some symptoms were reported less commonly in early stage disease including 
abdominal pain (stage I-II: 47%, stage III-IV: 58%) and abdominal distension (stage I-II: 36%, 
stage III-IV: 46%). A recent multi-cancer English population based study, which utilised 
routinely collected healthcare data, found that in patients with abdominal pain (the most 
common ovarian cancer symptom) more than 60% were diagnosed with a stage I-III cancer.94 
Where multiple symptoms were present, stage I-III cancers were even more likely. 
Collectively, these studies indicate that some women with early stage disease do develop 
symptoms and present in clinical practice, which provides an opportunity for early ovarian 
cancer detection.  
 
More than a dozen case control and cohort studies have investigated the association between 
symptoms and ovarian cancer diagnosis. While these studies are relatively consistent in 
reporting an increased risk of ovarian cancer diagnosis in women with abdominal distension, 
bloating and abdominal pain, there is considerable variation between studies as to which 
other symptoms are important.89 For example, Hamilton et al (in their routinely collected data 
case-control study in England) found that appetite loss was significantly associated with a 
subsequent diagnosis of ovarian cancer, while Goff et al (in their questionnaire-based case-
control study in the United States) found no significant association.91,92 Such differences are 
likely to be due to variation in study populations and study design.89  
 
The estimated predictive values of individual symptoms reported by studies have been 
modest. This is demonstrated by the estimated Positive Predictive Values (PPV) of symptoms 
identified by Hamilton et al (Table 1.1).91 These symptoms are common in women presenting 
to their GP. Lim et al examined the GP records of almost 20,000 women (aged 45-74 years) 
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who visited GP practices in England and found that, over the course of a 12 month period, up 
to half reported a symptom of possible ovarian cancer.95 So, while symptoms may occur more 
frequently in women with ovarian cancer, the vast majority of women with these symptoms 
will not have the disease.  
 
Table 1.1. Symptoms associated with ovarian cancer in multivariable analysis from 
Hamilton et al (2009)91 
Symptom PPV (%) 
Abdominal distension 2.5 
Appetite loss 0.6 
Postmenopausal bleeding 0.5 
Abdominal pain 0.3 
Abdominal bloating 0.3 
Urinary frequency 0.2 
Rectal bleeding 0.2 
 
Determining which symptomatic women presenting to primary care should undergo specialist 
investigation for ovarian cancer is a diagnostic challenge. To help guide this decision, many 
countries (including the UK) have developed recommendations on the initial assessment and 
testing of symptomatic women for ovarian cancer, which I will discuss in the next section. 
 
 
1.6 Initial assessment for ovarian cancer 
At the outset of my doctoral research, I undertook a review of published clinical guidelines 
covering the initial assessment of women for ovarian cancer. By systematically searching 
relevant databases, I identified 18 guidelines which provided recommendations on the initial 
assessment and investigation of possible ovarian cancer in symptomatic women.57,96–112 I 
compared these guidelines in terms of the symptoms they included, the physical 
examinations they recommended and the tests they advocated. I undertook this review to 
gain insight into current international recommended practice for the assessment of women 
for possible ovarian cancer in order to inform and contextualise my subsequent doctoral 
research studies. 
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A paper, based on this work, has been published:    
 
Variation in the initial assessment and investigation for ovarian cancer in symptomatic 
women: a systematic review of international guidelines. Garth Funston, Marije Van Melle, 
Marie-Louise Ladegaard Baun, Henry Jensen, Charles Helsper, Jon Emery, Emma J. Crosbie, 
Matthew Thompson, Willie Hamilton & Fiona M. Walter. BMC Cancer. 2019; 19:028 
 
In the remainder of this section, I discuss the key results of this review in order to provide an 
overview of the international clinical context of this thesis. The review methods are 
summarised in Box 1.2 and the related publication is included in Appendix A for reference. 
All tables and figures relating to my research within this section and subsequent sections of 




Box 1.2. Summary of review methods.   
*English language documents were screened, and data extracted, by me and another 
reviewer (Dr Marije van Melle). For documents published in other languages, this was 
performed by pairs of study team members fluent in the relevant language.   
Search strategy 
o Searches: Conducted between 1st-13th of March 2018 using key words and 
Medical Subject Heading (MeSH) terms relating to ovarian cancer and guidelines 
/consensus statements (any language) 
o Data sources:  
§ Medline, EMBASE and six guidelines databases  
§ >20 professional / government websites hand searched 
 
Selection criteria 
o Inclusion:  
§ Provided guidance on the initial assessment of women 
presenting with symptoms of possible ovarian cancer 
§ Produced by a professional or governmental body 
§ Published in the 10 years prior to the 13th March 2018 
 
o Exclusion: Guidance solely covers… 
§ management after a pelvic mass has been confirmed 
§ screening 
§ subgroups e.g. patients with BRCA mutations 
 
Screening and selection 
o Titles and summaries: Two reviewers independently screened titles and 
summaries* 
o Full text: If potentially relevant at screening, two reviewers independently 
assessed the full text  
o Disagreements: resolved by consensus 
 
Data extraction 
o Two reviewers independently extracted data against a specifically designed 
template* 
o Disagreements: resolved by consensus 
o Data extracted included:  
§ Background details e.g. development body, country  
§ Symptoms listed 
§ Recommended examinations 
§ Recommended tests 
 
Data synthesis 




Of the 18 guidance documents included in this review, two were developed in continental 
Europe (Germany and the Netherlands),96,105 five in the UK and Republic of Ireland,57,106–109 
three in Scandinavia (Denmark, Norway and Sweden),110–112 four in North America (United 
States and Canada)101–104 and four in Australasia (Australia and New Zealand)97–100 (Figure 
1.4). Thirteen documents were published in English. 
 
 
Figure 1.4. Countries of origin of included guidelines. 
Figure created on mapchart.net under CC BY-SA licence.113 
 
1.6.2 Symptoms and signs 
All guidance documents provided advice regarding the symptoms that should prompt a 
healthcare professional to consider ovarian cancer (a review inclusion criterion). One or more 
of the related terms bloating, abdominal distention and increased abdominal size/girth, were 
listed in all guidance documents (Figure 1.5). Five further symptom terms were included in 
the majority of documents: abdominal or pelvic pain (n=16), urinary frequency (n=14), early 
satiety (n=14), change in bowel habit (n=12) and loss of appetite (n=10). The remaining 20 
symptom terms were included in less than half of the documents. The number of ovarian 
cancer symptoms included in each document ranged from four to 14. Some documents simply 
listed symptoms which should prompt consideration for ovarian cancer while others detailed 
further factors which should be taken into account, including symptom frequency (e.g. 
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>12x/month), nature (e.g. persistent), duration (e.g. >1 year) and age at presentation (e.g. 
>50 years). 
 
Fourteen documents recommended performing a physical examination and highlighted 
possible signs of ovarian cancer. Thirteen advocated abdominal examination or mentioned 
abdominal signs. Nine recommended pelvic or gynaecological examination, with three 
specifying that this should include a speculum examination and three a bimanual or digital 
examination. Three documents recommended performing a rectal examination. The most 




Figure 1.5. Frequency of inclusion of symptom terms in guidelines.  
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1.6.3 Tests 
Guidance on the initial investigation of women with symptoms and or signs of possible 
ovarian cancer was provided in fifteen guidance documents. A wide range of testing strategies 
were recommended. I classified them (based on the number tests and the recommended 
order of testing) into one of five groups: ‘single test’ i.e. one test advocated; ‘dual testing’ i.e. 
performing two tests concurrently; ‘sequential testing’ i.e. performing a second type of 
investigation (second line) if the first type of investigation (first line) is abnormal; ‘multiple 
testing options’ i.e. where a range of investigation options were presented with no single 
investigation being advocated above another; and ‘no testing’ i.e. where no specific tests 
were recommended as part of the initial assessment. One document advocated a single test 
strategy; four a dual testing strategy; four a sequential testing strategy and three gave 




Figure 1.6. Recommended strategies for the investigation of women with symptoms of 
possible ovarian cancer. 
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The most commonly advocated tests for initial investigation were the serum ovarian cancer 
biomarker CA125 (11 documents) and ultrasound (12 documents) (Table 1.2). Four guidelines 
recommended that CA125 and ultrasound should be performed together (dual testing), three 
that CA125 should be performed first and an ultrasound only if the CA125 test is abnormal 
while one recommended the inverse – ultrasound then CA125 if an abnormality is found 
(sequential testing). Three simply listed the two tests as options for investigation.  
 
Additional blood tests (e.g. full blood count) and imaging tests (e.g. Computed Tomography 
[CT]) were also recommended by several guidelines. Two diagnostic prediction models (based 
on CA125 level, ultrasound findings and age / menopausal status) were recommended by 
Australian guidelines: The Risk of Malignancy Index (RMI) and the Assessment of Different 




Table 1.2. Summary of tests recommended for the assessment of symptoms and/or signs of ovarian cancer. 
Strategy Guideline When is testing advocated? Initial tests 
 
No testing prior 
to referral 
Integrated ovarian cancer patient 
pathway (Denmark) 
At point of specialist referral Note CA125 requested in primary care at 
time of referral so as to be available to the 
specialist. Not acted upon in primary care 
Ovarian cancer patient pathway 
(Norway) 
Post specialist referral Post referral  
Standardised ovarian cancer care 
pathway (Sweden) 
At point of specialist referral Note CA125 requested in primary care at 
time of referral so as to be available to the 
specialist. Not acted upon in primary care 
Single test 
Guideline on diagnostics, therapy 
and follow-up of malignant ovarian 
tumours (Germany) 
Signs or symptoms of OC Transvaginal US 







Scottish referral guidelines for 
suspected cancer (Scotland) 
Symptoms of OC  
Note: Ascites- refer urgently rather 
than test 
CA125 + pelvic US 
Management of epithelial ovarian 
cancer (Scotland) 
Symptoms of OC CA125 + pelvic US 
Assessment of symptoms that may 
be ovarian cancer: a guide for 
general practitioners (Australia) 
Mass identified clinically 
Note: No mass identified clinically- 
refer appropriately 
CA125 + transvaginal US Or 
CA125 + Abdominal US Or 
CA125 + CT 
Appropriate referral of women 
with suspected ovarian cancer 
(Australia) 
Suspicious findings on clinical 
examination 
CA125 + transvaginal US +/- calculation of 




Suspected cancer: recognition and 
referral (England) 
OC symptoms  
Note: Ascites or suspicious mass- 
refer urgently rather than test 
First line: CA125 
Second line: Abdominopelvic US (if CA125 is 
abnormal) 
Epithelial ovarian / fallopian tube / 
primary peritoneal cancer 
guidelines: recommendations for 
practice (UK) 
OC symptoms  
Note: Pelvic or abdominal mass- 
refer urgently rather than test 
First line: CA125 
Second line: Abdominopelvic US (if CA125 is 
abnormal) 
Ovarian cancer GP referral for 
symptomatic women 
(Ireland) 
History suspicious of OC but 
examination normal 
 Note: Suspicious pelvis mass or 
ascites- refer urgently rather than 
test 
First line: CA125 
Second line: US of pelvis (If CA125 35-200 
U/ml) 
Note: If CA125 >200 U/ml refer without US 
Ovarian cancer diagnosis pathway 
map 
(Ontario, Canada) 
Suspicion of OC  
Note: Tests may be performed 
prior to specialist referral but are 
not a requirement for referral. Can 
refer prior to testing  
First line: Transvaginal US and / or other 
imaging 
Second line: CA125, FBC, Renal Function + 
RMI  
 (If indicated: CEA, CA19-9, other tumour 










Optimal care pathway for women 
with ovarian cancer (Australia) 
 
Symptoms of OC Pelvic US + 
Routine blood tests + 
CA125 + 
Algorithms such as RMI, ADNEX +/- 
CT scan  
Genital tract cancers in 
females: ovarian, fallopian tube, 
and primary peritoneal cancers 
(British Columbia, Canada) 
Suspicion of OC  
Note: Imaging not essential for 
referral 
Transvaginal or abdominal US  
Blood tests: CA125,  CA19-9, CA15-3, CEA 









Ovarian cancer Including fallopian 
tube cancer and primary 
peritoneal cancer (USA) 
Suspicion of OC 
Note: Provides some advice on 
when particular tests are indicated. 
Appears to include both initial and 
pre-surgical tests 
US and/or abdominal/pelvic CT/MRI (as 
indicated) 
Chest CT or chest x-ray (as indicated) 
Complete blood count, chemistry profile 
and LFT 
CA125 or other tumour markers (as 
indicated: inhibin, b-hCG, AFP, LDH, CEA,  
CA19-9) 
Nutritional status 




on testing given 
Suspected cancer in primary care: 
guidelines for investigation, 
referral and reducing ethnic 
disparity (New Zealand) 
No recommendations  No recommendations 
The role of the obstetrician-
gynaecologist in the early 
detection of epithelial ovarian 
cancer in women at average risk 
(USA) 
No recommendations No recommendations 
Epithelial ovarian carcinoma 
(Netherlands) 
Suspicion of OC. Not clear which 
tests should be used and when 
they should be used for initial 
investigation 
Blood tests discussed: routine blood tests, 
CA125 +/- CEA 
 
OC = ovarian cancer,  US = ultrasound, MRI = magnetic resonance imaging, CT = computed tomography, PET = positron emission tomography,  
FBC = full blood count, CEA = carcinoembryonic antigen, CA19-9 = cancer antigen 19-9,  AFP = alpha-fetoprotein,  hCG = human chorionic 
gonadotropin, LDH = lactate dehydrogenase (LDH),  GI = gastrointestinal.
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1.6.4 Discussion of review findings 
Some international variation in recommendations for the initial assessment and investigation 
of possible ovarian cancer is to be expected given the significant differences between 
healthcare systems. For example, the review included guidelines from countries with national 
health services and private healthcare systems and from two countries where direct access 
to gynaecology is available. However, the review does demonstrate that there is no clear 
international consensus on what clinical features should prompt clinicians to consider ovarian 
cancer, what physical examinations should be carried out and what initial test(s) should be 
performed.  
 
The majority of guidelines included the four symptoms with the highest positive likelihood 
ratios for ovarian cancer in a recent systematic review by Ebell et al (abdominal distension, 
abdominal/pelvic pain, bloating and appetite loss).89 However, a wide range of other 
symptoms appeared in guidelines including those which were not found to substantially 
increase the likelihood of ovarian cancer in Ebell et al’s review e.g. nausea and back pain. 
Variation in the symptoms which appear in guidelines reflects the wide variation in the 
symptoms which studies have identified as being associated with ovarian cancer over the last 
two decades. Some guideline producers, such as NICE (the body which produces clinical 
guidelines for the NHS in England, Wales and Northern Ireland) and the Scottish Intelligence 
Guidelines Network (SIGN), followed a rigorous approach in their selection of which 
symptoms to include, informed by systematic reviews. Other guideline producers selected 
symptoms based on a single study or consensus approach.§ 
 
Although most guidelines recommended CA125 and ultrasound as tests for ovarian cancer, 
how they recommended using them varied considerably. Guidelines commonly mentioned 
the paucity of evidence on the diagnostic performance of CA125 and ultrasound for the 
detection of ovarian cancer in symptomatic women. For example, the NICE guidelines 
highlighted that they were not able to identify any studies comparing the performance of 
CA125 and ultrasound in primary care.114 Other guidelines mentioned that due to lack of 
                                                        
§ When the AGREEII tool was used to assess the quality of development and reporting of included guidelines, 
eight where identified as ‘unsatisfactory’ (a score of <50%) in the ‘Rigour of Development’ domain. This 
highlights potential issues with the quality of the development process for these guidelines (Appendix A). 
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evidence they used a consensus approach when making decisions about tests.108,109 One did 
not recommend any particular test due to the lack of evidence.100 How CA125 and ultrasound 
are used is likely to have consequences for ovarian cancer detection. A sequential testing 
approach (where both tests need to be abnormal to trigger specialist referral)57 may be 
specific but at the cost of lower sensitivity. Conversely, a dual-testing approach (where an 
abnormality in either test warrants referral)108,109 may be more sensitive but at the detriment 
of specificity. 
 
1.6.5 Review summary 
Recommended approaches for the initial assessment of ovarian cancer differ around the 
world. Two tests for ovarian cancer predominated in guidelines: ultrasound and CA125. 
However, recommendations differed on how and when these tests should be used. Lack of 
evidence on test performance in symptomatic women presenting in primary care was cited 
by several guideline producers as a key issue when determining which investigation(s) to 
include.  
 
1.7 NICE guidelines in depth 
In 2011, NICE published Clinical Guideline 122 (CG122): “Ovarian cancer: recognition and 
initial management”.65 The choice of symptoms and tests included was informed by a 
comprehensive review of the literature.114 In 2015, when multi-cancer guidance was 
published by NICE (NICE Guideline 12 [NG12], “Suspected cancer: recognition and referral”), 
CG122 recommendations on ovarian cancer detection were incorporated unaltered.57  
 
NICE recommendations on assessment, testing and referral for ovarian cancer are 
summarised in Figure 1.7. In women with symptoms which suggest ovarian cancer, NICE 
advocate a sequential testing approach in which CA125 forms the first-line test. If the CA125 
is abnormal (≥35 U/ml), the guidelines recommend performing an ultrasound. If the post-
CA125 ultrasound is abnormal, they recommend urgent referral to gynaecology via the 
suspected cancer pathway (a ‘two week wait’ referral). If CA125 is normal, or if CA125 is 





Figure 1.7. NG12 recommendations for the investigation and referral of suspected ovarian cancer. 
Adapted from Funston et al (2018).115
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1.8 Cancer Antigen 125 (CA125) 
As described in the previous section, CA125 is recommend as an initial test for ovarian cancer in 
women with relevant symptoms in England and a number of other countries around the world.116 
In this section, I provide some background on the CA125 test, summarise current knowledge of 
its diagnostic accuracy and discuss how frequently it is used within English primary care. 
 
1.8.1 What is CA125? 
In 1981 Bast et al developed a monoclonal antibody (ovarian cancer antibody 125 [OC125]) which 
bound to an antigen on a high molecular weight glycoprotein (MUC-16) on the surface of ovarian 
cancer cells.117 This antigen was later named CA125 (variously known as carbohydrate antigen 
125, cancer antigen 125).118 It was initially thought that CA125 was not expressed by normal 
epithelial ovarian tissue, but research has shown that the protein is present on the epithelial 
surface of healthy ovaries in addition to other healthy epithelial tissues including fallopian, 
endometrial, pancreatic, peritoneal, pleural, gastrointestinal and lung tissue.119,120 Its biological 
role is still debated but it may be involved in lubricating and protecting epithelial surfaces.121,122 
In cancer, it is thought to play a role in metastasis and the protection of cancer cells from 
elements of the immune system.121,122  
 
1.8.2 Serum CA125 levels 
In a landmark study, published in the New England Journal of Medicine in 1983, Bast et al 
reported that CA125 could be detected in the blood and that levels were above a cut-off of 35 
U/ml in 82% (83/101) of patients with ovarian cancer, 6% (9/143) of patients with benign diseases 
and 1% (9/888) of healthy women.118 Based on this research, a CA125 cut-off of ≥35 U/ml was 
widely adopted and is still used today. Subsequent studies found that the proportion of women 
with CA125 levels ≥35 U/ml varies by ovarian cancer stage. A review, which included 723 women 
with ovarian cancer, found that CA125 was elevated in >90% of stage II-IV cancer but only around 
half of stage I ovarian cancer prior to surgery.119 It is also less commonly elevated in women with 
mucinous histology, borderline tumours and non-epithelial tumours than in other tumour types 
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of ovarian cancer.119,123,124 A large meta-analysis (N=2,374) found that, overall, CA125 levels are 
≥35 U/ml in 80% of women with invasive or borderline ovarian tumours pre-surgery.125 
 
CA125 is not specific for ovarian cancer. A range of benign gynaecological and non-gynaecological 
conditions can elevate CA125 levels (Box 1.3). Studies have also reported that CA125 can be 
elevated in a number of non-ovarian malignancies, notably pancreatic cancer (45-61%),126–128 






Pelvic inflammatory disease136,137 
Benign ovarian cysts136,138 
Heart failure139,140 







Box 1.3. Benign and malignant conditions 
associated with elevated CA125 levels. 
 
In apparently healthy individuals, baseline CA125 levels are higher in premenopausal than 
postmenopausal women.143 Levels can fluctuate during pregnancy and the menstrual cycle.144,145 
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1.8.3 Clinical roles for CA125 
In addition to its role in detection of ovarian cancer in primary care, CA125 is widely used to 
monitor progress in women with ovarian cancer undergoing treatment following diagnosis and 
to detect relapse.120 It is also used within algorithms, such as the RMI, to help determine whether 
an adnexal tumour is benign or malignant to guide treatment decisions, as women with likely 
ovarian cancer should be managed by a gynaecological oncologist in a tertiary centre.65  
 
Studies have investigated potential roles for CA125 in diagnosis, prognosis and monitoring of a 
range of benign conditions. For example, it has been evaluated as a diagnostic and prognostic 
marker for endometriosis135,146 and heart failure.139,147 It has also been evaluated, in isolation and 
within biomarker panels, for the detection of cancers other than ovarian e.g. pancreatic 
cancer.126–128,148 Despite this research, it is not routinely used as a test for any diseases other than 
ovarian cancer. This may change with the recent development of multi-cancer ‘liquid biopsies’. 
For example, the CanerSEEK panel was developed as a single test for eight different cancers and 
combines 10 protein biomarkers alongside circulating tumour DNA. CA125 is included in 
CancerSEEK and was, in the original CancerSEEK case-control study, the most important protein 
biomarker in terms of CancerSEEK accuracy.149 In a sensitivity analysis, removing CA125 from 
CancerSEEK reduced the sensitivity of the test not only for ovarian cancer but for liver cancer, 
oesophageal cancer and lung cancer. 
  
1.8.4 The diagnostic accuracy of CA125 
The diagnostic performance of CA125 has been evaluated both in secondary care patients with a 
known pelvic mass and in apparently healthy asymptomatic postmenopausal women within the 
screening context.  
 
In women with an adnexal mass, a meta-analysis of 17 studies, which included a total of 2,374 
women, reported that CA125 had a sensitivity of 80% and a specificity of 75% for ovarian cancer 
prior to surgery.125 Studies have reported PPVs of 35-91% in this context.150,151  
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An early screening study, which included 1,010 postmenopausal women, found that performing 
a single CA125 test (cut-off >30 U/ml) had a specificity of 97%.151 Results from the Prostate, Lung, 
Colorectal and Ovarian (PLCO) cancer screening trial found that, when used annually in 
postmenopausal women, CA125 (≥35 U/ml) exhibited a sensitivity of 55%, and a PPV of 3.7%.152 
Subsequent screening studies have focused on the use of serial CA125 measurements (including 
within the Risk of Ovarian Cancer Algorithm [ROCA]) and of multimodal strategies combining 
CA125 testing with ultrasound.53,153,154  
 
A comprehensive systematic literature review, performed to inform the development of NICE 
CG122 in 2011, did not identify any studies evaluating CA125 in primary care.114 Subsequent 
surveillance reviews undertaken by NICE (most recently in 2020) have also failed to identify any 
relevant primary care evidence on CA125 diagnostic performance.155 In order to identify any 
additional relevant papers which might provide insight on CA125 performance in primary care, I 
searched PubMed for studies published between database inception and the 1st July 2019, using 
the keyword “CA125” or its variants and “primary care” or its variants. I applied no language 
restrictions. This identified one study (not mentioned in the NICE surveillance review) which 
described outcomes in 152 women with CA125 levels ≥35 U/ml in primary care within the 
catchment population of a single UK hospital. This study reported that 16 (11%) women were 
diagnosed with ovarian cancer and a further 16 with another form of cancer.156 I did not identify 
any other studies which provided insight into the diagnostic performance of CA125 in primary 
care. 
 
1.8.5 Spectrum effect 
The diagnostic performance of a test is influenced by the characteristics of the population in 
which it is being used. For example, secondary care studies have evaluated the performance of 
CA125 in women who all have either ovarian cancer, a benign pelvic mass or another 
gynaecological disease requiring surgery. These benign conditions are less prevalent in the 
primary care population. Where they are present in the primary care population they may, on 
average, be less severe. Benign ovarian masses and gynaecological conditions are known to be 
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associated with elevated CA125 levels. Therefore, it is likely that a greater proportion of women 
without ovarian cancer will have elevated CA125 levels in the specialist setting than the primary 
care setting due to the higher prevalence (and possibly greater severity) of benign CA125 
elevating conditions. In women with ovarian cancer, the severity of disease (tumour burden) is 
likely to be greater in women in the specialist setting who are about to undergo surgery than in 
women in primary care at the start of the diagnostic pathway. This may result in fewer false 
negative results in the specialist setting than the primary care setting, as disease burden is 
associated with higher CA125 levels. Tests tend to have higher specificity and lower sensitivity 
when moved from a population with a high prevalence of the disease of interest to one with a 
low prevalence of the disease of interest:  the spectrum effect.157  
 
Similarly, the PPV of a test varies depending on the prevalence of disease within a population. It 
is lower in populations with lower prevalence of the disease of interest and higher in populations 
with higher prevalence. The difference in the PPV of a given test when it is used in high and low 
risk populations can be dramatic.158 This can be crudely illustrated by comparing the PPV of a 
raised CA125 in women with a pelvic mass pre-surgery (35-91%),150,151 to asymptomatic women 
in the PLCO screening trial (3.7%).152 An understanding of the PPV and Negative Predictive Value 
(NPV) of a test within a given population is crucial to allow clinical interpretation i.e. what a 
normal and abnormal test mean in terms of a patient’s probability of having a disease. Without 
knowing the PPV of CA125 in primary care, patients and clinicians cannot make fully informed 
decisions about the need for further testing or referral. In addition, NICE uses PPV when making 
recommendations about cancer testing and referral in symptomatic patients. When developing 
NG12 in 2015, they recommended urgent cancer referral in symptomatic primary care patients 
where the PPV for an individual cancer was ≥3%.57 Prior to this thesis, no large studies had 
reported the PPV of a positive CA125 result in symptomatic women in primary care. 
 
1.8.6 How common is primary care CA125 testing? 
There is limited data on the number of women who have a CA125 test performed in the UK each 
year. A laboratory-based study estimated that in Oxfordshire, over a 3-month period at the start 
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of 2013, 70 / 10,000 women aged 50 years or older had a first CA125 test performed in primary 
care.159 The rate was lower for women aged 25-49 years (50 / 10,000 women).  
 
Not all women diagnosed with ovarian cancer have had a CA125 test performed in primary care 
prior to diagnosis. Using routinely collected primary care data from the Clinical Practice Research 
Datalink (CPRD) GOLD dataset, I found that, out of 1,223 women diagnosed in England (between 
2012 - 2015), 582 (48%) had a CA125 test performed in primary care in the year before their 
diagnosis.160 Some of the women without a CA125 test will have been diagnosed after presenting 
to the emergency department or incidentally in secondary care.88 Some may also have been 
referred via the urgent suspected cancer pathway without a CA125 following identification of 
ascites or a mass in primary care (in line with NICE guidelines). In addition, GPs do not always 
adhere to guidelines,161 and some GPs may have performed an ultrasound (without a prior CA125 
test) and referred after an abnormality was detected on the scan. 
 
1.9 Models and tools 
A multivariable prediction model is defined as a “mathematical equation that relates multiple 
predictors for a particular individual to the probability of or risk for the presence (diagnosis) or 
future occurrence (prognosis) of a particular outcome”.162 Such models can be used to guide the 
clinical management of patients. For example, the QRisk models predict the risk of a patient 
developing cardiovascular disease within 10 years.163 NICE recommends offering statin treatment 
if the QRisk model indicates that a patient’s 10-year risk of developing cardiovascular disease is 
≥10%.164 These models can be integrated into GP IT software in the form of electronic clinical 
decision support (eCDS) tools which alert the clinician when a given risk level is reached. 
Examples of currently available primary care cancer eCDS tools include QCancer and the 
electronic Risk Assessment Tool (eRAT) for cancer.165,166 These tools incorporate symptom 
information alongside patient demographics / risk factors (e.g. age) and test results (e.g. 
haemoglobin level and platelet count) in order to identify patients at a higher risk of undiagnosed 
cancer. The impact of these tools on patient outcomes (including diagnostic interval, stage at 
diagnosis and survival) remains unclear,167 but a pragmatic cluster randomised control trial is 
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currently underway to evaluate the effect of eRAT implementation on stage at cancer diagnosis 
and survival in multiple cancers (including ovarian).166  
 
In the screening and secondary care settings, a variety of multivariable models incorporating 
CA125 have been developed. It is these models, rather than the CA125 level alone, that are 
generally used to guide patient care. For example, the RMI (which includes menopausal status, 
CA125 level and specific ultrasound findings) is used in secondary care within the UK to decide 
whether patients should be managed in a tertiary care setting by a gynaecological oncologist.65 
Other secondary care models incorporating novel ovarian cancer blood tests, such as Human 
Epididymis protein 4 (HE4),168 have been developed for the same purpose. These models are not 
appropriate for UK primary care, as they require specialist interpretation of ultrasound data and 
/ or specialist blood test results. 
 
In the prostate cancer screening setting, multivariable models which incorporate patient 
demographics, examination findings and other blood tests alongside Prostate Specific Antigen 
(PSA), have been shown to outperform PSA alone in the detection of cancer.169 It is possible that 
that similar models incorporating CA125 along with other information available at the point of 
CA125 testing in primary care, including patient demographics (e.g. age), presenting symptoms 
and the results of routine blood tests, could outperform CA125 alone in the detection of ovarian 
cancer.  
 
1.10 Thesis methods 
I considered using different methodological approaches in order to achieve the thesis aim of 
evaluating the diagnostic performance of CA125 in primary care and developing and evaluating 
novel approaches to improve its performance. In this section I discuss the methodological options 
and my rationale for employing a cohort design using routinely collected data for all empirical 
studies within this thesis. 
 
Diagnostic accuracy studies frequently employ a prospective study design, in which appropriate 
participants are recruited by the research team to undergo the index test which is then compared 
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against a gold standard reference.170 A similar approach can be used in diagnostic modelling 
studies where model variable data is prospectively collected by researchers.171 Such an approach 
has the advantage of allowing participant selection and data collection to be carefully tailored to 
the study question. However, prospective data collection can be time consuming, expensive and 
logistically challenging, particularly when the outcome is rare.171 For example, in one study which 
sought to evaluate a symptom triggered testing approach for ovarian cancer detection, 5000 
women were approached in primary care clinics and screened for symptoms of possible ovarian 
cancer, with further investigations performed (CA125 and ultrasound) if relevant symptoms were 
present.172 However, only two ovarian cancers were identified in the cohort so few conclusions 
could be drawn.  
 
An alternative approach to prospective data collection is to use existing routinely collected data 
sources. In England, a number of routinely collected primary care data sources, which contain 
coded clinical information including test results, are available for use in research. In addition, 
information on cancers diagnosed in England is systematically collected at a national level and 
collated within a cancer registry, enabling researchers to identify which patients within their 
study have cancer.173 Such data sources have previously been used both to evaluate tests which, 
like CA125, are already in routine clinical use and to develop and validate novel cancer diagnostic 
prediction models.54,174–177 A major advantage in using these data sources is their large size: 
several UK primary care data sources each contain records for over 10 million patients,178–180 
which has enabled the study of outcomes, such as ovarian cancer, that are relatively rare in 
primary care.54,181 Where large numbers of study participants or large amounts of data are 
required, use of routinely collected data may be more economical (both financially and in terms 
of time) than prospective data collection.171 Routinely collected data studies may also better 
reflect the performance of a test as it is used in standard clinical practice than prospective 
studies, in which selection criteria are often rigorously applied by the research team.170  
 
While using routinely collected data to evaluate tests and to develop prediction models does 
have limitations, which I consider in this thesis, taking account of resource constraints and the 
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relative rarity of ovarian cancer in primary care, I judged that it was the most appropriate 
approach to achieve my thesis aim. I describe the data sources used in this thesis in depth in 
Chapter 2. In the appropriate chapters and sections, I discuss limitations arising from the use of 
routinely collected data including issues with data coding and missing data (Sections 2.5, 2.8, 
3.3.2, 3.5.2, 4.4.1, 6.2, 6.4.2, 7.2) participant selection (Sections 3.3.2, 6.2.5) and determination 
of clinical outcomes (2.5, 2.6, 3.4.1). 
 
Both cohort and case control study designs have previously been used to evaluate the diagnostic 
performance of tests. However, case-control studies can overestimate test diagnostic 
accuracy,182,183 and methodological guidelines discourage their use in diagnostic accuracy studies 
for this reason.170,184 In addition, while the PPV and NPV of a test for a given population can be 
estimated using a representative cohort of patients identified from that population, they cannot 
reliably be determined using a case control design, as the prevalence of the outcome may not 
reflect the prevalence of the disease within the population of interest. Given these 
considerations, I adopted a cohort study design in this thesis. The specification of this cohort is 
discussed in detail in Chapter 2. 
 
1.11 Summary 
Ovarian cancer is a relatively rare diagnosis in primary care, but it is the 6th most common cancer 
and the 6th most common cause of cancer death in UK women.2,12 There is evidence to indicate 
that expediting diagnosis in symptomatic women could improve patient outcomes. 
 
CA125 is recommended as the single first line test for ovarian cancer in women with possible 
symptoms of the disease presenting in primary care in England.57 The test is also recommended 
as part of the initial testing strategy in other countries including Scotland, the Republic of Ireland, 
Australia, Canada and the United States.116 However, the diagnostic accuracy of CA125 for the 
detection of ovarian cancer in primary care has not previously been established. The current 
CA125 cut-off of 35 U/ml (which is used in primary care internationally) was not chosen based on 
primary care evidence. Given the differences in populations, the diagnostic accuracy of CA125 in 
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primary care cannot be inferred from studies conducted within secondary care or screening 
settings. In order to understand how well CA125 performs in primary care it must be studied 
within a primary care population. In their 2020 surveillance report (and in previous surveillance 
reports) NICE called for research evaluating the diagnostic performance of CA125 in primary care 
in order to inform future guideline development.155 
 
In the secondary care setting, diagnostic prediction models have been developed which include 
patient demographics, imaging findings and novel biomarkers, alongside CA125. Models 
incorporating another common cancer biomarker, PSA, with information including patient 
demographics and examination findings, outperform PSA alone in the screening setting. It is 
possible that a prediction model incorporating CA125, alongside other variables available within 
primary care at the point of CA125 testing, could outperform CA125 alone in the detection of 
ovarian cancer. 
 
Studies have shown that CA125 can be elevated in a range of cancers other than ovarian cancer. 
However, the proportion of women with high CA125 levels in primary care due to these cancers 
has not previously been determined. 
 
In the following chapters, I describe work undertaken to address gaps in our understanding of 










A single dataset consisting of linked routinely collected data from CPRD GOLD, CPRD Small Area 
Levels, the National Cancer Registration and Analysis Service (NCRAS) and the Hospital Episodic 
Statistics Admitted Patient Care (HES APC) databases was obtained to conduct all primary 
research studies in this thesis (Chapters 3, 4 and 6). In this chapter, I first provide a brief overview 
of each of these data sources and describe the regulatory approval I obtained to use data from 
them for this thesis. I go on to define the baseline patient cohort. This directly formed the study 
cohort for Chapter 3 and subsets of patients were selected from this cohort for the research 
presented in Chapters 4 and 6. I describe the steps taken to prepare this baseline cohort and key 
variables used across multiple chapters. Where a variable is used only in a single chapter, relevant 
definitions and data preparation steps are described in that chapter. 
 
2.2 Data sources 
In this section I provide a summary of the data sources used within this thesis. 
 
2.2.1 The CPRD 
CPRD GOLD (subsequently referred to simply as CPRD) contains longitudinal, anonymised, coded, 
primary care data for 11 million UK patients, of whom 4.4 million were ‘active’ (alive and 
registered with a participating GP practice) in July 2013.178 It is broadly representative of UK 
demographics in terms of sex, ethnicity and age.178 CPRD data has been used in over 2,600 
research papers including many cancer diagnostic studies.185 
 
Individual GP practices sign up to contribute data to the CPRD. Data on all patients from 
participating practices are then included unless a patient actively opts out. Data are uploaded 
from practices to the CPRD on a regular (usually monthly) basis. As well as practice level 
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information, including geographical region, CPRD contains patient level demographics and 
detailed clinical information. In the UK, most clinical information within GP records, such as 
symptoms, diagnoses, immunisations and tests, is coded. Until recently Read codes were used; 
although a new coding system (SNOWMED) is now being applied, its implementation postdates 
the data collected for this thesis. Read codes are a hierarchical clinical classification system.186 
Each Read code is associated with a Read term which allows interpretation e.g. Read code 
“44a6.00” is associated with Read term “CA125 level”, and these map directly (1:1) to an internal 
CPRD coding system (Medcodes). Depending on the type of clinical activity, additional 
information can be recorded alongside the code within the CPRD. For example, in the case of 
blood tests, numerical test results and units of measurement may accompany the code. Each 
clinical code within the CPRD is dated and recorded against a unique patient identifier.  
 
CPRD data are subject to quality assurance procedures at both the patient and practice level. 
Patients are flagged as either ‘acceptable’ or ‘unacceptable’ for research based on an assessment 
of their records including checks for invalid age or gender and invalid clinical dates e.g. clinical 
information recorded prior to their date of birth.178 At a practice level, the quality of death 
recording and an assessment for gaps in recording is used to allocate an ‘up-to-standard’ (UTS) 
date, indicating when practice data is considered of sufficient quality for research.178 Despite 
these checks, the CPRD comprises data that was collected for clinical use rather than for research 
and its quality largely depends on the completeness and accuracy of coding within GP practices. 
Clinicians do not always code clinical information such as symptoms or diagnoses, which may 
instead be recorded in free text within a record. Since 2013, this free text information has not 
been collected by the CPRD and is no longer available for research purposes.187 However, the 
completeness and accuracy of blood test results within the CPRD is high as results are 
automatically transferred to the GP system from labs.178   
 
CPRD data can be linked at an individual patient level to a range of external data sources by a 
third party - NHS Digital.188 NHS Digital use a multi-step approach to match patients between 
data sources based on key variables (NHS number, date of birth, sex and postcode).188 Linkage to 
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external data sources can improve data completeness and allow for the analysis of information 
which is not recorded within the CPRD. For example, studies can obtain additional information 
on hospital admissions by linking CPRD data to HES or on mortality by linking to the Office of 
National Statistics death registration dataset. However, linkage is only available for a subset of 
practices in England (~58% of all CPRD practices). For the purposes of this thesis, a CPRD dataset 
was linked to NCRAS, HES APC and Small Area Level data. 
 
2.2.2 The NCRAS  
The NCRAS acts as the English cancer registry. Detailed information on tumours diagnosed in 
England are supplied to them from multiple sources including multidisciplinary team meetings, 
pathology reports, hospital records and death certificates.173,189 The NCRAS claim a near 100% 
case ascertainment.189 Following collection, data undergoes a rigorous quality assurance process 
to maximise accuracy. Major errors, such as an invalid diagnosis date, are only found in around 
0.1% of records.173 As well as the date of diagnosis and details on how the cancer was diagnosed 
(e.g. histological, radiological or death certificate), detailed information on the type of cancer is 
collected. This includes the tumour site, recorded using the International Classification of 
Diseases 10th revision (ICD10) codes, and tumour morphology and behaviour, recorded using  
ICD-O codes.51 The stage at diagnosis for ovarian cancer is recorded using the Tumour Nodes 
Metastasis (TNM) and/or the FIGO staging systems, which are essentially identical.52,190 Although 
NCRAS data is updated and released regularly, there is a lag time for linkage to the CPRD and at 
the time the dataset for this thesis was obtained, linkage was only available up to the end of 
December 2015.  
 
2.2.3 HES APC  
HES APC comprises data collected during patient admissions to NHS Hospitals in England. Data 
on over 270 variables are available within the HES APC, including demographic information and 
clinical information on diagnoses and procedures.191 CPRD linkage is available to all HES APC 
variables or to specific subsets of variables. For this thesis I requested data on a very limited HES 
APC subset of variables, in order to obtain ethnicity information. HES APC classifies ethnicity as 
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one of 11 categories, which map to the 2001 census.192 The ethnicity recorded between 
admissions for a given patient can vary within the HES APC. NHS Digital provide a single ethnicity 
for each patient which represents the most common ethnicity for that patient across all episodes 
within HES APC. 
 
2.2.4 Small area level data 
Various geographical deprivation metrics for CPRD patients in England can be obtained as a linked 
dataset. Townsend score is an area level measure of material deprivation calculated on the basis 
of level of unemployment, car ownership, house ownership and house overcrowding in an 
area.193 Areas are ranked on the basis of these variables and categorised to create a 5-level score 
in which high scores indicate greater deprivation. Originally calculated for the 1981 census, it has 
since been recalculated for the 2001 census.194 Patients within the CPRD are linked, on the basis 
of postcode, to small geographical areas with an average population of around 1,600 and 5-level 
Townsend scores derived using 2001 census data.194    
 
2.3 Regulatory approval and data delivery 
Access to CRPD data and linked datasets is governed by the Independent Scientific Advisory 
Committee (ISAC) for the Medicines and Healthcare products Regulatory Agency (MHRA). With 
input from Prof Fiona Walter, Prof Willie Hamilton, Prof Gary Abel and Mrs Margaret Johnson (a 
patient representative), I developed a protocol covering the primary research presented in this 
thesis. This was submitted to ISAC in July 2018 and approved, without the need for revision, in 
August 2018 (protocol number 18_184, Appendix B). However, the preparation of my linked 
dataset took over five months and it was not delivered to me until the 30th of January 2019. I 
downloaded the zipped dataset files from CPRD using a single use password. All data were stored 
and analysed on a secure server in Cambridge, in accordance with CPRD terms of use and data 
protection legislation. I was the only researcher with access to the raw data files. 
 
I submitted a minor amendment to ISAC on the 2/7/2019 and obtained permission to alter the 
primary clinical outcome definition and follow-up period (Appendix B). I made the decision to 
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make these changes prior to data analysis and I outline the rationale for these choices in Sections 
2.5 and 2.6.  
 
2.4 Baseline Cohort definition 
The baseline cohort was defined by the presence of a code for CA125 within the CPRD between 
the 1st of May 2011 and the 31st of December 2014. The first CA125 test during this period was 
selected as the index test. Codes used to identify CA125 entries are shown in Appendix C. The 1st 
of May 2011 was chosen as a start date as this fell just after the introduction of NICE CG122 which 
recommended CA125 use in primary care.114 The 31st of December 2014 was chosen to allow a 
follow-up period of 1 year in NCRAS for all women, and is further discussed in Section 2.6. Other 
inclusion criteria were:  
 
• Patient flagged as Acceptable for research (CPRD quality metric) 
• Registered at a practice which was UTS at the index test date (CPRD quality metric) 
• Patient aged ≥18 years at index test date 
• No CA125 test in the 12 months prior to index test date 
• No ovarian malignancy recorded in NCRAS data on or prior to the index test date 
  
As is recommended by the CPRD, I applied the Acceptable patient and UTS practice criteria to 
maximise the quality and completeness of data used in this thesis. Women with a CA125 test in 
the 12 months before the index test date were not included, as there is evidence that repeat 
blood tests in primary care may have a higher PPV than initial tests.175 While repeat testing and 
trends in CA125 results are of research interest, they are not the focus of this thesis. Women with 
previous ovarian cancer were not included in the cohort as I was interested in the detection of 
primary rather than recurrent ovarian cancer. 
 
2.5 Justification of data source for cancer diagnoses  
My intention, at the time of ISAC protocol submission, was to use codes for ovarian cancer 
recorded in either CPRD or NCRAS data (for patients in whom linkage was available) as evidence 
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of an ovarian cancer diagnosis. However, a publication by Badrick et al. in October 2018 (after 
the submission of the ISAC protocol) highlighted potential pitfalls to this approach.195  
 
Although many studies have used CPRD to identify cancer cases, NCRAS is generally considered 
the gold standard data source for cancer epidemiological studies as it collects diagnostic 
information from multiple sources, uses a hierarchical approach when determining date of 
diagnosis, records details on both the site and morphology of tumours in a standard and precise 
categorical format (ICD codes) and undertakes rigorous automated and manual quality control.173 
By contrast, the CPRD relies on manual coding of diagnoses by GP practice staff and it is not 
possible to determine the source of diagnostic information (e.g. histology or death certificate), 
so a hierarchical approach cannot be applied. No systematic quality controls are undertaken to 
ensure accuracy of CPRD diagnostic codes and diagnosis dates. Rather than ICD codes, cancer 
diagnoses are recorded within CPRD using Read codes, which are often so non-specific that they 
could refer to a benign or a malignant lesion (e.g. Read code: BB81.14, Read term: “[M]Ovarian 
serous tumour”) or to a lesion of the ovary or another site entirely (e.g. Read code: B4….00, Read 
term: “Malignant neoplasm of genitourinary organ”). 
 
Multiple studies have identified differences in recording of diagnoses between NCRAS data and 
CPRD. Arhi et al found that around 10% of cancers recorded in CPRD could not be confirmed in 
NCRAS data while Boggon et al reported the figure as 17%.196,197 Boggon et al also reported that 
6% of cancer cases recorded in NCRAS data were missing from CPRD. A recent study, by 
Strongman et al, found that 15% of ovarian cancers recorded within the CPRD (2000-2014) could 
not be confirmed using a ‘gold standard’ algorithm which drew information from multiple data 
sources including NCRAS.198 Badrick et al highlight that relying on CPRD data to identify outcomes 
could result in misclassification bias.195 In diagnostic accuracy studies, particularly where the 
outcome is relatively rare, this has the potential to markedly affect estimates of test accuracy. 
Given these issues, instead of using both CPRD and NCRAS codes, as proposed in the original 
protocol, I restricted the study sample to patients who were eligible for NCRAS linkage and relied 
solely on NCRAS data to identify ovarian cancer diagnoses. This ensured that the same data 
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source, and the one which is likely to be most accurate in terms of cancer recording, was used to 
identify outcomes for all women. This decision was taken prior to data analysis and an 
amendment was approved by ISAC (Appendix B).   
 
I used ICD10 codes consistent with the thesis definition of ovarian cancer as “an invasive or 
borderline tumour arising from the ovaries, fallopian tubes or peritoneum” to identify ovarian 
cancers in the dataset (Table 2.1).  
 
Table 2.1. ICD10 codes meeting the thesis definition of ovarian cancer. 
Code* Description 
C56 Malignant neoplasm of the ovary 
C57.0 Malignant neoplasm of the fallopian tube 
C48.1 
Malignant neoplasm of specified parts of the 
peritoneum 
C48.2 
Malignant neoplasm of the peritoneum, 
unspecified 
D39.1 
Neoplasm of uncertain or unknown 
behaviour of the ovary 
*All sublevel codes were included. E.g. C56.1 (“Malignant neoplasm of the right ovary”). 
 
2.6 Justification of follow-up period 
A ‘perfect’ diagnostic accuracy study necessitates performing a gold standard test on all patients 
at the same time as, or shortly after, the test under evaluation.170 This was not possible in this 
thesis, which instead relied on information collected on cancers diagnosed as part of standard 
clinical care. The length of follow-up period after CA125 testing was therefore important – it 
needed to be long enough to include cancers diagnosed as part of usual care, but short enough 
to minimise the risk of capturing incidental ovarian cancers, which were not present when the 
index CA125 test was performed, but which developed and were diagnosed later in the follow-
up window. 
 48 
While there were no comparable primary care studies on CA125 to help guide this decision, 
studies have evaluated the symptoms of ovarian cancer reported in primary care before diagnosis 
(case-control studies) and evaluated the performance of symptom-based tools in primary care. 
These studies have variously used follow-up periods of 6 months (a USA study),172 12 months,91 
and 24 months.54 A recent study (in which follow-up was limited to 12 months) found that the 
median diagnostic interval (time from first presentation in primary care to diagnosis) for ovarian 
cancer in England was 56 days, but that 10% of patients had intervals between 281-365 days.82 
This indicates that a follow-up period of 12 months is likely to pick up most, if not all, ovarian 
cancers present at the time of CA125 testing. Given the low incidence of ovarian cancer in the 
general population (Chapter 1), I believe that it is unlikely that significant numbers of incidental 
ovarian cancers arose and were diagnosed in the study cohort within 12 months after the index 
CA125 test.  
 
I considered applying a shorter follow-up period e.g. 6 months. However, this would have risked 
excluding a significant proportion of ovarian cancers, based on data from Price et al.82 I also 
hypothesised that in women with ovarian cancer, those with normal CA125 results (false 
negatives) were likely to take longer to diagnose after testing than those with abnormal results 
(true positives). If true, a 6-month follow-up period would have preferentially excluded women 
with normal CA125 results, introducing bias into estimates of test diagnostic accuracy. 
 
Ultimately, I included ovarian cancers diagnosed within the 12 months after the index CA125 
date (as recorded in NCRAS data) as my primary clinical outcome. I submitted and gained 
approval for an ISAC protocol amendment, as the original protocol applied a follow-up period of 
24 months (Appendix B). As NCRAS linkage was only available up to 31/12/2015 when the data 
for this thesis was acquired, only patients with an initial CA125 test in the CPRD on or before 
31/12/2014 were included, to allow 1-year follow-up of all patients in NCRAS data.  
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2.7 Data supplied by CPRD 
The CPRD provided records of 135,564 research Acceptable patients with a code for a CA125 test 
within their primary care record between 01/05/2011 – 30/9/2016. Linked NCRAS and HES APC 
data was provided for 72,182 women and Townsend score for 72,191 women. 
 
CPRD data was supplied in 51 sub-files which mapped to the file types outlined in Box 2.1. The 
files contained millions of entries (the clinical and test files alone consisted of over 100 million 
coded entries), the majority of which were of no relevance to my research. Prior to analysis, 
significant data preparation was required. 
 
Raw NCRAS data was supplied in 2 files. The first included the date of diagnosis, site of diagnosis 
(ICD10), morphology and behaviour (ICD-O) codes for each tumour (recorded against a tumour 
ID) for each patient (recorded against a patient ID) identified by the NCRAS between 1990-2015. 
The second file provided further data on stage for ovarian cancers diagnosed between 1/05/2011 
– 31/12/2015.  
 
A Small Area Levels data file containing numerical 5-level Townsend score (recorded against 
patient ID) was provided as was a HES APC file containing several variables including an 11-
category ethnicity variable (recorded against patient ID). The preparation and use of Townsend 
score and HES ethnicity data are described in Chapters 4 and 6 respectively.  
 
A linkage file, provided by the CPRD, indicated which patients had data from each linked data 
source (recorded against patient ID). 
 
I imported all files, which were supplied in text format, into Stata format (.dta) and performed all 




























Box 2.1. CPRD file types. 
  
• Patient file 
Patient data including unique patient identifier and 
demographics e.g. sex, year of birth 
 
• Practice file 
Data on GP practices e.g. unique identifier, geographical region 
 
• Staff file 
Data on staff performing coding e.g. practitioner type 
 
• Consultation file 
Data on consultation events e.g. type of consultation, date of consultation 
 
• Clinical file 
Large file containing data on a wide variety of clinical variables 
e.g. coded symptoms, diagnoses 
 
• Additional clinical file 
Further clinical information on certain clinical codes e.g. smoking status 
 
• Referral file 
Data relating to referrals e.g. date, specialty 
 
• Immunisation file 
Data on immunisations e.g. date, type 
 
• Test file 
Data on tests including laboratory investigations e.g. type, test level/result, test units 
 
• Therapy file 




2.8 Data preparation 
In this section, I describe the preparation of key variables used to select the baseline cohort in 
addition to several variables which, although not used in cohort selection, were utilised across 
multiple subsequent chapters of this thesis. 
 
2.8.1 CPRD: CA125 test preparation  
The CPRD supplied data for both NCRAS linkage eligible and ineligible patients. I used the linkage 
eligibility file to exclude patients without NCRAS linkage. Patients with a CA125 medcode 
between 01/05/2011 – 31/12/14 in their test file were then selected (69,394 CA125 codes for 
55,487 women).  
 
It was important to examine CA125 records to ensure that the data was complete and without 
obvious errors or quality issues. So, I inspected the CA125 levels (recorded as  numerical values), 
the units (coded as numbers which could be deciphered using additional ‘look-up’ files) and the 
laboratory upper reference limits (recorded as numerical values) for CA125 entries within the 
Test file.  
 
I identified 3,596 CA125 entries which had no CA125 level recorded. These may represent tests 
which were not performed or duplicate requests (in some cases multiple test entries on the same 
day were present). Where recorded, CA125 levels ranged widely from 0 to 32,470. High values 
were not unexpected as, although CA125 levels are reported to be below 35 U/ml in around 99% 
of healthy women,118 patients with advanced ovarian cancer can have levels in the tens of 
thousands.  
   
By convention, CA125 is measured and reported in international units (IU), often simply referred 
to as units (U) per millilitre (ml) or the equivalent international kilounits per litre (IKU/L) or 
kilounits per litre (KU/L). On examination of the units for CA125 entries I found that 5% did not 
have a unit recorded and 3% were associated with units not used to measure CA125, including 
mmol/L (commonly used to measure blood glucose) and μg/L (used for multiple blood tests 
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including carcinoembryonic antigen and ferritin). I explored the units by the 10 English 
geographical regions within CPRD and by GP practice to determine whether particular labs or 
practices were consistently using incorrect CA125 units, but errors were not restricted to a few 
regions or practices. For example, the erroneous mmol/L occurred for CA125 entries from all ten 
regions and more than 100 practices. The median CA125 level for entries in standard units was 
12 and the mean 39, compared to a median of 16 and a mean of 163 for levels with no unit or 
the incorrect unit. 2% of CA125 values associated with no unit or an erroneous unit were 
recorded as a having a level of 0 which is, physiologically, highly unlikely and which was not found 
for any of the 63,678 entries which possessed the correct unit.  
 
The CA125 upper reference limit of ‘normal’, derived by Bast et al in 1983 and subsequently used 
by NICE in their guidelines on ovarian cancer detection, is <35 U/ml. This is the reference value I 
use in this thesis. I therefore did not employ the laboratory upper reference limits provided in 
CPRD data for analysis, but I did examine them as a possible flag for data quality and 
completeness. I found that 7,833 entries had no upper reference limit recorded and a small 
number (115) had a clearly erroneous upper reference limit (“0”, “5”, “245”, “420” or “455”).  
 
Test result are generally automatically transferred from labs to GP practices and the information 
is then recorded within the Test file in CPRD data – this should maximise quality and minimize 
errors. Despite this, there were clear issues with both units of measurement and upper 
thresholds for some CA125 records. It is possible that CA125 entries with missing or erroneous 
units or upper thresholds represent true CA125 tests results, with errors being introduced at 
some point during transfer from lab to GP practice to CPRD. However, these entries could equally 
represent other test results erroneously coded under a CA125 test code. It is also technically 
possible for CA125 test results entered manually within a practice to appear within the Test file 
and errors or omissions could occur on manual data entry. Given the uncertainty surrounding 
these entries, and in order to maximise CA125 data quality, I excluded entries recorded in 
incorrect units or where no unit was given and entries with an incorrect upper threshold or where 
no threshold was given. I performed sensitivity analyses in Chapter 3 in which I included entries: 
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a) regardless of unit and b) regardless of upper reference limit. CA125 entries where the CA125 
level was missing were also excluded as a test level was essential to perform the primary research 
described in this thesis.  
 
I selected the first valid CA125 entry for each patient during the study period. A small number of 
patients had more than one CA125 entry on the initial test date, so the mean was taken to give 
a single CA125 value (index test result) on the initial test date (index test date). I then excluded 
patients with CA125 tests in the year before the index test date. 
 
2.8.2 CPRD: Age at index test date 
Only the year of birth is given in CPRD data to protect confidentiality. I assigned all patient the 
same day (1st) and month (July) of birth which was used to calculate patient age in years at index 
test date. This derived age was used to exclude patients <18 years old at the index test date and 
then in subsequent analyses. 
 
2.8.3 NCRAS: ovarian cancers 
I identified entries with an ICD10 topography code for ovarian cancer within NCRAS data and 
excluded patients with an ovarian cancer code dated on, or prior to, the index test date. The first 
code for ovarian cancer occurring in the 12 months following the index test date was identified 
and formed the primary clinical outcome. 
 
2.8.4 Baseline cohort 





Figure 2.1. Flow diagram illustrating the selection of patients for the baseline cohort. 
 
 
2.8.5 Additional NCRAS variables: morphology, behaviour and stage 
While not required to select the baseline cohort, knowledge of the behaviour, morphology and 
stage of ovarian tumours was essential to perform the research described in subsequent 
chapters. The coding and preparation of these variables is best described together and is 
therefore presented in this section, rather than in later chapters, to minimise duplication.  
 
Morphology and behaviour 
Tumours within linked NCRAS data are coded using 2 coding systems: ICD10 for tumour 
‘topography’ (site) and ICD-O for tumour ‘morphology’ and ‘behaviour’. An example of the code 
format is given in Figure 2.2. As well as providing an indication of the tumour site, the ICD10 
topography code indicates whether the tumour is of malignant / invasive, or of unknown / 
uncertain behaviour. The four-digit ICD-O morphology code provides details of the morphology 
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/ histology (the terms are used interchangeably in ICD-O and in this thesis) of tumours. Finally, a 
single digit denotes the ICD-O behaviour of the tumour.**  
 
Although information on tumour behaviour is provided both in the ICD10 topography code and 
the ICD-O behaviour code, it became apparent that neither of these could reliably be used to 
determine tumour behaviour due to changes in coding practices. The previous ICD-O coding 
system (ICD-O-2),199 recommended that borderline tumours were assigned a behaviour of “3” 
(malignant behaviour) whereas the most recent version of the coding system (ICD-O-3),51 
recommended coding them under “1” (unknown or uncertain behaviour). Likewise, borderline 
tumours were historically given an invasive ICD 10 code (“C”) but are now often coded using the 
unknown / uncertain behaviour code (“D”). An examination of my data revealed that most, but 
not all, tumours were coded using ICD-O-2 and borderline tumours were coded under both ICD10 
“C” and “D” codes.  
                                                        
** Information on tumour behaviour is provided both within the ICD10 topography code and ICD-O morphology / behaviour codes. This 
redundancy exists because the systems were not originally intended to be used together. The ICD-O system has a topography coding section 
which only provides information on site, not behaviour, but an ICD10 code is provided instead of this for CPRD-NCRAS linked data.  
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Figure 2.2. Schema illustrating the format of ICD10 and ICD-O codes using the example of “C56 8460/3”, coding a “malignant 
papillary serous cystadenocarcinoma”.
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Information on tumour behaviour is also contained within the ICD-O morphology codes and, 
while it is more complicated and time consuming than simply relying on ICD10 codes, these 
can be used in conjunction with ICD-O behaviour codes to accurately determine tumour 
behaviour. I manually compared these codes against the ICD-O coding handbooks and 
categorised tumours as of borderline or invasive behaviour. At the same time, I classified 
tumours on the basis of ICD-O morphology code into the histological groups outlined in Box 
2.2. While the majority of tumours could be classified by histological sub-type, some codes 
were non-specific e.g. “Neoplasm malignant” and “Carcinoma NOS”, necessitating the 
histological groups: “Unknown” and “Unknown epithelial”. It was not possible to further 
classify the serous tumour group into HGS and LGS as information on grade was recorded for 













     Box 2.2. Histological classification of 
      ovarian tumours applied in this thesis. 
 
My provisional behaviour and histology classification lists were reviewed by Dr Brian Rous, an 
experienced pathologist at the NCRAS who specialises in gynaecological tumours. He 
provided clarification on obscure codes and suggested minor changes to the provisional list. 
















There are separate fields within linked NCRAS data for the individual T, N and M components 
of the TNM tumour stage to be recorded, in addition to the final TNM stage and a FIGO stage. 
Where the final TNM stage was recorded I accepted it as the final tumour stage. However, I 
noted that for a small number of tumours (n=6), staging information was provided in 
individual T, N or M fields but no final TNM stage was listed. In consultation with Dr Rous, I 
used the individual TNM fields to derive the final TNM stage for these tumours. In some cases, 
a FIGO stage was listed but no information provided in the TNM fields. Where no TNM stage 
could be determined and a FIGO stage was present, I accepted the FIGO stage as the final 
tumour stage (n=15).  
 
Tumours were classified as: 
• Stage I 
• Stage II 
• Stage III  
• Stage IV  
• Stage unknown 
 
2.9 Chapter summary 
In this chapter I have described the data used during my doctoral research and its initial 
preparation. In addition, I have outlined the methodological decisions taken when specifying 
my baseline cohort and preparing key variables. In the following four chapters, I present four 
research studies (three of which use the data described within this chapter) that address my 





Chapter 3. The diagnostic performance of 
CA125 for the detection of cancer in primary 




In Chapter 1 of this thesis I highlight that, although CA125 is recommended in England and 
several other countries as a test for ovarian cancer in women with relevant symptoms in 
primary care, its diagnostic performance within this setting remains unknown. Our knowledge 
of CA125 performance comes from screening studies and studies conducted in the specialist 
setting, where the disease prevalence and the clinical characteristics of the population are 
distinct from primary care. To gain an accurate understanding of how CA125 performs within 
primary care it was important to evaluate it within an appropriate primary care population. 
As the incidence of ovarian cancer in primary care is low and CA125 is already widely used, 
and advocated by NICE, a prospective diagnostic accuracy study was not practical within this 
thesis. However, the fact that CA125 is widely used in primary care in England, and that test 
results are captured within the CPRD, provided an ideal opportunity to perform a cohort study 
using routinely collected data in order to evaluate how the test performs in real world primary 
care. In this chapter, I present a population-based cohort study which used data from the 
CPRD and the NCRAS to achieve the following thesis objectives:  
 
i) To evaluate the diagnostic accuracy of CA125 for a) ovarian cancer, b) non-ovarian 
cancers and c) all cancers combined, when used in English primary care. 
ii) To explore variations in the diagnostic accuracy of CA125 by patient age. 
iii) To explore the association between CA125 level and estimated probability of a) 
ovarian cancer and b) all cancers combined, in women undergoing CA125 testing 
in English primary care. 
iv) To identify the CA125 level at which a 3% probability of a) ovarian cancer and b) 
all cancers combined is reached in women undergoing CA125 testing in English 
primary care. 
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v) To explore variations in estimated cancer probability by age and determine the 
CA125 level at which a 3% probability of a) ovarian cancer and b) all cancers 
combined is reached in different ages. 
 
A paper, based on the work presented within this chapter, was recently published in PLOS 
Medicine (Appendix A): 
 
The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in 
primary care: a population-based cohort study. Garth Funston, Willie Hamilton, Gary Abel, 
Emma J. Crosbie, Brian Rous, Fiona M. Walter. PLOS Medicine. 2020; 17:e1003295 
 
3.2 Key concepts in the study design 
In this section I briefly outline key concepts relating to test diagnostic accuracy, which were 
important in informing the study design. I then discuss my rationale for including age as a 
variable in analyses and my rationale for examining the diagnostic accuracy of CA125 for non-
ovarian cancers.  
 
3.2.1 Diagnostic accuracy considerations 
In English primary care, a cut-off of ≥35 U/ml is used to interpret a patient’s CA125 result. 
Below this threshold the test is deemed ‘normal’ and further investigation for ovarian cancer 
is not recommended by NICE.114 Above this threshold the result is ‘abnormal’ and further 
investigation is recommended. The PPV of a test indicates the percentage of people with a 
test level above a given cut-off who have a condition of interest. It can be interpreted as the 
‘average’ probability or risk of disease in patients with an ‘abnormal’ test result. However, 
patients with an ‘abnormal’ CA125 test can have CA125 values which range from 35 U/ml into 
the tens of thousands of U/ml. Patients with very high CA125 levels are more likely to have 
ovarian cancer than those with borderline high CA125 levels. The PPV provides no information 
about the probability of cancer associated with a specific CA125 level and is therefore of 
limited use when interpreting an individual woman’s test result. 
 
Knowledge of the PPV, and other conventional test accuracy metrics for CA125, are important 
in order to understand how the test performs overall at the threshold currently used in clinical 
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practice. These metrics have not previously been calculated for a primary care population, 
and one of the objectives of this study was to address this. However, I also sought to estimate 
the probability of cancer at specific CA125 levels, as I believe this is likely to be more useful 
clinically than the overall PPV. Patients interpret risk differently and previous research has 
shown that there is variation in the level of risk at which patients opt for cancer 
investigation.200 Knowledge of the probability of cancer at their given CA125 level could help 
patients and their GPs interpret individual CA125 results and make informed decisions about 
further investigation.  
 
NICE revised their cancer guidance in 2015, using a ‘risk threshold’ of ≥3% as the threshold 
for urgent cancer investigation in symptomatic women. But ovarian cancer guidance, 
including the chosen CA125 cut-off of 35 U/ml, remained unchanged.57 In this study, I sought 
to calculate the CA125 level which equated to this 3% risk threshold. When developing their 
guidelines, NICE used PPV as the ‘risk threshold’, which was appropriate for symptoms given 
that they are effectively binary variables which can be ‘present’ or ‘absent’ (when severity 
and duration are not considered). However, such an approach is not appropriate for 
continuous variables with a wide range of values as, although the overall probability of 
disease above a given cut-off (i.e. the PPV) may be 3%, the probability at specific test values 
above that cut-off may vary considerably, as illustrated for a hypothetical test in Figure 3.1. 
Instead of calculating the CA125 cut-off that resulted in a 3% PPV, in this study I aimed to 
identify the specific CA125 level at which the probability of ovarian cancer reached 3%. I 




Figure 3.1. Representation of a hypothetical relationship between blood test level 
(continuous) and disease probability.  
 
3.2.2 Age 
As discussed in Chapter 1, the incidence of ovarian cancer rises markedly with increasing age; 
75% of cases occur in women aged ≥50 years.5 The low incidence of ovarian cancer in younger 
women is acknowledged within NICE recommendations on ovarian cancer, which state that 
ovarian cancer be considered in women with relevant symptoms “especially if 50 or over”.57 
Screening trials, such as UKCTOCS, have gone further by only including women aged 50 or 
older.154 The types of ovarian cancer which occur in younger and older women also vary. For 
example, germ cell ovarian cancers classically occur in younger women. In addition to cancer 
incidence and type, baseline CA125 levels vary by age with higher levels reported in younger 
groups of women.201,202 Given this, I chose to explore the effect of age on the diagnostic 
accuracy of CA125 within this study. I also took account of age when estimating cancer 
probability for different CA125 levels.  
 
3.2.3 Non-ovarian cancers 
CA125 is only recommended as a test for ovarian cancer in primary care and the main focus 
of this chapter, and indeed this thesis, is on its utility in ovarian cancer detection. However, 
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as discussed in Chapter 1, CA125 levels can be elevated in the presence of other types of 
cancer. Most ovarian cancer symptoms are nonspecific e.g. abdominal pain, weight loss and 
fatigue - these are common across multiple types of cancer, including malignancies 
sometimes associated with elevations in CA125. This overlap in cancer presentation is 
demonstrated in Table 3.1, which shows symptoms of ovarian cancer included in NG12 which 
are also listed as symptoms of other CA125-elevating cancers. I postulated that a proportion 
of women being tested for CA125, due to a suspicion of ovarian cancer, would actually have 
a non-ovarian cancer and that some would have elevated CA125 levels as a result of that non-
ovarian cancer. In light of this, I examined the diagnostic accuracy of CA125 for non-ovarian 
cancers and all cancers combined (ovarian and non-ovarian). 
 
Table 3.1. Symptom overlap between ovarian cancer and other cancers known to cause 
CA125 elevations. 
 Cancer 







pain • • • • •  
Loss of 
appetite •     • 
Weight 
loss • • • • • • 
Fatigue 
 •     • 
CIBH 
 • • •    
Some ovarian cancer symptoms (urinary urgency/frequency, abdominal distension/bloating 
and pelvic pain) are not shown, as they are not listed as symptoms of other CA125-elevating 
cancers in NICE guidelines. CIBH = change in bowel habit. 
 
3.3 Methods 
3.3.1 Study design and participants 
This study followed a cohort design utilising linked data from the CPRD and the NCRAS. The 
baseline cohort, the preparation of which is described in detail in Chapter 2, directly formed 
the study cohort. All women in this cohort were included in this study in order to maximise 
sample size and the precision of diagnostic accuracy estimates. To summarise, this cohort 
consisted of 50,780 women registered at GP practices in England who had a valid CA125 test 
recorded in their CPRD record between 1st of May 2011 and the 31st of December 2014. These 
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women had no history of ovarian cancer recorded by NCRAS on or prior to their first CA125 
test within the study period (the index CA125 test) and no CA125 tests recorded in CPRD in 
the year prior to the index test. All patients had NCRAS linkage, allowing for 12 months follow-
up in NCRAS after the index test date.  
 
3.3.2 Rationale for not restricting the cohort by symptom codes 
CA125 is only recommended as a primary care test in England for women presenting with 
specific symptoms. As such, I considered restricting the cohort to women with a code for any 
of the symptoms of possible ovarian cancer listed in NICE guidelines.57 I chose not to do this 
for two reasons. First, as discussed in Chapter 2, symptoms are not always coded within 
primary care records but instead may be recorded within the free text (access to which is no 
longer available for research). In one large CPRD based case-control study by Price et al, 
symptoms of bladder and pancreatic cancer were recorded in free text but not coded for 38% 
of patients.187 Symptoms are less likely to be coded for patients without cancer than with 
cancer. For example, Price et al found that 18% of haematuria in patients subsequently 
diagnosed with bladder cancer was only recorded in free text (not coded) compared to 42% 
of matched controls. Although the reasons for this are unclear, it may be that the symptoms 
in the cancer patients are more concerning to GPs or are more severe. Only including patients 
with a relevant symptom code before their CA125 test could therefore have biased the study 
results by preferentially selecting cancer patients and patients with more severe symptoms 
(who may have more severe disease and thus higher CA125 levels).  
 
Secondly, even if it had been possible to definitively identify patients with symptoms of 
possible ovarian cancer listed in NICE guidelines, GPs frequently don’t adhere to guidelines.161 
While there has never been an ovarian cancer screening program in England and it is unlikely 
that significant numbers of CA125 tests are performed in asymptomatic individuals in general 
practice, it is possible that this does occasionally occur, or that some CA125 tests are 
requested due to symptoms not listed in NICE guidelines. Instead of focusing on the 
performance of CA125 when used in concordance with guideline recommendations, I instead 
sought to determine its performance when used in real world primary care.  
  
 65 
3.3.3 Handling of CA125 data 
The preparation of index CA125 test data is described in Section 2.8.1. After visually 
inspecting this data, I generated two variables for subsequent analyses. First, I categorised 
women into two groups: CA125 ‘normal’ (<35 U/ml) and ‘abnormal’ (≥35 U/ml). This variable 
was used to assess diagnostic accuracy at the conventional threshold (Section 3.3.9). Second, 
as CA125 level data (as a continuous variable) was highly right-skewed, I log transformed it. 
CA125 level was also mean centred prior to analysis. This variable was used in all regression 
analyses described in Section 3.3.9. 
 
3.3.4 Handling of patient age 
The preparation of age at index test date is described in Section 2.8.2. After visually inspecting 
data on age, I used it to categorise women into ‘<50 years’ and ‘≥50 years’ age groups. These 
were chosen as the most appropriate age groups as: more than three quarters of ovarian 
cancers are diagnosed in women ≥50 years of age; age 50 is the standard age used to select 
women for screening and early detection studies;55,154 it is close to the mean age of 
menopause in the UK (51 years);203 and is highlighted in NICE guidelines on ovarian cancer 
detection.57 All analyses described within this chapter were first performed in the overall 
cohort then repeated by age group.  
 
On submission of the research paper on this study, a peer reviewer suggested that, as well as 
calculating the estimated cancer probability at specific CA125 levels in the two age groups, I 
perform analyses including age as a continuous variable in order to calculate the estimated 
probability of cancer at specific CA125 levels for specific ages. Although such an approach was 
not prespecified, it was in keeping with the study objectives. A variable consisting of mean 
centred age in years (as a continuous variable) was therefore generated for use in this 
analysis.  
 
3.3.5 Primary outcome 
The primary clinical outcome in this study was the diagnosis of ovarian cancer, as recorded 
using ICD10 codes in NCRAS data, in the 12 months following the index CA125 test (further 
described in Sections 2.5 and 2.6).  
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3.3.6 Secondary outcome 
The secondary clinical outcome in this study was the diagnosis of any form of cancer except 
non-melanoma skin cancer, as recorded using ICD10 codes in NCRAS data, within 12 months 
of the index CA125 test. Where a patient has both an ovarian cancer and another type of 
cancer, I considered that any CA125 elevations are much more likely to be due to the ovarian 
cancer. Therefore, I only considered non-ovarian cancers in women without ovarian cancer. I 
identified the first non-ovarian ICD10 code recorded in the 12 months following the index test 
date. In cases where women had more than one non-ovarian cancer diagnosis on the same 
day, I used the following approach to select a cancer based on behaviour:  
 
1) Malignant 
2) Unknown or uncertain behaviour 
3) In situ 
 
In the few instances where the cancers were of the same behaviour type (n=4), I selected a 
diagnosis arbitrarily. I used a pragmatic approach to categorise tumours by anatomical site 
on the basis of ICD10 codes. Most types of in situ cancers do not cause symptoms and 
therefore are unlikely to have been the trigger for CA125 testing. Therefore, in situ lesions 
were grouped separately from tumours of malignant behaviour and those of unknown 
behaviour. Tumours could generally be classified according to top order ICD10 codes but in a 
few instances lower order codes had to be examined. For example, D37 represents “neoplasm 
of uncertain behaviour of the oral cavity and digestive tract” and was categorised using lower 
order codes e.g. D37.1 (“neoplasm of uncertain behaviour of the stomach”) as an upper 
gastrointestinal (GI) cancer and D37.4 (“neoplasm of uncertain behaviour of the colon”) as a 
lower GI cancer. Occasionally, codes were too non-specific to be grouped on the basis of 
topographical site e.g. D48 (“neoplasm of uncertain behaviour: other”) and these are 
reported individually.  
 
Final classifications were reviewed by Dr Brian Rous (consultant pathologist at the NCRAS) 
who agreed with my assignments.  
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In this thesis when referring to cancers other than ovarian I use the term ‘non-ovarian cancer’. 
Where I discuss the combined non-ovarian and ovarian cancer groups I use the term ‘all 
cancers’. 
 
3.3.7 Sub-analysis: Invasive ovarian cancer  
The definition of ovarian cancer in this thesis included both borderline and invasive tumours. 
As discussed in Chapter 1, Borderline tumours are treated collectively with invasive tumours 
in NICE recommendations on CA125 testing,57 are staged using the same systems (FIGO or 
TNM), require surgical management and can relapse.204 Although their timely detection in 
symptomatic women is important, their prognosis is good even if detected late, in contrast to 
invasive ovarian cancers.204 To explore how the diagnostic accuracy of CA125 would differ if 
borderline tumours were not considered, I performed a sub-analysis in which invasive ovarian 
cancer formed the outcome. 
 
3.3.8 Descriptive outcome: ovarian morphology 
The morphology of ovarian cancers diagnosed within the cohort was identified from NCRAS 
data (Section 2.8.5) and described by age group (<50 years and ≥50 years).  
 
3.3.9 Statistical analyses 
I applied two distinct methodological approaches to analyse data in this study. First, I 
calculated conventional measures of CA125 diagnostic accuracy for a prespecified threshold. 
Second, I treated CA125 as a continuous variable, explored the estimated probability of 
cancer at specific CA125 levels and identified CA125 levels equating to a 3% probability of 
cancer. I describe each approach separately. 
 
Diagnostic accuracy for a prespecified cut-off  
I used the DIAGT program within Stata to calculate the following CA125 diagnostic test 
accuracy metrics, and associated 95% CI,205 applying the ≥35 U/ml cut-off: 
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• Sensitivity: True positives / (true positive + false negatives) 
• Specificity: True negatives / (true negatives + false positives) 
• Positive Predictive Value (PPV): True positives / (True positives + false positives) 
• Negative Predictive Value (NPV): True negatives / (False negatives + true negatives) 
 
These metrics were calculated for: 
• Ovarian cancer  
• Invasive ovarian cancer 
• All cancers  
 
And, after excluding patients with ovarian cancer: 
• Non-ovarian cancer 
 
All analyses were repeated by age group (<50 and ≥50 years). 
 
In Chapter 2, I described how CA125 entries associated with a) no, or incorrect, units and b) 
no, or incorrect upper, reference ranges, were dropped during baseline cohort preparation. 
To examine whether these decisions had an impact on my results, I performed sensitivity 
analyses, re-calculating the diagnostic accuracy of CA125 for ovarian cancer when these 
CA125 entries were not dropped. 
 
Area under the receiver operator characteristic curve (AUC) 
I used the roctab command in Stata,206 to calculate the AUC of CA125 for each outcome and 
repeated this by age group. AUC is a measure of test discrimination i.e. the ability of a test to 
distinguish those with a condition from those without a condition.207 AUC is calculated after 
constructing a receiver operator characteristic (ROC) curve, in which the sensitivity of a test 
is plotted (on the y-axis) against 1-specificty of a test (on the x-axis) at all test values (i.e. all 
potential cut-offs). The AUC therefore gives an indication of overall test performance rather 
than test performance at a particular threshold of interest. A test with no discrimination 
ability would have an AUC of 0.5 while a test with perfect discrimination ability would have 
an AUC of 1.  
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Cancer probability by CA125 level 
I used logistic regression analysis to examine the relationship between log CA125, as a 
continuous variable, and ovarian cancer diagnosis.  
 
I explored the nature of the relationship between log CA125 level and ovarian cancer, by 
introducing polynomial terms into the regression model, and found it to be non-linear. To 
account for this, I used restricted cubic splines.†† In restricted cubic splines the range of the 
continuous variable is essentially divided into a series of segments or ‘splines’ (piecewise 
cubic polynomials). Adjacent splines must be continuous at specific points known as ‘knots’ 
but between these knots there is great flexibility in the shape which they can take. The splines 
are restricted to be linear in the upper and lower tails, which adds stability to the model. 
Figure 3.2 illustrates some of the key features of restricted cubic splines.  
 
 
Figure 3.2. Key features of restricted cubic splines. 
This image was not constructed using real data and is presented simply for purpose of 
illustration. 
 
When using restricted cubic splines, two choices must be made: what number of knots to use 
and where they should be placed. As recommended by Harrell,208 I compared the Akaike 
                                                        
†† Splines were used in the final models, rather than polynomial terms, following feedback from a statistical 
peer reviewer who recommended this approach.338 
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Information Criterion (AIC) for models containing three, four and five knots. The five-knot 
model produced the smallest AIC and so I chose to use it. I also followed Harrell’s advice on 
knot positioning, placing them at standard, equally spaced percentiles of the marginal 
distribution of the variable (Appendix D).208 I utilised the mkspline function within Stata to 
generate the restricted cubic splines for the regression model. I used this regression model to 
predict the odds of cancer for a range of CA125 levels (1-1000 U/ml), then converted these 
odds into probabilities, using Stata code provided by Prof Gary Abel. 
 
All these steps were repeated using a) invasive ovarian cancer and b) all cancers, as the 
outcome. 
 
Cancer probability by CA125 level and age 
I repeated the logistic regression analysis for the <50 years and ≥50 years groups. I then 
constructed a multivariable regression model including splines for age in years, and log CA125 
level, applying the same approach as described above. Five knots were included for each 
variable (Appendix D). This regression model was used to predict the odds of ovarian cancer 
for CA125 levels (1-1000 U/ml) in women of different ages. These odds were converted to 
probabilities for women aged 30, 40, 50, 60, 70 and 80 years of age.  
 
I considered including an interaction term in my analysis, to account for any interaction 
between log CA125 and age. However, this term was not significant in an initial logistic 
regression model and so was not included in the final model. 
 
These steps were repeated using a) invasive ovarian cancer and b) all cancers, as the outcome. 
 
3.4 Results 
3.4.1 Study cohort 
The final study cohort consisted of 50,780 women. The selection of this cohort is described in 
detail in Chapter 2 (summarised in Figure 2.1). 
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3.4.2 Age and CA125 distributions 
The mean patient age within the cohort at index test date was 56 years (range: 18-102 years). 
The age distribution of the cohort is illustrated in Figure 3.3. 
 
 
Figure 3.3. Histogram illustrating the age profile of the study cohort. 
 
19,694 (38.8%) women were aged <50 years and 31,086 (61.2%) women were aged ≥50 years 
(Table 3.2).  
 
CA125 levels ranged from 1 U/ml - 32,470 U/ml, with a median value of 12 U/ml, (interquartile 
range [IQR]: 8-18). The median value in women aged <50 years was 13 U/ml (IQR: 9-20 U/ml) 
and in women ≥50 years 11 U/ml (IQR: 8-17 U/ml). 3,468 (6.8%) had an index CA125 level ≥35 
U/ml (Table 3.2). The proportion of women with CA125 levels ≥35 U/ml was slightly higher in 




Table 3.2. Patient numbers, incidence of raised CA125 tests (≥35 U/ml) and cancer 
incidence by age group. 
 <50 years >50 years Overall cohort 
Number of patients, N 19,694 31,086 50,780 



















3.4.3 Cancer incidence 
456 (0.9%) women were diagnosed with ovarian cancer in the year following the index test 
date (Table 3.2). The incidence of ovarian cancer was three times higher in the ≥50 years 
group (1.2%) than ≤50 years group (0.4%). In those not diagnosed with ovarian cancer 
(n=50,324), 1,321 (2.6%) women were diagnosed with another type of cancer in the 12 
months following the index test. 
 
3.4.4 Ovarian cancer morphology 
Of the ovarian cancers diagnosed, 98 (21.5%) were borderline tumours. The proportion of 
malignancies which were borderline varied by age, with 50% of tumours in the <50 years 
group and 15.4% in the ≥50 years group being of borderline malignancy (Table 3.3). Serous 
epithelial tumours were the most common tumour type, accounting for 48.6% of invasive 
tumours; 42.5% in the <50 years group and 71.7% the ≥50 year. 15% of invasive tumours in 
the <50 years group were of mucinous epithelial origin and 12.5% were of non-epithelial 




Table 3.3. Behaviour and histology of ovarian tumours by age group (<50 years and ≥50 
years). 
Behaviour and 






























Non-epithelial 5 8 13 
Unknown 2 20 22 
Borderline  
Borderline 40 58 98 
Total 80 376 456 
 
3.4.5 Diagnostic accuracy 
In this section I present the diagnostic accuracy metrics for ovarian cancer, invasive ovarian 
cancer and all cancers for the conventional CA125 cut-off (≥35 U/ml). The AUC of CA125 for 
each outcome in different age groups is also presented. 
 
Ovarian cancer 
The diagnostic performance characteristics of CA125, calculated after applying the standard 
cut-off (≥35 U/ml), are summarised in Table 3.4. At or above the 35 U/ml cut-off, CA125 
demonstrated a PPV of 10.1% (95% CI: 9.1-11.2), an NPV of 99.8% (95% CI: 99.7-99.8), a 
sensitivity of 77.0% (95% CI: 72.8-80.8%) and a specificity of 93.8% (95% CI: 93.6-94.0) for 
ovarian cancer. The PPV, sensitivity and specificity were all higher for the ≥50 group than the 
<50 years group. When the outcome was restricted to invasive ovarian cancers, CA125 
demonstrated a slightly lower PPV (8.8%, 95% CI: 7.8-9.8), and a higher sensitivity (84.9%, 
95% CI: 80.8-88.5). The PPV, sensitivity and specificity of CA125 were all higher for invasive 
tumours in the ≥50 group than the <50 years group. 
 
Overall, CA125 had an AUC of 0.92 for ovarian cancer. This was higher in the ≥50 years group 
(0.93) than the <50 years group (0.86). A similar pattern was seen when the outcome was 
restricted to invasive ovarian cancer (Table 3.4). 
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Sensitivity analyses 
In a sensitivity analysis in which CA125 entries were not dropped due to incorrect or 
unrecorded units during baseline cohort preparation (Section 2.8.1), the PPV (10.2%, 95% CI: 
9.2-11.3), NPV (99.8%, 95% CI: 99.7-99.8), specificity (93.8%, 95% CI: 93.6-94.0) and sensitivity 
(77.0%, 95% CI: 72.9-80.7) were similar to those for the main cohort. In a sensitivity analysis 
in which CA125 entries were not dropped due to erroneous or unrecorded upper thresholds, 
the PPV (10.1%, 95% CI: 9.1-11.1), NPV (99.8%, 95% CI: 99.7-99.8), specificity (93.7%, 95% CI: 
93.5-93.9) and sensitivity (77.5%, 95% CI: 73.5-81.2) were again similar to values for the 
baseline cohort.  
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Table 3.4. Measures of CA125 diagnostic accuracy for ovarian cancer, invasive ovarian 
























































































































































PPV, NPV, sensitivity and specificity are calculated for a cut-off of ≥35 U/ml. Accuracy 
characteristics for ‘non-ovarian’ cancer were calculated following exclusion of patients with 
ovarian cancer.  
 
All cancers 
Applying the ≥35 U/ml cut-off, the PPV of CA125 for all cancers combined was 21.2% (95% 
CI:19.8-22.6). This varied markedly by age, with a PPV of 6.1% (95% CI: 4.9-7.4) in the <50 
years group and 32.5% (95% CI: 30.4-34.6) in the ≥50 years group (Table 3.4). The overall 
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specificity of CA125 for all cancers was slightly higher than for ovarian cancer but the 
sensitivity of the test was much lower (41.4%, 95% CI: 39.1-43.7). 
 
Overall, CA125 had an AUC of 0.74 for all cancers. This was higher in the ≥50 years group 
(0.76) than the <50 years group (0.70). 
 
Non-ovarian cancer 
The incidence of non-ovarian cancers in those women without ovarian cancer (n=50,324) who 
had a CA125 <35 U/ml (n=42,207) was 2.0%, while the incidence in women with a CA125 ≥35 
U/ml, which equates to the PPV for non-ovarian cancers, was 12.3% (95% CI: 11.2-13.5). This 
varied dramatically between the <50 years group (PPV: 2.8%, 95% CI: 2.0-3.8) and ≥50 years 
group (PPV: 20.4%, 95% CI: 18.5-22.4) (Table 3.4). While the overall specificity of the test for 
non-ovarian cancers was high (94.4%, 95% CI: 94.2-94.5%), the sensitivity was very low 
(29.1%, 95% CI: 26.6-31.6). 
 
Figure 3.4 compares the incidence of non-ovarian cancer types between the <35 U/ml and 
≥35 U/ml groups, after exclusion of women with ovarian cancer. All cancer types occurred 
more frequently in the ≥35 U/ml group than the <35 U/ml group. Pancreatic cancer was 15 
times, lung cancer 13 times, uterine cancer nine times, upper GI cancer six times and lower 
GI cancer four times more common in the ≥35 U/ml group than the <35 U/ml group. A similar 
(small) proportion of women in each group were diagnosed with breast cancer (CA125 <35 





Figure 3.4. Percentages of women with non-ovarian cancer types in each CA125 group: <35 U/ml (n=47,207) and ≥35 U/ml (n=3,117). 
Women with ovarian cancer (n=456) were excluded. GI = gastrointestinal.
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The non-ovarian tumour categories most frequently associated with CA125 levels ≥35 U/ml 
are shown in Table 3.5. Although the proportion of women with non-ovarian cancers who 
had CA125 levels ≥35 U/ml was 29.1% overall, this varied by cancer type. 43 women in the 
cohort had a cancer of unknown primary, and a greater proportion of these women had a 
CA125 level ≥35 U/ml (83%), than for any other cancer type (including ovarian cancer). 93 
women were diagnosed with pancreatic cancer and 104 with lung cancer, almost half of 
whom had CA125 levels ≥35 U/ml. For the two most common categories of non-ovarian 
cancer - lower GI (n=255) and breast (n=154) - the proportion of women with CA125 levels 
≥35 U/ml was much lower, at 23% and 8% respectively.  
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*Cancers with fewer than ten cases with CA125 values ≥35 U/ml. 
 
3.4.6 Cancer probability analyses 
In this section I present the cancer probabilities derived following logistic regression analyses. 
As the 3% cancer probability is of primary interest in this study, figures in the main text 
illustrate probabilities close to this threshold. Figures showing the probability for each 
outcome at an extended range of CA125 levels (1-500 U/ml) are included in Appendix E. All 
estimated probabilities for ovarian cancer, invasive ovarian cancer and all cancers calculated 
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during this study (for CA125 levels 1-1000 U/ml) have been made freely available via the 
University of Cambridge Repository.209  
 
Cancer probability by CA125 level 
Figure 3.5 illustrates how the estimated probability of ovarian cancer, invasive ovarian cancer 
and all cancers increased with increasing CA125 level. A CA125 level of 53 U/ml equated to a 
probability of 3% (95% CI: 2.6-3.5) for ovarian cancer while a CA125 level of 18 U/ml equated 
to a probability of 3% (95% CI:2.8-3.2) for all cancers. In a sub-analysis in which invasive 
ovarian cancer formed the outcome, a CA125 level of 68 U/ml equated to a 3% (95% CI: 2.6-
3.5) cancer probability.  
 
Much greater estimated cancer probabilities were noted at higher CA125 levels. For example, 
at a CA125 level of 500 U/ml the estimated probability of ovarian cancer was 31.6% (95% CI: 
28.1-35.2) and all cancers, 60.6% (95% CI: 56.9-64.3) (Appendix E).  
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Figure 3.5. Relationship between CA125 level and estimated probability of ovarian cancer, invasive ovarian cancer and all cancers. 
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Cancer probability by CA125 level and age group 
Figure 3.6 shows the probability of ovarian cancer derived by repeating the logistic regression 
analysis by age group (<50 years and ≥50 years). This analysis revealed that the 3% ovarian 
cancer probability threshold was reached at a much lower CA125 level in the ≥50 years group 
(39 U/ml) than <50 years group (89 U/ml). At equivalent CA125 levels, the estimated 
probability of ovarian cancer was always greater in women aged ≥50 years than those <50 
years.  
 
A similar pattern was seen when analysis was repeated by age group for invasive ovarian 
cancer and all cancers (Appendix E). For all cancers, a CA125 of 47 U/ml in women under 50 
years and 14 U/ml in women ≥50 years equated to a 3% probability. 
 
 
Figure 3.6. Relationship between CA125 level and estimated probability of ovarian cancer 
in women <50 years and ≥50 years of age. 
 
Cancer probability by CA125 level and age in years 
Figure 3.7 illustrates the relationship between CA125 level and the estimated probability of 
ovarian cancer at the specific ages (30, 40, 50, 60, 70 and 80 years), derived from a logistic 
regression in which splines for both CA125 and age in years were included. The CA125 level 
equating to an estimated 3% ovarian cancer probability was 60 U/ml at age 30, increasing to 
104 U/ml at age 40 before falling through ages 50 and 60 to a low of 32 U/ml at age 70. This 
figure rose to 43 U/ml at age 80.  
 
<50 years ≥50 years 
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Similar age trends were noted when the analysis was repeated for invasive ovarian cancer 
and all cancers (Appendix E). For all cancers, a CA125 of 50 U/ml equated to a 3% estimated 
cancer probability at age 40, while the 3% threshold was reached at a CA125 level of only 7 
U/ml at age 70 and 80. 
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Figure 3.7. Relationship between CA125 level and estimated probability of ovarian cancer for women at age 30, 40, 50, 60, 70 and 80.  
CA125 levels which correspond to the closest integer probabilities of 3% are indicated in red. 95% confidence intervals are displayed in grey. 




3.5.1 Summary of key findings 
In this cohort study of 50,780 women who had a CA125 test performed in English general 
practice, 10.1% of those with a CA125 level at or above the conventional cut-off (35 U/ml) 
were diagnosed with ovarian cancer and 12.3% were diagnosed with a different type of 
cancer. Just under a third of women aged ≥50 years with a CA125 ≥35 U/ml were diagnosed 
with some form of cancer. A CA125 level of 53 U/ml equated to an overall ovarian cancer 
probability of 3%. However, there was marked variation between women of different ages 
with the 3% probability of ovarian cancer reached at lower CA125 levels in 70-year-old 
women than in younger or older women. Key findings are summarised against study 
objectives in Box 3.1. 
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Box 3.1. Key study findings against objectives. 
  
i) To evaluate the diagnostic accuracy of CA125 for a) ovarian cancer, b) non-ovarian 
cancers and c) all cancers combined, when used in English primary care. 
o At the conventional cut-off (≥35 U/ml), CA125 had a: 
§ PPV of 10.1% for ovarian cancer and 21.2% for all cancers  
§ PPV of 12.3% for non-ovarian cancer (following exclusion of ovarian 
cancer) 
§ Sensitivity of 77% for ovarian cancers, 41.4% for all cancers and 29.1% 
for non-ovarian cancer 
§ High specificity: 93.8% for ovarian cancer, 94.4% for all cancers and 
94.4% for non-ovarian cancer 
ii) To explore variations in the diagnostic accuracy of CA125 by patient age 
o CA125 exhibited superior PPV, sensitivity and specific in women aged ≥50 
than <50 
o 15.2% of women ≥50 years with a raised CA125 level had ovarian cancer 
o 20.4% of women ≥50 years with a raised CA125 level who did not have 
ovarian cancer had another type of cancer 
iii) To explore the association between CA125 level and estimated probability of a) 
ovarian cancer and b) all cancers combined, in women undergoing CA125 testing 
in English primary care 
o The estimated probability of cancer rose with CA125 level, reaching 31.6% 
for ovarian cancer and 60.6% for all cancers at 500 U/ml 
o The estimated probabilities at each CA125 level (1-1000 U/ml) were 
calculated and made freely available 
iv) To identify the CA125 level at which a 3% probability of a) ovarian cancer and b) 
all cancers combined was reached in women undergoing CA125 testing in English 
primary care 
o A CA125 level of 53 U/ml equated to a 3% estimated probability of ovarian 
cancer 
o A CA125 level of 18 U/ml equated to a 3% estimated probability of all 
cancers 
v) To explore variations in estimated cancer probability by age and determine the 
CA125 level at which a 3% probability of a) ovarian cancer and b) all cancers 
combined is reached in different ages 
o Cancer probabilities varied markedly by age e.g. 3% probability of ovarian 
cancer was reached at: 
§ Age 40: 104 U/ml 
§ Age 70: 32 U/ml 
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3.5.2 Study limitations 
I developed a simple model (based on CA125 level) and a multivariable model (based on 
CA125 level and age) in order to estimate the probability of cancer. Whilst a large cohort of 
women was selected from a data source which has wide national coverage and is generally 
representative of the population in England (the CPRD), the models were not validated. 
Ideally, the models should now undergo external validation in a separate data set to ensure 
reproducibility and generalisability before they are used in clinical practice.  
 
I employed restricted cubic splines to model the non-linear nature of the relationship 
between both age and CA125 level and cancer diagnoses. These provide a highly flexible 
approach to parametrising the fitted relationships. However, there is a large degree of 
uncertainty at the extremes of age and CA125 level, and so the cancer probabilities for very 
old and young women and those with very low CA125 levels should be treated with caution 
and interpreted within the context of the wide confidence intervals.  
 
The results of this study reflect real world use of CA125 in English primary care. International 
guidelines on CA125 testing vary, and how CA125 is used in primary care in other countries is 
likely to differ from practice in England.116 Baseline CA125 levels can be affected by 
population characteristics, such as ethnicity,210 which also vary from country to country. 
Therefore, some caution is needed when translating the study findings to other countries and 
healthcare systems. If the models developed in this study are to be used in a country with a 
markedly different healthcare system or population demographics, they should ideally be 
validated using data from that country.  
 
Previous studies have shown that CA125 has a lower sensitivity for the detection of early 
stage ovarian cancer than late stage ovarian cancer.119 Ovarian cancer staging data was 
contained within my dataset, but I took the decision not to calculate diagnostic accuracy 
metrics or cancer probabilities by stage. This was because the 12-month follow-up period 
used in this study provides ample time for cancers which are not immediately referred and 
diagnosed to progress from early to late stage. Therefore, any stage specific diagnostic 
accuracy metrics calculated from this study are likely to be misleading.  
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Given the nature of the data used in this study, it was not possible to ascertain with certainty 
why CA125 tests were requested, and I chose not to restrict the cohort based on symptom 
codes, as discussed in Section 3.3.2. Some symptoms are more strongly predictive of ovarian 
cancer than others,91 therefore the probability of cancer may vary based on the reason for 
testing e.g. fatigue vs pelvic mass. Other patient factors may also influence the probability of 
cancer. However, rather than developing a comprehensive diagnostic prediction model, this 
study sought to explore variation in the probability of cancer based on CA125 level in women 
of different ages in order to inform clinical practice. In Chapter 6, I build on this work to 
develop a much more comprehensive multivariable prediction model.  
 
3.5.3 Comparison with existing literature 
Ovarian cancer 
When producing CG122 in 2011, NICE estimated, on the basis of the most relevant data 
available at the time, that 0.81% of symptomatic women in primary care with a CA125 ≥35 
U/ml would have ovarian cancer.114 Economic modelling and the recommendation for 
sequential testing with CA125 followed by ultrasound if the CA125 result were abnormal, was 
predicated on this estimate. The research presented in this chapter indicates that the PPV is 
more than twelve times higher than estimated by NICE. This finding is consistent with the only 
other UK report of the PPV of CA125 in primary care, which found that 16 out of 152 women 
(11%) with a raised CA125 level had ovarian cancer.156 To estimate the PPV, NICE used 
diagnostic accuracy data from secondary care studies and, based on primary care research, 
assumed a prevalence of ovarian cancer in patients presenting with relevant symptoms of 
0.23%.114  However, GPs do not test all women presenting with symptoms such as abdominal 
pain or bloating for CA125; frequently there is an obvious (non-ovarian) cause for these 
symptoms. Previous research has shown that women selected for blood tests within primary 
care have a greater probability of having cancer than matched controls not selected for blood 
tests.175 So, it is not surprising that, in this study, the prevalence of ovarian cancer in CA125-
tested women was four times higher than the figure used by NICE in their PPV estimates. This 
highlights the importance of evaluating the performance of tests as they are used in a given 
setting and population whenever possible, rather than relying on extrapolated data.  
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The sensitivity of CA125 for ovarian cancer in this study was slightly lower – and the specificity 
was higher – than in published secondary care studies where testing was performed in 
women with a pelvic mass prior to surgery.125 This was expected as tests generally have lower 
sensitivity and higher specificity in populations with a lower disease prevalence – the 
spectrum effect (Chapter 1).157 As anticipated, the PPVs for ovarian cancer in my cohort were 
lower than in secondary care patients with pelvic masses (in whom the prevalence of ovarian 
cancer is relatively high),119 and higher than in asymptomatic screening populations (in whom 
the prevalence of ovarian cancer is relatively low).152  
 
This study found that the estimated probability of ovarian cancer for a given CA125 level rose 
with age to peak in women in their 70’s, which mirrors UK age-specific cancer incidence 
rates.5 The exception to this trend was very young women; the probability of ovarian cancer 
at a given CA125 level was higher in women aged 30 than aged 40. This may reflect GP testing 
practices in very young women (in whom ovarian cancer is extremely rare), with GPs having 
a strong rationale for requesting a CA125 test, thereby raising the pre-test probability.  
 
Non-ovarian cancer 
I believe that the most striking finding from this study was the high incidence of non-ovarian 
cancer in women with elevated CA125 levels, particularly those aged 50 years or more. This 
reflects the non-specific nature of ovarian cancer symptoms, and also that CA125 is frequently 
raised in women with a variety of non-ovarian malignancies.120 The only comparable primary 
care study, by Crawford et al, reported that 16 out of 152 women (11%) referred from primary 
care with a raised CA125 were diagnosed with a non-ovarian cancer.156 Even in asymptomatic 
screening populations, where symptom overlap does not play a role, a higher incidence of 
non-ovarian cancers has been noted in women with raised CA125 levels (6.9%) than women 
with normal CA125 levels (1.6%).211  
 
My decision to include non-ovarian cancers in this study was based on reports within the 
literature that elevations in CA125 can occur in specific types of non-ovarian cancer. While a 
systematic review of the diagnostic accuracy of CA125 for non-ovarian cancers was beyond 
the scope of this thesis, some comparison with published literature is warranted. Table 3.6 
compares the sensitivity of CA125 in this study for common CA125-elevating non-ovarian 
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cancers, with values obtained from the literature. The sensitivity of CA125 for pancreatic and 
endometrial/uterine cancer are similar between this study and several previous studies, while 
the sensitivity in this study is higher for lung cancer and lower for breast cancer than 
previously reported. These differences may be due to variations in case mix and cancer stage 
between studies.  
 
Table 3.6. Comparison of the sensitivity of CA125 (≥35 U/ml cut-off) for a variety of non-
ovarian cancers: current study vs the published literature 
 Sensitivity (%) 
Cancer type Current study Published studies 
Pancreatic 49 45 - 61126–128 
Lung 47 29 - 30119,129 
Endometrial/uterine 36 21 - 35130,131 
Breast 8 14 - 18119,142 
 
3.5.4 Clinical relevance of findings 
Testing in younger women 
39% of CA125 tests were performed in women <50 years of age. However, ovarian cancer is 
predominantly a disease of older and postmenopausal women. This is reflected in the study 
findings, as only 18% of ovarian cancers and 11% of invasive ovarian cancers occurred in 
women <50 years of age. All measures of test performance (save for NPV) were worse in 
women <50 years than ≥50 years. This was still the case when borderline tumours, which 
were more common in the younger age group and have less of a propensity to elevate CA125 
levels, were excluded. A greater proportion of invasive tumours in the <50 years group were 
mucinous epithelial and non-epithelial cancers, both of which have less propensity to elevate 
CA125 than serous epithelial cancer.119,124 Coupled with lower disease incidence and higher 
baseline CA125 levels, this likely contributed to poorer test performance in younger women.  
 
The results of regression analysis presented in this chapter indicate that, overall, only 1 in 110 
women <50 years with a CA125 of exactly 35 U/ml will have an ovarian cancer and only 1 in 
308 will have an invasive ovarian sub-type. Investigating younger women for ovarian cancer 
when there is a strong clinical suspicion is important, but given the low incidence of ovarian 
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cancer and relatively poor test performance in women under 50 years, I believe that CA125 
tests should be performed and interpreted with caution in this group.  
 
Non-ovarian cancers 
The numbers of women in the study cohort with a raised CA125 level who were diagnosed 
with each particular type of non-ovarian cancer was small, and the test sensitivity for most of 
these cancers was modest. In isolation, CA125 is unlikely to be a useful test for the detection 
of individual types of non-ovarian cancer in primary care. However, when considered 
collectively, the total number of non-ovarian cancers diagnosed in women with raised CA125 
levels actually exceeded that of ovarian cancers and, in women ≥50 years of age, a fifth of 
those with a raised CA125 who did not have ovarian cancer had another cancer type. Given 
this finding, a high CA125 level in a woman in primary care, especially if aged ≥50 years, should 
raise a suspicion of non-ovarian cancer. Clinicians should consider these cancers and whether 
further investigation is needed, particularly if ovarian cancer has been excluded.  
 
Cancer probabilities 
The PPV, which is often interpreted as the probability of a disease in patients with a positive 
test result, was calculated in this study for the conventional CA125 cut-off. Not unexpectedly, 
the regression analyses revealed that women with very high CA125 values had a very high 
estimated probability of being diagnosed with cancer. Conversely, those with CA125 levels 
around the conventional 35 U/ml cut-off had a much lower probability of being diagnosed 
with cancer than might be expected from the PPV. In this study I have quantified the risk of 
cancer in individuals with specific CA125 values at specific ages. This should be of more use 
clinically than the PPV.  
 
The estimated cancer probabilities should allow women and clinicians to interpret their 
individual CA125 test result and could inform health policy. For example, NICE currently 
recommends that women with a CA125 ≥35 U/ml, whether 35 U/ml or 350 U/ml, should be 
referred for an ultrasound scan, while no further investigations for ovarian cancer are 
advocated in women with levels below the cut-off. This means that some younger women 
with very low probabilities of ovarian cancer meet referral criteria, while some older women 
with estimated ovarian cancer probabilities in excess of 3% do not. Instead of using a single 
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35 U/ml cut-off, the results of this study could be applied to triage women of different ages, 
selecting those with a high estimated probability of ovarian cancer for expedited referral and 
investigation. Women with lower probabilities might, after discussion between clinician and 
patient, be investigated using routine ultrasound, recognising the fact that patients would opt 
for cancer testing at risk levels as low as 1%.200 Only a woman’s age and CA125 level are 
required to determine the cancer probability, so this information could readily be 
incorporated into laboratory IT systems, reported alongside the CA125 level and 
communicated to patients in clear terms e.g. “1 in 20 women of your age who have the same 
CA125 level in general practice will have ovarian cancer”. The implications of using different 
thresholds in clinical practice is considered further in Chapter 6 and potential approaches to 
integrate CA125 based models within the ovarian cancer diagnostic pathway are considered 
further in Chapter 7. 
 
3.5.5 Conclusions 
CA125 is a useful test for ovarian cancer detection in primary care, particularly in women aged 
50 years or more. This study has revealed that there is a high incidence of non-ovarian cancers 
in women with elevated CA125 levels in primary care. Given this, clinicians should consider 
alternative cancers when confronted with a patient with an elevated CA125, particularly if 
ovarian cancer has been excluded.  
 
The results of this study will enable patients and clinicians to interpret their individual CA125 
result in terms of the probability of cancer at the pertinent CA125 level and age, which should 
aid informed decision making. The findings will also enable policy makers to provide 
recommendations for post-CA125 investigations on the basis of the probability of 
undiagnosed cancer. This could facilitate the expedited investigation and referral of those 
women most likely to have the disease while providing reassurance for women who are 
unlikely to have cancer. 
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Chapter 4. Associations between primary 
care CA125 test result with test-to-diagnosis 




In the research described in Chapter 3 I found that, in English primary care, CA125 had a 
sensitivity of 77% for ovarian cancer at the conventional ≥35 U/ml cut-off. This indicates that, 
as it is currently used, the test ‘misses’ 23% of cases. NICE guidelines do not provide specific 
recommendations regarding the follow-up or further investigation of women with CA125 
levels <35 U/ml.57 Some clinicians have expressed concerns that using CA125 as the sole first 
line test for ovarian cancer could result in delayed diagnosis and worse outcomes in women 
with ovarian cancers not associated with high CA125.212 CA125 levels are less commonly 
elevated in early stage than late stage disease, so their main concern is that delay in diagnosis 
and treatment will provide time for early stage (usually curable) cancers to progress to late 
stage (usually incurable) cancers. 
 
In this exploratory study, I set out to determine whether having a normal (false negative), 
rather than an abnormal (true positive), pre-diagnostic CA125 test was associated with a 
longer time between testing and diagnosis. In addition, I sought to examine the association 
between CA125 test result and stage at diagnosis. As sub-types of ovarian cancer vary both 
in their propensity to elevate CA125 level and in their aggressiveness, I also wished to 
compare tumour type between women with normal and abnormal CA125 levels. Through 
these analyses, I addressed the following thesis objective: 
 
vi. To examine the association of pre-diagnostic primary care CA125 result with time 
between testing and diagnosis, tumour morphology and disease stage in ovarian 
cancer. 
 
A paper, based on the work within this chapter, was recently published in the British Journal 
of General Practice (Appendix A): 
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CA125 test result, test-to-diagnosis interval and stage in ovarian cancer at diagnosis: a cohort 
study using electronic health records. Garth Funston, Luke TA Mounce, Sarah Price, Brian Rous, 




4.2.1 Study design and participants 
This study followed a retrospective cohort design using data from the CPRD, the NCRAS and 
the Small Area Levels dataset. The study cohort consisted of women, identified from the 
thesis baseline cohort (Chapter 2), who had a diagnosis of ovarian cancer (as recorded within 
NCRAS data) in the 12 months following their initial CA125 test. Essentially, the cohort 
consisted of women who had the primary clinical outcome (ovarian cancer) in Chapter 3. 
 
4.2.2 Explanatory variables 
The principal explanatory variable of interest in this study was the CA125 test result. I also 
wished to control my analyses for key baseline patient characteristics, which might also be 
related to the study outcomes. In this section, I describe the explanatory variables and their 
preparation. 
 
CA125 test result 
In this study, I was primarily interested in exploring associations between false negative / true 
positive CA125 test results and patient outcomes. I therefore used the index CA125 level and 
applied the conventional ≥35 U/ml cut-off, categorising women into two groups: CA125-
normal (<35 U/ml) and CA125-abnormal (≥35 U/ml). 
 
Although this thesis does not focus on the utility of serial CA125 tests, it is possible that 
retesting might be useful in some circumstances e.g. borderline CA125 levels or persistent 
symptoms.55 Some international guidelines recommend retesting in certain circumstances. 
For example, in Ireland, interval CA125 retesting is recommended in primary care after 6 
weeks if an ultrasound, performed due to a high CA125 level, does not show evidence of 
cancer.107 I identified women in my cohort who had a repeat CA125 test performed (after the 
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CA125 levels vary with age, and published research indicates that there is an association 
between older age and longer primary care intervals in ovarian cancer.213 Given this, I felt that 
it was important to account for age within my analyses. Age in years, determined during 
baseline cohort preparation (Chapter 2), was identified for each patient included in this study. 
 
Symptom coding 
As discussed in Chapters 2 and 3, symptoms are not always coded in primary care records 
prior to a cancer diagnosis, and coding may occur when they are more concerning, severe or 
persistent. Given this, I postulated that the coding of symptoms might be associated with 
expedited referral and diagnosis and decided to include coding / lack of coding as a co-
variable in this study. A pre-developed list of Read codes, which maps to symptoms included 
in current NICE guidelines, was provided by Professor Willie Hamilton.82 From this list, I 
selected codes for symptoms of ovarian cancer in current NICE guidelines: abdominal / pelvic 
pain, abdominal distension / bloating, change in bowel habit, fatigue, weight loss, urinary 
frequency / urgency, loss of appetite, pelvic mass or ascites (Appendix C). I used these to 
identify women with a relevant symptom code in the 30 days before CA125 testing. 30 days 
was chosen as I was interested in symptoms related to CA125 testing - a month seemed a 
sufficient period to allow a CA125 test, requested in response to a given coded symptom, to 
be performed. I generated a two-category variable: “no symptom code recorded” and 
“symptom code recorded”. 
 
Deprivation 
Research has demonstrated an association between higher deprivation and late stage 
diagnosis in ovarian cancer.214 I chose to account for deprivation in my analyses. As discussed 
in Chapter 2, the Small Area Levels data within my linked dataset provided a Townsend score 
for each patient. This score was included as a five-level variable in my analyses. 
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4.2.3 Outcome variables 
I was interested in determining which types of ovarian cancers occurred in women with 
normal and abnormal index CA125 tests and in examining associations between CA125 test 
result and a) time between testing and diagnosis and b) stage at diagnosis. In this section, I 
describe the preparation of tumour morphology and the outcome variables. 
 
Test-diagnostic interval 
I calculated the number of days from the index test date to the date of diagnosis for each 




The preparation of tumour morphology data is described in detail in Chapter 2 and the 
morphology of cancers is presented by age group in Chapter 3. The greatest difference in 
behaviour and prognosis in ovarian cancer lies between borderline tumours and invasive 
tumours, so I first split cancers into these two groups. The distinction between invasive 
epithelial (usually aggressive) and non-epithelial (frequently indolent) tumours was also 
important. So, Invasive tumours were further categorised as ‘epithelial’, ‘non-epithelial’ or, 
when ICD-O codes were non-specific, as Invasive Not Otherwise Specified (NOS). This gave 
four categories: 
• Borderline 
• Invasive epithelial 
• Invasive non-epithelial 
• Invasive NOS 
 
Where possible, I also identified details of the histology of invasive epithelial tumours (e.g. 
clear cell and serous), and describe these within this chapter. 
 
Tumour stage 
The determination of cancer stage from NCRAS data is described in detail in Chapter 2. Where 
it is recorded, stage is categorised within NCRAS data as I, II, III or IV. The largest difference in 
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cancer outcomes in ovarian cancer exists between stage II and III, with 5-year net survival 
falling from 68% in stage II to 27% in stage III.16 Due to this, stage I and II ovarian cancer are 
often regarded as “early stage” and stage III and IV as “late stage” in ovarian cancer 
research.91,215,216 I adopted this approach for my analysis. 
 
4.2.4 Statistical analysis 
Different methods were required to compare tumour morphology between women with 
normal and abnormal CA125 test results, to examine the association between CA125 test 
result and length of test-diagnosis interval, and to examine the association between CA125 




A variety of different statistical approaches can be used to examine associations between 
variables and the length of pre-diagnostic intervals in cancer. Studies have employed linear 
regression,217 quantile regression,218 and survival models,219,220 amongst others. Accelerated 
Failure Time (AFT) models are a form of parametric model for survival or ‘time to event’ 
analysis. They have previously been used in CPRD diagnostic interval research.220 In AFT 
models, covariates act to accelerate or decelerate the time to an event (the ‘failure’). Time 
Ratios (TR’s) can be calculated, with a TR >1 indicating that a variable is associated with a 
prolonged time to an event and a TR <1 indicating that a variable is associated with an earlier 
event. For example, a TR of 1.5 indicates that a variable is associated with a 50% longer time 
to event than the comparator. I chose to use AFT models for my test-diagnosis interval 
analysis, in part because the interpretation of TRs is so simple and intuitive. 
 
I used the streg package within Stata to perform AFT model analyses to examine the 
association between variables and test-diagnosis interval.221 I first performed univariate 
analyses for each of the variables: CA125 test result (abnormal or normal), age in years 
(continuous variable), coded symptom (presence or absence) and Townsend score (five-
level). I then constructed a multivariable model which included all of these variables. The 
Wald test (testparm command in Stata) was used to assess the significance of the categorical 
Townsend score within the model.222 
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As AFT models are parametric, they assume a particular probability distribution in the data. 
Stata supports exponential, Weibull, log-normal, log-logistic and generalised gamma 
distributions when using AFT models.221 I performed analyses applying each of these 
distributions in turn. I then calculated and compared the AIC of the models. The log-logistic 
distribution provided the best-fit parameterisation (lowest AIC) and so I took it forward. 
 




First, I described the numbers and proportions of women with each type of ovarian cancer 
morphology by CA125 group. I used the two-tailed Fischer’s exact test to determine whether 
women with normal and abnormal CA125 levels differed significantly in their tumour 
morphology. Fischer’s exact test is similar to the Chi-square test, but is preferred when the 
counts in groups or categories are small.223 First, I ran the test with morphology classified into 
four categories (borderline, invasive epithelial, invasive non-epithelial, invasive NOS). I then 
re-ran the test with tumours classified into two groups: borderline and invasive (invasive 
epithelial, invasive non-epithelial and invasive NOS).  
 
Tumour stage 
Not all women with a diagnosis of ovarian cancer had a stage recorded in NCRAS data. 
Previous cancer studies have used different approaches to handle missing stage data, 
including treating all cancers with missing staging data as late stage (the ‘missing-is-late’ 
approach) or performing a ‘complete case’ analysis.224–226 A recent modelling study, which 
compared these two approaches against a ‘gold standard’ imputation approach (which 
utilised a range of variables, including survival time, to impute missing stage), reported that 
a complete case approach produced less biased results than a missing-is-late approach.225 I 
followed a complete case approach, only including women with complete staging data in my 
analyses of stage at diagnosis. In this subgroup, I used logistic regression analyses to examine 
associations between CA125 result and stage categorised as ‘early’ (I-II) or ‘late’ (III-IV). I first 
performed univariate analyses for each of CA125 test result, age, presence of a recorded 
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symptom and Townsend score, then constructed a multivariable model including all these 
variables. 
 
Given the more indolent course and favourable prognosis of borderline ovarian tumours, I 
excluded them and performed a sub-analysis for women with invasive ovarian tumours. 
 
In order to assess whether the CA125 test result was associated with missing stage, I ran 
logistic regression models in which CA125 test result was the independent variable and 
whether women had staging data ‘recorded’ vs ‘missing’ formed the binary dependant 
variable. 
 
I report crude and adjusted odds ratios (OR) with 95% confidence intervals and associated p-
values for all analyses. 
 
4.3 Results 
4.3.1 Cohort and baseline characteristics 
Of the 50,780 women within the baseline cohort, 456 had a diagnosis of ovarian cancer, 
recorded within NCRAS in the 12 months following the index CA125 test, and were included 
in this study. 105 women (23%) had a normal index CA125 test and 351 (77%) an abnormal 
index CA125 test (Figure 4.1). 
 
 
Figure 4.1. Identification of study cohort from baseline cohort. 
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Mean age was higher in women with an abnormal CA125 result (65 years) than a normal 
CA125 result (57 years). In addition, a greater proportion of women with an abnormal CA125 
result (60.4%) than a normal CA125 result (56.2%) had a coded symptom of possible ovarian 
cancer (Table 4.1). Townsend score was similar between those with normal and abnormal 
CA125 results. 
 
Table 4.1. Cohort baseline characteristics. 
 N Mean age at 
diagnosis 
[range] 
Patients with a symptom 
of possible ovarian cancer 
recorded pre-testing, N 
(%)* 







Level 1:    80 (22.8) 
Level 2:    100 (28.5) 
Level 3:    78 (22.2) 
Level 4:    61 (17.4) 
Level 5:    32 (9.1) 




Level 1:    24 (22.9) 
Level 2:    31 (29.5) 
Level 3:    25 (23.8) 
Level 4:    14 (13.3) 
Level 5:    11 (10.5) 




Level 1:    104 (22.8) 
Level 2:    131 (28.7) 
Level 3:    103 (22.6) 
Level 4:    75 (16.5) 
Level 5:    43 (9.4) 
*Percentage of each group with symptoms and Townsend score 
 
4.3.2 Repeat CA125 testing 
41 (9%) women had a repeat CA125 test performed prior to diagnosis. 30 women with an 
abnormal index CA125 had a repeat test, of which 29 (97%) remained abnormal. 11 women 
with a normal index CA125 test had a repeat test; 8 (73%) had an increase in their CA125 
level, but in only 3 cases (27%) was this increase sufficient to reach the ≥35 U/ml threshold. 
 
4.3.3 Tumour morphology 
The types of ovarian cancer which occurred in women in the cohort are summarised by CA125 
test result in Table 4.2. Borderline tumours accounted for almost half (49%) of tumours in 
women with normal CA125 results compared to 13% of tumours in women with abnormal 
CA125 tests. Invasive epithelial cancers were the most common category of tumour in women 
with abnormal results (81%). Examining the histology of invasive epithelial tumours revealed 
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that 52% of invasive tumours in the CA125 abnormal group were serous epithelial compared 
to 30% in the CA125 normal group. 
 
Tumour morphology differed significantly by CA125 test result, both when categorised 
broadly as ‘borderline’ and ‘invasive’ and when categorised into the four groups (borderline, 
invasive epithelial, invasive non-epithelial and invasive NOS) (p<0.001). 
 




































NOS = Not otherwise specified i.e. could not be classified as epithelial or non-epithelial based on the information 
within the cancer registry. P-value derived from Fisher’s exact test for independence. 
a 158 serous, 16 endometrioid, 14 mucinous, 14 clear cell, 13 other epithelial and 69 epithelial cancers of 
unknown morphology. 




4.3.4 Test-to-diagnosis interval 
Histograms of the test-diagnosis intervals in women with normal and abnormal CA125 tests 
results are shown in Figure 4.2. The median test-to-diagnosis interval in the cohort was 42 
days (interquartile range [IQR]: 25-62 days). In women with abnormal CA125 results it was 35 
days (IQR: 21-53 days) compared to 64 days (IQR: 42-127 days) in women with normal CA125 
results. 2% of women with abnormal CA125 results had a test-diagnosis interval of more than 










Figure 4.2. Histograms showing the distribution of test-diagnosis intervals in women with normal and abnormal CA125 tests.
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In a univariate AFT analysis, having a normal CA125 result was significantly associated with a 
longer test-diagnosis interval (Table 4.3). The TR of 2.0 (95% CI:1.7-2.4, p<0.001) indicates 
that the test-to-diagnosis interval was twice as long in women with normal than abnormal 
CA125 test results. In the multivariable analysis, the adjusted TR for CA125 test result 
remained unaltered. On univariate analysis, higher age was significantly associated with a 
slightly shorter test-diagnosis interval (TR 0.99, 95% CI: 0.99-0.99, p=0.004), but this 
association was not present in the multivariable analysis (TR: 1, 95% CI: 1.0-1.0, p<0.16). 
 
Table 4.3. Crude and adjusted associations between CA125 test result, age, presence / 
absence of a coded symptom of possible ovarian cancer and Townsend score with Test-to-
diagnosis intervals. 
 Unadjusted Adjusted 
 TR (95% CI) p value TR (95% CI) p value 
Abnormal 
CA125 
Reference - - - 






















- 0.75a - 0.77a 
Townsend 1 Reference - - - 




















 a Derived using the Wald test. 
 
4.3.5 Stage at diagnosis 
Staging information was missing for 75 (16%) women. A greater proportion of women in the 
normal CA125 group had missing stage (n=28, 27%) than in the abnormal group (n=47, 13%). 
In the restricted cohort of patients with a recorded stage, baseline characteristics were very 
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similar to the main ovarian cancer cohort (Appendix F). In this group (n=381), 172 (45%) had 
early stage and 209 (55%) had late stage disease. 35% (n=66) of those with an abnormal 
CA125 result were diagnosed with early stage disease compared to 86% (n=198) of those with 
a normal CA125 result. 
 
The results of the univariate and multivariable logistic regression analyses, performed to 
examine the association of CA125 test result and early stage diagnosis, are shown in Table 
4.4. On univariate analysis, the odds of early stage diagnosis were 11.2 times greater in 
women with normal than abnormal CA125 test results (95% CI: 5.7-22.1, p<0.001). Increasing 
age and the presence of a recorded symptom were inversely associated with early stage 
diagnosis on univariate and multivariable analyses. In the multivariable model, the odds of 
early stage diagnosis were 12.2 times higher in women with normal than abnormal CA125 
test results (95% CI: 5.8-25.15, p<0.001). 
 
In a sub-analysis, conducted after excluding borderline tumours (Appendix F), the odds of 
early stage diagnosis were still 9.1 times greater in women with normal than in women with 
abnormal CA125 tests (95% CI:4.0-19.8, p<0.001).  
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Table 4.4. The association between CA125 test result, age and presence / absence of a 
recorded symptom with early stage (I-II) diagnosis. 
 Unadjusted Adjusted 
 OR 
(95% CI) 
p value OR 
(95% CI) 
p value 
Abnormal CA125 Reference - Reference - 












Reference - - - 





Townsend score - 0.4 - 0.9 
Townsend 1 Reference - Reference - 




















* Derived using the Wald test.  
 
In a multivariable model, adjusted for age, symptom coding and Townsend score, the odds of 
having missing stage were 2.6 times higher in CA125 normal than CA125 abnormal women 
(95% CI: 1.5-4.6, p=0.001). No statistically significant association was identified when 




Women with normal CA125 results in primary care prior to ovarian cancer diagnosis took 
twice as long to be diagnosed following testing than those with abnormal results. Despite this, 
in women for whom staging data was available, 86% of those with normal CA125 results were 
diagnosed at an early stage compared to only 35% of those with abnormal CA125 results. In 
addition, indolent borderline ovarian tumours were more common, and aggressive invasive 
epithelial cancers less common, in women with normal than abnormal CA125 results. Key 




Box 4.1. Key results against thesis objective vi. 
 
4.4.1 Limitations 
Patients with severe disease, who often have more severe symptoms, frequently experience 
expedited diagnoses when compared to those with less severe disease. This observation is 
often referred to as the ‘sick quick’ phenomenon.76 As CA125 is also more likely to be elevated 
in women with more severe disease, this may act as a confounder. I have adjusted the 
analyses for the presence/absence of relevant coded symptoms, as symptoms may be more 
likely to be coded (rather than mentioned in free text) if they are more severe.187 However, I 
am unlikely to have been able to adjust fully for severity of presentation. 
 
vi) To examine the association of pre-diagnostic primary care CA125 result with time 
between testing and diagnosis, tumour morphology and disease stage in ovarian cancer. 
 
o Median test-diagnosis interval was: 
§ 34 days in women with an abnormal CA125 
§ 64 days in women with a normal CA125 
o Having a normal CA125 test result, rather than an abnormal CA125 test result, was 
associated with a doubling of the test-diagnosis interval 
 
o Tumour morphology differed significantly between women with normal and 
abnormal CA125 test results 
o Indolent borderline tumours were the most common tumour type in women with 
normal CA125 levels (49%) while invasive epithelial tumours were the most common 
tumour type in women with abnormal CA125 levels (81%) 
 
o Having a normal CA125 result was associated with early stage diagnosis. In women 
with a recorded stage, the odds of early stage diagnosis were 12 times higher in 
women with a normal rather than an abnormal CA125 test result 
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A normal CA125 result was significantly associated with missing stage. This is to be expected, 
as stage is less frequently recorded in the cancer registry for borderline tumours, which are 
more common in women with normal CA125s. It is reassuring that when borderline tumours 
were excluded no significant association between CA125 result and missing stage was 
identified and that a normal CA125 result was still strongly associated with early stage 
diagnosis. While I have no reason to suspect that study findings would differ substantially if 
staging data were available for all patients, the magnitude of the association between CA125 
result and stage should be interpreted with caution. 
 
The analysis of CA125 test and stage was exploratory. The observational nature of this study 
meant that, although I was able to report that women with normal CA125 levels were usually 
diagnosed at an early stage, I could not determine to what extent women with normal CA125 
tests experienced disease progression between having the CA125 test and being diagnosed. 
Without a controlled trial, or a further evaluation following a change in practice, it is not 
possible to determine whether shortening the test-diagnosis interval in CA125 normal women 
would result in earlier stage diagnosis in this group. 
 
4.4.2 Comparison with existing literature 
Previous studies have identified an association between false negative results in primary care 
for several other types of test and longer healthcare intervals. In one study, patients with a 
normal chest X-ray prior to lung cancer diagnosis experienced longer primary care intervals 
than those with an abnormal chest X-ray.227 While in another study, patients with a false 
negative rheumatoid factor in primary care prior to a rheumatoid arthritis diagnosis took 
longer to be referred to a specialist.228 Studies in other healthcare settings also indicate that 
false negative test results may delay diagnosis and treatment. For example, false negative 
breast and cervical cancer screening tests have been implicated in diagnostic delay and an 
association between false negative fine needle aspiration and delayed treatment has also 
been reported.229,230 It is possible that negative results could provide ‘false reassurance’ to 
patients, thereby delaying their re-presentation if symptoms persist, or provide false 
reassurance to healthcare professionals, prompting them to seek alternative diagnoses and 
delaying referral. However, the mechanisms by which delays occur in the presence of false 
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negative test results are not fully understood and I did not identify any studies exploring 
mechanism of delay due to false negative CA125 results. 
 
Few studies have investigated the relationship between false negative test results and 
outcomes in symptomatic patients. However, one study did find that patients with false 
negative fine-needle aspiration before thyroid cancer diagnosis had worse outcomes (greater 
vascular and capsular invasion, more frequent persistent disease post treatment).230  
Although women with normal CA125 results in my study took markedly longer to be 
diagnosed than those with abnormal CA125 results, they were generally diagnosed at an 
earlier stage. This finding could be due to differences in tumour type between the groups; 
borderline tumours were four times as common in women with normal CA125 (in whom they 
were the most common type of tumour) than in women with abnormal CA125 test results. 
Borderline tumours are known to cause less frequent elevations in CA125 than their invasive 
counterparts.204 Borderline tumours tend to grow slowly and spread late, with 80% diagnosed 
at an early stage.204 By contrast, invasive epithelial tumours, which typically have an insidious 
onset and poor survival, were much less common in women with normal than abnormal 
CA125 test results. Even within the invasive tumour category, serous epithelial tumours, 
which are particularly aggressive and more frequently diagnosed at a late stage than other 
invasive tumour types,119 were less common in women with normal than abnormal CA125 
test results. So, while the tumours in women with normal CA125 tests had more time to 
progress during the test-diagnosis interval, they were predominantly indolent and the 
majority did not advance from early to late stage during this time period. 
 
4.4.3 Implications for research and practice 
In the overall study cohort the median test-diagnosis interval was 14 days longer than the 
‘Faster Diagnosis Standard’, introduced in England in April 2020, which recommends that 
patients should receive a diagnosis of cancer within 28 days of being referred to a specialist 
by their GP.68 In women with abnormal CA125 results, the median test-diagnosis interval was 
only 7 days longer than this standard. While women with normal CA125 levels did take 
markedly longer to be diagnosed, it is somewhat reassuring that the majority of these women 
had indolent tumour types which were predominantly diagnosed at an early stage. 
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A significant amount of research effort in countries around the world is directed at developing 
alternative biomarkers to CA125 which are more sensitive for ovarian cancer.216,231 Given that 
most women with false negative CA125 test results were diagnosed at an early stage, this 
study raises the question of how much impact a more sensitive first line testing strategy could 
realistically have on stage at diagnosis and survival. A more sensitive first line testing strategy 
in primary care might be expected to reduce the test-to-diagnosis interval by a median of 
around a month (i.e. the median difference between the CA125 normal and abnormal CA125 
groups). However, a much greater proportion of women with normal CA125 levels had 
extreme diagnostic intervals e.g. >6 months; therefore, reducing the numbers of false 
negative results could result in a dramatic reduction in the test-diagnosis interval for some 
women. Although women with normal CA125 results often had more indolent forms of 
ovarian cancer, 15% of invasive cancers, and 12% of the HGS sub-type (the most aggressive 
form) occurred in this group. We cannot establish from this study what proportion of women 
with a normal CA125 result experienced disease progression during the prolonged test-
diagnostic interval. However, even a progression within the early stage group (e.g. from stage 
IA to IC or from I to II) has prognostic implications, particularly for aggressive invasive ovarian 
cancers. Although there is often a focus on achieving a ‘stage shift’ in early detection research, 
earlier diagnosis of ovarian cancer has the potential to reduce morbidity and mortality, even 
if a stage shift is not achieved, by detecting lower volume (less ‘bulky’) disease which is more 
amenable to complete surgical resection.55  As discussed in Chapter 1, complete 
cytoreduction (the removal of all visible tumour) is recognised as a key prognostic factor in 
ovarian cancer.70,72  
 
Prompt diagnosis also has other benefits. For example, delay in cancer diagnosis is associated 
with psychological distress and perceived delays can damage doctor-patient 
relationships.232,233 So, while this study demonstrates that large proportions of women do not 
end up with late stage disease as a result of false negative CA125 results (which should 
provide some reassurance for those using and being tested for CA125), there is potential to 
improve patient psychosocial outcomes by reducing the number of false negative results. 
Ultimately, prospective studies, or further retrospective database studies, would be needed 
to assess the impact of any novel first line testing approach, including the use of alternative 
thresholds for referral derived from the models presented in Chapter 2 and 6. 
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Current NICE guidelines provide no specific recommendations on follow-up in women with 
normal CA125 levels and persistent symptoms. However, safety netting and retesting with 
CA125 if symptoms persist or worsen is a potential option which warrants further evaluation. 
In this study, only a small proportion (9%) of women with normal initial CA125 results had a 
repeat test. There was an increase in levels in 73% of cases, but in only 27% of cases was this 
increase sufficient to reach the 35 U/ml threshold. This supports the idea put forward by some 
researchers that if a women has a rising CA125 level (even if it is below the 35 U/ml threshold) 
this should prompt further investigation.55 The Risk of Ovarian Cancer (ROCA) algorithm, used 
within the UKCTOCS trial, was developed for this reason and relies on changes from a 
woman’s baseline CA125 level to determine when further investigation is needed.234 
Alternatively, persistent symptoms in those with a normal initial CA125 test could prompt a 
different modality of testing e.g. ultrasound. Any potential follow-up strategy must take 
account of the burden of testing on those without ovarian cancer, given that only one in every 
451 women with a normal index CA125 test in primary care will have the disease (Chapter 3). 
 
4.5 Conclusion 
Women with false negative CA125 test results in primary care experienced markedly longer 
intervals between testing and ovarian cancer diagnosis than women with true positive CA125 
results. However, they more frequently had indolent forms of the disease and the majority 
were diagnosed at an early stage. It is reassuring that a large majority of women with false 
negative CA125 results did not progress from early to late stage disease as a result of a 
prolonged test-diagnosis interval. Nevertheless, expediting diagnosis in this group of women 





Chapter 5. Symptom based tools for 





In Chapter 1, I introduced the concept of diagnostic prediction models and highlighted several 
which are currently available for use in primary care. When planning my doctoral research, I 
postulated that a diagnostic prediction model, incorporating CA125 levels alongside other 
variables associated with ovarian cancer, might outperform CA125 alone in the detection of 
the disease. A key objective of my doctoral research was to develop such a prediction model. 
Prior to developing it, I wanted to perform a review of the literature in order to identify 
existing ovarian cancer detection tools and ensure that my planned prediction model (or one 
very similar to it) had not already been developed. I also wished to summarise the diagnostic 
performance of existing ovarian cancer detection tools to enable comparison with my model. 
Determining which variables to include within a prediction model is one of the most 
challenging aspects of model development. I saw a literature review as a key first step in 
identifying variables from existing tools which might be relevant for inclusion in my model.  
 
The model I planned to develop was predicated on CA125 i.e. it would be developed in women 
undergoing CA125 testing and would incorporate CA125 level. So, my initial intention was to 
perform a systematic review of tools which included CA125 as a variable. However, 
preliminary searches revealed that most of these tools combined CA125 with specialist 
biomarkers and/or imaging tests e.g. ultrasound. These specialist tests are not available 
within UK primary care and the results of imaging tests are not recorded in the CPRD, so I 
judged that a review focussed on CA125-based models would have been of very limited utility 
in helping to identify candidate variables for my model. 
  
Instead of performing a systematic review of CA125 based tools, I chose to perform a 
systematic review of symptom-based tools for ovarian cancer. Symptoms are the trigger for 
performing CA125 tests in primary care and are predictive of the presence of the disease in 
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their own right. However, as discussed in Chapter 1, not all symptoms are equally predictive. 
Given this, I saw symptoms as a key variable type for the development of my prediction 
model. Preliminary searches in MEDLINE revealed that a number of symptom-based tools for 
ovarian cancer had been developed and that some incorporated other types of variable e.g. 
cancer risk factors and test results. I determined that a systematic review of these tools would 
allow me to ascertain whether a prediction model combining CA125 with symptoms and 
other variables had previously been developed, and would also provide insight into potential 
candidate variables for my model.  
 
In this chapter I describe the steps I took to identify relevant symptom-based tool studies, 
provide an appraisal of study quality, summarise the variables included within tools and 
provide a comparison of their diagnostic accuracy.  The thesis aim addressed by this chapter 
is: 
 
vii. To perform a systematic review to identify published symptom predicated tools for 
ovarian cancer detection and to compare these tools in terms of a) included variables 
and b) diagnostic accuracy. 
 
A paper, based on the work presented within this chapter, was recently published in Cancers 
(Appendix A): 
 
Identifying ovarian cancer in symptomatic women: a systematic review of clinical tools. Garth 
Funston, Victoria Hardy, Gary Abel, Emma J. Crosbie, Jon Emery, Willie Hamilton, Fiona M. 
Walter. Cancers. 2020; 8:3686 
 
5.2 Methods 
5.2.1 Previous studies 
Prior to commencing this study, I reviewed several databases of systematic reviews to ensure 
that a similar review had not been published or was underway. I did not identify any published 
systematic reviews covering symptom-based tools for ovarian cancer detection. A Cochrane 
protocol for a series of reviews, designed to evaluate the diagnostic accuracy of tests and 
symptoms alone and in combination, was published in 2015.235 It is good research practice to 
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avoid duplicating systematic reviews (unless performing an update after a reasonable period), 
as this wastes time, effort and research funding. This contributed to my decision not to 
perform and publish a formal systematic review on the diagnostic accuracy of CA125 at the 
outset of my doctoral research. However, as of April 2021 (more than five years after the 
publication of the Cochrane protocol) none of the Cochrane reviews have been published.
I considered a literature review an essential step to inform the development of a prediction 
model during my PhD research and so chose to proceed with this systematic review. This 
review differs from the Cochrane review series in that it only includes tools which incorporate 
symptoms. In addition, while Cochrane diagnostic accuracy studies impose very stringent 
quality criteria during study selection, I did not exclude any studies on the basis of quality as 
I wished to identify all relevant published tools and identify which variables they included in 
order to inform my model development. So, while there may be a degree of overlap between 
this study and any reviews which may arise from the Cochrane protocol, I believe the results 
and their interpretation are likely to differ.  
 
5.2.2 Review registration and reporting 
Prior to conducting this review, I developed a study protocol and registered it with PROSPERO 
[CRD42020149879].  
 
I report the review in accordance with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) guidelines and include a PROSPERO checklist in Appendix G. 
 
5.2.3 Search strategy 
I developed a search strategy in MEDLINE to include terms for ovarian cancer, symptoms and 
prediction / diagnostic models / tools. Relevant Medical Subject Heading (MeSH) terms were 
also identified and included. Prior to performing the definitive search, I piloted the strategy 
to ensure that it identified several key papers.54,91,215 The final MEDLINE search strategy is 
included in Appendix H. I converted this strategy for use in Cochrane CENTRAL and EMBASE 
and searched all three databases from 1st January 2000 – 3rd March 2020. The start date was 
chosen to predate key ovarian cancer symptom studies.91,92 I considered it unlikely that 
symptom-based ovarian cancer detection tools would have been developed prior to the 
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publication of these symptom studies. No language restrictions were applied. I did not place 
any restrictions on the methodological design of studies, so both case-control and cohort 
studies were eligible for inclusion. In addition, no restrictions were placed on study setting, 
so studies conducted in the general population or the clinical setting were eligible for 
inclusion. As well as identifying studies through database searches, I screened the reference 
lists of included papers to identify any additional relevant publications.  
 
5.2.4 Eligibility criteria 
Studies were included if they a) described the development and or evaluation of a 
multivariable tool designed to identify patients with undiagnosed ovarian cancer, and b) 
provided the sensitivity and specificity of the tool or gave sufficient data to allow these 
metrics to be calculated. For the purposes of this review, I defined a multivariable tool as a 
combination of three or more variables used to detect, or predict the risk of, undiagnosed 
ovarian cancer. During my initial pilot searches I identified tools which took the form of 
diagnostic prediction models  (a “mathematical equation that relates multiple predictors for 
a particular individual to the probability of or risk for the presence… of a particular 
outcome”).162 I also identified tools which did not meet the above definition of a prediction 
model but met the broader definition of a decision / prediction rule (a decision making tool 
consisting of at least three variables which provides the probability of an outcome or suggests 
a course of action).236 I believed that both tools could help me identify candidate variables for 
my model so included both types of tool in this review. My broad definition of a multivariable 
tool encompasses formal multivariable diagnostic prediction models and clinical prediction 
rules.162,236 I considered variable ‘checklists’, in which only one variable in the list needs to be 
present for a positive tool result, to be a form of multivariable tool. As the focus of this review 
was on symptom-based tools, the tool under investigation had to include one or more 
symptoms for a study to be eligible. No other restrictions were placed on the types of variable 
that could be included.  
 
Studies on tools intended to estimate future risk of developing cancer rather than the current 
risk of having an undiagnosed cancer were excluded, as were studies on tools that solely 
provide an indication of the risk of ovarian cancer relapse or recurrence. I excluded studies in 
which all participants had a known pelvic mass, as this represents a highly selected high-risk 
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population. I excluded studies undertaken solely in paediatric (<18 years) populations, as I 
planned to develop my model in women ≥18 years of age who generally develop different 
types of ovarian tumour. Non-primary research studies e.g. review articles, and conference 
abstracts were also excluded.  
 
5.2.5 Study selection 
I exported the results from database searches into Endnote then added them to Rayyan;237 a 
software designed to facilitate duplicate removal and co-ordinate abstract screening by 
multiple reviewers. I removed duplicates from the searches using Rayyan. Following this, 
Victoria Hardy (the second reviewer on the study [VH]) and I independently screened the 
titles and abstracts of identified documents against an eligibility criteria checklist. Potentially 
eligible papers identified at the screening stage were obtained and then the full texts 
independently examined by me and VH against the eligibility criteria. We discussed any 
disagreements and resolved them by consensus.  
 
5.2.6 Data extraction 
I developed an Excel template for data extraction. Using this, I extracted information from 
each paper on: study characteristics (year of publication, location); study design 
(methodology, population, data source, outcome definition); tools (variables, tool 
development methods); and tool performance metrics (sensitivity, specificity, other 
diagnostic metrics). Where a study evaluated multiple tools, I extracted data relating to each 
tool separately. My extracted information was then checked against the full text papers by 
VH to ensure accuracy. 
 
5.2.7 Data synthesis 
When synthesising data, I paid particular attention to three key study and tool characteristics. 
First, the source of participant recruitment. For example, whether controls were recruited 
from the general population or from the healthcare setting (primary / secondary care). 
Symptoms may be more common in clinical controls (e.g. those attending gynaecology clinics) 
than in controls recruited from the general population, which could influence estimates of 
tool diagnostic performance.157 Second, whether the measures of tool accuracy were 
obtained directly from the patient sample in which the tool was developed (apparent 
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performance), by applying internal validation methods such as cross-validation (internal 
validation) or from an evaluation of the tool in a distinct patient sample (external 
validation).162 Tools usually exhibit poorer diagnostic performance in external validation 
studies than when evaluated in the original development sample, and external validation of 
tools is generally recommended before they are used in clinical practice.162 Third, I considered 
the type of tool being evaluated. Whether a tool is a simple symptom checklist, a checklist of 
symptoms and other variables (augmented symptom checklist) or a prediction model, is likely 
to affect its clinical utility. 
 
I tabulated and compared the variables included in each tool. I compared tools in terms of 
their sensitivity and specificity. For diagnostic prediction models, I compared AUC. AUC is a 
measure of model discrimination i.e. the ability of a model to identify those with a condition 
from those without a condition. I also compared model calibration (agreement between 
estimated and observed outcomes) of models where relevant calibration metrics were 
provided in papers. When planning this study, I hoped to perform a meta-analysis of 
diagnostic accuracy metrics. However, there was marked heterogeneity in included studies in 
terms of their designs, populations, variable definitions, outcome definitions and use of 
different thresholds. Multiple studies also failed to report numbers of patients with true 
positive / true negative / false positive / false negative results. Ultimately, I decided that a 
meta-analysis would not be informative. Instead, I summarised performance characteristics 
in tabular form and used a narrative synthesis approach.  
 
5.2.8 Risk of bias assessment 
I identified two possible tools which could be used to assess the risk of bias (ROB) of included 
studies: the Prediction model Risk Of Bias Assessment Tool (PROBAST),238 and the Quality 
Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.184 There is overlap between 
the tools, but PROBAST is specifically designed to assess ROB in prediction modelling studies 
whereas QUADAS-2 is designed to assess diagnostic accuracy studies. Each of these tools was 
potentially appropriate for assessing ROB in this review, so I piloted them on several studies. 
As many of the studies in this review evaluated decision rules rather than true prediction 
models, I found that multiple sections of PROBAST were of limited relevance to these studies. 
In addition, it failed to assess potential sources of bias in the assessment of tool diagnostic 
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accuracy in depth. By contrast, all sections of QUADAS-2 were of relevance to the review 
studies, but it did not fully consider the ROB from statistical approaches used to develop 
prediction models. Neither tool was ideally suited to assess for ROB in all included studies, 
given the diverse methods used. However, I chose to use QUADAS-2 in this review as the 
reported accuracy of tools, rather than the particular statistical approaches used to derive 
prediction models, was of greater interest.  
 
QUADAS-2 includes signalling questions (intended to identify areas of potential bias or 
concern over study applicability) covering four domains: 1) patient selection, 2) index test(s), 
3) reference standard and 4) flow and timing. Each domain is rated as of “high”, “low” or 
“unclear” (where insufficient information is provided) ROB. In domains 1-3 papers are also 
rated on their applicability (how well they match the review question), as of “high”, “low”, or 
“unclear” concern. VH and I each independently assessed the included studies using QUADAS-
2. Ratings were compared and disagreements resolved by consensus. 
 
5.3 Results 
5.3.1 Study selection 
I identified 2,331 records through database searches, of which 708 were duplicates. On 
examination of reference lists, I identified two additional relevant documents. A total of 1,625 
titles and abstracts were screened and 35 full text papers were obtained and examined 





Figure 5.1. PRISMA flow diagram illustrating the study selection process. 
 
5.3.2 Study characteristics 
Table 5.1 summarises key characteristics of included studies including setting, design, 
objectives, outcome and participants. Specific exclusion criteria are provided in Appendix H. 
Three studies were population-based (i.e. recruited participants at the population level),239–
241 five were primary care based,54,91,242–244 four were entirely hospital-based,245–248 and four 
were hospital-based but also recruited controls from screening trials rather than the clinical 
setting.215,249–251 All population and hospital-based studies were of case-control design. Two 
of the hospital based case-control studies included a proportion of controls with benign 
ovarian pathology.245,247 Three of the five primary care studies were of cohort design,54,242,243 
and the remaining two of case-control design.91,244  
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The number of women in each study varied markedly, with between 75 – 1,908,467 
participants and 24 – 1,885 patients with ovarian cancer per study. A range of different data-
sources were used by studies to collect variable information, including surveys or patient 
interviews (n=11), routinely collected primary care databases (n=6), and blood samples (n=4). 
All studies used ovarian cancer as an outcome, but how this was defined varied, with some 
only including invasive cancers or invasive epithelial cancers,239–241,245–248 and others including 
both invasive and borderline epithelial tumours or all types of ovarian cancer.54,91,215,242–
244,249–251 One study included ovarian cancer alongside other common cancers in a composite 
outcome, but did provide tool performance characteristics for each individual cancer.242 
Seven studies developed entirely new tools,54,91,215,239,242,244,251, six modified existing tools,245–
250 and eight externally validated existing tools.240,241,243,245–248,251  
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Table 5.1. Study characteristics. 
Author, date, 
country 































Cases: Women aged 19-88 years, 
histologically confirmed primary 
invasive ovarian carcinoma (1993 - 
2007) 
 
Controls: Aged ≥18 years, Hawaii 
resident ≥1 year, randomly selected 
from statutory state survey. 
Frequency-matched to cases (1:1) by 
age, ethnicity, interview time 











Cases: Resident in western 
Washington State, aged 35–74 years, 
diagnosed with a primary invasive 
epithelial ovarian tumour (Jan 2002 - 
Dec 2005) 
 
Controls: Selected by random digit 
dialling with stratified sampling in 5-
year age categories, 1-year calendar 
intervals, and two (urban vs suburban 











Cases: Aged 20-79 years with 
suspected OC subsequently diagnosed 
with invasive epithelial OC (Jan 2002 - 
Jun 2005) 
 
Controls: Frequency-matched based 
on age (5-year groups) and state of 





Primary care population 
Hamilton, 
2009, England 






Cases: Aged ≥40 years with primary 
OC diagnosed between 2000-2007 
 









 • •   OC (NOS) QResearch 
database180 
Aged 30-84 years, registered with GP 






















Aged 25–89 years, registered with GP 




















Cases: Aged ≥40 years with primary 
OC diagnosed between 2000-2007 
 







 •   • OC (NOS) THIN 
database253 
Women 30-84 years registered with 





Hospital + screening populations 
Goff, 2007, 
USA 
•  •   OC, 
including 
borderline 
Patient survey Cases: Women with a pelvic mass 
recruited in secondary care prior to 
OC diagnosis 
 
Controls: a) Healthy ‘high risk’b women 
enrolled in a screening study 254, b) 











•   •  OC (NOS) Patient 
survey, blood 
sample 
Cases: Women with a pelvic mass, 
recruited prior to OC diagnosis 
 
Controls: Healthy ‘high risk’b women 






•   •  OC (NOS) Patient 
survey, blood 
sample 
Cases: Women with a pelvic mass 
recruited in secondary care prior to 
OC diagnosis 
 
Controls: Healthy ‘high risk’b women 
enrolled in a screening study,254 












c) GP notes 
Cases: Women aged 50-79 years with 
primary OC recruited prior to 
diagnosis (Feb 2006 – Feb 2008) 
 
Controls: Screening trial 
participants,153  frequency matched on 






Hospital based population 
Kim, 2009, 
Korea 





Cases: OC diagnosis 
 
Controls: Women with benign ovarian 
cysts recruited prior to surgery and 













Cases: Women with epithelial OC 
recruited prior to surgery/diagnosis 
 
Controls: Age matched ‘healthy 







•   • • OC, 
excluding 
borderline 
Patient survey Cases: Women admitted to hospital 
for investigation and subsequently 
diagnosed with OC 
 
Controls: a) Women with benign 
ovarian pathology, b) those 

















Cases: Women undergoing surgery for 
a pelvic mass subsequently diagnosed 
with ovarian cancer 
 





a Data collected on borderline tumours but not included in their tool evaluation.   
b Women with high-risk family histories consistent with a possible BRCA1 mutation participating in the Ovarian Cancer Early Detection Study (OCEDS).254   
c Numbers varied by study component: questionnaire (191 case, 268 controls), interview (111 cases, 125 controls), GP notes (171 cases, 227 controls).  




5.3.3 Risk of bias 
The main potential sources of bias were identified in the “patient selection” and the “index 
test” QUADAS-2 domains (Figure 5.2). Case-control designs can overestimate test 
performance,183,184 so we flagged 13 studies as at high ROB for patient selection. In the “index 
test” domain, key potential sources of bias included failing to pre-define the tool threshold 
and retrospectively administering the tool after the outcome had been determined e.g. 
interviewing participants after the ovarian cancer diagnosis had been made. The majority of 
studies were judged as of low ROB for the “reference standard” and “flow and timing” 
domains. However, all primary care studies were flagged as at high ROB in the “reference 
standard” domain as they relied on codes within routinely collected GP data (e.g. the CPRD) 
to identify ovarian cancer diagnoses, supplemented in two studies by death registration 
data,54,242 rather than hospital pathology or cancer registry data. The review question in this 
study was broad, so concern over the applicability of studies was judged as low. An exception 
was the “reference standard” domain of a single study which used a composite cancer 
outcome.242  
 
Study Risk of bias domain 
Patient 
selection 
Index test Reference 
standard 
Flow & timing 
Lurie, 2009         
Rossing, 2010         
Jordan, 2010         
Hamilton, 2009         
Hippisley-Cox, 2012         
Hippisley-Cox, 2013         
Grewal, 2013         
Collins, 2013         
Goff, 2007         
Andersen, 2008         
Andersen, 2010         
Lim, 2012         
Kim, 2009         
Macuks, 2011         
Shetty, 2015         
Jain, 2018         
Figure 5.2. QUADAS-2 Risk of Bias Assessment. 
Green = “Low”, Orange = “High”, Blue = “Unclear” Risk of Bias.  
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5.3.4 Tool variables 
In total the 16 studies evaluated 21 distinct tools, of which five were diagnostic prediction 
models.162 I grouped the variables included in tools into four categories: 1) demographics, 2) 
personal and family medical history, 3) symptoms, and 4) test results (Table 5.2). All tools 
included symptoms (as per the review inclusion criteria), with 14 including only symptoms. 
Four tools incorporated demographic variables, two incorporated personal and family 
medical history, and six incorporated test results.  
 
The most common demographic variable included was age (n=3). This was incorporated as a 
continuous variable in the QCancer prediction models (n=2) developed by Hippisley-Cox et al 
and as a dichotomised variable (<50 years or ≥50 years) in an ovarian cancer score developed 
by Grewal et al.54,244 One tool included menopause as a variable.246 The QCancer models were 
the only tools to include family history of cancer.  
 
Nineteen different symptoms were incorporated within tools (discounting those in the multi-
cancer tool developed by Hippisley-Cox et al).242 Five symptoms (abdominal pain, pelvic pain, 
distension, bloating, appetite loss) were included in more than half of tools and a further six 
symptoms (feeling full quickly, difficulty eating, postmenopausal bleeding, urinary frequency, 
palpable abdominal mass / lump, rectal bleeding) were included in at least a quarter of tools.  
 
Three different types of test result were included within tools: Haemoglobin (n=2), CA125 
(n=3) and HE4 (n=2). 
 
Six tools were based on an existing one – the Goff Symptom Index (SI) – which had been 
modified to include additional demographic, symptom or test result variables. Studies 
frequently defined variables slightly differently - tool specifications (including the variable 
definitions used) are summarised in tabular form in Appendix H.
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    • • • •  • •          
Modified 
Goff SI 1 
(Kim, 2009) 






















    • • •        •  Abnormal vaginal 
bleed. 




      •        •  Abnormal vaginal 
bleed. 











    • •  •  •      • Urinary, urgency    
Lim SI 1 
(Lim, 2012) 
    • • • • • •  •   •      
Lim SI 2 
(Lim, 2012) 





    •  •  •   • • •       
Modified 
Goff SI 2 
(Shetty, 
2015) 
    • • • • • • • •    • Urinary urgency    
Augmented symptom checklists 




    • • • •  • •        •  




    • • • •  • •         • 





    • • • •  • •        • • 
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breast pain, lump 








•   
 130 
OC Score A 
(Grewal, 
2013) 
    •  • • •    • •  •     
OC Score B 
(Grewal, 
2013) 
    •  • • •    • •  •     
OC Score C 
(Grewal, 
2013) 
•    •  • • •    • •  •     
a Consensus statement released by the Society of Gynaecologic Oncologists (SGO), the Gynaecologic Cancer Foundation and the American Cancer Society. The terms used 
to describe a given symptom varied subtly between studies - full details of each tool, including symptom terminology and duration and frequency criteria, are included in 
Appendix H. Abbreviations: PMH = past medical history, FH= family history, Abdo. = abdominal, Distens. = distension, Bloat. = bloating, Postmen. = postmenopausal, Bleed. 
= bleeding, Freq. = frequency, Hb = haemoglobin, CA125 = cancer antigen 125, HE4 = human epididymis protein 4, SI = symptom index, OC = ovarian cancer, BMI = body 
mass index, Endomet. = endometrial, T2DM = type 2 diabetes mellites, COPD = chronic obstructive pulmonary disease, GI = gastrointestinal, CIBH = change in bowel habit. 
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5.3.5 Evaluation of tool performance 
Table 5.3 summarises the reported diagnostic accuracy metrics of the tools, the source of 
accuracy metrics (apparent performance vs internal validation vs external validation), and the 
recruitment setting (population vs primary care vs hospital vs hospital + screening) by tool 
category (symptom checklist vs augmented checklist vs prediction model). 
 
Most studies calculated the diagnostic performance of a tool directly from the patient sample 
in which the tool was developed (apparent performance) or by applying internal validation 
methods such as splitting the sample into development and validation sets (internal 
validation). Four tools – the Society of Gynaecologic Oncology (SGO) consensus criteria, Goff 
SI, QCancer Ovarian, Modified Goff SI 1 – were independently validated in an external dataset. 
The combination of Goff SI and CA125 was evaluated in several studies, but the CA125 
thresholds used varied, so no particular combination was externally validated. There was 
some overlap in evaluation of tools between healthcare settings, but no tool evaluated in 
primary care was evaluated in another setting or vice versa.   
 
The most widely studied tool was the Goff SI, which was evaluated in nine 
studies.215,240,241,245,246,248–251 However, two of these studies used subsets of women from the 
original development study.249,250 Deviations from the original Goff SI, in how variables were 
defined, were noted in several studies (Appendix H). The only tool to be externally validated 
in more than one setting was the Goff SI.  
 
5.3.6 Tool diagnostic accuracy 
In this section, I compare the accuracy of diagnostic tools. As discussed in Chapter 1, the 
population in which tests and tools are evaluated can affect their diagnostic performance. 
Therefore, I compared the accuracy of tools by study setting.   
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Table 5.3. Tool diagnostic accuracy metrics. 
Tool 
(threshold) 



















Goff, 2007   •   •  ≥50 yrs: 66.7 
< 50 yrs: 86.7 
≥50 yrs: 90 









Kim, 2009    •   • 56.9 87.6 - - 
Rossing, 
2010 
























   •   • 83.3 48.3 - - 
Jain, 2018    •   • 77.8 87.8 - - 
Lim, 2012   •    • 61.4-75.7e 89.6-98.9e - - 
Modified 
Goff SI 1 
Kim, 2009    • •   65.5 84.7 - - 
Shetty, 
2015 
   •   • 71.6 88.5 - - 
7-symptom 
Index 












Lurie, 2009 •    •   54 93 - 
- 
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Hamilton SI Hamilton, 
2009 





















Lim SI 1 Lim, 2012   •   •  69.6-91e 76-91e - - 





 •    •  71.9 82.9 0.5 - 
Modified 
Goff SI 2 
Shetty, 
2015 
   • •   77 88.5 - - 
Augmented symptom checklists 









Goff SI or 
CA125 (>35 
U/ml) 
Jain, 2018    • •   97.8 68.9 - - 





   • •   79.1 100 - - 





   • •   70.8 100 - - 





   • •   70.8 100 - - 



















Any 1 of 3 










Any 2 of 3 










Goff SI & 1 
















   • •   50 100 - - 






   • •   45.8 100 - - 




























 •    •  42.2 95.6 1.1 - 
Collins, 
2013 



































 •   •   58.5 97.3 - 0.89 




 •   •   57.6 97.3 - 




 •   •   75 90.1 - 0.89 




 •   •   58.9 97.3 - 




 •   •   85.4 85.1 - 0.88 




 •   •   72.6 91.3 - 
A Study used a subset of patients from Goff, 2007.  b Calculated using external data from screening studies.152,255  c Calculated using external Australian population level data.  
d Calculated using external data from US and UK screening studies and Australian population level data.256,257  e Sensitivity and specificity varied by data collection method 
(Questionnaire, Telephone, GP notes).  f Biomarker level (CA125, HE4) dichotomised at 95th percentile in control group – levels above that deemed abnormal.   
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Hospital setting 
All but two tools evaluated in hospital populations (including hospital + screening 
populations) incorporated the Goff SI. Two of these were externally validated – the Goff SI 
itself and a modified version of the index which incorporated additional symptoms (Modified 
Goff SI 1). The Goff SI was externally validated in six studies and demonstrated sensitivities 
which ranged from 56.9% to 83.3% (an outlier result) and specificities from 48.3% (an outlier 
result) to 98.9%. The Modified Goff SI 1 had a sensitivity of 71.6% and a specificity of 88.5% 
in a single external validation study.  
 
Augmenting symptom checklists with baseline risk factors and test results generally led to a 
reduction in sensitivity and increase in specificity, or vice versa, depending on the threshold 
used. For example, the addition of the serum ovarian cancer biomarker CA125 to the Goff SI 
by Anderson et al (2008) led to a reduction in tool sensitivity if both variables were required 
to be abnormal for a positive tool result. If only one was required to be abnormal for a positive 
tool result, specificity was reduced.249  
 
Population setting 
In women recruited from the population setting, two symptom checklists were externally 
validated side by side – the Goff SI and SGO consensus criteria. The sensitivities and 
specificities of the tools differed between the studies. However, within each study they were 
similar, with an in-study maximum difference in sensitivity of 3.4% and in specificity of 2.4% 
between the tools.  
 
The two population-based case-control studies (Rossing et al and Jordan et al) used external 
disease prevalence figures (sourced from screening studies and population level statistics) to 
estimate PPVs for the Goff SI and SGO consensus criteria, if they were applied in the general 
population. The tools had similar estimated PPVs within each study, but PPVs were higher in 
Rossing et al (0.63-1.12%) than in Jordan et al (<55 years: 0.04-0.05%, ≥55 years: 0.18-0.31%).  
 
Primary care 
A single tool (QCancer Ovarian), which took the form of a prediction model and combined 
symptom variables with demographics, family history and routine blood test results, 
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underwent external validation in a primary care setting. When the threshold for abnormality 
was set to include the 5% of women at the highest predicted risk of cancer, QCancer Ovarian 
had a sensitivity of 43.8% and specificity of 95%. When the threshold was set to include 
women at the 10% highest risk, the sensitivity increased to 64.1% but specificity fell to 90.1%. 
Several scores, developed by Grewal et al, demonstrated higher sensitivities and specificities 
than QCancer Ovarian at the 5% risk threshold (OC Score B ≥4) and 10% risk threshold (OC 
Score C ≥4), but these diagnostic accuracy measures were calculated from the same dataset 
used in score development.  
 
PPVs were reported for QCancer tools at a range of thresholds (Table 5.3). The PPVs at any 
given risk threshold were similar in the three studies evaluating QCancer tools. For example, 
values ranged from 0.5-0.8% when the threshold was set to identify the 10% of women at 
highest risk.  
 
Discrimination was reported for 5 tools - all had similar AUCs within the ‘good’ range (0.84-
0.89). QCancer Ovarian exhibited an AUC of 0.86 on external validation. Tool calibration was 
assessed for QCancer tools by graphically comparing the predicted cancer risk at two years 
with the observed risk by predicted risk deciles.54,242,243 The authors reported that the models 
showed good calibration on internal validation. On external validation, QCancer Ovarian had 




This is the first systematic review to compare the diagnostic performance of symptom-based 
tools for ovarian cancer detection. I identified 16 studies that had evaluated 21 tools designed 
to help detect women with undiagnosed ovarian cancer. These tools comprised simple 
symptom checklists, checklists which included symptoms, demographics and tests, and 
multivariable diagnostic prediction models. The diagnostic performance of the majority of 
tools was evaluated solely within the datasets in which they were developed. Four tools were 
independently externally validated; one in multiple population settings. On external 
validation, these four tools demonstrated similar (moderate) diagnostic accuracy.  
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Several checklists, developed in secondary care populations, contained CA125. None of these 
had been evaluated in primary care. This review did not identify any prediction models 
incorporating CA125 alongside symptoms.  
 
The variables incorporated within the tools identified in this review were considered as 
possible candidate variables when I developed a primary care diagnostic prediction model for 
ovarian cancer (Chapter 6).  
 
Key study findings are summarised against the relevant thesis objective in Box 5.1. 
 
 
Box 5.1. Key results against thesis objective vii. 
  
vii) To perform a systematic review to identify published symptom predicated tools for 
ovarian cancer detection and to compare these tools in terms of a) included variables and 
b) diagnostic accuracy 
 
o This systematic review identified 16 studies evaluating 21 symptom-based tools 
 
o Studies were conducted in different settings / populations:  
§ The general population 
§ Primary care 
§ Secondary care +/- screening populations 
 
o Three types of tool were identified:  
§ Symptom checklists 
§ Checklists of symptoms + risk factors or tests (augmented symptom 
checklists) 
§ Diagnostic prediction models 
 
o Tools included various combinations of: 
§ Patient demographics 




o Three symptom checklists and one prediction model were externally validated and 
demonstrated similar (moderate) accuracy 
 







I chose to keep the review question and inclusion criteria broad in order to identify all relevant 
tools, and their constituent variables, in order to inform the development of my prediction 
model (Chapter 6). However, the identified studies were extremely heterogeneous in their 
design, populations, variable definitions, outcome definitions and thresholds, which 
ultimately precluded any meaningful meta-analyses. For example, although the Goff SI was 
evaluated in nine studies there was marked overlap between the participants in three studies; 
control groups ranged from apparently healthy general population participants to hospital 
gynaecology patients (with or without benign pathology); ovarian cancer definitions differed; 
and deviations in the parameters of the SI itself (e.g. required symptom duration and 
frequency criteria) were noted. While I chose not to perform any meta-analysis, the results 
demonstrate how the Goff SI performs in different circumstances.  
 
All included studies were at high risk of bias in at least one QUADAS-2 domain, which limits 
the conclusions that can be drawn. 
 
5.4.3 Tool variables 
All of the tools in this review were symptom-based, but they varied markedly in the symptoms 
they included. This mirrors discrepancies in the literature and within national guidelines, as 
described in Chapter 1, as to which symptoms are associated with ovarian cancer. Some 
variation is also to be expected given the diverse methodologies and populations used to 
develop the different tools. Despite this, the symptoms with the highest positive likelihood 
ratios for ovarian cancer in a recent systematic review (distension, bloating, abdominal or 
pelvic pain) were incorporated into all but a few tools.89 Invariably, the more cancer-
associated symptoms that are included in symptom checklists, the higher the sensitivity of 
the tool, but this comes at a cost to specificity as demonstrated by several studies which 
compared different symptom combinations.239,245,251 This was cited by Goff et al as a rationale 
for not including urinary symptoms in the Goff SI.215 However, minor variation in symptoms 
often had limited impact on performance. For example, on external validation, two studies 
reported similar diagnostic accuracy metrics for the Goff SI and SGO criteria (which differed 
on several symptoms). Also, on internal validation, Lim et al concluded that changing several 
of the symptoms made relatively little difference to tool diagnostic accuracy.251  
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In multiple studies, symptom checklists were augmented by ovarian cancer biomarkers with 
the aim of improving tool diagnostic accuracy. This approach naturally led to a reduction in 
tool specificity (where either symptoms or an abnormal test resulted in a positive tool) or 
sensitivity (where symptoms and an abnormal test were needed for a positive tool). This 
highlights a major limitation of checklist tools. If ovarian cancer biomarkers are to be included 
alongside symptoms or other variables within tools, this loss of performance could be avoided 
by incorporating them within prediction models as per the inclusion of anaemia in QCancer 
Ovarian. Also, a prediction model approach allows for the inclusion of biomarkers as 
continuous variables, the importance of which is discussed in Chapter 3.  
 
5.4.4 Tool performance 
Variation in the reported sensitivity and specificity of the most widely evaluated tool, the Goff 
SI, was noted between studies. This variation is likely to be due in part to the marked 
differences in study design, populations and outcome definitions. Despite these differences, 
in five of the six external validation studies (including two large population-based studies) the 
Goff SI had a sensitivity in excess of 60% and in all but the smallest study, which included only 
24 ovarian cancers and 31 controls, its specificity exceeded 85%. The sensitivities and 
specificities of the two other externally validated symptom checklists – the SGO consensus 
criteria and the modified Goff SI 1 - were similar. Give this, it seems unlikely that significant 
improvements in the diagnostic accuracy of checklists (or models) will be achieved by 
developing new tools with minor modifications to the symptoms. However, demographic and 
test variables did add to, and were retained in, QCancer models. It is possible that the 
performance of these models might be improved by incorporating further predictive 
demographic or test information.  
 
5.4.5 Clinical relevance 
Although a couple of studies included in this review evaluated the diagnostic accuracy of 
checklists incorporating ovarian cancer biomarkers (CA125 and / or HE4), most of the 
identified tools were instead developed in order to help select patients for testing. Such tools 
could be used to identify women at increased risk of undiagnosed ovarian cancer for CA125 
testing in primary care. The CA125 predicted models I have developed and present within this 
thesis could then be used to further inform clinical decision making.  
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Several of the tools identified in this review are already available for use within the clinical 
setting in the form of eCDS tools. For example, QCancer tools are integrated within some UK 
general practice IT systems (EMIS software) and they can alert the clinician if the risk of 
ovarian cancer in an individual reaches a certain level. eCDS tools have been shown to 
improve practitioner performance and patient care in some circumstances.258,259 However, 
there are multiple barriers to their implementation and they do not always lead to improved 
outcomes.259,260 In addition to accuracy (the focus of this review), a tool’s cost effectiveness, 
acceptability to patients and clinicians, and impact on timely ovarian cancer detection and 
survival need to be evaluated. Currently, a large clustered randomised control trial is seeking 
to help address this by investigating the clinical impact of implementing a suite of electronic 
cancer risk assessment tools (including an electronic version of the Hamilton ovarian SI) in UK 
general practice.166 Studies have also sought to evaluate the impact of using tools as part of 
‘proactive symptom triggered testing’ programs i.e. where women are actively screened using 
the tool, with further testing for ovarian cancer occurring if the tool is positive.‡‡ In one study 
in the United States, 5,000 women were approached in primary care clinics and screened for 
symptoms using the Goff SI, with further investigations performed if the Goff SI was 
positive.172 However, conclusions were limited as only 2 ovarian cancers were identified in 
the study window. The DOvE trial also employs a proactive symptom triggered testing 
approach, supported by media campaigns, in which women can self-refer and are screened 
for a range of symptoms prior to study inclusion. Although the final DOvE results are yet to 
be published, a pilot study reported that participants had lower tumour burden and more 
resectable disease than women diagnosed via the standard clinical pathway.55 
 
When considering the clinical utility of a tool it is important to assess the proportion of 
women who are ‘tool positive’ who ultimately have ovarian cancer i.e. the PPV. The primary 
care cohort studies in this review indicated that between 1 in 100 and 1 in 200 women who 
were QCancer tool positive (5% or 10% risk thresholds) had the disease. Although these 
figures may appear low, evidence indicates that some patients would opt for cancer testing 
in clinical presentations with PPVs below 1%.200 Further, having a positive tool result in the 
                                                        
‡‡ Such approaches are often referred to as ‘symptom triggered screening’ in North America (see Goff et al 
2013339) 
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clinical setting does not necessarily mean that further investigation will automatically occur, 
as there may be a clear alternative cause for the symptoms - the tool is simply intended as a 
diagnostic aid to highlight the risk of ovarian cancer to the clinician. In proactive symptom 
triggered testing programs the tool is more than just a diagnostic aid - it is the initial triage 
step which will dictate whether further ovarian cancer tests take place. The two population 
studies reporting PPVs relied on external ovarian cancer prevalence figures, but their PPV 
estimates were similar to that reported in the pilot DOvE study (0.76% in women ≥50 years).55 
Further research is needed to help determine whether, given this PPV, follow-up testing in 




Over 20 symptom-based tools, incorporating a wide variety of variables, have been developed 
to help identify women with ovarian cancer. Four tools – the Goff SI, a modified version of 
the Goff SI, SGO consensus criteria and QCancer Ovarian – have undergone independent 
external validation and exhibit similar sensitivities and specificities. These tools could play a 
role in selecting women for CA125 testing, but their acceptability, cost effectiveness and 
clinical impact need to be evaluated. While checklists including CA125 were identified, these 
either had poor sensitivity or specificity depending on the threshold used to indicate a 
‘positive’ tool result. No prediction models were identified which included CA125.  
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Chapter 6. The development and internal 
validation of ovarian cancer diagnostic 
prediction models for use in symptomatic 




During my doctoral research I sought not only to evaluate how well CA125 performed, but to 
develop novel approaches to augment its performance. Studies have shown that models 
which incorporate a test result alongside other variables associated with a disease can have 
greater diagnostic accuracy than the test alone. For example, prediction models which 
incorporate PSA, demographics, clinical examination findings and additional test results have 
been shown to significantly outperform PSA alone in the detection of prostate cancer in the 
screening setting.169 In Chapter 3, I described the development of a model combining CA125 
level and patient age to estimate the probability of ovarian cancer. As this model contained 
only two variables, it had the advantage of simplicity. However, the predictive ability of 
models tends to improve when multiple important predictive variables are included. Ewout 
Steyerberg, one of the world’s leading experts on prediction models, recommends 
considering between 5 and 20 variables when developing a clinical prediction model.171 In the 
systematic review presented in Chapter 5, I found that a range of variables including patient 
demographics, family and personal medical history, symptoms and test results, had been 
incorporated into tools used for ovarian cancer detection. I postulated that a model 
incorporating these types of variables alongside CA125 would outperform CA125 alone in the 
detection of ovarian cancer in symptomatic women undergoing testing in primary care.   
 
When developing a new prediction model, it is important to evaluate its overall performance 
in terms of its discrimination and calibration. It is also important to consider its diagnostic 
accuracy at clinically relevant thresholds, as thresholds are invariably used to guide 
management when models are implemented in clinical care pathways. For example, NICE 
recommends offering high statin treatment if the QRisk model indicates that a patient’s 10-
year risk of developing cardiovascular disease is ≥10%.164 
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In this chapter, I describe the development of two multivariable diagnostic prediction models 
intended for use in symptomatic women undergoing CA125 testing in primary care. I detail 
their overall performance on internal validation. Given the importance of selecting the most 
appropriate ‘action thresholds’ for use in clinical practice, I also describe the accuracy of 
different model-derived risk-based thresholds. Finally, I explore the potential diagnostic 
implications of applying these thresholds in primary care, using my study cohort as an 
exemplar.  
 
This study addresses my final two thesis objectives:  
 
viii) To develop and internally validate an ovarian cancer diagnostic prediction model 
incorporating symptoms, test results (including CA125), and risk factors. 
ix) To explore the potential diagnostic implications of implementing ‘action 
thresholds’, based on prediction model derived estimated ovarian cancer 
probabilities, within primary care. 
 
The following paper, based on the work described within this chapter, has been submitted 
for publication and, at the time of thesis submission, is under review:  
 
Could ovarian cancer prediction models improve the triage of symptomatic women in primary 
care? A modelling study using routinely collected data. Garth Funston, Gary Abel, Emma J. 
Crosbie, Willie Hamilton, Fiona M. Walter. 
 
6.2 Methods 
6.2.1 Sample size considerations 
This study was performed using data obtained to undertake the CA125 diagnostic accuracy 
study described in Chapter 3. In order to maximise the sample size, I used data from all 
available patients who met selection criteria (Section 6.2.5). No formal sample size calculation 
was performed prior to analysis.  
 
New recommendations for calculating minimum sample sizes for clinical prediction modelling 
studies have recently been published (after this study was commenced) by Riley et al.261 They 
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suggest an approach to calculating the minimum sample size required for modelling studies 
based on the number of predictors being considered, the number of participants, the disease 
incidence and the expected model performance. However, traditionally, the number of 
Events Per Variable (EPV) has been considered the key factor in ensuring adequate sample 
size for prediction model studies.162,171 The EPV is the number of outcomes (in the case of this 
study, ovarian cancers) per predictor being considered for model inclusion (known as 
‘candidate predictors’).171 More strictly, EPV calculations should take account of the total 
number of degrees of freedom from candidate variables.262 For example, if ethnicity is 
categorised into five groups, it would have 4 degrees of freedom and so should be thought of 
as 4 ‘variables’ in EPV calculations. Any other terms included during the model development 
processes, such as interaction and polynomial terms, should also be considered in EPV 
calculations. Too low an EPV risks ‘overfitting’ the model to the derivation sample, so that it 
performs well within that sample but poorly when evaluated in another sample.171 
Importantly, Steyerberg recommends that any variable which is chosen based on patterns 
within the data should be counted within the EPV calculations.  
 
There is significant debate in the literature with regard to the recommended minimum 
number of EPVs for model development studies. The most widely quoted figure is 10 EPVs, 
but some simulation studies indicate that this may be too stringent, with 5 EPVs suggested as 
a minimum.263,264 While the study sample size and number of outcomes was dictated by 
available data, I was mindful of the EPV guidance when identifying variables for model 
development and aimed for an EPV close to 10, with an absolute minimum of 5.  
 
6.2.2 Model variables 
In his highly influential book on clinical prediction models, Steyerberg comments that model 
specification is “the most difficult part of prediction modelling” and that “it is virtually 
impossible to obtain a reliable answer to the question: which predictors are important and 
which are not?”.171 This neatly sums up one of the key challenges I faced in this study: which 
variables, from the myriad recorded within the CPRD, should I include as variables in my 
models? Steyerberg recommends that clinical expertise and evidence from the literature 
should be used as a first step in selecting variables.171 After a list of candidate variables are 
selected based on available evidence and experience, there are two options: include all of the 
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identified variables in the model (full model approach), or use data driven methods to select 
the final variables for model inclusion from the list of candidates. Data driven approaches are 
useful in removing variables which have little or no predictive effect within the model. 
Reducing the number of variables within a model may also improve clinical utility as less 
information needs to be collected when using them.171 I developed two models within this 
study: Model 1 and Model 2. Model 1 was pre-specified (full model approach) and consisted 
of age and CA125. This model is analogous to the age and CA125 model presented in Chapter 
3. Model 2 contained age, CA125 and other variables associated with ovarian cancer risk. To 
determine which variables to include in Model 2 I used a two-step approach: 
 
1) Selection of candidate variables based on expertise and the literature (pre-modelling) 
 
2) Selection of final model variables using data driven selection procedures (during 
modelling) 
 
In the next two sections I describe the first step in variable selection for Model 2. Selection of 
the final variables for Model 2 using data driven procedures is described within Section 6.2.8. 
 
6.2.3 Identifying possible candidate variables 
The first step I took in identifying candidate variables was to carry out a systematic review of 
ovarian cancer detection tools, described in Chapter 5. This identified three broad categories 
of variable: 1) symptoms, 2) tests, and 3) baseline risk factors (demographics, personal and 
family medical history). I considered variables in any of these categories for Model 2. 
However, few of the included studies were explicit about how candidate variables were 
selected and, for those which were explicit, few appeared to have followed a systematic 
approach in their selection. It was not feasible to perform a systematic review, or series of 
reviews, covering all possible risk factors, tests and symptoms of ovarian cancer in order to 
inform variable selection in this study. Instead, I chose to supplement my systematic review 
of ovarian cancer tools with information from high level evidence sources, to help ensure that 
key predictors were not missed from my model (Box 6.1). Using these sources, I developed a 
provisional list comprising more than 40 candidate variables. This list was reviewed by the 
multidisciplinary research team consisting of experienced GPs (Prof Willie Hamilton, Prof 
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Fiona Walter), a statistician (Prof Gary Abel) and a gynaecological oncologist (Prof Emma 
Crosbie). The final list of candidate variables was agreed upon at a consensus meeting. The 
following questions were used to help select candidate variables from the provisional list: 
 
1) Is the variable routinely recorded within primary care records / is there likely to be 
significant missing data? 
2) Is there reasonable evidence for an association with ovarian cancer e.g. from 
systematic reviews and meta-analyses? 
3) Is the variable very similar to other variables that warrants inclusion? If so, would it be 
appropriate to include only one? 
 




A list of variables which were considered, but ultimately rejected as candidates, is included in 
Appendix I alongside the rational for their exclusion. Two excluded variables warrant further 
Symptoms 
 




Key primary care research studies and systematic reviews 
 
Baseline risk factors 
 
World Cancer Research Fund / American Institute for Cancer Research reports on “Diet, 
nutrition, physical activity and ovarian cancer”274 
 
International Agency for Research on Cancer monographs on the identification of 
carcinogenic hazards to humans41 
 
Cancer Research UK: Ovarian cancer risk factor statistics278 
 
Key narrative review articles25,319,322,340 
 
Key systematic reviews and meta-analyses 
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discussion due to their strong associations with ovarian cancer: germline BRCA mutations and 
a family history of BRCA-associated cancers.  
 
As discussed in Chapter 1, germline BRCA mutations significantly increase the risk of ovarian 
cancer in carriers: the cumulative risk for BRCA 1 carriers by age 70 has been estimated at 39-
59%.20,21 Risk of ovarian cancer is also greater in women with family history of breast or 
ovarian cancers, with risk increasing if multiple first degree relatives are affected at a young 
age or at multiple sites.25,26 Of note, family history of ovarian cancer was included in the 
QCancer Ovarian prediction model (Chapter 5). 
 
Despite their importance as risk factors for ovarian cancer, I harboured concerns over the 
quality of the recording of these variables within primary care records. I developed Read code 
lists (Appendix C) for each variable using the code browser supplied by the CPRD. I used these 
lists to identify women in my baseline cohort who had a relevant code within CPRD (recorded 
prior to CA125 testing) and who were subsequently diagnosed with ovarian cancer. I 
compared the proportions of women with relevant codes to figures drawn from the literature 
(Table 6.1). No BRCA mutations were recorded in women prior to CA125 testing and the 
proportions of women with a coded family history of ovarian and breast cancer was much 
lower than published figures. While this comparison has limitations (due to differences in the 
populations, study design and outcome definitions) it did support the assertion that there is 
likely significant missing data pertaining to BRCA status and family history of cancer in the 
CPRD. In addition to poor coding of family cancer history, I felt it was also possible that it 
would be subject to ‘recording bias’, with GPs more likely to ask about and code family history 
if they had a strong suspicion of ovarian cancer.   
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Table 6.1. Comparison of the proportion of ovarian cancer cases in the baseline cohort 
who had codes for a) germline BRCA mutation and b) family history of breast and ovarian 
cancer, with figures drawn from the literature (case-control studies).  
Variable CA125 cohort, %  Published studies, %  
Germline BRCA mutation 0 10-1525 
Family history of ovarian 
cancer 
1.2 2.6-6.2265–267 





6.2.4 Included candidate variables 
19 candidate variables were chosen for inclusion in data driven variable selection procedures 
(Box 6.2). In this section, I summarise the rationale for their inclusion.  
 
Symptoms 
As discussed in Chapter 1, studies have shown that certain symptoms are more common in 
women with ovarian cancer than in healthy controls. Symptoms have previously been 
included in primary care ovarian cancer prediction models e.g. QCancer Ovarian (Chapter 5). 
However, not all symptoms of ovarian cancer are equally predictive. For example, the most 
recent systematic review of ovarian cancer symptoms indicates that abdominal distension is 
more indicative of ovarian cancer (higher positive likelihood ratio) than other symptoms such 
as abdominal pain, appetite loss and fatigue.89 In addition, studies have shown that the PPVs 
for combinations of symptoms are higher than for individual symptoms. Given this, I posited 
that the type of symptom(s) a woman has might contribute to the diagnostic performance of 




Box 6.2. Model 2 candidate variables. 
CIBH = change in bowel habit, IBS = irritable bowel syndrome, CRP = C-reactive protein, BMI 
= body mass index 
 
In the review presented in Chapter 5, 19 different symptoms were included within the various 
ovarian cancer tools. Given the limitations on number of candidate variables, I could not 
include all of these symptoms. Ultimately, I chose the symptoms listed in current NICE 
guidelines as candidates. Most patients who underwent CA125 testing in my cohort are likely 
Symptoms 
• Abdominal / pelvic pain 





• Urinary frequency / urgency 
• Weight loss 














• Personal history of breast cancer 
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to have done so due to one of these symptoms. The NICE list is broad and includes the 
symptoms most strongly associated with ovarian cancer in a recent systematic review: 
abdominal distension, abdominal and pelvic pain, bloating and loss of appetite.89 
Pragmatically, using the NICE symptom list might allow any models developed in this study to 
be more easily incorporated into the current diagnostic pathway.  
 
New diagnoses of Irritable Bowel Syndrome (IBS) in women ≥50 years is unusual and may 
represent misattribution of symptoms such as bloating and change in bowel habit which are 
due to ovarian cancer.92,268 Whilst new IBS does not represent a single symptom, it is 
discussed alongside symptoms in NICE guidelines and I have included it in the symptom 
category in this study for consistency.  
 
Blood tests 
In addition to CA125, two other blood tests were included in the ovarian cancer tools 
identified in my systematic review: HE4 and haemoglobin. HE4 is a promising ovarian cancer 
biomarker (I am currently conducting a prospective pilot study comparing its performance 
against that of CA125 in primary care). However, it is not available within English primary care 
and so could not be included as a candidate variable. By contrast, haemoglobin level (as part 
of a full blood count) is one of the most commonly requested tests in primary care.269 A low 
haemoglobin level was a predictor of ovarian cancer (2.3 fold increased risk) in the QCancer 
ovarian model and so I included haemoglobin level as candidate variable.  
 
Several other routinely performed blood tests have emerged as primary care cancer 
biomarkers in the last few years, most notably platelet count, albumin level and inflammatory 
markers. A large primary care case control study reported that the 2-year incidence of cancer 
was significantly greater in primary care patients with a raised platelet count than a normal 
platelet count.174 Ovarian cancer was the 4th most common cancer in the female 
thrombocytosis group within that study. Low albumin is common in women with ovarian 
cancer in the secondary care setting.270 In addition, a retrospective primary care cohort study 
has reported an association with hypo-albuminaemia and cancer diagnosis (within 12 months 
of testing).271 In 2019 a large primary care case control study found that the one-year 
incidence of cancer was higher in patients with elevations in the inflammatory markers C-
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reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR) and Plasma Viscosity (PV) than 
in patients with normal inflammatory marker levels.175 While research has predominantly 
focussed on the value of platelets, albumin and inflammatory markers as biomarkers for 
cancer in general (rather than specifically for ovarian cancer) I considered that there was 
sufficient evidence to include them as candidate variables.  
 
CRP, ESR and PV are associated with similar inflammatory processes and there is little 
difference between the inflammatory markers in terms of their association with cancer in 
primary care.175 Therefore, in the interests of limiting the number of candidate variables, I 
took only CRP (the most common of the three tests within the baseline cohort) forward into 
data driven variable selection procedures.  
 
Risk / protective factors 
• Age 
As discussed in earlier chapters, the incidence of ovarian cancer varies markedly by age. As 
such, age was included as a candidate predictor variable. 
 
• Ethnicity 
Ovarian cancer incidence rates in England are lower in women of Asian and Black ethnicity 
than of White ethnicity.7,272 Age standardised rates in England (2002-2006) ranged from 17.4-
18.1/100,000 for white women, 9.2-15.5/100,000 in Asian women and 6.6-12.1/100,000 in 
black women. Information on ethnicity was available from both the CPRD and HES APC and, 
on the basis of previous research, I anticipated only around 3% of women would have a 
missing ethnicity in both data sources.273   
 
• Adult attained height 
The 2018 World Cancer research Fund (WCRF) report on diet, nutrition, physical activity and 
ovarian cancer (which is informed by a series of high quality systematic literature reviews) 
found convincing evidence that adult attained height is associated with increased risk of 
ovarian cancer.274 A number of other systematic reviews and meta-analyses have also found 
a significant association between increasing height and increased ovarian cancer risk.36–38 
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Height itself is unlikely to be a causative factor in ovarian cancer development but rather a 
marker for environmental and genetic factors associated with the disease.  
 
• Body Mass Index (BMI) 
In their 2014 report on diet, exercise, physical activity and ovarian cancer, the WCRF reported 
that there was strong evidence that higher body fatness (as measured by BMI) is associated 
with increased risk of ovarian cancer.274 This finding has been corroborated by a number of 
large studies and meta-analyses.34–37  
 
• Personal history of breast cancer 
As discussed earlier in this chapter, genetic mutations, including germline BRCA mutations, 
substantially increase the risk of both ovarian and breast cancer. There is also evidence that 
women with a personal history of breast cancer are at increased risk of subsequent ovarian 
cancer.275 While I discounted BRCA mutations and family cancer history as potential variables 
due to poor data recording, I judged that personal history of breast cancer could be included 
as historical NCRAS data on all cancers diagnosed within the cohort was available (obtained 
specifically for this purpose). 
 
6.2.5 Defining the study cohort 
I saw symptoms as a key category of candidate variable for the development of Model 2. 
However, the fact that symptoms are not always coded within CPRD posed a methodological 
issue - if the baseline cohort were to be used for model development, patients with symptoms 
recorded within free text who lacked a symptom Read code would be misclassified. This could 
lead to biased model estimates, particularly if symptoms are more likely to be coded in severe 
presentations / disease. To mitigate this issue, I applied further restrictions to the baseline 
cohort, excluding women who lacked a Read code for a symptom of ovarian cancer (as listed 
in current NICE guidelines) in their CPRD record in the 12 months prior to their index test date.  
 
NICE recommends that women with a pelvic mass or ascites on examination be referred on 
the urgent cancer pathway rather than be tested for CA125 in primary care, due to the high 
predictive values of these signs.89,114 The models developed in this study were intended to be 
used to help make decisions on further investigation and referral in CA125 tested women. I 
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did not feel that it would be useful, or appropriate, to use these models in primary care in 
women who had such strongly predictive features of disease and who already warranted 
further investigation. I therefore chose to exclude women with a code for a pelvic mass or 
ascites in their CPRD record in the 12 months prior to the index test date.   
 
I utilised a pre-existing symptom Read code list, kindly provided by Professor Willie Hamilton, 
to identify symptoms and signs of ovarian cancer in CPRD in order to define my cohort. To 
ensure that the code list was complete and up-to date, I carried out searches for key symptom 
terms using the Read code browser provided by the CPRD. I identified a few additional 
relevant terms (Appendix C) which were added to the list. I also identified codes for a 
diagnosis of IBS (Appendix C), to be used in women ≥50 years of age, and included them in 
the list. 
 
When preparing my list of candidate variables I considered including a history of 
oophorectomy as a protective factor. However, this was discussed at the consensus meeting 
and we agreed that including women with bilateral oophorectomies would not be 
appropriate as the incidence of ovarian cancer in these women is extremely low.276 For this 
reason, most of the ovarian cancer detection tool studies identified in the systematic review 
(Chapter 5), specifically excluded women with bilaterally oophorectomies. I followed their 
example. I developed a Read code list for bilateral oophorectomy, which was reviewed by 
Professor Emma Crosbie before use (Appendix C). This list was used to exclude women with 
a code for bilateral oophorectomy in their CPRD record at any point prior to the index test 
date. 
 
6.2.6 Preparation of candidate variables 
In this section, I describe the preparation of candidate variables in my study cohort prior to 
statistical analyses. The data source for each variable, in addition to the period of variable 
inclusion (e.g. ever vs the 12 months pre-index test date) and details of any data 
categorisation, are summarised in Table 6.2. As the models were intended to be used at the 
point when a CA125 test has been performed and result made available to the GP, I only 
considered predictor variable data recorded on, or prior to, the index test date. The exception 
to this was ethnicity, as a patient’s ethnicity should remain unchanged. To maximise 
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completeness and minimise the amount of data which had to be imputed I included ethnicity 
recorded at any point in a patient’s record.   
 
Table 6.2. Preparation of candidate variables. 




CPRD Binary for each symptom. 
Presence/absence of: 
abdominal/pelvic pain, appetite loss, 
bloating, distension, change in bowel 
habit, fatigue, urinary 
frequency/urgency, new IBS (≥50 years 
old), weight loss 
In the 12 months prior to CA125 
testing 
Blood biomarkers 
CA125 CPRD Continuous First valid CA125 level in study 
period 




Most recent record on or in the 
12 months prior to the CA125 
test date 




Most recent record on or in the 
12 months prior to the CA125 
test date 





Most recent record on or in the 
12 months prior to the CA125 
test date 





Most recent record on or in the 
12 months prior to the CA125 
test date 
Risk / protective factors 
Age274,278 CPRD Continuous (years) On date of CA125 testing 





Most frequently recorded273 
Height36–38,274 CPRD Continuous (cm) Most recent on/prior to CA125 
test date recorded when ≥18 
years old 
BMI34,35,274 CPRD Continuous (Kg/m2) Most recent on/in the 10 years 
prior to CA125 test date when 










The updated ovarian cancer symptom code list was used to identify all relevant coded 
symptoms in the 12 months prior to the index test date. Each of the nine symptoms were 
coded as a separate binary variable (present / absent). 
 
Blood tests 
While all women in the cohort had a valid CA125 level recorded, not all women had recent 
tests for platelets, albumin or CRP. I considered imputing missing biomarker levels and 
including them in my analyses as continuous variables. However, this would have limited the 
clinical utility of the model as it could then only be used in practice if levels of all biomarkers 
were known for a patient (unless a series of models were developed). I also considered 
dichotomising the biomarkers into a) normal or not performed vs b) raised, as Hippisley-Cox 
et al did for haemoglobin level in the QCancer Ovarian model. There were two arguments 
against this approach. Firstly, dichotomising continuous data leads to a significant loss of 
information; as was demonstrated in Chapter 3, risk can vary substantially with specific test 
levels above a given threshold. Secondly, in their work on inflammatory markers, Watson et 
al found that patients who had a blood test performed had a significantly higher risk of cancer 
than those who did not, even if that test was normal.175 So, I judged that whether or not a 
woman has had a particular test might be predictive in its own right. 
 
Ultimately, I chose to include all blood tests, save for CA125, as categorical variables. Using 
patterns within the data to decide upon categories can lead to overfitting and so is not 
recommended by Steyerberg.171 Therefore, I avoided data driven categorisation and used 
information from published studies, existing models and standard reference ranges to 
categorise each blood test into 3-4 categories (including a no test group). The distributions of 
test levels were only reviewed to ensure that no group was particularly small (<~2% of the 
cohort), as small groups can affect the reliability of prediction model estimates.171 
 
• CA125 
The preparation of CA125 level data has been described previously (Chapter 2). The index 
CA125 level was kept as a continuous variable for analyses. 
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• Platelet count  
Codes for platelet count (Appendix C), recorded in the test file of the CPRD on or in the 12 
months preceding the index test date, were identified. Where multiple platelet counts 
existed, the most recent was used. Where multiple platelet counts occurred on the same day, 
I used the mean.  
 
The standard upper reference range for platelets is 450 x 109/L. However, there is evidence 
that patients with ‘high normal’ platelet counts in primary care have a greater incidence of 
cancer than those with ‘low normal’ counts.279 This was taken into account when categorising 
platelets. 4 categories were used:   





• Haemoglobin level 
I identified codes for haemoglobin level (Appendix C), recorded in the test file of the CPRD on 
or in the 12 months preceding the index test date. Entries recorded in g/L were converted to 
g/dl. Where multiple haemoglobin levels existed, the most recent was used. Where multiple 
haemoglobin levels were recorded on the same day, I used the mean.  
I categorised women into three groups: 




• Albumin level 
I identified codes for albumin level (Appendix C), recorded in the test file of the CPRD on or 
in the 12 months preceding the index test date. Where multiple levels existed, I used the most 
recent. Where multiple albumin levels were recorded on the same day, I used the mean. I 
Initially categorised albumin level in line with Merriel et al,271 with hypalbuminaemia broken 
down into ‘mild’, ‘moderate’ and ‘severe’. These groups were small (severe 
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hypoalbuminaemia [<30g/L] contained only 140 women), so I generated a single 
hypoalbuminaemia group. The final categories were: 
 
1) Not tested 
2) <35 g/L 
3) ≥35 g/L 
 
• CRP level 
Codes for CRP level (Appendix C), recorded in the test file of the CPRD on or in the 12 months 
preceding the index test date, were identified. Where multiple levels existed, I used the most 
recent. Where multiple CRP levels were recorded on the same day, I used the mean. 
Reference ranges for CRP vary depending on the clinical application e.g. assessment for acute 
infection or as a risk marker for cardiovascular disease. Greater than 3 mg/L is often 
considered abnormal.280 I categorised women into the following groups:  
 
1) Not tested 
2) <3 mg/L 
3) 3-9.99 mg/L 




The preparation of patient age is described in Chapter 2. I used age in years at index test date, 
as a continuous variable, in this study. 
 
• Ethnicity 
Ethnicity is recorded within the CPRD using hierarchical codes which map to 1991 and 2001 
census categories. I used a Read code list, developed by Mathur et al,273 to identify codes for 
ethnicity recorded at any point within a woman’s CPRD record. These codes can be classified 
into 16 census categories which further collapse into 5 overarching groups (Table 6.3). A 
patient may have ethnicity coded more than once within their CPRD record and have different 
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coded ethnicities. I followed the approach taken by Mathur et al to determine patient 
ethnicity from CPRD:273 
1) If a single ethnic group was recorded, I accepted that group 
2) If more than one ethnic group was recorded, I accepted the most common ethnic 
group 
3) If more than one ethnic group was recorded with the same frequency (i.e. a ‘tie’), I 
accepted the most recent ethnic group recorded 
4) If there was a tie on the most recent date, I recorded CPRD ethnicity as missing 
 
Not all patients have an ethnicity recorded within the CPRD, but HES APC data provided an 
additional source of ethnicity information. In HES APC, ethnicity is classified as one of 11 
categories which map to the 5 ethnic groups listed in Table 6.3. Only one ethnicity is recorded 
for each patient in HES APC (HES use a similar approach to that used by Mathur et al to 
prepare ethnicity before it is provided to researchers).192 Where ethnicity data was missing in 
CPRD, I accepted the HES ethnicity.  
 
Table 6.3. Five group and 16 group ethnic categories. 
Five ethnic groups 16 ethnic categories 
White British or mixed British 
Irish 
Other White 
Mixed White + Black Caribbean 
White + Black African 
White + Asian 
Other mixed 
Asian Indian or British Indian 
Pakistani or British Pakistani 
Bangladeshi or British Bangladeshi 
Other Asian 
Black Caribbean  
African 
Other Black 
Other ethnic groups Chinese 
Other 
 
I initially classified ethnicity into the five groups, but the numbers of women in individual 
ethnic groups, other than White, were small e.g. 160 women (0.56%) were of Mixed ethnicity. 
So, I further collapsed five group ethnicities into two groups: “White” and “other ethnicity”. 
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Where no ethnicity could be identified, either from CPRD or HES APC data, multiple 
imputation was used to replace it (Section 6.2.7).  
 
• Height 
Patient height was identified from the Additional file in the CPRD. As the majority of women 
reach their maximum height by age 18 years, I used data recorded when women were 
≥18years.281 Heights recorded in metres were converted to cm. Implausible values for height 
were excluded (<1.21m and >2.14m). The plausible height range used encompasses both the 
lower and upper 99.6 centiles for women at age 18 years and has previously been used in 
CPRD research.282,283 After excluding implausible heights, I identified the most recent height 
recorded (on or prior to the index test date) for each patient. Multiple imputation was used 
to replace missing height data (Section 6.2.7). 
 
• Body Mass Index (BMI) 
I calculated BMI for patients using the most recent plausible weight (excluding <20kg) 
recorded within the Additional file of the CPRD in the ten years prior to the index test date, 
and the most recent height (excluding <1.21m and >2.14m) recorded on or prior to the index 
test date. Plausible ranges were informed by the literature.283,284 I took the pragmatic 
approach of excluding weights recorded more than ten years prior to the index test date due 
to the possibility of significant weight change during that period. Measurements recorded at 
ages <18 years were also excluded. Where more than one weight or height were recorded on 
the same day, I used the mean in my BMI calculation. As in other CPRD studies, where no BMI 
could be calculated directly from weight and height due to missing data, I accepted the most 
recent directly entered BMI value recorded in CPRD on, or in the ten years prior to, the index 
test date.35,283 I excluded implausible BMI measurements (<5kg/m2 and >200kg/m2). The 
choice of a plausible BMI range was informed by the literature.35,283 Where no BMI could be 
ascertained, it was replaced by multiple imputation (Section 6.2.7).  
 
• Personal history of breast cancer 
I identified women with in situ or invasive primary breast cancer recorded in either the cancer 
registry (ICD10 codes C50 and D05) or the CPRD (code list provided by Professor Willie 
Hamilton, Appendix C) on or prior to the index test date. Although there are issues with 
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recoding of cancer diagnoses in the CPRD (as discussed in Chapter 2), I chose to include it as 
a data source to improve completeness as cancer registry data is only available from 1990 
onwards. 
 
6.2.7 Missing data 
A proportion of women did not have a recorded ethnicity, height or BMI. I could have 
excluded patients without complete data for all candidate predictors and have performed a 
complete case analysis (CCA). However, this would have reduced the sample size and could 
have introduced a selection bias. An alternative approach to CCA is to impute the missing 
information into the data set. Simple approaches can be used, such as replacing missing 
continuous data with the mean value or missing categorical data with the modal group. 
However, these approaches do not account for correlations between different variables and 
underestimate variability in the data. Using correlations between variables within a dataset, 
regression imputation can be used to predict and impute missing data to create a single 
complete dataset, but this approach fails to capture the inherent uncertainty in the imputed 
data points. For these reasons multiple imputation (MI) is often the favoured approach to 
imputation.171 In MI, an imputation model uses correlations between variables within the 
dataset to replace missing data multiple times, thereby generating multiple complete 
datasets. This allows the uncertainty in the imputed values to be captured. Following the 
imputation step, analysis is performed separately on each imputed dataset and then the 
results are combined across the datasets. A downside of multiple imputation is that working 
with multiple datasets complicates data handling and analysis.285  
 
When considering which approach to use for missing data (complete case analysis vs MI) it is 
helpful to explore the potential ‘mechanism’ by which the data is missing. There are three 
broad mechanisms of missingness: 
 
1) Missing completely at random (MCAR) – Neither unobserved data nor the missing value 
predicts missingness 
 
2) Missing at random (MAR) – Other known variables (observed data) predict missingness 
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3) Missing not at random (MNAR) – The value of the missing variable itself predicts whether 
it is missing 
 
I explored potential mechanisms of missingness within my data, using logistic regression, and 
found that missing ethnicity, height and BMI were associated with other candidate variables. 
This indicates that their mechanism of missingness is not MCAR and so a CCA approach would 
not have been appropriate, as the retained patients may not be representative of the 
sample.171 It is not generally recommended that MI be performed if a NMAR mechanism is 
suspected (due to the risk of biased imputations) but there is no way to distinguish MAR from 
MNAR without obtaining the missing data. For the purposes of this study I assumed that 
missing data were MAR and used a MI approach.  
 
I used multivariate imputation by chained equation (MICE) to impute missing data.286 MICE 
allows different models to be chosen for the imputation of different types of variable e.g. 
linear regression for continuous variables and logistic regression for binary variables. Linear 
regression was used to impute height and BMI data while logistic regression was used for 
two-category ethnicity. An imputation model should contain at least as many variables as the 
prediction model (the principal of congeniality).171 So, all candidate variables (main effect and 
non-main effect) and the outcome variable, were included in my imputation model. Where 
variables were transformed, this was done prior to their inclusion in the MI model. When 
performing MI, the number of imputations must be specified. Stata recommends performing 
a minimum of 20 imputations.287 Some authors recommend that the number of imputations 
should be similar to the proportion of patients with missing data.288,289 14.2% of women in 
my study cohort had missing data for one or more variables, so I chose to perform 20 
imputations thereby generating 20 ‘complete’ datasets. Following imputation, I examined the 
means, standard errors and ranges of imputed BMI and height data and the categories of 
ethnicity, confirming that imputed data were reasonable.  
 
6.2.8 Model derivation  
Prior to model derivation, I mean-centred all continuous variables. BMI and CA125 level were 
right skewed, so were log transformed. As discussed in Chapter 3, the relationship between 
log CA125 and age with ovarian cancer is non-linear, so restricted cubic splines (5-knots) were 
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once again generated for log CA125 and age.208 To account for a possible interaction between 
CA125 level and age I generated an interaction term. 
 
Model 1 (age and CA125 level) was pre-specified and was derived by performing logistic 
regression on the study dataset. In order to develop Model 2, a logistic regression model 
containing all predictor variables was fitted to the data using the mi estimate command, 
which applied Rubin’s rules to adjust coefficients and standard errors for the variability 
between the 20 imputed datasets.287 To select the final variables for inclusion in Model 2, I 
used a backward elimination approach removing the least significant variable, then refitting 
the model and repeating until all retained variables had a p value of ≤0.05. The Wald test was 
used to assess the significance of each categorical variable. There is no consensus within the 
literature as to which significance threshold to use in data driven variable selection 
procedures.171 For small data sets, large p-values are often recommended while for very large 
samples small p-values are recommended.171 Given a reasonably large study sample size, I 
chose to apply the standard p-value. Variable coefficients were used as weights for both 
models. 
 
For Model 2, I examined 19 candidate variables with a total of 32 degrees of freedom (main 
effect and non-main effect), giving an EPV of 9. 
 
6.2.9 Discrimination and calibration 
In order to assess model discrimination, I calculated the AUC of each model. For Model 2, the 
AUC was calculated for each imputed dataset and Rubin’s rules were used to combine results 
across imputed datasets. Calculating the AUC directly from the data from which the models 
were developed provided the apparent performance. However, apparent performance can 
give an overly optimistic impression of model performance due to overfitting. I used 10-fold 
cross-validation as a method of internal validation in order to assess for optimism in AUC 
estimates. In 10-fold cross-validation, the sample is split into ten equal groups, the model is 
developed in one of these groups and tested on the remaining sample.171 This is repeated ten 
times so that each group is used both in development and testing of the model. The mean 
AUC across the ten iterations is then calculated. I used the cvAUROC user written command 
in Stata to perform this analysis.290 For Model 2, I calculated the cross-validation AUC for each 
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imputed data-set then combined these across imputed datasets in accordance with Rubin’s 
rules. The directly computed AUCs were compared with the cross-validation AUCs in order to 
quantify model optimism.  
 
For the purpose of comparison, the AUC of CA125 was calculated directly from the study 
cohort using the Roctab command in Stata.206 
 
As recommended by Van Calster et al,291 I calculated the calibration slope (with 95% 
confidence intervals) of models on internal validation (10-fold cross validation). I used a 
version of cvAUROC command which had been modified for this purpose by Prof Gary Abel. 
For Model 2, this code used Rubin’s rules to combine the results across imputed datasets in 
order to give a single slope metric. The calibration slope provides an indication of whether, 
on average, a model over- or under-estimates risk. The perfect slope is 1. Slope values less 
than 1 indicate that the model estimated probabilities are too extreme (too high in those at 
high risk and too low in those at low risk).291 A slope greater than 1 indicates the reverse.   
 
6.2.10 Thresholds for further investigation 
I devised thresholds to identify women with a ≥1%, ≥2% and ≥3% probability of undiagnosed 
ovarian cancer based on the models. The lowest threshold – ≥1% – was selected as patients 
have reported that they would opt for cancer investigations at this risk level.200 The highest 
threshold – ≥3% – was chosen to match the risk threshold used by NICE in 2015 when making 
recommendations on urgent specialist cancer investigation or referral for symptomatic 
primary care patients.57 I compared the diagnostic accuracy (sensitivity, specificity, PPV and 
NPV) of these model thresholds with that of CA125 at the conventional cut-off (≥35 U/ml).114 
I compared specificity, PPV and NPV of the model thresholds to that of CA125 cut-offs with 
equivalent sensitivities. This allowed me to explore whether there was any benefit, in terms 
of diagnostic accuracy, in using model derived probability thresholds to guide management 
rather than simply using different CA125 cut-offs. I applied the thresholds to the study cohort 
and prepared schemata to illustrate the potential implications of using different model 





6.3.1 Study cohort 
After applying the additional exclusion criteria to the baseline cohort, 29,962 women 
remained and formed the cohort for this study (Figure 6.1). Of these, 279 (0.9%) were 
diagnosed with ovarian cancer in the 12 months following CA125 testing. 
 
 
Figure 6.1. Application of additional study criteria to the baseline cohort. 
 
 
The baseline characteristics of the cohort are shown in Table 6.4. The mean patient age was 
55 years (range 18-101 years, standard deviation: 15 years). Ethnicity was missing for 1,234 
(4.1%), height for 1,721 (5.7%) and BMI for 2,986 (10%) women. 14.2% of women had missing 
data for at least one of these variables. Where recorded, mean height and BMI were very 
similar to those reported for women in the Health Survey of England.292  
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Table 6.4. Cohort baseline characteristics.  
Figures shown are numbers, (percentage), [standard deviation] and {interquartile range}. 
Variable  N=29,962 
Risk / protective factors 
Mean age (years) 55 [15] 
Ethnicity: 
White 26,511 (88.5) 
Other ethnicities* 2,217 (7.4) 
Mean height (cm)  162 [6.8] 
Median BMI (Kg/m2) 25.8 {22.8-29.7} 
Personal history breast cancer 1,168 (3.9) 
Symptoms 
Abdominal/pelvic pain 17,538 (58.5) 
Appetite loss 203 (0.7) 
Bloating 5,649 (18.9) 
Distension 821 (2.7) 
CIBH 5,808 (19.4) 
Fatigue 3,968 (13.2) 
Urinary frequency/urgency 1,503 (5) 
≥50yrs of age with new IBS 286 (1) 
Weight loss 1,168 (3.9) 
Blood biomarkers 
Median CA125  12 {8-17} 
Albumin: 
Not tested 3,723 (12.4) 
<35 g/L 834 (2.8) 
≥35 g/L 25,405 (84.8) 
Haemoglobin: 
Not tested 1,648 (5.5) 
<12g/dl 3,089 (10.3) 
≥12g/dl 25,225 (84.2) 
Platelets: 
Not tested 1,679 (5.6) 
<300x109/L 20,442 (68.2) 
300-449x109/L 7,314 (24.4) 
≥450x109/L 527 (1.8) 
CRP: 
Not tested 13,181 (44) 
<3 mg/L 6,907 (23.1) 
3-9.99 mg/L 7,370 (24.6) 
≥10 mg/L 2,504 (8.4) 
 
The majority of women (n=17,538, 58.5%) had abdominal/pelvic pain recorded in the year 
prior to CA125 testing. Bloating and change in bowel habit were also common, recorded for 
5,649 (18.9%) and 5,808 (19.4%) women respectively. Appetite loss was the least common 
symptom, recorded for only 203 (0.7%) women.  
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The majority of patients had blood tests performed in the year before CA125 testing. An 
albumin level was recorded for 26,239 (87.6%), haemoglobin level for 28,314 (94.5%), 
platelets for 28,283 (94.4%) and CRP for 16,781 (66%) women.  
 
6.3.2 Final models 
Of the 19 candidate variables considered for inclusion in Model 2, age, ethnicity, BMI, height, 
abdominal/pelvic pain, distension, CA125 level, platelet level and albumin level were retained 
after backward elimination procedures. The coefficients and odds ratios for variables included 
in the models are presented in Table 6.5 for reference. In Model 2, the Other ethnic category 
was associated with lower odds of ovarian cancer than White ethnic category. Increasing log 
BMI and height were both associated with increasing odds of ovarian cancer, as were the 
coding of abdominal/pelvic pain and abdominal distension. Unexpectedly, the odds of ovarian 
cancer were lower in groups of women with a recorded platelet count and a recorded albumin 
level than in the no-test group, although confidence intervals spanned 1 for several of these 
test groups.
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Table 6.5. Coefficients and odds ratios for variables included in Model 1 and Model 2. 
 Model 1 Model 2 
Variable Coef. (95% CI) Odds ratio (95% CI) Coef. (95% CI) Odds ratio (95% CI) 
Baseline risk factors 
Age: 
Age spline 1 
 
-0.079 
(-0.136 – -0.022) 
 
0.924 
(0.873 – 0.978) 
 
-0.077 
(-0.136 – -0.018) 
 
0.926 
(0.873 – 0.982) 
Age spline 2 
 
0.537 
(0.223 – 0.852) 
1.712 
(1.250 – 2.345) 
0.520 
(0.199 – 0.841) 
1.682 
(1.220 – 2.319) 
Age spline 3 
 
-2.169 
(-3.910 – -0.428) 
0.114 
(0.020 – 0.652) 
-2.025 
(-3.798 – -0.253) 
0.132 
(0.022 – 0.777) 
Age spline 4 1.712 
(-0.516 – 3.940) 
5.539 
(0.597 – 51.420) 
1.542 
(-0.724 – 3.808) 
4.674 
(2.81x10-6 – 0.018) 
Ethnicity: 
White 




Other   -0.906 
(-1.756 – -0.055) 
0.404 
(0.173 – 0.947) 
Log BMI   0.965 
(0.224 – 1.705) 
2.624 
(1.251 – 5.503) 
Height (cm)   0.040 
(0.017 – 0.062) 
1.041 
(1.017 – 1.064) 
Symptoms 
Abdominal / pelvic pain   0.412 
(0.089 – 0.735) 
1.510 
(1.093 – 2.087) 
Distension   0.648 
(0.034 – 1.261) 
1.911 
(1.035 – 3.530) 
Tests 
Log CA125: 
Log CA125 spline 1 
 
1.129 
(-2.386 – 4.643) 
 
3.092 
(0.092 – 103.862) 
 
1.043 
(-2.429 – 4.516) 
 
2.839 
(0.088 – 91.447) 
Log CA125 spline 2 -7.114 
(-26.469 – 12.241) 
0.0008 
(3.19x10-12 – 2.07x105) 
-6.592 
(-25.805 – 12.622) 
0.001 
(6.21x10-12 –  3.03x105) 
Log CA125 spline 3 82.537 
(-17.899 – 182.973) 
7.01x1035 
(1.69x10-08 – 2.91x1079) 
78.551 
(-21.420 – 178.521) 
1.30x1034 
(4.98x10-10 –   3.39x1077) 
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Log CA125 spline 4 -143.749 
(-267.564 – -19.934) 
3.72x10-63 
(6.3x10-117 – 2.20x10-09) 
-137.307 
(-260.776 – -13.839) 
2.33x10-60 
(5.6x10-114 – 9.77x10-07) 
Platelets: 
No test 




<300x109/L   -0.699 
(-1.350 –  -0.048) 
0.497 
(0.259 – 0.953) 
300 – 449 x109/L   -0.378 
(-1.053 – 0.297) 
0.685 
(0.349 – 1.346) 
≥450 x109/L   -0.103 
(-0.885 – 0.678) 
0.902 
(0.413 – 1.971) 
Albumin: 
No test 






  -1.241 
(-1.951 – -0.531) 
0.289  
(0.142 – 0.588) 
≥35 g/L   -0.106 
(-0.625 – 0.413) 
0.899  
(0.535 – 1.511) 
Coef. = variable coefficient. CI = confidence interval
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6.3.3 Discrimination and validation 
The AUC of CA125 alone, calculated directly from the study dataset, was 0.932. Model 1 and 
Model 2 both had an AUC of 0.938, when calculated directly from the dataset (apparent 
performance) (Table 6.6). On cross-validation, both models had an AUC of 0.935. There was 
little difference between apparent and cross-validation AUCs for each model, indicating that 
overfitting/optimism was minimal. A ROC curve for CA125 and cross-validation ROC curves 
for the models are included in Appendix J for reference. Both models had calibration slopes 
close to 1, indicating that overall they did not markedly over or underestimate risk. However, 
confidence intervals were wide. 
 
Table 6.6. Model discrimination and calibration. 
Model Apparent AUC Cross-validation AUC Cross-validation 
calibration slope (95% CI) 
Model 1 0.938 0.935 1.01 (0.606-1.42) 
Model 2 0.938 0.935 1.05 (0.673-1.42) 
AUC = area under the curve 
 
6.3.4 Thresholds for further investigation 
As the more parsimonious Model 1 exhibited the same AUC and similar calibration metrics to 
Model 2, my evaluation of thresholds for further investigation focussed on Model 1. The 
diagnostic accuracies of Model 1 thresholds (for the detection of ovarian cancer within 12 
months of CA125 testing) are shown in Table 6.7. In order to examine whether using the 
Model had any benefit over using different CA125 cut-offs, these are presented alongside 
CA125 cut-offs with equivalent sensitives. At the ≥1% probability threshold, the specificity of 
Model 1 was 3.1% higher than a CA125 cut-off with the same sensitivity (≥23 U/ml), while 
there was a less marked difference at higher model probability thresholds. For all model 
thresholds, the PPV was higher than for CA125 cut-offs with equivalent sensitivities.  
 
The ≥1% model threshold was 7.9% more sensitive, but 5.4% less specific, than the national 
CA125 cut-off. The ≥2% model threshold had the same sensitivity as the national CA125 cut-
off and similar specificity. A ≥3% model threshold was 2.9% less sensitive and 2.4% more 
specific than the national CA125 cut-off.  
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Table 6.7. Diagnostic accuracy metrics for a range of Model 1 thresholds and CA125 cut-
offs with equivalent sensitivities.  



























































Figure 6.2 illustrates the potential implications of applying the different model thresholds to 
the study cohort of 29,962 women. In comparison to the national CA125 cut-off, applying a 
probability threshold of ≥1% resulted in an additional 1,622 women being identified for 
further evaluation for ovarian cancer. Of these, 22 (1.4%) had ovarian cancer (i.e. an 
additional 1 in every 74 women identified for further evaluation had ovarian cancer). Applying 
a ≥3% model probability threshold, instead of the current CA125 cut-off, resulted in 706 fewer 
women being identified for further evaluation of whom 8 (1.1%) had ovarian cancer. Applying 
a ≥2% model threshold, instead of the current CA125 threshold, resulted in 58 fewer women 











A model consisting of CA125 and age demonstrated excellent discrimination and calibration 
for the identification of ovarian cancer in symptomatic women undergoing CA125 testing in 
primary care in England. Incorporating additional baseline risk factors, symptom type and 
routine blood test results within the model did not improve performance. Although the AUC 
of this model was only slightly higher than that of CA125 alone, at a fixed sensitivity Model 1 
showed superior specificity and PPV at a range of thresholds. When a ≥1% probability 
threshold was applied to my cohort, rather than the current CA125 cut-off (≥35 U/ml), one in 
74 of the additional women identified by the model had ovarian cancer. Key study findings 
are summarised against objectives in Box 6.2. 
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Box 6.2. Key results against chapter objectives. 
 
6.4.2 Study limitations 
The dataset used in this study provided information on a wide range of variables for a large 
number of women. However, use of routinely collected data did limit the candidate variables 
I considered for Model 2. For example, I did not include family history of ovarian cancer, a 
viii) To develop and internally validate an ovarian cancer diagnostic prediction 
model incorporating symptoms, test results (including CA125), and risk 
factors 
o A diagnostic prediction model (Model 2) was developed which incorporated 
nine variables: 
§ Baseline risk factors: age, ethnicity, BMI, height  
§ Symptoms: abdominal/pelvic pain, distension 
§ Test results: albumin level, platelet count and CA125 level  
o This model showed excellent discrimination, with minimal evidence of 
optimism on cross-validation 
o However, this performance was matched by a much simpler model comprising 
age and CA125 level (Model 1) 
 
ix) To explore the potential diagnostic implications of implementing ‘action 
thresholds’, based on prediction model derived estimated ovarian cancer 
probabilities, within primary care 
o When applied to my study cohort of 29,962 women: 
§ A ≥3% Model 1 probability threshold was 2.9% less sensitive, 2.4% 
more specific and had a 6.6% higher PPV than the current CA125 cut-
off 
§ A ≥1% Model 1 probability threshold was 7.9% more sensitive but 5.6% 
less specific, with a 5% lower PPV, than the current CA125 cut-off 
o On applying a ≥1% Model 1 probability threshold to my cohort, rather than the 
current CA125 cut-off, one in 74 of the additional women identified by the 




strong risk factor, due to concerns over data completeness and recording bias. Concerns over 
the lack of coding of symptoms within CPRD led me to exclude 19,691 women (who did not 
have a symptom coded in the 12 months prior to CA125 testing) from my study cohort. In so 
doing, my sample size was reduced so the risk of model overfitting and of imprecise 
probability estimates increased. This limited the number of candidate variables I included in 
model development. While this approach ensured that I developed my models in a population 
of women with at least one relevant symptom of possible ovarian cancer, it did not entirely 
resolve the problem with missing symptom information. For example, a woman may have 
abdominal pain coded, and so be included in the study cohort, but a second symptom e.g. 
bloating, may be recorded in free text rather than being coded. There is also the possibility 
that the models may not be fully generalisable to women with a symptom which has not been 
coded, as symptom coding may be a marker for symptom/disease severity or GP concern. An 
alternative approach would have been to include all women from my baseline cohort in this 
study, regardless of whether they had a coded symptom or not. With such an approach I 
would have been quantifying the predictive ability of having a symptom coded 
(acknowledging that some patients may have un-coded symptoms). This would have been 
appropriate given the way in which clinical prediction models are often used in clinical 
practice: an algorithm embedded within the GP software searches the patient record and 
provides the clinician with a risk level and clinical recommendation based on the coded data. 
 
I was conscious of the of EPV recommendations when selecting candidate variables for model 
development. The final EPV of 9 for Model 2 was just below the commonly recommended 
EPV of 10. However, following model development I performed a post hoc calculation of the 
minimum recommended sample size for this study, in line with the new guidelines from Riley 
et al published in 2020, using the pmsamplesize command in Stata.293 Given an outcome 
proportion of 0.093, an EPV of 32 and a Cox-Snell R2 (a measure of model performance) of 
0.013,§§ the minimum recommended sample size for this study was 21,994 women. This 
provides added reassurance that my sample size was adequate.  
 
                                                        
§§ The R2 was calculated using a predeveloped excel template (provided by Prof Gary Abel) and assumed an 
AUC of 0.92. 
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Although potential predictors of ovarian cancer were carefully identified from the literature 
in order to develop Model 2, there are several possible explanations as to why their inclusion 
did not ultimately improve model performance.  
 
In contrast to the prediction model studies reviewed in Chapter 6, all women in my model 
development cohort had at least one symptom of possible ovarian cancer. Therefore, the 
predictive effect of having a relevant symptom was, to some extent, already accounted for 
prior to model development. In addition, I only included women who had been selected by 
their GP for CA125 testing. GPs do not test all women with symptoms such as bloating or 
abdominal pain for ovarian cancer: my cohort is likely to consist of those women who, on the 
basis of their clinical presentation, were judged at to be at higher risk. It is possible that if my 
models were developed as part of a prospective study in which all women with relevant 
symptoms presenting to primary care were tested for CA125, the risk associated with having 
a symptom would have been more accurately accounted for and Model 2 may have 
outperformed Model 1. However, the aim of this study was not to develop a model for use in 
all women presenting to their GP with possible symptoms of ovarian cancer, but to develop 
a model to aid the triage of women who are tested for CA125 by their GP. 
 
Missing data on symptoms may have limited the performance of Model 2 as the predictive 
effect of a given symptom could not be fully accounted for. I only included women with a 
coded symptom in my model development cohort, but symptom coding may indicate more 
severe symptomology or a greater suspicion of ovarian cancer,187 so my model development 
cohort may have had a higher overall risk of ovarian cancer than my baseline cohort. It is 
possible that if Model 2 had been developed using the entire CA125 tested cohort, and if all 
symptoms were accurately coded, strongly predictive symptoms such as abdominal 
distension may have had a greater predictive effect within the model. Even within my model 
development cohort, missing data on symptoms could have limited model performance as 
although all patients had one symptom coded they may have had other symptoms which 
were not coded and so the predictive effect of a given symptom may not have been accurately 
accounted for within the model.  
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I selected baseline risk factors as candidate variables for Model 2 based on the published 
literature. However, the risk associated with most of these variables in the literature was 
relatively modest e.g. an increase in height of 10cm was associated with a relative risk of 1.16 
in one meta-analysis.36 While both height and BMI were retained within Model 2, their 
contribution to ovarian cancer prediction within a symptomatic population, when included 
alongside CA125 (a very strong predictor), was ultimately negligible. 
 
I internally validated models using a cross-validation approach. This indicated that there was 
minimal model overfitting (which can be caused by limited sample size and data driven 
variable selection techniques). However, internal validation does not provide an indication of 
the generalisability of the models outside the study sample. This study utilised the CPRD GOLD 
database, which collects data from GP practices using Vision software. The structure and 
recording of variables in other databases, which collect primary care data from practices using 
alternative IT software (such as QResearch which collects data from GP practices using EMIS 
software), may differ from that of CPRD GOLD. In addition to structural differences there are 
also likely to be differences in the populations and cancer incidence rates between databases 
e.g. due to different UK regional coverage. For these reasons, models tend to perform less 
well on external validation. If the models developed in this study are to be implemented 
within English primary care, they should ideally be externally validated to ensure adequate 
performance.  
 
6.4.3 Comparison with existing literature 
In the systematic review presented in Chapter 5 I did not identify any primary care diagnostic 
prediction models which included symptoms and CA125. Existing primary care diagnostic 
prediction models, such as QCancer Ovarian,54 were developed in general primary care 
populations (which included both women with and without symptoms) with the aim of 
identifying higher risk women for tests such as CA125, whereas I developed the models in this 
study within an entirely symptomatic CA125 tested population. Similarly, the performance 
metrics of secondary care diagnostic models, such as the Risk of Ovarian Malignancy 
Algorithm (ROMA) and the Risk of Malignancy Index (RMI), are not comparable as they were 
developed in women known to have a pelvic mass, with the aim of distinguishing between 
benign and malignant masses.294,295 These models also include more specialist tests (ROMA: 
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the HE4 biomarker, RMI: transvaginal ultrasound). This is the first study to develop and 
internally validate multivariable CA125 predicated models within the symptomatic primary 
care population. 
 
6.4.4 Model variables 
Baseline patient risk factors, routine blood test results and the type of symptoms with which 
patients present, have previously been found to be predictive of ovarian cancer in general 
practice,296 and so were included as candidate variables in this study. Variables in each of 
these categories were predictive of ovarian cancer (to some extent) and were therefore 
selected during data driven procedures for inclusion in Model 2. However, the odds ratios for 
the majority of these variables were modest and confidence intervals wide. The numbers of 
patients with some model variables were low e.g. only 2.7% of women had distension, which 
limits the contribution a variable can have to the overall AUC of a model. Surprisingly, the 
association of platelet count and albumin level with ovarian cancer within Model 2 were the 
opposite of what was anticipated - odds were lower in women who had a test than in those 
who had not had a test. The reasons for this are unclear, but it is possible that GPs request 
multiple blood tests, including CA125, if they are uncertain of the cause of a symptom, 
whereas they request CA125 in isolation if they have a high suspicion of ovarian cancer. 
 
I did not develop a prediction model containing only CA125 level. Age is available for all 
patients within GP records and laboratory systems and implementing a model with age and 
CA125 in clinical practice would be no more complex than implementing one consisting solely 
of CA125 level. By contrast, the number of variables in Model 2 would make its 
implementation more complex and its use more challenging (e.g. a user would have to enter 
BMI, height and ethnicity manually if not coded in the patient record) for no material gain 
over Model 1 in terms of diagnostic performance.  
 
6.4.5 Clinical relevance of findings 
If alternative ‘action thresholds’ were to be implemented in clinical practice, in place of the 
≥35 U/ml CA125 cut-off, the results of this study indicate that there is diagnostic benefit in 
selecting them using Model 1 rather than simple CA125 cut-offs, particularly at lower risk 
levels. The model has the additional benefit that the individual probability of ovarian cancer 
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can be provided to the patient, if they wish it, and be used to help inform individual decisions 
on whether to have further investigation or not. It also allows action to be taken at particular 
risk thresholds set out in guidelines e.g. the ≥3% NICE threshold for urgent investigation. Use 
of a low model probability threshold in clinical practice e.g. ≥1%, in place of the ≥35 U/ml 
CA125 cut-off, might expedite diagnosis of some ovarian cancer cases but would increase the 
number of women without cancer who undergo unnecessary further investigation. In Chapter 
7, I consider this in more detail and discuss how Model 1 thresholds might be incorporated 
within the ovarian cancer diagnostic pathway in England. 
 
6.5 Conclusion 
A model consisting of age and CA125 level performed well for the detection of ovarian cancer 
in symptomatic women in English primary care. Including additional variables within the 
model did not improve performance. Following external validation, this model could be used 








The overarching aim of this thesis was to evaluate the diagnostic performance of CA125 for 
the detection of cancer when used in primary care and to develop and evaluate novel 
approaches to improve its performance and clinical utility.  
 
In Chapter 3, I presented the first large study to evaluate the accuracy of CA125 in primary 
care, which demonstrated that the test performs well for the detection of ovarian cancer in 
this setting. At 10.1%, the PPV of CA125 at the national cut-off (≥35 U/ml) was 12 times higher 
than the estimate NICE used to inform the development of guidelines covering testing for 
ovarian cancer in primary care in 2011.114 
 
Through logistic regression analyses, I demonstrated that the probability of ovarian cancer 
varies markedly depending on the specific CA125 level and patient age. This means that the 
overall PPV of CA125 at the conventional cut-off is of limited use to clinicians and patients 
when interpreting their individual CA125 results. Instead, I present (and have made freely 
available)209 estimated ovarian cancer probabilities (based on CA125 level and age) which 
could be used by patients and GPs to inform individual decisions about the need for further 
investigation.  This information could also be used by policy makers to inform guidelines so 
that thresholds for referral are based on an individual’s cancer probability rather than a 
generic CA125 cut-off.   
 
This thesis primarily focusses on ovarian cancer detection. However, perhaps the most 
striking finding was that older women without ovarian cancer but with elevated CA125 levels 
had a very high probability of having another form of cancer (e.g. 20.4% if ≥50 years with a 
CA125 ≥35 U/ml). This reflects the non-specific nature of ovarian cancer symptoms (which 
overlap with symptoms of other malignancies) and the non-specific nature of CA125 itself 
(which can be raised in a variety of other malignancies). Most of these other cancers have 
more accurate triage tests, so CA125 is unlikely to be of value as an investigation for any 
specific cancer (other than ovarian) in primary care. However, recognition by clinicians, 
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patients and policy makers that a high CA125 level is a multi-cancer risk marker in older 
women, could aid earlier diagnosis.  
 
In Chapter 4, I explored the association between pre-diagnostic, primary care CA125 test 
result (‘normal’ vs ‘abnormal’) with test-diagnosis interval and stage in women with ovarian 
cancer. I found that, although women with normal CA125 results took markedly longer to be 
diagnosed than those with abnormal CA125 results, they commonly had indolent tumour 
types and were usually diagnosed at an early stage. This should provide some reassurance for 
those using, and being tested for, CA125 in primary care. However, given the study design, I 
was unable to determine what proportion of women with false negative CA125 results 
progressed during their extended test-diagnosis intervals. Even progression within the early 
stage cancer category (e.g. from I to II), or an increase in tumour burden, will have prognostic 
implications for women. Given the long test-diagnostic intervals experienced by a proportion 
of women with normal CA125 results (>6 months in 15%), their expedited diagnosis could 
improve outcomes.  
 
In Chapter 5, I presented a systematic review of symptom predicated multivariable tools for 
the detection of ovarian cancer. I identified 21 tools, including several secondary care 
checklists which incorporated CA125 alongside symptoms, but no CA125 containing 
prediction models. Four tools (none of which incorporated CA125) had undergone external 
validation and exhibited similar (moderate) diagnostic accuracy. Such tools could be used in 
primary care to select women for ovarian cancer tests such as CA125, but further evaluation 
is needed to determine their acceptability, cost-effectiveness and clinical impact. The 
variables included in tools fell into three categories: 1) symptoms, 2) risk / protective factors 
and 3) tests. This helped guide my selection of candidate variables for my subsequent 
prediction modelling study (Chapter 6). 
 
In Chapter 6, I described the development and internal validation of ovarian cancer diagnostic 
prediction models for use in symptomatic women who have had a CA125 test performed in 
primary care. In women with a relevant symptom code in their GP records in the year prior to 
CA125 testing (a sub-sample of my baseline cohort), a model consisting of age in years and 
CA125 level exhibited excellent discrimination on cross-validation (AUC: 0.94%). Including 
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information on symptom type, baseline risk factors and routine blood test results in the 
model, alongside CA125 and age, did not improve performance.  
 
I explored the sensitivity and specificity of various model-based probability thresholds and 
considered the implications of applying them to the study cohort. A model threshold, set to 
detect women with a ≥1% estimated probability of ovarian cancer, had a 7.9% higher 
sensitivity but 5.4% lower specificity compared with a CA125 cut-off of ≥35 U/ml. The overall 
PPV of this ≥1% model probability threshold remained high at 6.9%. Applying this threshold 
to my cohort in place of a CA125 of ≥35 U/ml, 1 in every 74 additional women identified had 
ovarian cancer. Using this model threshold in clinical practice as an action threshold might 
help identify more women with ovarian cancer in a timely way, but would also result in more 
women without ovarian cancer undergoing unnecessary further investigation.  
 
Collectively, the evidence presented in this thesis indicates that CA125 is a useful test for the 
detection of ovarian cancer in primary care and that a high CA125 level should also raise the 
suspicion of other types of cancer, especially if ovarian cancer has been excluded. A relatively 
simple multivariable prediction model (age + CA125) can provide patients and clinicians with 
the estimated probability of ovarian cancer, which could be used to inform individual 
decisions about the need for further investigation. This information could also be used by 
policy makers, such as NICE, when developing guidelines so that referral recommendations 
are based on cancer probability.  
 
7.2 Strengths and limitations 
I have set out the strengths and limitations of each study in detail within the relevant 
chapters. Here, I summarise important strengths and limitations which should be considered 
when interpreting my thesis findings and their clinical implications. 
 
I consider the use of data from the CPRD as a major strength. The CPRD, which is considered 
generally representative of the UK population in terms of key demographics,178 provided 
information on 50,780 CA125 tested women, making this one of the largest studies ever 
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conducted on CA125 or the diagnosis of ovarian cancer to date.*** Moreover, by using 
routinely collected data, I could evaluate the performance of the test as it is used within 
routine general practice. Blood test results are automatically transferred from laboratories to 
GP records (and then collected within the CPRD). While I identified some issues with CA125 
recording (e.g. issues with units), the data generally appeared to be of high quality. Another 
strength of this study was the use of NCRAS data to identify outcomes. Not only is NCRAS 
considered more accurate than CPRD and HES in terms of cancer recording,198 but it also 
provides information on tumour type and stage at diagnosis which were used within this 
thesis.    
 
However, routinely collected data has its limitations. A significant limitation of CPRD and 
NCRAS is the presence of missing data. As symptoms are not always coded in GP records, it 
was unclear why some CA125 tests were performed in the baseline cohort. The recording of 
stage has improved in NCRAS in recent years but is not complete:198 stage was missing for 
16% of ovarian cancers in my baseline cohort. Moreover, missing stage was more common 
for women with normal CA125 levels prior to diagnosis (likely due to the higher proportion of 
borderline tumours in this group), which could have introduced bias into my stage analysis in 
Chapter 4. Due to concerns over the coding of symptoms, I excluded 39% of my baseline 
cohort (who did not have a relevant symptom code in the year prior to CA125 testing) from 
my model development cohort in Chapter 6. Excluding women without a symptom code may 
have introduced selection bias, as symptoms are more likely to be coded (rather than 
recorded in the free text) in patients with, than without, cancer.187 However, a model 
consisting CA125 and age (analogous to Model 1) was also developed using the whole 
baseline cohort (Chapter 3).  
 
Cross-validation of the CA125 level and age-based model in Chapter 6 indicated that there 
was minimal overfitting. Nevertheless, it is possible that, due to differences in populations or 
CA125 testing patterns or recording, the model may perform differently when evaluated in 
alternative databases such as QResearch or CPRD AURUM,179 or in clinical practice using 
                                                        
*** In the UKCTOCS trial slightly fewer women (50,640) had a CA125 test.154 The work presented in Chapter 3 
includes more CA125 tested women than any other study at the time of writing (April 2021).  
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different GP records systems. TRIPOD guidelines and Steyerberg recommend that external 
validation should ideally be performed prior to clinical implementation of new prediction 
models to ensure generalisability of predictions.162,171 This was not feasible as part of this 
thesis, but I am planning to externally validate my CA125 and age based model as part of a 
post-doctoral study. 
 
7.3 Key clinical implications 
I have presented the clinical implications of each research study in detail in the relevant 
chapters. Here, I consider how the findings of this thesis as a whole could be used to improve 
cancer diagnostic pathways. 
 
7.3.1 Ovarian cancer 
Current NICE guidelines on ovarian cancer detection were developed using an estimated PPV 
for CA125 which, although it was based on the best available evidence at the time, this thesis 
has shown to be incorrect.114 Economic modelling and the recommendation for sequential 
primary care testing (CA125 then ultrasound) before referral, was predicated on this 
estimate. In light of the findings presented in this thesis I recommend that these guidelines 
be reviewed and a fresh economic evaluation performed.  
 
My logistic regression analyses indicated that older women with CA125 levels above 35 U/ml 
already have a probability of ovarian cancer ≥3% (e.g. 32 U/ml equates to a 3% probability in 
a 70-year-old). Yet, under NICE guidelines, these women are required to have an ultrasound 
in primary care before they qualify for an urgent cancer referral. As primary care ultrasounds 
usually take several weeks to be performed in England,297 this could delay ovarian cancer 
diagnosis. In addition, NICE requires that both the primary care CA125 test and ultrasound be 
abnormal for a woman to qualify for an urgent specialist referral. Given that ultrasound can 
be normal in women with elevated CA125 levels prior to ovarian cancer diagnosis,152 such a 
sequential primary care testing approach also risks delaying diagnosis due to false negative 
ultrasound results. The models presented in this thesis could be used to select women for 
urgent cancer pathway referral, in line with the NICE 3% threshold, thereby helping to ensure 
that women at high risk of undiagnosed cancer receive prompt specialist assessment, 
diagnosis and treatment.  
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In addition to selecting women at high risk for urgent referral, the CA125 and age-based 
model presented in this thesis could be used to identify women at ‘low risk but not no risk’ of 
ovarian cancer. For example, those with a probability of ovarian cancer between 1-3%, who 
might be offered non-urgent evaluation or interval re-assessment. This evaluation could 
involve interval CA125 re-testing, as most women who are retested in primary care prior to 
diagnosis have rising CA125 levels (Chapter 4), a referral for a non-urgent transvaginal 
ultrasound or, given the additional risk of non-ovarian cancers, perhaps a referral to a Rapid 
Diagnostic Centre (RDC) (Section 7.3.4). As demonstrated in Chapter 6, applying a 1% model 
threshold will identify more ovarian cancers than the current CA125 cut-off. This could help 
reduce diagnostic delay related to false negative CA125 results (Chapter 4), which has the 
potential to improve patient outcomes.  
 
Figure 7.1 illustrates an example of a two-tier risk-stratified triage approach using model 
probability thresholds. Such an approach is likely to result in more non-urgent investigation 
in primary care (‘low risk but not no risk’ women) and more urgent cancer referrals (higher 
risk women). Any such change in guidelines would require a full health economic evaluation, 
to assess the potential impact of the strategy on the healthcare service and on patients, as 
most of those investigated would ultimately not be diagnosed with ovarian cancer. A health 
economic evaluation would also be valuable in ensuring that the most appropriate model 
thresholds are chosen for use in the risk-based triage approach. The model thresholds 
presented within this thesis are of particular relevance to the healthcare system in England. 
However, following validation in appropriate local data-sets, the model could be used to 




Figure 7.1. Example risk-based triage system employing model probability thresholds. 
 
7.3.2 CA125 testing in young women 
Given that ovarian cancer is rare in younger women, it was surprising that 39% of CA125 tests 
in my baseline cohort were performed in women under 50 years of age. Age is known to play 
a part in whether women opt for cancer investigation, with a large vignette study finding that 
women aged 40-59 are more likely to opt for investigation when presented with the same 
clinical scenario as women aged ≥70 years.200 While further research would be needed to 
understand why there is such a high rate of CA125 testing in younger women, it represents 
relative over-testing in younger (lower risk) women compared to older (higher risk) women. 
The models presented in this thesis take account of age and, if used in practice, should aid 
the interpretation of CA125 results in younger women, who have relatively low ovarian cancer 
probabilities even at CA125 levels around the national cut-off. This could help avoid 
unnecessary further investigation. Reducing the number of younger women who undergo 
inappropriate CA125 tests in the first place could also help prevent unnecessary further 
investigations and referrals. Guidelines and GP education material should reinforce that 
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ovarian cancer is relatively rare in younger women and also that CA125 is less accurate (lower 
AUC and lower sensitivity, specificity and PPV at the ≥35 U/ml cut-off) in this age group.    
 
7.3.3 Other cancers 
A key clinical message of this thesis is that a high CA125 level in older women in primary care 
should raise the suspicion of non-ovarian cancer if ovarian cancer has been excluded. 
International guidelines, including those produced by NICE, should be updated to highlight 
this. Various approaches could be taken to help identify these cancers in a timely way. These 
are considered in the next section.  
 
7.3.4 The diagnostic pathway 
This thesis focusses on the initial testing step within the diagnostic pathways for ovarian 
cancer, but timely detection of ovarian cancer also depends on the accuracy of subsequent 
steps of the pathway. The refining ovarian cancer test accuracy scores (ROCkeTS) study, a 
large prospective study evaluating a range of diagnostic tests and algorithms for ovarian 
cancer in UK secondary care (including different approaches for ultrasound interpretation), is 
due to report later in 2021. ROCkeTS could provide insight into the most appropriate post-
CA125 testing strategy for ovarian cancer.298 However, the research presented in this chapter 
highlights the need for any such strategy not only to consider ovarian cancer, but also to 
consider non-ovarian cancers. Transvaginal ultrasound may detect endometrial cancer and 
some cancers which cause marked ascites, but is likely to miss many (if not most) CA125 
elevating non-ovarian malignancies in addition to a proportion of ovarian cancer. Further 
research is required to identify the most appropriate diagnostic strategy, but I would like to 
highlight three possible approaches to post-CA125 testing that I believe warrant 
consideration and further evaluation (Figure 7.2).  
 
a) Increased awareness and targeted cancer investigation 
NICE guidelines recommend that if a woman has an abnormal CA125 test but a normal 
ultrasound scan, the GP should consider alternative causes for the patient’s symptoms.57 If 
GPs are made aware of the high risk of non-ovarian cancer in these women they could use 
available patient information (including patient risk factors and symptoms) and clinical 
judgement to select the most appropriate targeted cancer investigations or make a specialist 
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referral where appropriate. This could be supported by education programs and by updating 
NICE guidelines to highlight the high cancer risk in this group and to encourage GPs and 
gynaecologists to consider whether further cancer specific investigations are needed.  
 
b) Referral to a Rapid Diagnostic Centre (RDC) 
The symptoms with which patients present to their GP prior to cancer diagnosis are often 
non-specific and, as discussed in Chapter 3, may be caused by multiple different types of 
cancer.57,299 A recent study from Denmark found that in the year prior to diagnosis of an 
abdominal cancer, patients frequently underwent specific investigations more appropriate 
for the diagnosis of another type of cancer.300 For example, >10% of patients diagnosed with 
oesophageal cancer had an abdominal ultrasound scan and >7% of patients with renal cancer 
had a gastroscopy or colonoscopy procedure. In patients with non-specific symptoms, the risk 
of individual cancers may be relatively low, but the combined risk of having some form of 
cancer can be relatively high.57,301 This reflects the situation in women 50 years or older with 
high CA125 levels but no ovarian cancer. 
 
Multidisciplinary Diagnostic Centres (MDCs) were first set up in Denmark in 2012,302 and have 
now been successfully trialled across five sites in England as part of the Accelerate Coordinate 
Evaluate (ACE) program.303 Their aim is to expedite diagnosis in patients with non-specific 
(‘low risk but not no risk’) symptoms by providing rapid assessment and access to a range of 
urgent cancer tests which are often not available to GPs in the community (e.g. urgent 
abdominopelvic CT). Based on this model, a roll-out of Rapid Diagnostic Centres (RDCs) across 
England was recommended as part of the NHS long term plan published in 2019.68 Specific 
guidance was also published by NHS England in 2019 which recommended that all Cancer 
Alliances set up at least one RDC before the end of 2020,304 but this roll-out has been affected 
by the COVID-19 pandemic. Women with high CA125 levels (or a high cancer probability 
derived from the all-cancer model, Chapter 3) but a normal ultrasound scan, could be referred 
directly to RDCs in order to expedite cancer investigation, diagnosis and treatment. 
 
c) Direct access urgent CT scans  
CT can detect multiple CA125-elevating cancer types including ovarian, lung and pancreatic 
cancer.305–308 It is already recommended in some countries as an alternative (or additional) 
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investigation to ultrasound in women with symptoms of possible ovarian cancer.116 CT could 
serve as a multi-cancer test in women in England with high CA125 levels (or a high all-cancer 
probability derived from the cancer model, Chapter 3) but normal ultrasound scans.†††  
 
In his 2020 report on diagnostic services in England, Professor Sir Mike Richards 
recommended the establishment of ‘community diagnostic hubs’ which would provide access 
to a range of specialist investigations (including CT) to GPs.309 If established, these hubs could 
facilitate direct GP access to CT investigation in women with high CA125 levels and normal 
ultrasound scans. Alternatively, CT imaging could be requested in secondary care, in women 
referred to gynaecology due to suspicion of ovarian cancer, following specialist assessment 
and investigation for ovarian pathology.  
 
A CT based testing approach would require substantial research prior to any widespread 
implementation – I discuss this further in Section 7.4.3.  
                                                        
††† I have already been contacted by a clinical group in England who are considering how best to implement 
such an approach in their region. 
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Figure 7.2. Possible cancer diagnostic strategies in women with high CA125 levels but 
normal ultrasound scans. 
 
7.4 Further research 
7.4.1 Ovarian cancer models 
While a CA125 and age based diagnostic prediction model has potential clinical utility,  
significant further work is required to translate this model into clinical practice and to ensure 
its effectiveness (Figure 7.3).  
 
Ideally, the model should undergo external validation in a distinct dataset to ensure 
generalisability. A number of datasets are available including the large CPRD AURUM 
database.179 A health economic evaluation should also be performed to help determine 
whether a two-tier, risk-based triage approach (discussed above) is likely to be cost effective 
and to help determine which model probability thresholds should be implemented.  
 
The model must then be integrated within clinical IT systems in a way that is useful for GPs. 
Studies have reported regulatory and technical challenges in implementing models and this 
is further complicated by the fact that there are multiple distinct clinical IT systems used by 
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GPs in the UK and that each system operates in a different way.310 GPs have reported a 
number of barriers to the use of eCDS tools, including lack of time (e.g. when data has to be 
entered manually), prompt fatigue (when the clinical system provides an ‘alert’ at a given 
model risk level), interoperability issues with software (when the eCDS tool is not embedded 
within the GP IT system), lack of trust in the tool and a belief that it does not aid clinical 
decision making.259,310 A key advantage of my ovarian cancer model is its simplicity: only age 
and the CA125 level are required. This means that it could either be integrated within 
laboratory IT systems or GP software. The probability estimate and a clinical recommendation 
could then be provided alongside the CA125 lab result so it is available to the GP when they 
come to review the report and discuss the result with the patient. Therefore, the information 
would be provided at a time point when it is of most use to the GP, no information need be 
self-populated and the risk of prompt fatigue and interference with workflow would be 
minimal. Qualitative work involving GPs and patients should be undertaken to elucidate their 
views on the acceptability of options for implementation in order to ensure that the model is 
implemented in a way which helps rather than hinders clinical decision making. A pilot 
implementation study could also be performed to ensure that there are no major barriers to 
its use.310  
 
 




I plan to develop a grant application to support the further evaluation and implementation of 
this model as outlined above. If this work is successful, I anticipate submitting evidence to 
NICE in order for them to consider recommending the model for use as part of the ovarian 
cancer diagnostic pathway. Following implementation, a mixed methods study could be 
performed to assess tool uptake and its impact on clinical decision making. Routinely 
collected primary care and NCRAS datasets could be used to assess the clinical impact of the 
model on diagnostic interval, stage at diagnosis and survival.166 
 
7.4.2 International utility of the model 
As demonstrated in the review in Chapter 1, CA125 is already used in primary care in a 
number of countries other than England.  Its use is not currently recommended in primary 
care in some countries due to a lack of evidence on test accuracy, but this thesis provides 
evidence that CA125 performs well in primary care. The CA125 and age-based ovarian cancer 
prediction model presented within this thesis could therefore have international utility.  
 
 The performance of CA125 and the model may differ in countries where the characteristics 
of the population are distinct (e.g. different ethnicity) or the test is used differently (e.g. lower 
threshold for testing) from England. I am currently working with collaborators on a project 
which will explore the use and accuracy of CA125 in a primary care dataset from the north-
west of the United States. If successful, I anticipate collaborating on a study using a large 
routinely collected data source from the United States, such as that available from the 
healthcare provider Kaiser Permanente,311 to validate my diagnostic prediction model. 
 
7.4.3 Post-CA125 testing: non-ovarian cancers 
The finding that older women with high CA125 levels in primary care are at high risk of non-
ovarian cancer is novel. Therefore, the pathways to diagnosis of women with non-ovarian 
cancer in this group have not been explored. It is unclear what proportion of women with 
non-ovarian cancers will be detected on transvaginal ultrasound. It is plausible that having a 
raised CA125 level could result in diagnostic delay in these women (as they enter the wrong 
diagnostic pathway) but further research is needed to determine if this is the case. I am 
currently exploring the potential for using routinely collected primary / secondary care data 
or an existing dataset from a clinical trial, to examine the sensitivity of ultrasound for non-
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ovarian cancers in women with high CA125 levels and to describe their ultimate pathway to 
diagnosis.  
 
I have presented three potential approaches for the investigation of older women with 
elevated CA125 levels but without ovarian cancer. Given the high risk of ovarian cancer in 
these women, I recommend that Approach a (recommend GPs consider targeted 
investigations for other cancers) be implemented in England without delay. Approach b 
(referral to an RDC) could also be adopted as RDCs are rolled out and its impact evaluated 
within the wider evaluation of RDCs in England.309 Approach c (performing a direct access 
urgent CT scan) would require further research before implementation to determine whether 
it is beneficial. Research would need to evaluate the accuracy of CT for non-ovarian cancer in 
this group. Given the risk of overdiagnosis, the potential for harm (both psychological and 
physical) from false positive CT scan results and the fact that the majority of women 
undergoing CT would ultimately not be diagnosed with cancer, it would also be important to 
ascertain the acceptability and the cost effectiveness of such an approach. 
 
I plan to develop a postdoctoral fellowship application focussed on optimising the post 
CA125-testing strategy and diagnostic pathway for the detection of both ovarian and non-
ovarian cancers. 
 
7.4.4 The best initial test(s) 
This thesis has focussed on CA125, as this is the recommended first line test for ovarian cancer 
in England. However, as highlighted in the review in Chapter 1, this approach is not universal. 
Even within the UK there is variation, with both CA125 and ultrasound recommended in 
parallel as first line tests in Scotland.109 There are no published studies which compare 
different first line tests or test combinations for the detection of ovarian cancer in primary 
care.114 Studies conducted in other settings have shown that CA125 is normal in some women 
and ultrasound abnormal (or vice versa) prior to ovarian cancer diagnosis.55,114,152 Using the 
tests in parallel is therefore likely to result in better sensitivity but at the cost of specificity, 
something which was acknowledged by NICE when developing ovarian cancer guidelines in 
2011.114 A comparison of the diagnostic performance of CA125 and ultrasound (alone and in 
combination) would be useful to help to determine the optimal primary care testing strategy. 
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CPRD now provide linkage to the HES Diagnostic Imaging Dataset (HES DID) which provides 
information on what imaging tests have been performed and when.312 However, it does not 
include the results of those imaging tests. I am not aware of any available large UK dataset 
which contains coded or free text information on primary care requested ultrasound results. 
This makes the evaluation of ultrasound in primary care much more challenging than the 
evaluation of CA125. A further challenge in using routinely collected data to compare CA125 
and ultrasound in England is that ultrasound is the second line test: not all women who have 
a CA125 test will have had an ultrasound scan. Ideally (if routinely collected data is to be 
used), the comparison should be made using data from a country, such as Scotland, where 
both tests are recommended as first line investigations. I am currently exploring available 
regional datasets within the UK, and also internationally, which could be used to compare the 
performance of these tests alone and in combination. This may necessitate the use of natural 
language processing (NLP) techniques to extract outcome information from ultrasound scan 
reports.313  
 
7.4.5 Biomarkers for other cancers 
I believe that the work presented within this thesis demonstrates that to understand how a 
test performs within primary care it must be studied within a primary care population. It is 
important that this is recognised when translating new biomarkers from higher risk settings 
to primary care. The recently published CanTest framework provides a ‘best practice’ guide 
for researchers, outlining the steps that should be undertaken, from the initial evaluation of 
a newly discovered test in a high risk population to its implementation and assessment in a 
low risk population.314 This could help improve the implementation of cancer diagnostic tests 
within primary care in the future. 
 
However, CA125 is not the only cancer biomarker to be implemented in primary care without 
prior evaluation of its diagnostic performance within this setting. Just as CA125 is 
recommended by NICE for women presenting with symptoms of possible ovarian cancer, PSA 
is recommended for men presenting with symptoms of possible prostate cancer.57 In their 
comprehensive 2015 evidence review, NICE identified a single, small (N=582) study on PSA 
diagnostic performance in symptomatic men, conducted in the United States, with which to 
inform their recommendations.57 PSA is a common primary care test: a recent cohort study 
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(which used routinely collected data from over 2 million men) found that more than a fifth of 
men in England (aged 40-74 years) had at least one PSA test performed in primary care with 
10 years follow-up.315 This rose to 44% with 19 years follow-up (1998-2017). An 
understanding of the diagnostic accuracy of PSA in primary care (both in symptomatic men 
and in men undergoing opportunistic screening) and knowledge of the probability of prostate 
cancer at specific PSA levels could help guide decisions on the need for specialist referral. It 
could also inform guidelines both in the UK and internationally. I intend to apply the methods 
learnt during my doctoral research to evaluate PSA and develop clinically useful prediction 
models which incorporate the test level. At the time of thesis submission, a grant proposal 
(on which I am co-principal investigator) is at the second stage of the review process for an 
NIHR grant. If successful, the work described in Chapter 3 and Chapter 6 will effectively be 
repeated for PSA. This grant proposal was informed by my experiences during my doctoral 
research and I have adjusted the methods accordingly. For example, rather than exclude men 
without a symptom code (as I did during model development in Chapter 6) we plan to include 
all men. This means that we will consider the predictive power of the presence of a symptom 
code within our models, which is appropriate given that eCDS tools are usually auto-
populated with coded information drawn from the patient clinical record.  
 
7.5 Conclusion 
The research presented within this thesis improves our understanding of the diagnostic 
performance of CA125 when used in primary care. It demonstrates that, at the conventional 
cut-off (≥35 U/ml), the test has a high PPV, NPV, specificity and sensitivity for ovarian cancer. 
However, it also shows that the probability of ovarian cancer varies dramatically depending 
on a woman’s specific CA125 level and age. The probability of ovarian cancer, derived from a 
relatively simple CA125 and age-based model, could be used in clinical practice to help 
patients and GPs interpret individual test results and make informed decisions about the need 
for further investigation. This information could also be used by policy makers to support a 
risk-based triage system, so that national referral thresholds for ovarian cancer are based on 
the probability of disease in an individual, rather than using a generic CA125 cut-off.  
 
The novel finding that older women with elevated CA125 levels who do not have ovarian 
cancer are at high risk of other forms of cancer should change clinical practice both in England 
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and internationally. While further research is needed to determine the most appropriate 
approach to investigate these women, it is important that clinicians are aware that elevated 
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Abstract
Background: Women with ovarian cancer can present with a variety of symptoms and signs, and an increasing range
of tests are available for their investigation. A number of international guidelines provide advice for the initial
assessment of possible ovarian cancer in symptomatic women. We systematically identified and reviewed the
consistency and quality of these documents.
Methods: MEDLINE, Embase, guideline-specific databases and professional organisation websites were searched in
March 2018 for relevant clinical guidelines, consensus statements and clinical pathways, produced by professional or
governmental bodies. Two reviewers independently extracted data and appraised documents using the Appraisal for
Guidelines and Research Evaluation 2 (AGREEII) tool.
Results: Eighteen documents from 11 countries in six languages met selection criteria. Methodological quality varied
with two guidance documents achieving an AGREEII score! 50% in all six domains and 10 documents scoring !50%
for “Rigour of development” (range: 7–96%). All guidance documents provided advice on possible symptoms of ovarian
cancer, although the number of symptoms included in documents ranged from four to 14 with only one symptom
(bloating/abdominal distension/increased abdominal size) appearing in all documents. Fourteen documents provided
advice on physical examinations but varied in both the examinations they recommended and the physical signs they
included. Fifteen documents provided recommendations on initial investigations. Transabdominal/transvaginal
ultrasound and the serum biomarker CA125 were the most widely advocated initial tests. Five distinct testing
strategies were identified based on the number of tests and the order of testing advocated: ‘single test’, ‘dual
testing’, ‘sequential testing’, ‘multiple testing options’ and ‘no testing’.
Conclusions: Recommendations on the initial assessment and investigation for ovarian cancer in symptomatic
women vary considerably between international guidance documents. This variation could contribute to differences in
the way symptomatic women are assessed and investigated between countries. Greater research is needed to evaluate
the assessment and testing approaches advocated by different guidelines and their impact on ovarian cancer
detection.
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tests, Cancer biomarkers, Symptom-triggered testing, Primary care, Clinical guidelines, Cancer pathways
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: gf272@cam.ac.uk
1The Primary Care Unit, Department of Public Health and Primary Care,
University of Cambridge, Cambridge, UK
Full list of author information is available at the end of the article
Funston et al. BMC Cancer         (2019) 19:1028 
https://doi.org/10.1186/s12885-019-6211-2
Background
Worldwide, ovarian cancer is the seventh most common
cancer in women, with over 200, 000 new cases each
year [1]. While once considered a silent killer, it is now
recognised that symptoms occur in all stages of disease,
although studies differ in the symptoms they report and
the positive predictive value (PPV) they attribute to each
symptom [2–5]. Given the modest PPVs of individual
symptoms, e.g. 0.3% for abdominal pain and 2.5% for
abdominal distension, symptoms alone cannot be used
to diagnose ovarian cancer, but are routinely used to
guide further assessment, including physical examination
and testing [4].
An increasing range of tests are used in the initial investi-
gation of symptomatic women for ovarian cancer, includ-
ing the serum protein biomarker CA125 and imaging
modalities such as transabdominal and transvaginal ultra-
sound, Computed Tomography (CT) and Magnetic Reson-
ance Imaging (MRI). Algorithms that combine test results
with patient characteristics such as age or menopausal
state e.g. the Risk of Malignancy Index (RMI) and the
ADNEX model, have also been developed to help predict
ovarian cancer risk in women presenting with a pelvic
mass [6, 7]. However, debate exists regarding the most
accurate testing strategy for ovarian cancer. There is very
limited research evaluating tests for the initial investigation
of symptoms within the primary care setting [8, 9], where
most women with this condition first present [10].
Given the discrepancies in the research literature on
symptoms and the variety of testing options available,
guidance documents, such as clinical practice guidelines,
consensus statements and clinical care pathways, have
been produced to aid clinicians in making practical deci-
sions regarding the management of women with possible
ovarian cancer. As these documents have the potential
to significantly affect the care and healthcare outcomes
for large numbers of patients, they should be rigorously
developed, grounded in the evidence, and make unam-
biguous recommendations [11, 12].
In this review, we set out to systematically identify and
assess the quality of international guidance documents
covering the initial assessment for ovarian cancer in
symptomatic women. In addition, we aimed to assess the
consistency of guidance documents in terms of the
symptoms and signs they include and the physical exam-
inations and tests they recommend, to gain an insight
into international variation in clinical practice.
Methods
Study selection
We selected documents that provided guidance on the
initial assessment of women presenting with symptoms
that might represent ovarian cancer i.e. an assessment
conducted at the point at which women present with
symptoms and enter a given healthcare system. As such,
guidance documents that solely provided advice on in-
vestigation or management of women after a pelvic mass
had been identified, a specialist referral made or a diag-
nosis of ovarian cancer given, were excluded. As this
review focussed on guidance for women presenting with
symptoms, the most common mode of ovarian cancer
presentation [10, 13], documents which solely provided
advice on screening of asymptomatic women or on the
investigation of incidental pelvic masses, were excluded.
Documents where guidance was limited to sub-groups
of patients, e.g. hereditary cancer syndromes, were also
excluded. Only documents produced by professional or
governmental bodies and published within the ten years
before 13th March 2018 were included. There were no
language restrictions.
Search strategy
Searches were conducted in Embase and MEDLINE. The
MEDLINE search strategy is presented in Additional file 1:
Figure S1. Additional searches were performed in guideline
specific databases, namely, the National Guideline Clearing
House, the Turning Research Into Practice (TRIP) data-
base, the Guidelines International Network, the Canadian
Partnership Against Cancer guidelines database, the Can-
adian Medical Association Infobase and the National Insti-
tute of Health and Care Excellence (NICE) website. All
searches were performed between 1st and 13th of March
2018. The websites of more than 20 relevant international
governmental and professional bodies were hand searched
to supplement the database searches.
Guideline selection
Two reviewers independently assessed titles and abstracts.
Where either reviewer felt that a document met selection
criteria or that it was not possible to exclude on the basis
of title and summary alone, the full text was obtained and
reviewed against the criteria. Disagreements were resolved
by consensus.
Data extraction
Two reviewers, fluent in the language of guideline publi-
cation, independently extracted data using a specifically
developed template. Discrepancies in extraction were re-
solved by consensus.
Information on document characteristics (e.g. develop-
ment body, year of development) and the process of
development was collected. We classified documents
into one of four categories, which best described their
intended purpose and the development process, namely:
(1) full Clinical Practice Guidelines (recommendations
on patient care, informed by a systematic review of the
evidence and taking account of benefits, harms and al-
ternatives) [11]; (2) Short Guides (focused summary
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recommendations for patient care, not necessarily based
on a full systematic literature review); (3) Consensus State-
ments (clinically relevant advice based on the opinion of
an expert panel) [14], and (4) Clinical Pathways (a struc-
tured multidisciplinary plan of patient care, not necessarily
based on a full systematic literature review) [15].
The healthcare system for which a guideline is devel-
oped will influence the recommendations. We applied a
simplified version of the classification system developed
by Bohm et al, categorising healthcare systems into three
groups: National Health Service, National/Social Health
Insurance and Private Health System [16].
Data relating to three components of the initial patient
assessment were extracted: symptoms, physical examina-
tions/signs, and investigations. Documents were cate-
gorised into the following five groups, based on the
number of tests and the order of testing advocated:
‘single test’ i.e. one test advocated; ‘dual testing’ i.e. per-
forming two tests concurrently; ‘sequential testing’ i.e.
performing a second type of investigation (second line)
if the first type of investigation (first line) is abnormal;
‘multiple testing options’ i.e. where a range of investiga-
tion options were presented with no single investigation
being advocated above another; and ‘no testing’ i.e.
where no specific tests were recommended as part of the
initial assessment.
Quality assessment
The AGREEII instrument was used to assess the quality of
guidance development and reporting of included guidance
documents [12]. This validated tool consists of 23 items
divided into six domains: ‘Scope and Purpose’, ‘Stake-
holder Involvement’, ‘Rigour of Development’, ‘Clarity of
Presentation’, ‘Applicability’ and ‘Editorial Independence’.
Each item is rated on a scale from one (criteria not met)
to seven (criteria fully met). While developed for clinical
practice guidelines, it has been used to assess other types
of guidance document [14]. Two reviewers independently
assessed each guidance document using the AGREEII tool.
Assessments were compared and differences of three or
more points per item were discussed and resolved by con-
sensus. Combined scores for each domain were obtained
using the following equation: (Obtained score – minimum
possible score)/(maximum possible score – minimal pos-
sible score) ! 100 [12]. We took a score of !50% in a
particular domain to indicate ‘satisfactory’ quality [17].
Results
Guideline selection
Our searches identified 846 documents, of which 178
were duplicates. The titles and summaries of 668 docu-
ments were screened, and 62 full text documents were
obtained for further scrutiny. Eighteen documents met
our selection criteria (Fig. 1).
Guideline characteristics
Of the 18 documents that met the selection criteria, two
were developed in continental Europe, five in the United
Kingdom (UK) and Republic of Ireland, three in Scandi-
navia, four in North America and four in Australasia
(Table 1) [18, 21–37]. Thirteen documents were pub-
lished in English. Ten documents were categorised as
full clinical practice guidelines, three as short guides,
four as clinical pathways and one as a consensus state-
ment. Documents varied in their intended audience and
scope. Some dealt only with the initial assessment and
referral of symptomatic patients and were aimed primar-
ily at primary care practitioners [24, 26, 32–34]. Others
also dealt with definitive diagnosis and treatment, often
devoting more attention to this than initial assessment,
and appeared to have a broader target audience includ-
ing primary care practitioners and specialists [21, 22, 25,
29, 31, 35, 36]. Nine documents were developed for
countries with National/Social Health Insurance Sys-
tems, seven for countries with National Health Services
and two for a country with a Private Healthcare System.
Quality assessment
Two guidance documents scored !50% in all six do-
mains (Additional file 1: Table S1). Scores for the Rigour
of Development domain (which appraises the process of
evidence identification, synthesis, assessment and recom-
mendation formulation) ranged from 7 to 96%, with 10
documents scoring !50% (Table 1).
Symptoms
All guidance documents provided advice regarding pre-
senting symptoms that should prompt a doctor to con-
sider ovarian cancer. The numbers of guidelines in which
each symptom was included is shown in Fig. 2. One or
more of the related terms bloating, abdominal distention,
increased abdominal size or girth, were listed as symptoms
of ovarian cancer in all documents, abdominal or pelvic
pain in 16 documents, urinary frequency in 14 documents
and feeling full or early satiety in 14 documents. We iden-
tified 20 symptom terms that were included in under 50%
of documents. The number of symptom terms included in
the recommendations of documents ranged from four to
14 (Additional file 1: Table S2). Some documents simply
listed symptoms doctors should be aware of in relation to
ovarian cancer, while others provided further details on
symptom frequency (e.g. > 12x/month), nature (e.g. per-
sistent), duration (e.g. > 1 year) and age at presentation
(e.g. > 50 years).
Physical examinations and signs
Fourteen documents provided guidance on physical
examination or the signs associated with ovarian cancer
(Table 2). Thirteen of these documents specifically
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advocated abdominal examination or mentioned abdom-
inal signs. Nine documents specifically advocated pelvic
or gynaecological examination, three of which detailed
that this should include a speculum examination, three a
bimanual or digital examination and one a vaginal exam-
ination, while three documents recommended a rectal
examination.
Tests
Fifteen documents provided advice on the initial investi-
gation of symptoms and were categorised based on the
number and order of tests recommended (Table 3). One
document advocated a single test strategy, four a duel
testing strategy, four a sequential testing strategy, three
gave multiple testing options, and three did not advocate
testing prior to referral, although two of these did rec-
ommend that a CA125 sample be taken at the point of
specialist referral so as to be available to the specialist.
One document could not be categorised as it was un-
clear when and how tests should be used in the initial
assessment for ovarian cancer [21]. The most commonly
advocated tests for initial investigation were CA125 (11
documents) and ultrasound (12 documents). Several
guidelines also recommended using additional cancer
biomarkers such as CA19–9, CEA, AFP and HCG, rou-
tine blood tests including full blood count and renal
function, imaging tests including CT and MRI, and the
risk tools RMI and ADNEX.
Although the majority of guidelines used symptoms as
the trigger for initiating tests, the two Australian short
guides indicated that testing for ovarian cancer should be
conducted if there was a suspicion on clinical examination
[23, 24]. Conversely, guidelines from Ireland, England,
Scotland, the UK, Sweden and Norway recommended that
concerning findings on examination should prompt an ur-
gent referral to a specialist rather than tests [18, 31–34, 37].
Discussion
In the absence of effective screening programmes, most
women are diagnosed with ovarian cancer following the
Fig. 1 PRISMA flow diagram illustrating the document selection process. *Guidance covered the assessment/management of pre-identified pelvic
masses (N = 11), other aspects of ovarian cancer e.g. treatment (N = 11) and cancers other than ovarian cancer (N = 6)
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Table 1 Characteristics of guidance documents presented by geographical area
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onset of symptoms [10, 13]. In this review, we identified
and compared international guidance documents on the
initial assessment and investigation for possible ovarian
cancer in symptomatic women. Our results highlight sig-
nificant differences between international guidelines, not
only in the clinical features they suggest should trigger a
suspicion of ovarian cancer, but also in the initial exami-
nations and investigations they advocate.
The stage distribution of ovarian cancer at diagnosis,
and ovarian cancer survival, varies between countries [38].
A positive correlation has been demonstrated between
national survival and the readiness of primary care practi-
tioners to investigate or refer women with symptoms of
possible ovarian cancer [39]. International variation in the
way symptomatic women are assessed and investigated
could also contribute to differences in the timeliness of
ovarian cancer diagnosis and survival. Although guidelines
are not always followed [40], they do influence practice
[41, 42], and variation in international guidelines is likely
to indicate differences in clinical practice internationally.
International comparative research is ongoing to investi-
gate differences in access to tests for ovarian cancer and
survival [43]. Several studies have sought to evaluate the
impact of national urgent cancer referral guidelines on
timeliness of diagnosis and/or survival [42, 44, 45], but
there is little research similarly evaluating the effect of
guidelines which advocate symptom-triggered testing for
ovarian cancer [46]. Studies are needed to evaluate the
impact of such guidance to ensure that the recommended
approaches are effective, for example, by comparing stage
distribution and cancer survival pre- and post- implemen-
tation of guidance. Comparing the impact of cancer detec-
tion guidelines between countries is challenging, not least
as it relies on the use of standardised endpoints (stage,
survival) which are not always uniformly recorded. Initia-
tives such as the International Cancer Benchmarking Part-
nership [43], may improve consistency in the recording of
such outcomes and so aid international comparisons.
Guideline developers have to consider the healthcare
system for which they are developing guidance. The
guidance from countries with National Health Services
was, in general, specific on symptoms and signs and gave
clear recommendations on which tests should be per-
formed and in what order. In contrast, guidance from
the USA, which has a Private Healthcare System, was
much less prescriptive, providing different options for
the clinician. This is likely to reflect the fact that Na-
tional Health Services aim to provide uniform services
and level of care across a country/region and must plan
for this, while the care provided in a country with a
Private Healthcare System may differ depending on the
private provider. Similarly, guideline recommendations
Table 1 Characteristics of guidance documents presented by geographical area (Continued)
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may be influenced by the speciality of the clinician per-
forming the initial assessment within a healthcare system
e.g. GP/family physician and/or gynaecologist. Gynaecol-
ogists may be more competent with, and willing to per-
form, gynaecological examinations and better equipped
to interpret complex tests and algorithms. Direct access
to gynaecologists is available in the USA and Germany
and guidance from these countries included a range of
specialist tests [47, 48]. In contrast, in countries like the
UK, Ireland, Australia and Scandinavia, where GPs play
a strong gatekeeping role and where a referral is gener-
ally required prior to gynaecology assessment, a limited
number of tests were recommended.
Over the last 15 years a number of studies have ex-
plored associations between ovarian cancer and symp-
toms; however, differences exist between the symptoms
they have identified and their predictive values. Most
documents in this review included symptoms widely
regarded as increasing the likelihood of an ovarian can-
cer being present, for example, abdominal distension
and pelvic pain [4, 5, 49]. Some documents also included
symptoms such as fatigue, nausea, back pain and the
generic term ‘urinary symptoms’, which are more con-
troversial, and were not found to increase the likelihood
of ovarian cancer in a recent comprehensive systematic
review [49]. Some variation may be due to the type of
evidence that guideline developers chose to consider.
For example, UK guideline developers appear to have
taken account of all relevant international studies when
deciding which symptoms should be included in the
guidance [8]. In contrast, USA guidelines included a
more restricted list of symptoms derived from the influ-
ential Ovarian Cancer Symptom Index which was devel-
oped in the USA [50]. As almost all published studies
exploring associations between ovarian cancer and
symptoms have been undertaken in the UK and the
USA, guideline developers outside these countries must
rely on international evidence to inform their recom-
mendations [49]. Further large, high quality research
studies, undertaken in countries around the world,
would improve our understanding of the symptomology
of ovarian cancer and help resolve disagreements over
which symptoms should be included in guidelines.
Given the range of AGREEII scores guidelines obtained
in the Rigour of Development domain, discrepancies in
symptoms and other recommendations are likely stem in
part from differences in the scope and quality of evidence
reviews undertaken by guideline developers. It is likely
that where a rigorous systematic approach is not followed,
important research, for example on symptoms, may be
missed. All guidance documents in this review are likely
to influence patient care and should be developed rigor-
ously and be explicit about the development process.
Different strategies could help encourage this, which in
Fig. 2 Symptoms included in guidelines
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Table 2 Physical examinations recommended and ovarian cancer signs noted within guidance documents
Document Type of examination specified Signs
Continental Europe
Epithelial ovarian carcinoma (Neth) Not specified - Pelvic mass / abdominal mass
- Ascites
- Pleural effusion
- Increased uterine / vaginal prolapse
- Enlarged supraclavicular lymph nodes
Guideline on diagnostics, therapy and follow-up of
malignant ovarian tumours (Ger)
Abdominal and pelvic / gynaecological
examination (including digital and speculum)
- Ovarian mass
United Kingdom and the Republic of Ireland
Epithelial Ovarian / Fallopian Tube / Primary
Peritoneal Cancer Guidelines: recommendations for
practice (UK)
Examination - Pelvic or abdominal mass
Suspected cancer: recognition and referral (Eng) Physical examination - Ascites
- Pelvic / abdominal mass (not obviously
uterine fibroids)
Ovarian cancer GP referral for symptomatic women
(Ire)




- Palpable ovaries in postmenopausal
women
Scottish referral guidelines for suspected cancer
(Scot)a
Abdominal palpation - Ascites
- Pelvic or abdominal mass (not
obviously uterine fibroids,
gastrointestinal or urological in origin)
Management of epithelial ovarian cancer (Scot) Not specified - Not specified
Scandinavia
Integrated ovarian cancer patient pathway (Den) Gynaecological examination
(including palpation and speculum)
- Ascites
- Pelvic mass
Ovarian cancer patient pathway (Nor) Not specified - Not specified
Standardised ovarian cancer care pathway (Swed)b Palpation of superficial lymph nodes, abdominal
palpation, rectal examination and auscultation
of the heart and lungs
- Pleural effusion (unexplained)
- Ascites
Australasia
Assessment of symptoms that may be ovarian
cancer: a guide for general practitioners (Aus)
Abdominal palpation, pelvic assessment,
vaginal and rectal examination
- Firm resistance on abdominal palpation
- Unexplained fullness
-Fullness + shifting dullness on
percussion
- Hard irregular mass in the pouch of
Douglass
- Adnexal mass
Appropriate referral of women with suspected
ovarian cancer (Aus)
Not specified - Not specified
Optimal care pathway for women with ovarian
cancer (Aus)
General and pelvic examination - Not specified
Suspected cancer in primary care: guidelines for
investigation, referral and reducing ethnic disparity
(NZ)
Abdominal palpation and pelvic examination - Not specified
North America
Ovarian cancer: including fallopian tube cancer and
primary peritoneal cancer (USA)
Abdominal and pelvic examination - Suspicious palpable pelvic or abdominal
mass
- Ascites or abdominal distension
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turn could help to harmonise symptoms in international
guidelines. For example, funders could have guidelines in-
dependently appraised following development, using the
AGREEII checklist, and publish the results alongside the
guidelines. In addition, many guidelines are published in
peer reviewed journals. Guideline developers could be re-
quired to submit an AGREEII style checklist as part of the
submission process. While not all guideline development
groups have the significant resources required to develop
all elements of clinical guidelines de novo, this may not be
necessary. For example, the guidance from the New
Zealand Guideline Group was based on 2005 NICE guid-
ance and adapted to suit the New Zealand healthcare sys-
tem. Collaboration by international guideline producers
on aspects of guidelines such as symptoms, which are
likely to differ little between healthcare systems or coun-
tries, could also help reduce duplication, ensure quality
and increase consistency.
A pelvic or gynaecological examination was specifically
recommended by half of the guidelines, with three speci-
fying that a speculum and three a bimanual or digital
examination, be performed. However, Myres et al.’s re-
view, which included studies on examinations performed
by gynaecologists pre-surgery and in the screening
setting, found that less than half of adnexal masses are
picked up on bimanual examination [51]. GPs might be
less skilled at identifying pelvic masses, but a recent re-
view identified no studies evaluating their competence
at performing pelvic examinations for gynaecological
cancer [52].
Most documents recommended the use of ultrasound
and/or CA125 in the initial investigation for ovarian
cancer. However, guidelines varied in the sequence of
testing, and a variety of other serum biomarkers, im-
aging modalities and risk algorithms were included in
some. This variation may result in part from differences
in the funding and available resources within different
healthcare systems. For example, consideration of costs
and resource implications played a role in the decision
by NICE to recommend the relatively cheap and widely
accessible CA125 test rather than ultrasound as the first
line investigation [8]. There is little high quality evidence
for tests used in the initial investigation of possible ovar-
ian cancer [8], often necessitating consensus opinion
[34, 35], with one guideline making no recommenda-
tions on testing because of the lack of evidence [26].
Evidence from secondary care and screening studies in-
dicates that CA125 and ultrasound differ in their diagnos-
tic accuracy [8, 53, 54]. Therefore, the test(s) chosen, and,
where they are used in combination, the order of testing,
may have important implications for cancer detection. For
example, a sequential testing approach, where both tests
need to be abnormal to trigger specialist referral [33], will
be more specific at the cost of lower sensitivity. Con-
versely, a dual-testing approach, where an abnormality in
either test warrants referral [34, 35], will be more sensitive
but sacrifices specificity and economy.
This is the first study to systematically identify and
compare international guidance documents on the initial
assessment and investigation for possible ovarian cancer
in symptomatic women. Direct comparisons between
the testing strategies employed in different countries
must be interpreted with reference to the healthcare
system for which the guidance was produced. Although
we performed a comprehensive literature search, it is
possible that we did not identify all relevant guidance
documents e.g. healthcare guidelines not published on-
line or not available outside the region or country of
publication. We attempted to obtain all relevant docu-
mentation on the development process of guidelines in-
cluded in this review, contacting guideline producers for
additional information when necessary, to allow us to
perform comprehensive AGREEII appraisals. However, it
is possible that we did not gain access to all relevant
documents e.g. unpublished search strategies or evidence
reviews.
Table 2 Physical examinations recommended and ovarian cancer signs noted within guidance documents (Continued)
Document Type of examination specified Signs
The role of the obstetrician-gynaecologist in the
early detection of epithelial ovarian cancer in
women at average risk (USA)
Not specified - Not specified
Ovarian cancer diagnosis pathway map (Ont, Can) Directed physical examination. Pelvic examination
including speculum and bimanual examinations
and examination of the external genitalia
- Suspicious palpable pelvic or abdominal
mass
- Ascites
Genital tract cancers in females: ovarian, fallopian
tube, and primary peritoneal cancers (BC, Can)
A physical examination of the abdomen and
pelvis including a pelvi-rectal examination
- Abdominal mass
aAs recorded on associated Microsite and Short guidance document. The full guideline covers all gynaecological cancers with examinations and findings listed
together. Microsite and Short guideline lists examinations and signs by cancer site
bBoth a full clinical practice guideline covering initial assessment, definitive diagnosis and treatment, and a short version focusing on initial assessment and
investigation in primary care, are available. Guidance on initial assessment differed slightly between the two documents. The presented data was extracted from
the short guide
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Table 3 Summary of tests recommended for the assessment of symptoms and/or signs of ovarian cancer
Strategy Guideline When is testing advocated? Initial tests
Single test Guideline on diagnostics, therapy and
follow-up of malignant ovarian tumours
(Ger)
Signs or symptoms of ovarian cancer
(OC)
Transvaginal US
Note: CT, MRI, PET CT may be used in
specific cases
Dual testing Scottish referral guidelines for suspected
cancer (Scot)
Symptoms of OC
Note: Ascites- refer urgently rather than
test
CA125 + pelvic US
Management of epithelial ovarian cancer
(Scot)
Symptoms of OC CA125 + pelvic US
Assessment of symptoms that may be
ovarian cancer: a guide for general
practitioners (Aus)
Mass identified clinically
Note: No mass identified clinically- refer
appropriately
CA125 + transvaginal US Or
CA125 + Abdominal US Or
CA125 + CT
Appropriate referral of women with
suspected ovarian cancer (Aus)
Suspicious findings on clinical
examination
CA125 + transvaginal US +/" calculation
of Risk of Malignancy Index (RMI)
Sequential testing Suspected cancer: recognition and referral
(Eng)
OC symptoms
Note: Ascites or suspicious mass- refer
urgently rather than test
First line: CA125
Second line: Abdominopelvic US (if CA125
is abnormal)
Epithelial ovarian / fallopian tube / primary
peritoneal cancer guidelines:
recommendations for practice (UK)
OC symptoms
Note: Pelvic or abdominal mass- refer
urgently rather than test
First line: CA125
Second line: Abdominopelvic US (if CA125
is abnormal)
Ovarian cancer GP referral for symptomatic
women
(Ire)
History suspicious of OC but
examination normal
Note: Suspicious pelvis mass or ascites-
refer urgently rather than test
First line: CA125
Second line: US of pelvis (If CA125 35–200
u/ml)
Note: If CA125 > 200 u/ml refer without
US
Ovarian cancer diagnosis pathway map
(Ont, Can)
Suspicion of OC
Note: Tests may be performed prior to
specialist referral but are not a
requirement for referral. Can refer prior to
testing
First line: Transvaginal US and / or other
imaging
Second line: CA125, FBC, Renal Function +
RMI
(If indicated: CEA, CA19–9, other tumour
markers e.g. AFP, LDH, HCG)
Multiple testing
options
Optimal care pathway for women with
ovarian cancer (Aus)
Symptoms of OC Pelvic US +
Routine blood tests +
CA125 +
Algorithms such as RMI, ADNEX +/"
CT scan
Genital tract cancers in females: ovarian,
fallopian tube, and primary peritoneal
cancers (BC, Can)
Suspicion of OC
Note: Imaging not essential for referral
Transvaginal or abdominal US
Blood tests: CA125, CA19–9, CA15–3, CEA
< 40 yrs old: AFP, HCG, LDH
Ovarian cancer Including fallopian tube
cancer and primary peritoneal cancer
(USA)
Suspicion of OC
Note: Provides some advice on when
particular tests are indicated. Appears to
include both initial and pre-surgical tests
US and/or abdominal/pelvic CT/MRI (as
indicated)
Chest CT or chest x-ray (as indicated)
Complete blood count, chemistry profile
and LFT
CA125 or other tumour markers (as
indicated: inhibin, !-hCG, AFP, LDH, CEA,
CA19–9)
Nutritional status
GI evaluation (as indicated)
No testing prior to
referral
Integrated ovarian cancer patient pathway
(Den)
At point of specialist referral Note CA125 requested in primary care at
time of referral so as to be available to the
specialist. Not acted upon in primary care
Ovarian cancer patient pathway (Nor) Post specialist referral Post referral
Standardised ovarian cancer care pathway
(Swed)
At point of specialist referral Note CA125 requested in primary care at
time of referral so as to be available to the




Suspected cancer in primary care:
guidelines for investigation, referral and
reducing ethnic disparity (NZ)
No recommendations No recommendations
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Conclusion
Multiple international guidance documents provide advice
on the initial assessment and investigation for possible
ovarian cancer in symptomatic women. These documents
differ markedly in the symptoms they include and the
physical examinations and clinical investigations they rec-
ommend. Given this, it is probable that patient care and
the likelihood of cancer detection will vary depending on
the guidance document followed. Studies evaluating the
role of examinations and the diagnostic performance of
testing strategies for the initial assessment of possible
ovarian cancer in symptomatic women are needed to aid
the development of more evidence-based guidelines.
Supplementary information
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The serum biomarker cancer antigen 125 (CA125) is widely used as an investigation for
possible ovarian cancer in symptomatic women presenting to primary care. However, its
diagnostic performance in this setting is unknown. We evaluated the performance of CA125
in primary care for the detection of ovarian and non-ovarian cancers.
Methods and findings
We studied women in the United Kingdom Clinical Practice Research Datalink with a CA125
test performed between 1 May 2011–31 December 2014. Ovarian and non-ovarian cancers
diagnosed in the year following CA125 testing were identified from the cancer registry.
Women were categorized by age: 50 years and 50 years. Conventional measures of test
diagnostic accuracy, including sensitivity, specificity, and positive predictive value, were cal-
culated for the standard CA125 cut-off ( 35 U/ml). The probability of a woman having can-
cer at each CA125 level between 1–1,000 U/ml was estimated using logistic regression.
Cancer probability was also estimated on the basis of CA125 level and age in years using
logistic regression. We identified CA125 levels equating to a 3% estimated cancer probabil-
ity: the “risk threshold” at which the UK National Institute for Health and Care Excellence
advocates urgent specialist cancer investigation.
A total of 50,780 women underwent CA125 testing; 456 (0.9%) were diagnosed with
ovarian cancer and 1,321 (2.6%) with non-ovarian cancer. Of women with a CA125 level
 35 U/ml, 3.4% aged 50 years and 15.2% aged 50 years had ovarian cancer. Of women
with a CA125 level 35 U/ml who were aged 50 years and who did not have ovarian can-
cer, 20.4% were diagnosed with a non-ovarian cancer. A CA125 value of 53 U/ml equated
to a 3% probability of ovarian cancer overall. This varied by age, with a value of 104 U/ml in
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All data used in this study are available from CPRD
40-year-old women and 32 U/ml in 70-year-old women equating to a 3% probability. The
main limitations of our study were that we were unable to determine why CA125 tests were
performed and that our findings are based solely on UK primary care data, so caution is
need in extrapolating them to other healthcare settings.
Conclusions
CA125 is a useful test for ovarian cancer detection in primary care, particularly in women
 50 years old. Clinicians should also consider non-ovarian cancers in women with high
CA125 levels, especially if ovarian cancer has been excluded, in order to prevent diagnostic
delay. Our results enable clinicians and patients to determine the estimated probability of
ovarian cancer and all cancers at any CA125 level and age, which can be used to guide indi-
vidual decisions on the need for further investigation or referral.
Author summary
Why was this study done?
• CA125 is widely used as a test for ovarian cancer in women presenting with relevant
symptoms, both in the UK and internationally.
• CA125 has been extensively evaluated in the specialist care setting and in screening
studies but little was known about its diagnostic performance in primary care, where
most patients with ovarian cancer first present.
What did the researchers do and find?
• We evaluated the diagnostic performance of CA125 in 50,780 women undergoing test-
ing in English general practice.
• Of women with CA125 levels above the current abnormal cut-off, 10.1% were diagnosed
with ovarian cancer and a further 12.3% with another form of cancer.
• Cancer was more common in women with abnormal CA125 levels if they were 50
years of age.
• We developed models to estimate the probability of ovarian cancer and all cancer based
on a woman’s age and CA125 level.
What do these findings mean?
• Clinicians should consider the possibility of non-ovarian cancer, in addition to ovarian
cancer, in women with high CA125 levels.
• Our models will enable patients and clinicians to determine the estimated probability of
cancer based on an individual’s age and CA125 level.
• This information can be used to help make decisions about the need for further investi-
gation or urgent referral to a specialist.
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Scores.
• The findings should also help inform guidelines, as they will allow recommendations
for further testing to be made on the basis cancer probability rather than a single CA125
cutoff.
Introduction
Ovarian cancer is the eighth most common cancer to affect women worldwide, accounting for
over 384,000 deaths in 2018 [1]. Survival depends on stage at diagnosis, with five-year net sur-
vivals of 93% for stage I, 68% for stage II, 27% for stage III, and 13.4% for stage IV disease [2].
Most women are diagnosed following a symptomatic presentation [3], and, in healthcare sys-
tems in which general practitioners (GPs) play a gatekeeping role, this initial presentation usu-
ally takes place in primary care [4].
Symptoms can occur at all stages of ovarian cancer [5]. However, they are usually nonspe-
cific and are common in women without ovarian cancer, so they only have modest positive
predictive values for the disease [5,6]. The serum biomarker cancer antigen 125 (CA125) is
widely used in countries around the world, including the United States, Australia, Canada, and
Ireland, as an investigation for ovarian cancer in symptomatic women presenting to primary
care [7]. In 2011, the United Kingdom National Institute for Health and Care Excellence
(NICE) recommended that women with symptoms of possible ovarian cancer be tested for
CA125 in primary care, with further investigation advocated in those with CA125 levels 35
U/ml [8]. The chosen cutoff of 35 U/ml is the conventional upper limit of normal for CA125
and derives from a study in which 1% of healthy women and 82% of patients with ovarian can-
cer had a CA125 level>35 U/ml [9].
CA125 has been studied extensively in screening studies and in women in secondary care
with pelvic masses but not in women presenting with symptoms of possible ovarian cancer in
primary care. The NICE recommendations on CA125 testing for symptomatic women are
based on extrapolated secondary care and screening data rather than primary care data [8].
The performance characteristics of a test vary with disease prevalence, disease severity, and the
prevalence of other conditions that elevate test levels, so it is important to evaluate CA125
within the intended population [10].
When evaluating the diagnostic performance of a test such as CA125, it is standard practice
to report accuracy characteristics, including the positive predictive value (PPV), after applying
a particular cutoff. However, the PPV provides the “average” probability of disease for all
women with a test level at or above the set cutoff rather than the probability of disease at a
given test level. Knowledge of the probability of cancer at any given CA125 level is likely to be
more clinically useful than the PPV, as it would allow patients and clinicians to interpret their
individual CA125 test results, which could help guide decisions on the need for further investi-
gations. NICE revised their cancer guidance in 2015, using a “risk threshold” of 3% as the
threshold for urgent cancer investigation in symptomatic women, but ovarian cancer guid-
ance, including the chosen CA125 cut-off of 35 U/ml, remained unchanged [11]. Knowledge
of the estimated probability of cancer at each CA125 level could help inform health policy both
in the UK and internationally.
The primary aim of this study was to explore the relationship between CA125 level and
ovarian cancer probability, to identify the CA125 level at which a 3% probability of ovarian
cancer was reached. Given the nonspecific nature of ovarian cancer symptoms, and reports
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indicating CA125 is commonly elevated in other cancers [12,13], a second aim was to explore
the relationship between CA125 level and the probability of all cancers. To allow comparison
with existing literature on CA125 diagnostic accuracy, we also calculated conventional test per-




The study was approved by the Independent Scientific Advisory Committee (ISAC) for the
Medicines and Healthcare Products Regulatory Agency (protocol number 18_184). All data
were provided to researchers in an anonymized form, and individual consent was not
required.
Data source
This was a retrospective cohort study using linked data from the Clinical Practice Research
Datalink (CPRD) GOLD dataset and the National Cancer Registration and Analysis Service
(NCRAS). The CPRD GOLD dataset contains anonymized, coded, primary care data includ-
ing demographics, laboratory results, symptoms, and diagnoses for around 11 million
patients. It is broadly representative of the UK population [14]. The NCRAS (English cancer
registry) collects cancer registration data on patients, including detailed information on
tumor topography, stage, and date of diagnosis. NCRAS obtains data from multiple sources
including hospitals, GP surgeries, and death certificates and reports a near 100% case ascer-
tainment [15]. Linkage of CPRD and NCRAS data was performed at a patient level by a
third party, National Health Service (NHS) Digital [16]. As NCRAS only collects details of
cancers diagnosed in England, the study was restricted to English general practices. The
approved ISAC protocol, which covers several linked studies, is included in the S1 Text and
S2 Text.
This report conforms to the STARD and RECORD statements [17,18]. A completed
STARD checklist is included with this article (S3 Text).
Participants
We included women with a code for CA125 measurement in primary care (S1 Table) between
1 May 2011 and the 31 December 2014. There has never been a national ovarian cancer screen-
ing program in the UK, and the only indication for CA125 testing in English primary care is a
presentation with a symptom of possible ovarian cancer. As such, we assumed that CA125-
tested women were symptomatic.
Women who were<18 years old or registered at a GP practice not deemed “up-to-stan-
dard” on data quality by CPRD on the date of their first CA125 test during this period were
excluded [14]. Women with a record of ovarian cancer in NCRAS data on or before the
CA125 test date were also excluded, as were women with a CA125 test in the 12 months before
the first CA125 test during the study period. Only CA125 entries recorded in standard equiva-
lent units of CA125 measurement (U/ml, IU/ml, KU/L, KIU/L) were accepted. Although
NICE recommends a CA125 cutoff of 35 U/ml, individual laboratory cutoffs varied. We
excluded CA125 values associated with spurious laboratory cutoffs (245, 420, and 455 U/ml)
and those where no cutoff was given. Subsequent sensitivity analyses, including CA125 entries
recorded in all units and associated with all laboratory upper cutoffs, had minimal impact on
our results. The first CA125 test during the study period was used in analyses.
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Clinical outcomes
Primary outcome. Our primary clinical outcome was the diagnosis of ovarian cancer, as
recorded using International Classification of Diseases (ICD)-10 codes in NCRAS data, in the
12 months following the initial CA125 test. With reference to the International Federation of
Gynaecology and Obstetrics (FIGO) and WHO classifications [19,20], we defined ovarian can-
cer as an ovarian malignancy (C56), a fallopian tube malignancy (C57.0), a peritoneal malig-
nancy (C48.1, C48.2), or a neoplasm of uncertain behavior of the ovary (D39.1). We assumed
that cancer diagnosed within 12 months of the initial CA125 test was present at the time of
testing. It is possible that incidental ovarian cancers may arise and be diagnosed in the year fol-
lowing testing or that it may take longer than 1 year from presentation in primary care to diag-
nosis. A period of 1 year, which has been used widely in similar studies [21,22], was chosen as
a compromise between minimizing the inclusion of incidental cancers and maximizing the
inclusion of relevant cancers.
Our primary outcome included borderline ovarian tumors, as these are treated collectively
with invasive tumors in NICE recommendations on CA125 testing and generally require sur-
gical management [23]. Although their timely detection in symptomatic women is important,
borderline tumors are less likely to cause an elevation in serum CA125, and their prognosis is
very good even if detected late [23]. We therefore performed a subanalysis in which invasive
ovarian cancer formed the outcome.
Secondary outcome. Our secondary outcome was the diagnosis of non-ovarian cancers.
The earliest record of cancer, excluding nonmelanoma skin cancers, was identified in the 12
months following initial CA125 testing in women without ovarian cancer. We refer to this
group of cancers as “non-ovarian cancer.” Where we discuss the combined non-ovarian and
ovarian cancer groups, we use the term “all cancers.”
Descriptive outcomes. In order to report the symptoms that may have triggered CA125
testing, symptoms coded in the 30 days before CA125 testing were identified from CPRD data
using a code list of ovarian cancer symptoms from current NICE guidelines [11].
Ovarian cancer stage was determined using the Tumor Nodes Metastasis (TNM) staging
system or, where not recorded, the FIGO staging system, and the proportions of ovarian can-
cers at each stage identified [19].
The histology of invasive ovarian tumors was identified from NCRAS data and categorized
on the basis of ICD10 codes.
Statistical analysis
We calculated the PPV, negative predictive value (NPV), sensitivity, and specificity of CA125
for ovarian cancer at or above the current cut-off (35 U/ml). A nonparametric receiver opera-
tor characteristic (ROC) curve was constructed, and the area under the curve (AUC) deter-
mined. This analysis was repeated for invasive ovarian cancer and all cancers combined. After
excluding ovarian cancer patients, it was also repeated for non-ovarian cancer. As ovarian can-
cer incidence is greater in older women and most cases occur in women post-menopause, we
repeated all analyses for women <50 years and 50 years of age [24].
We used logistic regression to examine the relationship between CA125, as a continuous
variable, and ovarian cancer diagnosis. CA125 level was highly skewed, and so it was log-trans-
formed prior to regression analysis. Log CA125 was centered on a value of 3, the closest integer
to the mean. The relationship between log CA125 level and ovarian cancer was nonlinear. To
account for this, we used restricted cubic splines. As recommended by Harrell [25], we com-
pared the Akaike Information Criterion (AIC) for models containing 3, 4, and 5 knots. The
5-knot model produced the smallest AIC and so was taken forward. Knots were placed at
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standard, equally spaced percentiles of the marginal distribution of the variable (S4 Text) [25].
This regression model was used to predict the odds of cancer for a range of CA125 levels (1–
1,000 U/ml), which were then converted into probabilities.
The logistic regression analysis was repeated for the<50 years and 50 years age groups.
Significant differences were noted between these groups in terms of the estimated ovarian can-
cer probabilities. Given this, and on the recommendation of a peer reviewer, we constructed a
multivariable regression model including age in years (mean centered) as a continuous vari-
able and CA125 level, applying the same approach as described here previously. Five knots
were included for each variable (S4 Text). This regression model was used to predict the odds
of ovarian cancer for CA125 levels (1–1,000 U/ml) in women of different ages. Results for
women aged 30, 40, 50, 60, 70, and 80 years of age are presented as examples in this paper.
All the aforementioned steps were repeated for our secondary outcome and for the invasive
cancer subanalysis. Full details of all models are included in S4 Text.
Statistical software. All analyses were performed in Stata version 15.1 (StataCorp, www.
stata.com). The DIAGT module was used to calculate summary diagnostic accuracy statistics
[26]. All confidence intervals (CI) are reported at the 95% level.
Results
After exclusions, our cohort consisted of 50,780 women (Fig 1).
The ovarian cancer incidence in the cohort was 0.9% and was 3 times higher in the 50
years group than the<50 years group (Table 1). The median interval between CA125 testing
and ovarian cancer diagnosis was 42 days (interquartile range: 25–62 days) and the mean
patient age was 56 years (range: 18–102 years).
Cancer stage
Of the 456 ovarian cancers, 172 (37.7%) were stage I or II, and 209 (45.8%) were stage III or
IV. No stage was recorded in 75 (16.4%) cases (S2 Table).
Cancer morphology and histology
Of the ovarian cancers diagnosed, 21.5% (n = 98) were borderline tumors. The proportion of
malignancies that were borderline varied with age, with 50% of tumors in the<50 years group
and 15.4% in the 50 years group being borderline (S3 Table). Serous epithelial tumors were
the most common tumor type, accounting for 48.6% (n = 174) of invasive tumors. In the<50
years group, 12.5% (n = 5) of invasive tumors were of nonepithelial origin compared with
2.5% (n = 8) in the 50 years group.
Recorded symptoms
Symptoms of possible ovarian cancer were recorded for 24,269 women (47.8%) on the same
day or in the 30 days preceding CA125 testing; the most common was abdominal pain
(Table 2). Multiple symptoms were recorded in 1,477 (6.1%) women.
Diagnostic performance applying the standard cutoff ( 35 U/ml)
The diagnostic performance characteristics of CA125 were calculated after applying the stan-
dard cutoff ( 35 U/ml) (Table 3). At or above the 35 U/ml cutoff, CA125 demonstrated a
PPV of 10.1% (95% CI 9.1–11.2), an NPV of 99.8% (95% CI 99.7–99.8), a sensitivity of 77.0%
(95% CI 72.8–80.8%) and a specificity of 93.8% (95% CI 93.6–94.0) for ovarian cancer. The
AUC was 0.92 (95% CI 0.90–0.93). The AUC was greater in the 50 years group (AUC: 0.93,
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95% CI 0.92–0.95) than the <50 years group (AUC 0.86, 95% CI 0.82–0.91) and the PPV, sen-
sitivity and specificity were also higher in the 50 group.
When the outcome was restricted to invasive ovarian cancers, CA125 demonstrated a
slightly lower PPV (8.8%, 95% CI 7.8–9.8), and a higher sensitivity (84.9%, 95% CI 80.8–88.5)
(Table 3).
Of the 50,324 women without ovarian cancer, 1,321 (2.6%) were diagnosed with a non-
ovarian cancer. The incidence of non-ovarian cancers in women with a CA125 <35 U/ml was
Table 1. Patient numbers, incidence of raised CA125 tests ( 35 U/ml) and cancer incidence by age group.
<50 years  50 years Overall cohort
Number of patients, N 19,694 31,086 50,780


















CA125, cancer antigen 125.
https://doi.org/10.1371/journal.pmed.1003295.t001
Fig 1. Flow diagram illustrating the identification of the study cohort and application of exclusion criteria. UTS is a quality metric, provided by CPRD,
which indicates if the data from a GP practice are of sufficient quality to be used in research [14]. CA125, cancer antigen 125; CPRD, Clinical Practice Research
Datalink; NCRAS, National Cancer Registration and Analysis Service; UTS, up to standard.
https://doi.org/10.1371/journal.pmed.1003295.g001
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Table 2. Ovarian cancer symptoms and signs coded in the 30 days prior to CA125 testing.
Symptom/sign Patients, N (%)
Abdominal pain 11,933 (49.2)
Abdominal distension or bloating 5,686 (23.4)
Change in bowel habit 2,866 (11.8)
Fatigue 1,692 (7.0)
Pelvic pain 1,632 (6.7)
Weight loss 913 (3.8)
Urinary frequency 552 (2.3)
Abdominal or pelvic mass 419 (1.7)
Loss of appetite 113 (0.5)
Urinary urgency 86 (0.4)
Ascites 26 (0.1)
% is the proportion of patients with a given symptom out of the total number of patients who have a coded symptom
(N = 24,269). Categories are not mutually exclusive: a patient may have had more than 1 symptom coded.
CA125, cancer antigen 125.
https://doi.org/10.1371/journal.pmed.1003295.t002
Table 3. Performance characteristics of CA125 for ovarian cancer, invasive ovarian cancer, non-ovarian cancers and all cancers.
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PPV, NPV, sensitivity and specificity are calculated for a cutoff of  35 U/ml. Accuracy characteristics for “non-ovarian” cancer were calculated following exclusion of
patients with ovarian cancer.
AUC, area under the curve; CA125, cancer antigen 125; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
https://doi.org/10.1371/journal.pmed.1003295.t003
PLOS MEDICINE The diagnostic performance of CA125 for the detection of cancer in primary care
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003295 October 28, 2020 8 / 18
2.0%, whereas the incidence in women with a CA125 35 U/ml, which equates to the PPV for
non-ovarian cancers, was 12.3% (95% CI 11.2–13.5) (Table 3). This varied markedly between
the<50 years group (PPV 2.8%, 95% CI 2.0–3.8) and 50 years group (PPV 20.4%, 95% CI
18.5–22.4). The PPV for all cancers was 21.2% (95% CI 19.8–22.6). Almost half of patients
diagnosed with pancreatic and lung cancer in our cohort had CA125 levels 35 U/ml
(Table 4).
The probability of cancer by CA125 level
Fig 2 shows the relationship between CA125 level and the estimated probability of can-
cer, derived from logistic regression analyses. A CA125 level of 53 U/ml equated to a
probability of 3% (95% CI 2.6–3.5) for ovarian cancer, whereas a CA125 level of 18 U/ml
equated to a probability of 3% (95% CI 2.8–3.2) for all cancer. In a subanalysis in which
invasive ovarian cancer formed the outcome, a CA125 level of 68 U/ml equated to a 3%
probability.
Repeating the analysis in the <50 years and 50 years groups revealed that a much higher
CA125 level was required to reach the 3% probability for ovarian cancer in the<50 years
group (89 U/ml) than 50 years group (39 U/ml) (S4 Fig).
Table 4. Cancers diagnosed in women without ovarian cancer.
Cancer type
(ICD10 codes)
N N < 35 U/ml
(%)












































































“Other” consists of cancers with fewer than 10 cases with CA125 values 35 U/ml. The cancers included in this
group and their frequencies are shown in S4 Table.
CA125, cancer antigen 125; ICD-10, International Classification of Diseases, 10th revision.
https://doi.org/10.1371/journal.pmed.1003295.t004
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The probability of ovarian cancer by age and CA125 level
Fig 3 illustrates the relationship between CA125 level and the estimated probability of ovarian
cancer at specific ages, derived from a logistic regression analysis. The probability of ovarian
cancer at a given CA125 level varied markedly by age. The CA125 level required to reach the
3% ovarian cancer probability threshold fell from 104 U/ml in 40-year-old women to 32 U/ml
in 70-year-old women. Similar age trends were noted when the analysis was repeated for inva-
sive ovarian cancer (S5 Fig) and all cancer (S6 Fig).
Discussion
In this cohort study of over 50,000 women who underwent CA125 testing in English general
practice, 10.1% of those with a CA125 at or above the conventional cutoff (35 U/ml) were
Fig 2. Relationship between CA125 level and estimated probability of ovarian cancer, invasive ovarian cancer, and all cancers. Estimated probabilities up to 8%
are shown for ovarian cancer, invasive ovarian cancer, and all cancers. CA125 levels that correspond to the closest integer probabilities of 3% are indicated. The
probabilities, which equate to a CA125 level of 35 U/ml, are also marked. Confidence intervals (95%) are displayed. Graphs showing probabilities at an extended
range of CA125 values (up to 500 U/ml) for ovarian cancer, invasive ovarian cancer, and all cancer are included in S1 Fig, S2 Fig, and S3 Fig, respectively. Data used
to construct these graphs (up to a CA125 level of 1,000 U/ml) are available via the University of Cambridge Repository [27]. CA125, cancer antigen 125; CI,
confidence interval.
https://doi.org/10.1371/journal.pmed.1003295.g002
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diagnosed with ovarian cancer, and 12.3% were diagnosed with a different cancer. Almost a
third of women aged 50 years with a CA125 35 U/ml were diagnosed with some form of
cancer. A CA125 level of 53 U/ml equated to an overall ovarian cancer probability of 3%—the
threshold at which the UK NICE advocates urgent investigation or referral in symptomatic
women. Marked variation was noted between women of different ages, with the 3% probability
reached at lower CA125 levels in 70-year-old women than younger or older women.
Study limitations
This study relied on coded routinely collected data, so it was not possible to determine exactly
why CA125 tests were requested. However, the only indication for CA125 testing in UK pri-
mary care is to investigate symptoms of possible ovarian cancer. We identified symptoms
recorded before CA125 testing, which may have been the trigger for testing. In contrast to
CA125 results, which are automatically transferred into the GP system from laboratories,
symptoms are not always coded but instead are often recorded in the free text within the GP
record, which cannot be accessed for research purposes [28]. We did not restrict our analysis
to women with a coded ovarian cancer symptom as this could introduce bias, given that symp-
toms are more likely to be coded if they are severe or persistent [28].
Fig 3. Relationship between CA125 level and estimated probability of ovarian cancer for women of different ages. Estimated ovarian cancer
probabilities are shown in relation to CA125 level for women of 30, 40, 50, 60, 70, and 80 years of age. CA125 levels that correspond to the closest integer
probabilities of 3% are indicated in red. Confidence intervals (95%) are displayed. Data used to construct these graphs (up to a CA125 level of 1,000 U/ml)
are available via the University of Cambridge Repository [27]. CA125, cancer antigen 125.
https://doi.org/10.1371/journal.pmed.1003295.g003
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Our results reflect real-world use of CA125 in English general practice. How CA125 is used
in primary care in other countries may differ from practice in England. Baseline CA125 levels
may also be affected by population characteristics, such as ethnicity, smoking status, and past
medical history [29]. We did not include these variables in our analysis as our aim was to
develop simple models that allow the estimated probability of cancer to be reported alongside
the CA125 result in general practice, without the need to collect further detailed information
from the patient. Although this study has significant international relevance, caution is needed
when translating our findings to other countries and healthcare systems.
We report ovarian cancer stage at diagnosis, but CA125 diagnostic accuracy was not ana-
lyzed by stage. As CA125 tests were performed at variable intervals in the 12 months preceding
diagnosis, such an analysis is likely to be misleading as an unknown number of cancers will
have progressed during that period.
We have employed restricted cubic splines to model the nonlinear nature of the relation-
ship between both age and CA125 level and cancer diagnoses. Although these provide a flexi-
ble approach to parameterizing the fitted relationships, there is a large degree of uncertainty at
the extremes of age and CA125 level, and so the cancer probabilities for very old and young
women and those with very low CA125 levels should be treated with caution, and the large CI
noted.
Results in the context of other studies
In their 2011 ovarian cancer guidelines, NICE estimated that 0.81% of symptomatic primary
care women with a CA125 35 U/ml would have ovarian cancer [8]. Economic modeling and
the recommendation for sequential testing with CA125 followed by ultrasound if the CA125
were abnormal was predicated on this estimate. Our findings indicate that the PPV is more
than 12 times higher than estimated. This is consistent with the only other UK report of the
PPV of CA125 in primary care, which found that 16 out of 152 women (11%) with a raised
CA125 level had ovarian cancer [13]. The sensitivity of CA125 for ovarian cancer in our study
was slightly lower—and the specificity higher—than reported in studies in which testing was
performed in women with a pelvic mass prior to surgery in secondary care [30]. This is to be
expected as tests generally have lower sensitivity and higher specificity in populations with a
lower disease prevalence—the spectrum effect [10]. As anticipated, the PPVs for ovarian can-
cer in our cohort were lower than in secondary care patients with pelvic masses [31] and
higher than in asymptomatic screening populations [32].
One of the most striking findings in our study was the high incidence of non-ovarian can-
cers in those with elevated CA125 levels, particularly in women aged 50 years or older. This
reflects the nonspecific nature of ovarian cancer symptoms and also that CA125 is frequently
raised in women with a variety of non-ovarian malignancies [12]. Crawford and colleagues
reported that 16 out of 152 women (11%) referred from primary care with a raised CA125
were diagnosed with a non-ovarian cancer [13]. Furthermore, in asymptomatic screening pop-
ulations, a higher incidence of non-ovarian cancers has been noted in women with raised
CA125 levels (6.9%) than with normal CA125 levels (1.6%) [33].
We found that the estimated probability of ovarian cancer for a given CA125 level rose
with age to peak in women in their seventies, which mirrors UK age-specific cancer inci-
dence rates [34]. The exception was very young women—the probability of ovarian cancer at
a given CA125 level was higher in women aged 30 than aged 40. This probably reflects GP
testing practices in very young women (in whom ovarian cancer is extremely rare), with GPs
having a strong reason to request a CA125 test in these women, thereby raising the pretest
probability.
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Clinical interpretation of the findings
Of the CA125 tests performed, 39% were in women <50 years of age; however, ovarian cancer
is predominantly a disease of older and postmenopausal women. This is reflected in our find-
ings, as only 18% of ovarian cancers and 11% of the invasive subtype occurred in women
under 50. All measures of test performance, save for the NPV, were worse in women under 50
years than 50 years and over, even when borderline malignancies (which were more common
in the younger age group) were excluded. A greater proportion of invasive tumors in the<50
years group were mucinous epithelial and nonepithelial cancers, both of which have less pro-
pensity to elevate serum CA125 than other ovarian cancer types, likely contributing to poorer
test performance in the younger age group [31]. The results of our regression analysis indicate
that, overall, only 1 in 110 women<50 years with a CA125 of exactly 35 U/ml will have an
ovarian cancer, and only 1 in 308 will have an invasive subtype. Investigating younger women
for ovarian cancer when there is high suspicion is important, but given the low incidence of
ovarian cancer and relatively poor test performance in women under 50 years, CA125 tests
should be performed and interpreted with caution in this group.
The total number of non-ovarian cancers diagnosed in women with raised CA125 levels
exceeded that of ovarian cancers, but the numbers of women with each type of non-ovarian
cancer was small. In isolation, CA125 is unlikely to be a useful test for the detection of individ-
ual types of non-ovarian cancer in primary care, most of which have superior triage tests.
However, given our study findings, a high CA125 level in a woman 50 years should raise a
suspicion of non-ovarian cancer. Clinicians should consider these cancers and whether further
investigation is required, particularly if ovarian cancer has been excluded. Research is needed
to determine the most appropriate follow-up and testing strategy for these women in order to
ensure prompt diagnosis.
When assessing test performance, it is standard practice to evaluate test characteristics
using a cutoff, above which the test is deemed abnormal and below which it is deemed normal.
As per convention, we have presented this for CA125, applying the standard 35 U/ml cutoff.
However, where the probability of having a disease varies markedly with the test level, PPV is
of limited value in informing decisions about individual patients, as it effectively provides an
average probability of disease for all women with “abnormal” results. In this study, women
with very high CA125 values had a very high probability of being diagnosed with cancer. Con-
versely, those with CA125 levels around the 35 U/ml cutoff had a much lower probability of
being diagnosed with cancer than the PPV would appear to indicate. In this study, we have
quantified the risk of cancer in individuals with specific CA125 values at specific ages. This
should be of much more use clinically than PPVs.
Estimated cancer probabilities will allow women and clinicians to interpret their individual
CA125 result and could inform health policy both in the UK and internationally. For example,
NICE currently recommend that women with a CA125 35 U/ml, whether 35 U/ml or 1,000
U/ml, should be referred for an ultrasound scan, whereas no further investigations for ovarian
cancer are advocated in women with levels below the cutoff. Instead, our results could be used
to triage women of different ages, selecting those with a high probability of ovarian cancer for
expedited referral and investigation. Women with a probability in excess of the NICE risk
threshold of 3% could be referred via the urgent cancer pathway for specialist gynecology
assessment and/or imaging. Women with lower probabilities might, after discussion between
clinician and patient, be investigated using routine ultrasound, recognizing the fact that
patients would opt for cancer testing at risk levels as low as 1% [35]. As only a woman’s age
and CA125 level are required to determine the cancer probability from our results, this infor-
mation could readily be incorporated into laboratory information technology (IT) systems,
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reported alongside the CA125 level, and communicated to patients in clear terms, e.g., “1 in 30
women of your age who have the same CA125 level in general practice will have ovarian
cancer.”
Although we have focused on the UK NICE 3% probability threshold for urgent cancer
referral, our results would also allow alternative thresholds for referral to be implemented. A
lower probability threshold may lead to the detection of more cancers, but this would come at
the cost of larger numbers of cancer-free women being referred and further investigated,
which can have negative consequences such as increased patient anxiety and financial cost
[36]. Conversely, employing a higher probability threshold would lead to fewer cancer-free
women being referred unnecessarily, but more cancers may be missed. A full health economic
evaluation would greatly improve understanding of the implications of applying different
referral thresholds.
The Refining Ovarian Cancer Test Accuracy Scores (ROCkeTS) study, a large ongoing pro-
spective study in the UK evaluating a range of diagnostic tests and algorithms for ovarian can-
cer in secondary care, may provide insight into the most appropriate post-CA125 testing
strategy [37]. Any such strategy should take account of the high incidence of non-ovarian can-
cers in women with high CA125 levels, as pelvic ultrasound alone will miss many of these
malignancies. Other imaging modalities such as computed tomography (CT), which can detect
multiple CA125 elevating cancers including ovarian, lung, and pancreatic cancer [38–40] and
which is already used in several countries to investigate symptomatic women with elevated
CA125 levels [7], could be appropriate. Further research is also needed to determine whether
CA125 re-testing in primary care should be performed in women who have a normal ultra-
sound scan but persistent symptoms, as there is evidence from screening studies that a rising
CA125 is associated with a higher risk of ovarian cancer, even if ultrasound is normal [41].
Conclusions
CA125 is a useful test for detecting ovarian cancer in primary care, particularly in women aged
50 years and over. Given the high incidence of non-ovarian cancers in women with elevated
CA125 levels, clinicians should consider alternative cancers particularly when ovarian cancer
has been excluded. The results of this study will enable patients and clinicians to interpret their
CA125 result in terms of the probability of cancer at the pertinent CA125 level and age. The
findings will also allow policy makers to provide recommendations for post-CA125 investiga-
tions on the basis of the probability of undiagnosed cancer, which could enable the expedited
investigation and referral of those women most likely to have a cancer.
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Simple Summary: Most women with ovarian cancer are diagnosed after they develop symptoms—
identifying symptomatic women earlier has the potential to improve outcomes. Tools, ranging from simple
symptom checklists to diagnostic prediction models that incorporate tests and risk factors, have been
developed to help identify women at increased risk of undiagnosed ovarian cancer. In this review,
we systematically identified studies evaluating these tools and then compared the reported diagnostic
performance of tools. All included studies had some quality concerns and most tools had only been
evaluated in a single study. However, four tools were evaluated in multiple studies and showed moderate
diagnostic performance, with relatively little difference in performance between tools. While encouraging,
further large and well-conducted studies are needed to ensure these tools are acceptable to patients and
clinicians, are cost-effective and facilitate the early diagnosis of ovarian cancer.
Abstract: In the absence of e↵ective ovarian cancer screening programs, most women are diagnosed
following the onset of symptoms. Symptom-based tools, including symptom checklists and risk
prediction models, have been developed to aid detection. The aim of this systematic review was to
identify and compare the diagnostic performance of these tools. We searched MEDLINE, EMBASE
and Cochrane CENTRAL, without language restriction, for relevant studies published between
1 January 2000 and 3 March 2020. We identified 1625 unique records and included 16 studies,
evaluating 21 distinct tools in a range of settings. Fourteen tools included only symptoms; seven also
included risk factors or blood tests. Four tools were externally validated—the Go↵ Symptom Index
(sensitivity: 56.9–83.3%; specificity: 48.3–98.9%), a modified Go↵ Symptom Index (sensitivity: 71.6%;
specificity: 88.5%), the Society of Gynaecologic Oncologists consensus criteria (sensitivity: 65.3–71.5%;
specificity: 82.9–93.9%) and the QCancer Ovarian model (10% risk threshold—sensitivity: 64.1%;
specificity: 90.1%). Study heterogeneity precluded meta-analysis. Given the moderate accuracy of
several tools on external validation, they could be of use in helping to select women for ovarian
cancer investigations. However, further research is needed to assess the impact of these tools on the
timely detection of ovarian cancer and on patient survival.
Keywords: ovarian cancer; symptoms; early detection; risk assessment; diagnostic prediction model;
triage tool; ovarian cancer symptoms
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1. Introduction
Ovarian cancer is the eighth most common cancer to a↵ect women worldwide, accounting for
over 384,000 deaths in 2018 [1]. Outcomes are strongly linked to stage at diagnosis, with five-year
survivals of 90% and 4% for UK women diagnosed at stages I and IV, respectively [2]. Given this,
large ovarian cancer screening trials have been conducted, but these have so far failed to demonstrate
a significant reduction in long-term mortality [3,4]. In the absence of e↵ective screening programs,
the majority of ovarian cancers are diagnosed following symptomatic presentation [5,6], and a focus
has been placed on the early detection of symptomatic disease [7].
While once regarded as a ‘silent killer’, many studies have demonstrated that a range of symptoms
are more common in women with ovarian cancer than in control subjects and that symptoms occur at
all stages of the disease [8]. Clinical guidelines in countries around the world recommend that patients
presenting with symptoms of possible ovarian cancer undergo investigation, although debate remains
over which symptoms are indicative of disease and should be included in guidelines [7]. To facilitate
the early detection of symptomatic cancer, researchers have developed a number of symptom-based
checklists for use either when patients first present in the clinical setting or in ‘symptom-triggered
screening’ programs, in which symptoms are proactively solicited [9–11]. More sophisticated tools,
which can take the form of diagnostic prediction models [12], have also been developed to incorporate
test results and ovarian cancer risk factors alongside symptoms, in a bid to improve tool performance.
Several of these tools have been incorporated into clinical computer systems, which, then, automatically
alert the clinician to consider ovarian cancer investigations when relevant symptoms are present or
when the risk of undiagnosed cancer reaches a certain level. However, the relative limitations and
merits of the various available tools remain unclear. In this systematic review, we aimed to identify and
compare the diagnostic performances of symptom-predicated tools for the detection of ovarian cancer.
2. Methods
2.1. Eligibility Criteria and Searches
This review was conducted and is reported in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Table S1); a study protocol was registered
with PROSPERO [CRD42020149879]. We searched MEDLINE, EMBASE and Cochrane CENTRAL
for keywords relating to ovarian cancer, symptoms and prediction/diagnostic tools to identify papers
published between 1 January 2000 and 3 March 2020 (Text S1). The start date was chosen to predate
the publication of key ovarian cancer symptom papers [13,14]. No language restrictions or restrictions
on methodological design were applied. No restrictions were placed on study setting, so studies
conducted in the general population or in primary, secondary, or tertiary care were all eligible for
inclusion. Reference lists of included papers were screened to identify any additional relevant papers.
Studies were included if they (a) described the development and or evaluation of a multivariable
tool designed to identify patients with undiagnosed ovarian cancer and (b) provided the sensitivity and
specificity of the tool or gave su cient data to allow these metrics to be calculated. For the purposes
of this review, we defined a multivariable tool as a combination of three or more variables used to
detect or predict the risk of undiagnosed ovarian cancer. This broad definition encompasses traditional
multivariable diagnostic prediction models and clinical prediction rules [12,15]. We considered variable
‘checklists’, in which any one variable in the list needed to be present for a positive result, to be a
form of multivariable tool. As the focus of this review was on symptom-based tools, the tool under
investigation had to include at least one symptom for a study to be eligible. No other restrictions were
placed on the type of variable that could be included in a tool. Studies on tools intended to estimate
future risk of developing ovarian cancer rather than the current risk of having an undiagnosed ovarian
cancer were excluded, as were studies on tools that solely provide an indication of the risk of relapse or
recurrence. We excluded studies in which all participants had a pelvic mass—as this represents a highly
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selected high-risk population—and studies undertaken solely in paediatric (<18 years) populations.
Non-primary research studies were also excluded.
2.2. Study Selection
The online Rayyan software was used to facilitate abstract screening and study selection [16].
Following removal of duplicates, two reviewers (G.F. and V.H.) independently screened titles and
abstracts against eligibility criteria. Potentially eligible papers identified at the screening stage were
obtained and the full texts were independently examined against eligibility criteria by two reviewers
(G.F. and V.H.). Any disagreements were resolved by consensus.
2.3. Data Extraction and Synthesis
Data extraction was performed by one reviewer (G.F.) and checked against full-text papers
by a second reviewer (V.H.) to ensure accuracy. Using a predeveloped template, information was
extracted on study characteristics (year of publication and location), study design (methodology,
population, data source and outcome definition), tools (variables and tool development methods),
and tool performance metrics (sensitivity, specificity and other diagnostic metrics). Where a study
evaluated multiple tools, data relating to each tool were extracted separately.
Sensitivity and specificity were used to compare tool accuracy. For diagnostic prediction models,
area under the receiver operator characteristic curve (AUC) was used to compare discrimination (the
ability of a tool to identify those with a condition from those without a condition) and calibration
(agreement between estimated and observed outcomes). Due to the marked heterogeneity of included
studies in terms of the study designs, populations, variable definitions, outcome definitions and
use of di↵erent tool thresholds, and the failure of multiple studies to report numbers of patients
with true positive/true negative/false positive/false negative results, we were unable to perform any
meta-analyses. Instead, performance characteristics were summarised in tabular form and using
a narrative synthesis approach. When synthesising data, we paid particular attention to several
study and tool characteristics. First, the source of participant recruitment. For example, whether
controls were recruited from the general population or after entry into healthcare, as symptoms may
be more common in clinical controls than population controls, which could influence measures of
tool sensitivity and specificity [17]. Second, whether the measures of tool accuracy were obtained
directly from the patient sample in which the tool was developed (apparent performance), by applying
internal validation methods, such as splitting the sample into development and validation sets or using
cross-validation techniques (internal validation), or from a separate analysis in a distinct population
(external validation) [12]. Tools usually exhibit poorer diagnostic performance in external validation
studies than when evaluated in the original development sample, and external validation of tools
is recommended before they are used in clinical practice [12]. Third, we considered whether tools
consisted solely of symptoms or symptoms in addition to other variables, as this is likely to impact the
clinical utility of the tool.
2.4. Risk of Bias Assessment
The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was used to assess
the risk of bias and applicability of the included studies [18]. QUADAS-2 includes signalling questions
(intended to identify areas of potential bias or concern over study applicability) covering four domains:
(1) patient selection, (2) index test(s), (3) reference standard and (4) flow and timing. Each domain was
rated as having “high”, “low” or “unclear” (where insu cient information is provided) risk of bias.
Domains 1–3 were also rated for applicability as “high”, “low” or “unclear” concern. Two reviewers
(G.F. and V.H.) independently assessed each study using QUADAS-2. Ratings were compared and
disagreements were resolved by consensus.
Cancers 2020, 12, 3686 4 of 21
3. Results
3.1. Study Selection
In total, 2331 records were identified from database searches, of which 708 were duplicates.
Two additional records were identified from examination of reference lists. A total of 1625 titles and
abstracts were screened, and 35 full-text papers were examined. Sixteen studies met the eligibility
criteria and were included (Figure 1).
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i re 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram
illustrating the study s lection process.
3.2. Study Characteristics
The characteristics of the included studies are summarised in Table 1 and additional exclusion criteria
are detailed in Supplementary Material Table S2. Three studies were population-based [19–21], five studies
were based in a primary care setting [14,22–25], four studies were entirely hospital-based [26–29] and four
studies were hospital-based but also recruited controls from screening studies [30–33]. All population-
and hospital-based studies were of case-control design. Two of the studies that recruited from the
hospital setting included a proportion of controls with benign ovarian pathology [26,28]. Three of the
five primary care studies were of cohort design [22–24], and the remaining two were of case-control
design [14,25]. The studies used a variety of data sources for variables, including pre-existing routinely
collected primary care data (n = 6), information from surveys or patient interviews (n = 11) and blood
samples (n = 4). Study sizes varied markedly, with 75–1,908,467 participants and 24–1885 women ith
ovarian cancer per study. While all studies used ovarian cancer as an outcome, how this was defined
differed, with some only including invasive epithelial cancer or specifically stating that they excluded
borderline tumours [19–21,26–29], and others apparently including both invasive and borderline epithelial
tumours or all ovarian cancers [14,22–25,30–33]. One study included ovarian cancer alongside other
common cancers in a composite outcome, but tool performance characteristics for each cancer were given
separately [23]. Seven studies developed entirely new tools [14,19,22,23,25,30,33], six modified existing
tools [26–29,31,32] and eight externally validated existing tools [20,21,24,26–29,33].
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a Data collected on borderline tumours but not included in their tool performance evaluation. b Women with high-risk family histories consistent with a possible BRCA1/2 mutation in their
families, participating in the Ovarian Cancer Early Detection Study (OCEDS) [37]. c Numbers varied by study component: questionnaire (191 cases, 268 controls), telephone interview (111
cases, 125 controls) and GP notes (171 cases, 227 controls). d Controls with benign gynaecological disease were also included in study but are excluded from the review, as performance was
examined separately to healthy controls and no overall specificity measure was given. Study design and Objectives denoted by “•”. Abbreviations: OC = Ovarian cancer; NOS =Not
otherwise specified; GP = General practice; US = Ultrasound.
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3.3. Risk of Bias
The main potential sources of bias were identified in the “patient selection” and the “index test”
domains (Figure 2). As the case-control design can lead to overestimation of test performance [18],
13 studies were flagged as being at high risk of bias for patient selection. Key potential sources of
bias identified for studies in the “index test” domain included failing to pre-define the tool threshold
and retrospectively administering the tool after the outcome had been determined, e.g., questioning
participants after the ovarian cancer diagnosis had been made. The risk of bias was generally judged
as low for the “reference standard” and “flow and timing” domains. However, all primary care studies
were flagged as being at high risk of bias in the “reference standard” domain as they relied on general
practitioner (GP) records to identify ovarian cancer diagnoses, supplemented in two studies by death
registration data [22,23] rather than hospital or cancer registry histological diagnoses. Concern over
the applicability of studies was judged as low, save for the “reference standard” domain of one study
which used a composite cancer outcome [23].
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4. Tool Variables
The studies evaluated a total of 21 distinct tools, of which five were diagnostic prediction models
develop d sing appropri te statistical meth ds from w ich variable weights were derived [12].
We grouped variables included in the tools into four categories: (1) patient demographics, (2) personal
and family medical history, (3) symptoms and (4) test results (Table 2). By definition, all tools included
symptoms, with 14 including only symptoms. Four tools incorporated demographics, two incorporated
personal and family medical history and six incorporated test results. Five symptoms (abdominal
pain, pelvic pain, distension, bloating and appetite loss) were included in more than half ( 11) of the
tools and a further six symptoms (feeling full quickly, di culty eating, postmenopausal bleeding,
urinary frequency, palpable abdominal mass/lump and rectal bleeding) were included in at least a
quarter ( 6) of the tools. Six tools were based on an existing tool—the Go↵ Symptom Index (SI)—which
was modified to include additional symptom or test result variables. Specifications of each tool,
including how variables were defined, are included in the Supplementary Material Table S3.
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(Grewal, 2013) • • • • • • •
OC Score B
(Grewal, 2013) • • • • • • •
OC Score C
(Grewal, 2013) • • • • • • • •
* Consensus statement released by the Society of Gynaecologic Oncologists (SGO), the Gynaecologic Cancer Foundation and the American Cancer Society. The presence of a variable
within a model is denoted by “•”. The terms used to describe a given symptom varied subtly between studies—full details of each tool, including symptom terminology and duration and
frequency criteria, are included in Supplementary Material Table S3. Abbreviations: PMH = past medical history; FH = family history; Abdo. = abdominal; Distens. = distension; Bloat. =
bloating; Postmen. = postmenopausal; bleed. = bleeding; Freq. = frequency; Hb = haemoglobin; CA125 = cancer antigen 125; HE4 = human epididymis protein 4; SI = symptom index; OC
= ovarian cancer; BMI = body mass index; endomet. = endometrial; T2DM = type 2 diabetes mellites; COPD = chronic obstructive pulmonary disease; GI = gastrointestinal; CIBH =
change in bowel habit.
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4.1. Evaluation of Tool Performance
The diagnostic performance of the included tools is summarised in Table 3. Measures of diagnostic
performance for the majority of the tools were obtained directly from the patient sample with which
the tool was developed (apparent performance) or by applying internal validation methods, such as
splitting the sample into development and validation sets (internal validation), with only four tools—the
Society of Gynaecologic Oncology (SGO) consensus criteria, Go↵ SI, QCancer Ovarian, Modified
Go↵ SI 1—undergoing independent validation with an external dataset. Although the Go↵ SI in
combination with CA125 was evaluated in several studies, the CA125 thresholds used varied markedly,
so no studies were considered to have externally validated the same combination. There was overlap
in evaluation of tools between healthcare settings, but no tool evaluated in primary care was evaluated
in another setting or vice versa.
The most widely studied tool was the Goff SI, which was evaluated in nine studies [20,21,26,27,29–33],
but two of these used data from subsets of women in the original tool development study [31,32].
Apparent deviations from the original Goff SI in how variables were defined were noted in several studies
(Table S4). The Goff SI was the only tool to be externally validated in groups of women recruited from
more than one setting.
4.2. Tool Diagnostic Accuracy
4.2.1. Hospital Setting
All but two tools evaluated in hospital populations incorporated the Goff SI. Two of these underwent
external evaluation—the original Goff SI and a modified version incorporating additional symptoms
(Modified Goff SI 1). The Goff SI, which was externally validated in six studies, demonstrated sensitivities
which ranged from 56.9% to 83.3% (an outlier result) and specificities from 48.3% (an outlier result) to
98.9%. A modified version of the Goff SI (Modified Goff SI 1) demonstrated a sensitivity of 71.6% and a
specificity of 88.5% in a single external validation study.
Augmenting symptom checklists with baseline risk factors and test results generally led to a reduction
in sensitivity and an increase in specificity, or vice versa, depending on the threshold used. For example,
the addition of the serum ovarian cancer biomarker CA125 to the Goff SI by Anderson et al. (2008) led to a
reduction in tool sensitivity—if both variables were required to be abnormal for a positive tool result—or
in tool specificity—if only one was required to be abnormal for a positive tool result [31].
4.2.2. Population Setting
In women recruited from the population setting, two symptom checklists were externally validated
side by side—the Go↵ SI and the SGO consensus criteria. While the sensitivities and specificities of the
tools di↵ered between the studies, within each study, they were similar, with an in-study maximum
di↵erence in sensitivity of 3.4% and specificity of 2.4% between the tools.
4.2.3. Primary Care
A single tool (QCancer Ovarian), which took the form of a prediction model and combined
symptom variables with demographics, family history and routine blood test results, underwent
external validation in a primary care setting. When the threshold for abnormality was set to include
the 5% of women at the highest predicted risk, QCancer Ovarian had a sensitivity of 43.8% and
a specificity of 95%, while when the threshold was set to include women at the 10% highest risk,
the sensitivity increased to 64.1% but the specificity fell to 90.1%. Several scores, developed by Grewal
et al., demonstrated higher sensitivities and specificities than QCancer Ovarian at the 5% risk threshold
(OC Score B   4) and 10% risk threshold (OC Score C   4), but diagnostic accuracy measures were
derived from the same dataset used in score development.
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Table 3. Tool diagnostic accuracy.
Tool Study


























Andersen, 2008 a • • 64(52.1–74.8)
88.2
(83.6–91.9) - -
Kim, 2009 • • 56.9 87.6 - -








<55 yrs: 0.04) d
-
Andersen, 2010 a • • 63.5(51.5–74.4)
88.3
(81.7–93.2) - -
Macuks, 2011 • • 83.3 48.3 - -
Jain, 2018 • • 77.8 87.8 - -
Lim, 2012 • • 61.4–75.7 e 89.6–98.9 e - -
Modified Go↵ SI 1
Kim, 2009 • • 65.5 84.7 - -
Shetty, 2015 • • 71.6 88.5 - -
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Hippisley-Cox, 2012 • • 63.2 90.8 0.8 084(0.83–0.86)
Collins, 2013 • • 64.1 90.1 0.5 0.86(0.84–0.87)
QCancer Ovarian (Top
5% risk)
Hippisley-Cox, 2012 • • 42.2 95.6 1.1 -
Collins, 2013 • • 43.8 95 0.6 -
QCancer Ovarian (Top
1% risk) Hippisley-Cox, 2012 • • 13.9 99.3 2.1 -
QCancer Ovarian (Top
0.5% risk) Hippisley-Cox, 2012 • • 11 99.6 3.2 -
QCancer Ovarian (Top
0.1% risk) Hippisley-Cox, 2012 • • 3.9 99.9 5.5 -
QCancer Female (Top
10% risk) Hippisley-Cox, 2013 • • 61.6 90 0.6
0.84
(0.82–0.86)
OC Score A (Score   3) Grewal, 2013 • • 58.5 97.3 -
0.89
OC Score A (Score   4) Grewal, 2013 • • 57.6 97.3 -
OC Score B (Score   3) Grewal, 2013 • • 75 90.1 -
0.89
OC Score B (Score   4) Grewal, 2013 • • 58.9 97.3 -
OC Score C (Score   3) Grewal, 2013 • • 85.4 85.1 -
0.88
OC Score C (Score   4) Grewal, 2013 • • 72.6 91.3 -
a Study used a subset of patients from Go↵, 2007. b Calculated using external data from screening studies. [39,40]. c Calculated using external Australian population-level data. d
Calculated using external data from US and UK screening studies and Australian population-level data. [41,42]. e Sensitivity and specificity varied by data collection method (questionnaire,
telephone interview, GP notes). f Biomarker level (CA125, HE4) dichotomised at 95th percentile in control group—levels above that deemed abnormal. The Recruitment setting and the
source of accuracy estimate are denoted by “•”. Abbreviations: OC = ovarian cancer; CI = confidence interval; AUC = area under the receiver operator characteristic curve; PPV = positive
predictive values; yrs = years.
Cancers 2020, 12, 3686 16 of 21
Discrimination was reported for five tools (Table 3), all of which had similar AUCs within the
‘good’ range (0.84–0.89), with QCancer Ovarian exhibiting an AUC of 0.86 on external validation.
Tool calibration was assessed for QCancer tools by graphically comparing the predicted cancer risk at
two years with the observed risk by predicted risk deciles [22–24]. Authors reported good calibration
on internal validation. On external validation, QCancer Ovarian had reasonable calibration but
overpredicted risk, particularly in older women [24].
4.2.4. Positive Predictive Values
The three cohort studies conducted in primary care reported positive predictive values (PPV) for
QCancer tools at a range of thresholds (Table 3). The PPVs at any given risk threshold were similar—for
example, values ranged from 0.5 to 0.8% when the threshold was set to identify the 10% of women at
highest risk. Two case control studies (Rossing et al. and Jordan et al.) used external disease prevalence
figures from screening studies and available population-level statistics to estimate the PPVs of the Go↵
SI and SGO consensus criteria—if they were to be used in general populations. The tools had similar
estimated PPVs within each study, but PPVs were higher in Rossing et al. (0.63–1.12%) than in Jordan
et al. (<55 years: 0.04–0.05%,  55 years: 0.18–0.31%).
5. Discussion
To our knowledge, this is the first systematic review to compare the diagnostic performance
of existing symptom-based tools for ovarian cancer detection. We identified 21 symptom-based
tools designed to help identify women with undiagnosed ovarian cancer. These tools comprised
simple symptom checklists, checklists which included both symptoms and tests and more complex
diagnostic prediction models which incorporated symptoms, test results and baseline risk factors.
While the diagnostic performances of most tools were evaluated solely within the study development
datasets, four tools were independently externally validated, with one being validated in multiple
population settings. Externally validated tools demonstrated similar moderate diagnostic performances.
Our findings should inform future studies evaluating the clinical impact of validated symptom-based
tools when implemented in clinical practice.
5.1. Study Strengths and Limitations
The main strengths of this study were its systematic approach, broad search strategy and liberal
eligibility criteria, which enabled us to identify and compare the performances of a wide variety of tools.
However, the identified studies were extremely heterogeneous in their designs, populations, variable
definitions, outcome definitions and thresholds, which ultimately precluded any meaningful meta-analyses.
For example, although the Goff SI was evaluated in nine studies, there was overlap between the participants
in three studies, control groups ranged from apparently healthy general population participants to hospital
gynaecology patients (with or without benign pathology), ovarian cancer definitions differed and deviations
in the parameters of the SI itself, in terms of symptom duration and frequency criteria, were noted in
several studies. While meta-analysis was not deemed appropriate, our results demonstrate how the Goff SI
performs under different conditions. An additional limitation was that all included studies were at high
risk of bias in at least one QUADAS-2 domain, which limits the conclusions that can be drawn.
5.2. Comparison of Tools
Although all tools were symptom-based and designed to help identify women with ovarian cancer,
they varied markedly in the symptoms they included. This mirrors discrepancies in the literature and
within national guidelines as to which symptoms are associated with the disease and probably reflects
di↵erences in study methodologies and study populations [7]. Despite this, the symptoms with the
highest positive likelihood ratios for ovarian cancer in a recent systematic review (distension, bloating,
abdominal or pelvic pain) were incorporated into the majority of tools [8]. The more cancer-associated
symptoms that are included in a checklist, the higher the sensitivity of the tool is likely to be, but at the
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cost of reducing specificity, as demonstrated by several of the included studies [19,26,33]. This was
cited by Go↵ et al. as a rationale for not including urinary symptoms in the Go↵ SI [30]. Ultimately,
variation in which additional symptoms a tool includes may have limited impact on tool performance;
on external validation, two studies reported similar diagnostic accuracy metrics for the Go↵ SI and the
SGO criteria (which di↵ered on several symptoms), and on internal validation, Lim et al. concluded
that changing several of the symptoms made relatively little di↵erence to tool diagnostic accuracy [33].
In multiple studies, symptom checklists were augmented by ovarian cancer biomarkers with
the aim of improving tool diagnostic accuracy. This approach naturally led to a reduction in tool
specificity (where either symptoms or an abnormal test resulted in a positive tool) or sensitivity
(where symptoms and an abnormal test were needed for a positive tool). If ovarian cancer biomarkers
are to be included alongside symptoms within tools, this loss of performance could be avoided by
incorporating them within prediction models, as per the inclusion of anaemia in QCancer Ovarian.
As the prediction model threshold can be set at a desired risk level, biomarkers, such as CA125 and
HE4, could be incorporated without harming tool performance. However, this would require women
to have specialist ovarian cancer markers performed in order for the tool to be used, which significantly
limits clinical utility. A more practical approach would be to incorporate tools within a two-step
pathway in which symptom-based tools (which do not include specialist test variables) are used to
help select higher-risk women for specialist ovarian cancer tests.
Variation in the reported sensitivity and specificity of the most widely evaluated tool, the Go↵ SI,
was noted between studies. This variation is likely to be due, in part, to the marked di↵erences in
study design, populations and outcome definitions which precluded meta-analysis across these studies.
Despite these di↵erences, in 5 of the 6 external validation studies (including two large population-based
studies), the Go↵ SI had a sensitivity in excess of 60%, and in all but the smallest study, which included
only 24 ovarian cancers and 31 controls, its specificity exceeded 85%. The sensitivities and specificities
of the two other externally validated symptom checklists—the SGO consensus criteria and the
modified Go↵ SI 1—were similar, as were those of the only externally validated diagnostic prediction
model—QCancer Ovarian (applying a 10% risk threshold). Given the similarity in performance of
the various existing validated tools, future research e↵orts may be better directed at evaluating the
impact of using available tools in practice rather than developing further tools consisting of di↵erent
symptom combinations.
5.3. Clinical Relevance
Two distinct uses for tools were identified by the authors of the included studies: (1) assessment
of women presenting symptomatically in the standard clinical setting to identify those at higher risk
of undiagnosed cancer and to inform decision making and further investigation, and (2) proactive
‘symptom-triggered screening’ programs in which women are actively screened using the tool,
with further testing for ovarian cancer occurring if the tool is positive. Several of the tools identified in
this review are already available for use within the standard clinical setting in the form of electronic
clinical decision support tools (eCDSTs). QCancer tools are integrated within some UK general
practice IT systems and alert the clinician if the risk of ovarian cancer in an individual reaches a
certain level, prompting them to consider ovarian cancer as a possible diagnosis. eCDSTs have been
shown to improve practitioner performance and patient care, but there are multiple barriers to their
implementation and they do not always lead to improved outcomes [43,44]. Therefore, even if eCDSTs
are deemed to have acceptable diagnostic accuracy, their cost-e↵ectiveness, acceptability to patients
and clinicians and their impact on timely ovarian cancer detection and survival need to be evaluated.
Currently, a large, clustered, randomised control trial is seeking to help to address this by investigating
the clinical impact of implementing a suite of electronic cancer risk assessment tools (including an
electronic version of the Hamilton ovarian SI) in UK general practice [45]. Studies have also sought to
evaluate the impact of using tools as part of ‘symptom-triggered screening’ programs, but none have
taken the form of randomised control trials—the gold standard approach—and so findings should
Cancers 2020, 12, 3686 18 of 21
be interpreted with caution. In one study, 5000 women were approached in primary care clinics and
screened for symptoms using the Go↵ SI, with further investigations performed if the Go↵ SI was
positive [11]. However, conclusions were limited as only two ovarian cancers were identified in the
study window. The Diagnosing Ovarian and Endometrial Cancer Early (DOvEE) trial also employs a
proactive symptom-triggered testing approach, supported by media campaigns, in which women can
self-refer and are screened for range of symptoms prior to study inclusion. Although the final DOvEE
results are yet to be published, a pilot study reported that participants had lower tumour burden and
more resectable disease than women diagnosed via the standard clinical pathway [9].
When considering the clinical utility of a tool, it is important to assess the proportion of women
who are ‘tool-positive’ who ultimately have ovarian cancer, i.e., the PPV. Primary care cohort studies
indicated that between 1 in 200 and 1 in 100 women who were QCancer tool-positive (5% or 10%
risk) had the disease. Although these figures may appear low, evidence indicates that patients would
opt for cancer testing at PPVs of 1% [46]. Further, having a positive tool result in the clinical setting
does not necessarily mean that further investigation will automatically occur, as there may be a clear
alternative cause for the symptoms—the tool is simply intended as a diagnostic aid to highlight the
risk of ovarian cancer to the clinician. In addition, the most common follow-up tests—CA125 and
transvaginal ultrasound—are relatively non-invasive, and CA125 is known to perform well when
used in a symptomatic primary care population [47], although invasive investigations/surgery may
ultimately be needed to determine whether ovarian cancer is present. In proactive symptom-triggered
screening programs, the tool is more than just a diagnostic aid—it is the initial screening step which
will dictate whether further ovarian cancer tests take place. The two population studies reporting
PPVs relied on external ovarian cancer prevalence figures, but their PPV estimates were similar to that
reported in the pilot DOvEE study (0.76% in women   50 years) [9]. Further research is needed to
help determine whether, given this PPV, follow-up testing in proactive symptom-triggered testing
programs is acceptable to women and improves outcomes. The definitive diagnosis of ovarian cancer
often involves invasive procedures/surgery, which has contributed to patient morbidity in key ovarian
cancer screening trials [3,39]. Although initial findings indicate that proactive symptom triggered
testing approaches lead to minimal unnecessary surgery [9,11], large trials are needed to confirm
that the implementation of symptom-based tools in clinical practice does not lead to significant
excess morbidity.
6. Conclusions
Over 20 symptom-based tools have been developed in di↵erent populations to help assess women
for ovarian cancer, but the majority have not been validated. Four symptom-based tools—the Go↵ SI,
a modified version of the Go↵ symptom Index, SGO consensus criteria and QCancer Ovarian—have
undergone independent external validation and exhibit similar sensitivities and specificities. These tools
could have an important role to play in the detection of ovarian cancer, but further large well-conducted
studies are needed to assess their cost-e↵ectiveness, their acceptability, their e↵ect on the timeliness of
ovarian cancer diagnosis and their impact on clinical outcomes, including patient survival.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/12/3686/s1,
Table S1: PRISMA Checklist. Text S1: MEDLINE search strategy. Table S2: Specific study exclusions. Table S3:
Tool specifications. Table S4: Deviations from the original Go↵ SI in validation studies.
Author Contributions: Conceptualization, G.F.; methodology, G.F., F.M.W. and W.H.; formal analysis, G.F. and
V.H.; data curation, G.F. and V.H.; writing—original draft preparation, G.F.; writing—review and editing, G.F.,
V.H., G.A., E.J.C., W.H., F.M.W. and J.E.; supervision, F.M.W., G.A., E.J.C. and W.H.; funding acquisition, F.M.W.
and W.H. All authors have read and agreed to the published version of the manuscript.
Funding: This research arises from the CanTest Collaborative, which is funded by Cancer Research UK
[C8640/A23385], of which G.F. is Clinical Research Fellow, V.H. is a PhD student, G.A. is the Senior Statistician,
J.E. is Associate Director, and W.H. and F.M.W. are Directors. E.J.C. is supported through the NIHR Manchester
Biomedical Research Centre (IS-BRC-1215-20007). The funders of this study had no role in the study design,
data collection, data analysis, data interpretation, or writing of the report.
Cancers 2020, 12, 3686 19 of 21
Conflicts of Interest: Two studies included in this review were conducted by W.H. W.H. played no role in study
selection or quality assessment. All other authors declare no conflicts of interest. The funders had no role in the
design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the
decision to publish the results.
References
1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer
J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]
2. Cancer Research UK. Ovarian Cancer Survival Statistics. Available online: http://www.cancerresearchuk.
org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/survival#heading-Three
(accessed on 20 May 2020).
3. Jacobs, I.J.; Menon, U.; Ryan, A.; Gentry-Maharaj, A.; Burnell, M.; Kalsi, J.K.; Amso, N.N.; Apostolidou, S.;
Benjamin, E.; Cruickshank, D.; et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of
Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 2016, 387, 945–956. [CrossRef]
4. Pinsky, P.F.; Yu, K.; Kramer, B.S.; Black, A.; Buys, S.S.; Partridge, E.; Gohagan, J.; Berg, C.D.; Prorok, P.C.
Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up.
Gynecol. Oncol. 2016, 143, 270–275. [CrossRef] [PubMed]
5. Barrett, J.; Sharp, D.J.; Stapley, S.; Stabb, C.; Hamilton, W. Pathways to the diagnosis of ovarian cancer in the
UK: A cohort study in primary care. BJOG 2010, 117, 610–614. [CrossRef]
6. National Cancer Intellegence Network. Routes to Diagnosis 2006–2016 by year, V2.1a. Available online:
http://www.ncin.org.uk/publications/routes_to_diagnosis (accessed on 21 May 2020).
7. Funston, G.; Melle, V.M.; Ladegaard Baun, M.-L.; Jensen, H.; Helpser, C.; Emery, J.; Crosbie, E.; Thompson, M.;
Hamilton, W.; Walter, F.M. Variation in the initial assessment and investigation for ovarian cancer in
symptomatic women: A systematic review of international guidelines. BMC Cancer 2019, 19, 1028. [CrossRef]
8. Ebell, M.H.; Culp, M.B.; Radke, T.J. A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer.
Am. J. Prev. Med. 2016, 50, 384–394. [CrossRef]
9. Gilbert, L.; Basso, O.; Sampalis, J.; Karp, I.; Martins, C.; Feng, J.; Piedimonte, S.; Quintal, L.; Ramanakumar, A.V.;
Takefman, J.; et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: Results from
the prospective DOvE pilot project. Lancet Oncol. 2012, 13, 285–291. [CrossRef]
10. Go↵, B.A.; Lowe, K.A.; Kane, J.C.; Robertson, M.D.; Gaul, M.A.; Andersen, M.R. Symptom triggered
screening for ovarian cancer: A pilot study of feasibility and acceptability. Gynecol. Oncol. 2012, 124, 230–235.
[CrossRef]
11. Andersen, M.R.; Lowe, K.A.; Go↵, B.A. Value of Symptom-Triggered Diagnostic Evaluation for Ovarian
Cancer. Obstet. Gynecol. 2014, 123, 73–79. [CrossRef]
12. Moons, K.G.M.; Altman, D.G.; Reitsma, J.B.; Ioannidis, J.P.A.; Macaskill, P.; Steyerberg, E.W.; Vickers, A.J.;
Ransoho↵, D.F.; Collins, G.S. Transparent reporting of a multivariable prediction model for individual
prognosis or diagnosis (TRIPOD): Explanation and elaboration. Ann. Intern. Med. 2015, 162, W1–W73.
[CrossRef]
13. Go↵, B.A.; Mandel, L.S.; Melancon, C.H.; Muntz, H.G. Frequency of symptoms of ovarian cancer in women
presenting to primary care clinics. JAMA 2004, 291, 2705–2712. [CrossRef] [PubMed]
14. Hamilton, W.; Peters, T.J.; Bankhead, C.; Sharp, D. Risk of ovarian cancer in women with symptoms in
primary care: Population based case-control study. BMJ 2009, 339, b2998. [CrossRef] [PubMed]
15. Laupacis, A.; Sekar, N.; Stiell, I.G. Clinical prediction rules: A review and suggested modifications of
methodological standards. J. Am. Med. Assoc. 1997, 277, 488–494. [CrossRef]
16. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a web and mobile app for systematic
reviews. Syst. Rev. 2016, 5, 210. [CrossRef]
17. Usher-Smith, J.A.; Sharp, S.J.; Gri n, S.J. The spectrum e↵ect in tests for risk prediction, screening,
and diagnosis. BMJ 2016, 353, i3139. [CrossRef]
18. Whiting, P.F.; Rutjes, A.W.S.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.G.;
Sterne, J.A.C.; Bossuyt, P.M.M. Quadas-2: A revised tool for the quality assessment of diagnostic accuracy
studies. Ann. Intern. Med. 2011, 155, 529–536. [CrossRef]
Cancers 2020, 12, 3686 20 of 21
19. Lurie, G.; Thompson, P.J.; McDu e, K.E.; Carney, M.E.; Goodman, M.T. Prediagnostic symptoms of ovarian
carcinoma: A case-control study. Gynecol. Oncol. 2009, 114, 231–236. [CrossRef]
20. Rossing, M.A.; Wicklund, K.G.; Cushing-Haugen, K.L.; Weiss, N.S. Predictive value of symptoms for early
detection of ovarian cancer. J. Natl. Cancer Inst. 2010, 102, 222–229. [CrossRef]
21. Jordan, S.J.; Coory, M.D.; Webb, P.M. Re: Predictive Value of Symptoms for Early Detection of Ovarian
Cancer. JNCI J. Natl. Cancer Inst. 2010, 102, 1599–1601. [CrossRef]
22. Hippisley-Cox, J.; Coupland, C. Identifying women with suspected ovarian cancer in primary care:
Derivation and validation of algorithm. BMJ 2012, 344, d8009. [CrossRef]
23. Hippisley-Cox, J.; Coupland, C. Symptoms and risk factors to identify women with suspected cancer in
primary care: Derivation and validation of an algorithm. Br. J. Gen. Pract. 2013, 63, e11–e21. [CrossRef]
24. Collins, G.S.; Altman, D.G. Identifying women with undetected ovarian cancer: Independent and external
validation of QCancer® (Ovarian) prediction model. Eur. J. Cancer Care (Engl.) 2013, 22, 423–429. [CrossRef]
25. Grewal, K.; Hamilton, W.; Sharp, D. Ovarian cancer prediction: Development of a scoring system for primary
care. BJOG An Int. J. Obstet. Gynaecol. 2013, 120, 1016–1019. [CrossRef]
26. Kim, M.-K.; Kim, K.; Kim, S.M.; Kim, J.W.; Park, N.-H.; Song, Y.-S.; Kang, S.-B. A hospital-based case-control
study of identifying ovarian cancer using symptom index. J. Gynecol. Oncol. 2009, 20, 238–242. [CrossRef]
27. Macuks, R.; Baidekalna, I.; Donina, S. Diagnostic test for ovarian cancer composed of ovarian cancer symptom
index, menopausal status and ovarian cancer antigen CA125. Eur. J. Gynaecol. Oncol. 2011, 32, 286–288.
28. Shetty, J.; Priyadarshini, P.; Pandey, D.; Manjunath, A.P. Modified Go↵ Symptom Index: Simple triage tool
for ovarian malignancy. Sultan Qaboos Univ. Med. J. 2015, 15, e370–e375. [CrossRef]
29. Jain, S.; Danodia, K.; Suneja, A.; Mehndiratta, M.; Chawla, S. Symptom index for detection of ovarian
malignancy in indian women: A hospital-based study. J. Indian Acad. Clin. Med. 2018, 19, 27–32.
30. Go↵, B.A.; Mandel, L.S.; Drescher, C.W.; Urban, N.; Gough, S.; Schurman, K.M.; Patras, J.; Mahony, B.S.;
Robyn Andersen, M. Development of an ovarian cancer symptom index: Possibilities for earlier detection.
Cancer 2007, 109, 221–227. [CrossRef]
31. Andersen, M.R.; Goff, B.A.; Lowe, K.A.; Scholler, N.; Bergan, L.; Dresher, C.W.; Paley, P.; Urban, N. Combining a
symptoms index with CA 125 to improve detection of ovarian cancer. Cancer 2008, 113, 484–489. [CrossRef]
32. Andersen, M.R.; Go↵, B.A.; Lowe, K.A.; Scholler, N.; Bergan, L.; Drescher, C.W.; Paley, P.; Urban, N. Use of a
Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol. Oncol. 2010, 116, 378–383. [CrossRef]
[PubMed]
33. Lim, A.W.W.; Mesher, D.; Gentry-Maharaj, A.; Balogun, N.; Jacobs, I.; Menon, U.; Sasieni, P. Predictive value
of symptoms for ovarian cancer: Comparison of symptoms reported by questionnaire, interview, and general
practitioner notes. J. Natl. Cancer Inst. 2012, 104, 114–124. [CrossRef] [PubMed]
34. Merritt, M.A.; Green, A.C.; Nagle, C.M.; Webb, P.M.; Bowtell, D.; Chenevix-Trench, G.; Green, A.; Webb, P.;
DeFazio, A.; Gertig, D.; et al. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of
epithelial ovarian cancer. Int. J. Cancer 2008, 122, 170–176. [CrossRef] [PubMed]
35. QResearch The QResearch Database. Available online: https://www.qresearch.org (accessed on 8 January 2019).
36. THIN® The Health Improvement Network. Available online: https://www.the-health-improvement-network.
com/en/ (accessed on 9 November 2020).
37. Lowe, K.A.; Shah, C.; Wallace, E.; Anderson, G.; Paley, P.; McIntosh, M.; Andersen, M.R.; Scholler, N.;
Bergan, L.; Thorpe, J.; et al. E↵ects of personal characteristics on serum CA125, mesothelin, and HE4 levels
in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol. Biomark. Prev. 2008,
17, 2480–2487. [CrossRef]
38. Menon, U.; Gentry-Maharaj, A.; Hallett, R.; Ryan, A.; Burnell, M.; Sharma, A.; Lewis, S.; Davies, S.; Philpott, S.;
Lopes, A.; et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and
stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of
Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009, 10, 327–340. [CrossRef]
39. Buys, S.S.; Partridge, E.; Greene, M.H.; Prorok, P.C.; Reding, D.; Riley, T.L.; Hartge, P.; Fagerstrom, R.M.;
Ragard, L.R.; Chia, D.; et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO)
cancer screening trial: Findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol. 2005,
193, 1630–1639. [CrossRef]
Cancers 2020, 12, 3686 21 of 21
40. Jacobs, I.; Prys Davies, A.; Bridges, J.; Stabile, I.; Fay, T.; Lower, A.; Grudzinskas, J.G.; Oram, D. Prevalence
screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.
Br. Med. J. 1993, 306, 1030–1034. [CrossRef]
41. Cancer Incidence Projections Australia 2002 to 2011; Australian Institute of Health and Welfare; Australasian
Association of Cancer Registries; National Cancer Strategies Group: Canberra, Australia, 2005.
42. Australian Demographic Statistics; Australian Bureau of Statistics D: Canberra, Australia, 2007.
43. Chima, S.; Milley, K.; Reece, J.C.; Milton, S.; McIntosh, J.G.; Emery, J.D. Decision support tools to improve
cancer diagnostic decision making in primary care: A systematic review. Br. J. Gen. Pract. 2019, 69, e809–e818.
[CrossRef]
44. Chiang, P.C.; Glance, D.; Walker, J.; Walter, F.M.; Emery, J.D. Implementing a qcancer risk tool into
general practice consultations: An exploratory study using simulated consultations with Australian general
practitioners. Br. J. Cancer 2015, 112, S77–S83. [CrossRef]
45. Hamilton, W. Electronic Risk Assessment for Cancer for Patients in General Practice (ISRCTN22560297).
Available online: http://www.isrctn.com/ISRCTN22560297 (accessed on 30 October 2020).
46. Banks, J.; Hollinghurst, S.; Bigwood, L.; Peters, T.J.; Walter, F.M.; Hamilton, W. Preferences for cancer
investigation: A vignette-based study of primary-care attendees. Lancet Oncol. 2014, 15, 232–240. [CrossRef]
47. Funston, G.; Hamilton, W.; Abel, G.; Crosbie, E.J.; Rous, B.; Walter, F.M. The diagnostic performance of
CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort
study. PLoS Med. 2020, 17, e1003295. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
a liations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Research
Garth Funston, Luke TA Mounce, Sarah Price, Brian Rous, Emma J Crosbie, Willie Hamilton 
and Fiona M Walter
CA125 test result, test-to-diagnosis interval, and 
stage in ovarian cancer at diagnosis:
a retrospective cohort study using electronic health records 
INTRODUCTION
Ovarian cancer is the sixth most common 
cancer to affect women in the UK, with 
>7000 women diagnosed each year.1 It has 
the worst prognosis of all gynaecological 
cancers, accounting for >4000 UK deaths 
annually.2 Although, overall, ovarian cancer 
prognosis is relatively poor, this varies 
markedly based on tumour type: studies 
conducted in the US and Sweden report 
that 5-year relative survival rates are 48% 
for invasive epithelial cancer (the most 
common type), compared with 93% for 
ovarian germ-cell tumours and 97% for 
borderline tumours.3,4 
Most women with ovarian cancer are 
diagnosed after presenting with symptoms 
in primary care. However, the symptoms 
— such as bloating and abdominal pain 
— are non-specific and, therefore, have 
relatively low positive predictive values for 
the disease.5,6 In 2011, the National Institute 
for Health and Care Excellence (NICE) 
advocated testing for the serum biomarker 
cancer antigen 125 (CA125) in women with 
symptoms of possible ovarian cancer in 
primary care.7 NICE recommended that 
women with an elevated CA125 (ö35 U/
ml) should undergo ultrasound testing;7 
however, they did not provide guidance on 
the follow-up or investigation of women 
with ‘normal’ (<35 U/ml) CA125 levels. 
Many other countries — including Ireland, 
Australia, Canada, and the US — also 
recommend CA125 as a primary care test 
for ovarian cancer.8 
CA125 is a glycoprotein found in healthy 
ovaries, but blood levels commonly 
increase in ovarian cancer; around 80% of 
women with ovarian cancer have raised 
CA125 levels pre-surgery.9 CA125 is more 
frequently elevated in advanced, rather than 
early-stage, disease and in some tumour 
types than others.10 Concerns have been 
expressed that using CA125 as a single first-
line investigation might delay diagnosis and 
lead to worse outcomes in women whose 
ovarian cancer is not associated with CA125 
levels ö35 U/ml,11 yet there is little research 
exploring the relationship between CA125, 
time to diagnosis, and outcomes. 
In this study, the authors examined the 
association of initial primary care pre-
diagnostic CA125 results with the time 
between testing and diagnosis (test-to-
diagnosis interval), tumour morphology, 
and disease stage in women with ovarian 
cancer.
METHOD
Study design, setting, and data sources
This retrospective cohort study utilised data 
from the Clinical Practice Research Datalink 
(CPRD) GOLD database, a dataset containing 
Abstract
Background
In the UK, the cancer antigen 125 (CA125) test 
is recommended as a first-line investigation in 
women with symptoms of possible ovarian cancer.
Aim
To compare time between initial primary care 
CA125 test and diagnosis, tumour morphology, 
and stage in women with normal (<35 U/ml) and 
abnormal (ö35 U/ml) CA125 levels prior to ovarian 
cancer diagnosis.
Design and setting
Retrospective cohort study using English primary 
care and cancer registry data.
Method
Associations between CA125 test results and test-
to-diagnosis interval, stage, and ovarian cancer 
morphology were examined.
Results
In total, 456 women were diagnosed with ovarian 
cancer in the 12 months after having a CA125 
test. Of these, 351 (77%) had an abnormal, and 
105 (23%) had a normal, CA125 test result. The 
median test-to-diagnosis interval was 35 days 
(interquartile range [IQR] 21–53) for those with 
abnormal CA125 levels, and 64 days (IQR 42–127) 
for normal CA125 levels. Tumour morphology 
differed by CA125 result: indolent borderline 
tumours were less common in those with 
abnormal CA125 levels (n = 47, 13%) than those 
with normal CA125 levels (n = 51, 49%) (P<0.001). 
Staging data were available for 304 women with 
abnormal, and 77 with normal, CA125 levels. Of 
those with abnormal CA125 levels, 35% (n = 106) 
were diagnosed at an early stage, compared to 
86% (n = 66) of women with normal levels. The 
odds of being diagnosed with early-stage disease 
were higher in women with normal as opposed 
to abnormal CA125 levels (odds ratio 12.2, 95% 
confidence interval = 5.8 to 25.1, P<0.001). 
Conclusion
Despite longer intervals between testing and 
diagnosis, women with normal, compared with 
abnormal, CA125 levels more frequently had 
indolent tumours and were more commonly 
diagnosed at an early stage in the course of 
the disease. Although testing approaches that 
have greater sensitivity might expedite diagnosis 
for some women, it is not known if this would 
translate to earlier-stage diagnosis.
Keywords
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postcode-linked deprivation measures 
(provided by CPRD), and data from the National 
Cancer Registration and Analysis Service 
(NCRAS), which acts as the English cancer 
registry. CPRD GOLD comprises anonymised, 
coded primary care data, including laboratory 
results and diagnoses, for around 7% of the 
UK population.12 The deprivation dataset 
consists of a five-level Townsend score — an 
area-level deprivation metric, in which higher 
scores indicate greater material deprivation. 
NCRAS data consists of detailed information 
on cancers diagnosed in England, including 
stage and morphology.13 CPRD–NCRAS 
linkage was performed at patient level by 
NHS Digital.14 
In order to match the coverage of NCRAS, 
this study was restricted to England. 
Study period and cohort
A data sample obtained for a related study15 
was used. The sample consisted of women 
with a CA125 test recorded in CPRD GOLD 
between 1 May 2011 and 31 December 
2014. From this sample, the following were 
excluded: 
• women aged <18 years; 
• those registered at a GP practice not 
deemed by the CPRD to be ‘up to 
standard’ regarding data quality;12 
• those with a record of ovarian cancer on, 
or before, the CA125 test date; and 
• women who had a CA125 test in the 
12 months prior to the first CA125 test 
during the study period. 
In order to maximise data quality, only 
CA125 entries recorded in standard CA125 
units (U/ml, IU/ml, KU/L, or KIU/L) and 
with a laboratory upper reference limit were 
accepted. Similarly, CA125 values associated 
with clearly erroneous upper reference 
limits (such as 245 U/ml, 420 U/ml, and 
455 U/ml) were excluded, as these could 
also indicate issues with the recording or 
coding of CA125 values.15 The authors then 
identified women who had been diagnosed 
with ovarian cancer, as recorded in NCRAS 
data, within 12 months of CA125 testing. 
This group formed the study cohort.
Ovarian cancer, on the basis of codes 
from the tenth revision of the International 
Classification of Diseases (ICD-10), was 
defined as an ovarian malignancy (C56), a 
fallopian tube malignancy (C57.0), a peritoneal 
malignancy (C48.1 and C48.2), or a neoplasm 
of uncertain behaviour of the ovary (D39.1).15 
Fallopian and peritoneal cancers arise from 
the same tissue type and are diagnosed, 
staged, and treated in the same way as cancer 
arising from the surface of the ovary. 
Borderline tumours are non-invasive, 
usually diagnosed at an early stage, and 
have a good prognosis. However, these 
may recur and, generally, require surgery. 
Borderline tumours are included in NICE 
guidance on ovarian cancer detection.7 
CA125 category
NICE recommends using a CA125 cut-off of 
35 U/ml.7 Therefore, women were classified 
on the basis of the initial CA125 test into two 
groups: 
• abnormal: CA125 level of ö35 U/ml; and 
• normal: CA125 level of <35 U/ml. 
Covariates
A code list was used to identify symptoms of 
possible ovarian cancer included in current 
NICE guidelines16 — namely, abdominal/
pelvic pain, abdominal distension/bloating, 
change in bowel habit, fatigue, weight loss, 
urinary frequency/urgency, loss of appetite, 
pelvic mass, or ascites — that had been 
recorded in CPRD GOLD in the 30 days prior 
to CA125 testing. Level of deprivation was 
determined using the five-level Townsend 
score in the deprivation measures dataset. 
Test-to-diagnosis interval
The date of cancer diagnosis is recorded 
for all tumours in NCRAS data. The test-to-
diagnosis interval (days from first CA125 test 
in the year before diagnosis to diagnosis date, 
as recorded in NCRAS data) was calculated 
for all women. 
Cancer stage and morphology
Tumour behaviour, morphology, and stage 
were identified from the NCRAS data. 
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How this fits in 
Cancer antigen 125 (CA125) is used as an
initial test for women who present to 
primary care with symptoms of possible 
ovarian  cancer, but research has shown 
that CA125 levels are normal in 23% of 
women prior to diagnosis. In the present 
study it was found that, although women 
with normal CA125 test results take longer 
to receive a diagnosis after testing than 
those with abnormal results, they are more 
likely to have less aggressive, more-curable 
forms of disease, and be diagnosised at an 
earlier cancer stage. This provides some 
reassurance for those using, and being 
tested for, CA125. However, improving 
the sensitivity of primary care testing 
approaches for ovarian cancer could still 
be of benefit to patients.
Tumours were classified on the basis of 
ICD-10 codes as: ‘borderline epithelial’, 
‘invasive epithelial’, ‘invasive non-epithelial’, 
and ‘invasive not otherwise specified (NOS)’. 
Stage was categorised as early (stage I–II) or 
late (stage III–IV). 
Statistical analysis
Accelerated failure time (AFT) models were 
used to examine the association between 
CA125 test results and test-to-diagnosis 
intervals. AFT models are a parametric 
time-to-event analysis previously utilised in 
CPRD research.17 AFT models can be used 
to calculate time ratios. A time ratio >1 
indicates that a variable prolongs the time to 
an event (for example, diagnosis), whereas a 
ratio <1 indicates that the variable reduces 
the time to the event. A univariate model 
was constructed to examine the relationship 
between the CA125 test result and test-to-
diagnosis interval. A multivariable model 
was constructed incorporating age, a binary 
variable denoting the presence/absence of 
relevant symptoms prior to CA125 testing, 
and Townsend score. The presence or 
absence of a symptom was included as 
there is evidence that symptoms are more 
likely to be coded, rather than recorded in 
free text (which is unavailable for research), 
when they are more severe/persistent — 
which could result in expedited referral and 
diagnosis.18 Weibull, generalised gamma, 
log-normal, and log-logistic distributions 
were examined. Log-logistic distribution 
was the best-fit parameterisation, according 
to the Akaike information criterion. Time 
ratios with associated P-values and 95% 
confidence intervals (CIs) were reported.
Fisher’s exact test was used to assess 
whether women with abnormal and normal 
CA125 test results differed significantly in 
tumour morphology. Pairwise analyses were 
then performed to assess whether there 
was a statistically significant difference for 
each morphology category. The authors 
corrected for multiple comparisons, setting 
the significance level at P = 0.01.19 
In a subgroup for whom stage data were 
recorded, logistic regression was used to 
examine the association between the 
CA125 test result and the disease stage 
at diagnosis. Adjustments were made for 
age, the presence/absence of a recorded 
symptom, and the Townsend score. Given the 
favourable prognosis of borderline tumours, 
a subanalysis was performed that excluded 
these. The authors explored the relationship 
between explanatory variables with missing 
stage data using logistic regression. Crude 
and adjusted odds ratios (ORs) with 95% CIs 
and associated P-values are reported.
All analyses were performed using Stata 
(version 15.1).
RESULTS
The CPRD provided data on 55 519 women 
who were eligible for NCRAS linkage and 
who had a CA125 test between 1 May 2011 
and 31 December 2014. After exclusions, 
456 women diagnosed with ovarian cancer in 
the 12 months following CA125 testing were 
included in the study (Figure 1). Of these, 105 
women (23%) had a normal initial CA125 
result and 351 (77%) an abnormal CA125 
result. A total of 41 (9%) women had a repeat 
CA125 test performed prior to diagnosis. 
Thirty women with an abnormal initial CA125 
test result had a repeat test; for 29 (97%) of 
these, the result of the repeat test was also 
abnormal. Eleven women with a normal 
initial CA125 test had a repeat test and eight 
(73%) of these had an increase in their CA125 
level; however, in only three cases (27%) was 
this increase sufficient to reach the ö35 U/ml 
threshold (data not shown). 
Mean age was higher in those with 
abnormal CA125 test results than those with 
normal CA125 test results, and a greater 
proportion of women with abnormal CA125 
test results had a coded symptom of possible 
ovarian cancer (Table 1). 
Test-to-diagnosis interval
The overall median test-to-diagnosis interval 
in the cohort was 42 days (interquartile range 
[IQR] 25–62) (data not shown). The interval 
was 35 days (IQR 21–53) for those with 
abnormal CA125 test results and 64 days 
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Women, identified by CPRD,
with a CA125 test between
1 May 2011 and 31 December 2014, and
NCRAS linkage,
n = 55 519
Excluded
• Invalid CA125 test: n = 3667a
• Not UTS at test date: n = 76
• Aged <18 years at test date: n = 39
• CA125 prior to study start date but within
12 months of initial CA125 during study period:
n = 422
• Ovarian malignancy on/prior to test date:
n = 535
Excluded
• No ovarian cancer diagnosis: n = 50 324
Women with a valid CA125 test and no prior
ovarian cancers,
n = 50 780
Women diagnosed with ovarian cancer






Figure 1. Application of selection criteria. aNo CA125 
value, no or incorrect units, or no or spurious 
upper threshold recorded. CA125 = cancer antigen 
125. CPRD = Clinical Practice Research Datalink. 
NCRAS = National Cancer Registration and Analysis 
Service. UTS = up to standard.
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(IQR 42–127) for those with normal CA125 test 
results (Table 2). AFT models demonstrated 
a statistically significant association between 
CA125 test results and the test-to-diagnosis 
interval. A time ratio of 2.0 (95% CI = 1.7 to 2.4, 
P<0.001) indicated that the test-to-diagnosis 
interval for those women with normal CA125 
test results was twice as long as for those 
with abnormal CA125 test results. The time 
ratio remained unaltered when adjusting for 
age, the presence/absence of a recorded 
symptom, and Townsend score. 
Tumour morphology
Tumour morphology differed significantly, in 
statistical terms, by CA125 result (P<0.001) 
(Table 3). Invasive epithelial cancers were the 
most common type in women with abnormal 
CA125 test results (81%), whereas borderline 
tumours were the most common type in 
women with normal CA125 test results 
(49%). Serous tumours accounted for 52% of 
invasive tumours in those with an abnormal 
CA125 test result, compared with 30% in 
those with a normal CA125 test result (data 
not shown).
Stage at diagnosis
Staging information was missing for 
75 women: 47 with an abnormal CA125 test 
result and 28 with a normal CA125 test result. 
In women with an abnormal CA125 test 
result in whom stage was recorded (n = 304), 
106 (35%) were diagnosed with early-stage 
disease. In women with a normal CA125 test 
result in whom stage was recorded (n = 77), 
66 (86%) were diagnosed with early-stage 
disease (data not shown).
Logistic regression, performed on data 
for patients with recorded disease stage 
and adjusted for age, the presence/absence 
of a recorded symptom, and Townsend 
score demonstrated that the odds of being 
diagnosed with early-stage disease were 
12.2 times higher in women with normal 
than abnormal CA125 test results (Table 4). 
A subanalysis conducted after excluding 
borderline tumours demonstrated a 
statistically significant association between 
having a normal CA125 test result and 
being diagnosed at an early stage (OR 9.0, 
95% CI = 4.0 to 19.8) (see Supplementary 
Table S2). 
There was strong evidence to support 
an association between having a normal 
CA125 test result and having missing cancer 
stage at diagnosis in a logistic regression 
model; no such association was identified 
when borderline tumours were excluded 
from analysis (data not shown).
DISCUSSION
Summary
Women with normal CA125 test results in 
primary care, prior to receiving a diagnosis 
of ovarian cancer, took twice as long to be 
Table 1. Patient groups and baseline characteristics
 Townsend score, n (%)
  Mean age at  Patients with a symptom   
  diagnosis, of possible ovarian cancer 
CA125 test result n years (range) recorded pre-testing, n (%)a Level 1 Level 2 Level 3 Level 4 Level 5
Abnormal  351 65 (22–93) 212 (60) 80 (23) 100 (28) 78 (22) 61 (17) 32 (9)
Normal 105 57 (18–87) 59 (56) 24 (23) 31 (30) 25 (24) 14 (13) 11 (10)
Overall cohort 456 63 (18–93) 271 (59) 104 (23) 131 (29) 103 (23) 75 (16) 43 (9)
CA125 = cancer antigen 125.
Table 2. Median intervals by CA125 test result, and crude and adjusted associations between CA125 test 
result and test-to-diagnosis interval
 Unadjusted association Adjusted associationa 
  Median test-to-diagnosis     
CA125 test result n interval in days, n (IQR) Time ratio (95% CI) P-value Time ratio (95% CI) P-value
Abnormal  351 35 (21–53) Reference <0.001 Reference <0.001
Normal  105 64 (42–127) 2.0 (1.7 to 2.4) — 2.0 (1.6 to 2.4) —
aAdjusted for age, presence/absence of a recorded symptom, and Townsend score. Individual associations for all variables are displayed in Supplementary Table S1. CA125 = cancer 
antigen 125. IQR = interquartile range.
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diagnosed following testing as those with 
abnormal CA125 test results. Despite this, 
in women for whom staging data were 
available, 86% of those with normal CA125 
test results were diagnosed at an early 
stage compared with only 35% of those with 
abnormal CA125 test results. In addition, 
indolent borderline ovarian tumours were 
more common, and aggressive invasive 
epithelial cancers were less common, in 
women with normal CA125 test results 
than in women with abnormal CA125 test 
results.
Strengths and limitations 
A major strength of this study is its large 
size — the sample is equivalent to >6% of all 
ovarian cancers diagnosed in the UK each 
year. The results should be generalisable 
to women tested for CA125 in primary care 
prior to ovarian cancer diagnosis, as the 
primary care database used is generally 
representative of the UK population.12 In 
addition, ovarian cancer diagnoses were 
identified from NCRAS, which reports a 
near-100% case ascertainment.13 
This study does, however, have some 
limitations. When defining the cohort, it 
was assumed that cancer diagnosed within 
12 months of the initial CA125 test was 
present at the time of testing. A period 
of 1 year, which has been used in similar 
studies15,20,21 and was specified prior to data 
analysis,15 was chosen as a compromise 
between minimising the inclusion of 
incidental cancers and maximising the 
inclusion of relevant cancers. Examining a 
longer follow-up was not possible as NCRAS 
data were only available until the end of 
2015. However, given that only one woman 
out of 456 was diagnosed in month 12, 
extending follow-up is unlikely to alter the 
results. A shorter follow-up period — for 
example, 6 months — was not examined 
as this would have preferentially excluded 
patients from the group with normal CA125 
test results (who have longer test-diagnosis 
intervals); the results would, therefore, have 
been biased.
Patients with severe disease, who 
often have severe symptoms, frequently 
experience expedited diagnoses when 
compared with those with less severe 
disease — an observation sometimes 
referred to as the ‘sick quick’ phenomenon.22 
As CA125 levels are also more likely to 
be elevated in women with more-severe 
disease, this may act as a confounder. The 
analyses were adjusted for the presence/
absence of relevant coded symptoms, as 
symptoms may be more likely to be coded 
(rather than mentioned in free text) if they 
are more severe,18 but it is unlikely that it 
was possible to adjust fully for severity of 
symptoms and disease. 
The authors considered adjusting for 
ethnicity in the analyses, but this was not 
done as not all patients have an ethnicity 
recorded in CPRD GOLD.23 The authors 
are not aware of any evidence within 
the literature indicating that ethnicity is 
associated with either diagnostic interval or 
stage at diagnosis for ovarian cancer, and 
would not expect the inclusion of ethnicity 
to markedly alter the results.
There was a statistically significant 
association between having a normal 
CA125 result and having missing stage at 
diagnosis. This is to be expected, as stage 
is less frequently recorded in the cancer 
registry for borderline tumours, which are 
more common in women with normal 
CA125 test results. It is reassuring that 
when borderline tumours were excluded 
no statistically significant association 
Table 3. Tumour morphology by CA125 test result
 Invasive tumour
  Borderline Epithelial,  Non-epithelial,  NOS,  Overall analysis, 
 n tumour, n (%) n (%) n (%) n (%) P-value
Abnormal CA125 351 47 (13) 284a (81) 4 (1) 16 (5) <0.001 
test result
Normal CA125 105 51 (49) 39b (37) 9 (9) 6 (6) — 
test result
Pairwise analysis,  — <0.001 <0.001 <0.001 0.6 — 
P-value
aSerous, n = 158; endometrioid, n = 16; mucinous, n = 14; clear cell, n = 14; other epithelial, n = 13; epithelial 
cancers of unknown morphology, n = 69. bSerous, n = 16; endometrioid, n = 4; mucinous, n = 8; clear cell, n = 3, 
other epithelial, n = 4; epithelial cancers of unknown morphology, n = 4. P-values are derived from Fisher’s exact 
test for independence. CA125 = cancer antigen 125. NOS = not otherwise specified, that is, could not be classified as 
epithelial or non-epithelial based on the information in the cancer registry. 
Table 4. The association between CA125 test results, age, and the 
presence/absence of a recorded symptom with early (stage I–II) 
diagnosis
 Unadjusted Adjusteda
Variable n OR (95% CI) P-value OR (95% CI) P-value
Abnormal CA125 test result 304 Reference — Reference —
Normal CA125 test result 77 11.2 (5.7 to 22.1) <0.001 12.2 (5.8 to 25.5) <0.001
Age  — 0.95 (0.93 to 0.96) <0.001 0.94 (0.92 to 0.96) <0.001
No symptom record 148 Reference — — —
Symptom record 233 0.51 (0.33 to 0.77) 0.001 0.35 (0.21 to 0.59) <0.001
aModel also adjusted for Townsend score. Data not shown for Townsend score as the variable was statistically 
insignificant ( P = 0.9). CA125 = cancer antigen 125. OR = odds ratio.
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between the CA125 result and missing 
stage was identified, and a normal CA125 
result was still strongly associated with 
early-stage diagnosis. Although there is 
no reason to suspect that study findings 
would differ markedly if staging data were 
available for all patients, the magnitude of 
the association between CA125 result and 
stage should be interpreted with caution.
Comparison with existing literature
Previous research has identified an 
association between false negative results 
and longer healthcare intervals: in one 
study, patients with a negative chest X-ray 
who went on to be diagnosed with lung 
cancer experienced longer primary care 
intervals than those with an abnormal 
chest X-ray;24 in another study, patients 
with a false negative rheumatoid factor 
in primary care, prior to a rheumatoid 
arthritis diagnosis, took longer to be 
referred to a specialist.25 Research indicates 
that receiving an 'all clear' diagnosis (no 
cancer) following testing in primary care 
can provide reassurance to patients, which 
can lead to delayed re-presentation if 
symptoms persist or recur.26 Similarly, false 
reassurance could affect GPs, prompting 
them to seek alternative diagnoses and 
delaying referral.24,27
Few studies have investigated the 
relationship between false negative results 
and cancer outcomes in patients who are 
symptomatic, although one — by Yeh et al 28 
— did find that patients with false negative 
fine-needle aspiration results, who were 
then diagnosed with thyroid cancer, were 
more likely to have vascular and capsular 
invasion and experience persistent disease 
post-treatment. 
In the study presented here, for the 
majority of women with normal CA125 test 
results, cancer was detected at an early 
stage; this was in contrast with women with 
abnormal results, despite those with normal 
CA125 test results having longer test-to-
diagnosis intervals. This finding could be due 
to differences in tumour type. In the study 
presented here, borderline tumours were 
nearly four times as common in women 
with normal, rather than abnormal, levels of 
CA125. Borderline tumours less frequently 
cause elevations in CA125 than their invasive 
counterparts, tend to grow slowly, and 80% 
are diagnosed at an early stage.29 In contrast, 
invasive epithelial tumours, which typically 
have an insidious onset and poor survival, 
were twice as common in women with 
abnormal than normal CA125 levels. Further, 
aggressive invasive serous tumours, which 
are more frequently diagnosed at a later 
stage and more frequently elevate CA125 
levels than other invasive tumour types,10 
accounted for half of invasive tumours in 
women with abnormal CA125 test results 
and only a third of invasive cancers in women 
with normal CA125 test results. 
The authors employed the NICE advocated 
threshold of 35 U/ml in the present study to 
categorise results as ‘normal’ or ‘abnormal’. 
However, this is an oversimplification: recent 
research has shown that the probability of 
ovarian cancer is much higher in women 
with a CA125 level of 34 U/ ml compared 
with those with a CA125 level of 1 U/ml,15 yet 
these results are all classified as ‘normal’ 
under NICE guidelines (and within this study). 
Newly developed CA125-based primary care 
prediction models could help select women 
for further investigation or referral (instead of 
the 35 U/ml threshold),15 but require further 
evaluation.
Implications for research and practice
CA125 test results detected 77% of ovarian 
cancer cases in the cohort and 88% of 
the invasive epithelial subtype, which is 
responsible for the majority of ovarian 
cancer mortality.30 Abnormal CA125 test 
results are, therefore, helpful in identifying 
women with possible ovarian cancer, 
especially the most lethal type. However, a 
normal CA125 test result does not exclude 
disease. 
It is reassuring that most women with 
normal CA125 test results were diagnosed 
at an early stage, despite taking longer 
to be diagnosed. However, given the 
observational nature of this study, it was 
not possible to determine to what extent 
women with normal CA125 test results 
experienced disease progression or worse 
survival rates as a result of their prolonged 
test-to-diagnosis intervals. Diagnostic 
strategies that use novel serum biomarkers 
or imaging modalities in combination with 
CA125 may detect additional ovarian cancer 
cases,8,31 which could expedite diagnosis in 
some women. However, large, prospective 
studies would need to be undertaken to 
determine whether implementing more 
sensitive testing strategies would lead 
to earlier stage diagnosis and improved 
survival. 
Regardless of its impact on survival, 
reducing unnecessary delay in ovarian 
cancer diagnosis is likely to be beneficial 
for women with normal CA125 test results. 
Delay in cancer diagnosis is associated 
with psychological distress, particularly 
among women,32 and perceived delays can 
damage doctor–patient relationships.33 
Earlier diagnosis of ovarian cancer could 
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reduce morbidity, even if a stage shift is 
not achieved, by detecting lower-volume 
disease.31 Possible strategies to reduce 
diagnostic delay could include appropriate 
safety netting with reassessment, and 
undertaking re-testing or alternative 
investigations (for example, ultrasound), if 
symptoms persist or worsen. In the study 
presented here, only a small proportion of 
women with normal results in their initial 
CA125 test had a repeat test. In 73% of repeat 
tests, there was an increase in CA125 levels, 
but in only 27% was this increase sufficient 
to reach the 35 U/ml threshold — this 
supports the idea that rising levels below 
the 35 U/ml threshold could be used to 
prompt further investigation.31 The nature, 
duration, and severity of presentation 
should also be considered when deciding 
on a follow-up strategy. For example, if a 
patient develops a pelvic mass (which has 
a high positive predictive value for ovarian 
cancer) an urgent referral is warranted,16,34 
whereas alternative follow-up strategies, 
such as referral for ultrasound or CA125 
re-testing, may be more appropriate for 
less highly predictive presentations. 
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CA125 is recommended as the first line test in women presenting with symptoms of 
possible ovarian cancer in England. This study sought to develop and internally validate 
CA125 based diagnostic prediction models, and to explore potential diagnostic implications 
of implementing model-based thresholds for further investigation in primary care. 
 
Methods 
This retrospective cohort study used routinely collected primary care and cancer registry 
data from symptomatic, CA125 tested women in England (2011-2014). A total of 29,962 
women were included, of whom 279 were diagnosed with ovarian cancer. Logistic 
regression was used to develop two models to estimate the probability of ovarian cancer: 
Model 1 consisted of age and CA125 level alone; Model 2 incorporated further risk factors. 
Model discrimination (AUC) was evaluated using 10-fold cross-validation. The sensitivity and 
specificity of various model ovarian cancer risk thresholds (  -  were compared with 
that of the current CA125 cut-off U/ml). The implications of applying these thresholds 
to our cohort were examined.  
 
Results 
Model 1 exhibited excellent discrimination (AUC: 0.94) on cross-validation. The inclusion of 
additional variables (Model 2) did not improve performance. At a risk threshold of 1% 
Model 1 exhibited greater sensitivity (86.4% vs 78.5%) but lower specificity (89.1% vs 94.5%) 
than CA125 U ml . Applying the  model threshold to our cohort, in place of the 
current CA125 cut-off, 1 in every 74 additional women identified for further investigation 
had ovarian cancer.  
 
Interpretation 
A model incorporating age and CA125 level alone performed well for the identification of 
ovarian cancer in symptomatic women. Following external validation, it could be used as 
part of a risk-based triage  system, in which women at high risk of undiagnosed ovarian 
cancer are selected for urgent specialist investigation while omen at lo  risk but not no 
risk  are offered non-urgent investigation or interval CA125 re-testing. Such an approach has 
the potential to expedite ovarian cancer diagnosis, but further research is needed to 




Ovarian cancer is the 6th most common cancer to affect UK women and has the worst 
prognosis of any gynaecological malignancy.1 Survival is highly dependent on the stage at 
diagnosis with five-year survivals of 90% and 4% for UK women diagnosed at stage I and IV 
respectively.2 Although several large screening trials have been conducted, as yet they have 
failed to demonstrate a long term survival benefit.3,4 In the absence of screening programs, 
the majority of women with ovarian cancer are diagnosed after they present to their GP 
with symptoms;5,6 thus timely diagnosis of these women may improve cancer outcomes. 
 
In 2011, the National Institute for Health and Care Excellence (NICE) recommended that 
women presenting to their GP with symptoms of possible ovarian cancer in England, Wales 
and Northern Ireland be tested for the serum biomarker Cancer Antigen 125 (CA125).7 
Further investigation with ultrasound was advocated if CA125 levels were  U ml  
However, this threshold was not based on primary care evidence. 23% of women with 
ovarian cancer have levels of less than 35 U/ml in primary care prior to diagnosis,8 and 
safety concerns have been raised over the potential clinical impact of delayed diagnoses in 
this false negative group.9 In addition, even if woman have markedly elevated CA125 levels 
(indicating a very high likelihood of undiagnosed ovarian cancer), they still must undergo 
GP-requested ultrasound before they are eligible for an urgent t o eek ait  cancer 
pathway referral to a specialist.  
 
We recently developed a diagnostic prediction model based on age and CA125 level in order 
to estimate the probability of ovarian cancer in individual women undergoing testing in 
primary care in England.8 If implemented in clinical practice, such models would allow 
women to be triaged using the risk of undiagnosed ovarian cancer, so that those at greatest 
risk undergo urgent specialist investigation, those at lo  risk but not no risk  are monitored 
or undergo non-urgent investigation, and those at very low risk (the majority) can be 
reassured. Such primary care evidenced risk-based triage strategies may reduce diagnostic 
delay and thereby improve patient outcomes. 
 
This study had three objectives. First, as previous studies have shown that a range of patient 
risk factors and blood tests can help predict undiagnosed ovarian cancer,10 we sought to 
develop a comprehensive diagnostic prediction model, making best use of variables 
routinely available in primary care. Second, to compare the diagnostic performance of this 
model with that of a simpler model comprising age and CA125. Third, to explore the 
potential implications of implementing different model risk thresholds on ovarian cancer 




This study is reported in accordance with transparent reporting of a multivariable prediction 
model for individual prognosis or diagnosis (TRIPOD) guidelines. A completed checklist is 
included (online supplementary appendix 1). 
 
Data source 
We conducted a retrospective cohort study using linked data from the Clinical Practice 
Research Datalink (CPRD) GOLD, Hospital Episode Statistics Admitted Patient Care dataset 
(HES APC) and the National Cancer Registration and Analysis Service (NCRAS). The CPRD 
GOLD dataset contains anonymised, coded, primary care data including demographics, 
laboratory results and symptoms for around 11 million patients and is broadly 
representative of the UK population.11 The HES APC dataset includes information about 
hospital admissions and patient demographics, including ethnicity.12 The NCRAS (the English 
cancer registry) collects cancer registration data on patients, including detailed information 
on tumour topography and diagnosis date. The NCRAS obtains data from hospitals, GP 
surgeries, and death certificates and reports a near 100% case ascertainment.13 Linkage of 
CPRD and NCRAS data was performed at a patient level by a third party, National Health 
Service (NHS) Digital.14 NCRAS only collects details of cancers diagnosed in England, so the 
study was restricted to English general practices.  
 
Participants 
We identified women with a code for CA125 measurement in primary care between 1st May 
2011 and the 31st December 2014 and included all women who met study criteria in order 
to maximise sample size. We excluded women who were <18 years old or registered at a GP 
practice not deemed up-to-standard  on data qualit  b  CPRD on the date of their first 
CA125 test during this period.11 Women with a record of ovarian cancer in NCRAS data on or 
before the CA125 test date were also excluded, as were women with a CA125 test in the 12 
months before the first CA125 test during the study period. To maximise data quality, only 
CA125 entries recorded in standard equivalent units of CA125 measurement (U/ml, IU/ml, 
KU/L, KIU/L) were accepted, and CA125 values associated with spurious laboratory cut-offs 
(245, 420 and 455 U/ml), or those where no cut-off was given, were excluded. As our aim 
was to develop models for use in symptomatic women, and we wished to develop a model 
which included symptom variables, we restricted the cohort to those who had a recognised 
symptom of possible ovarian cancer recorded in the year prior to CA125 testing. A code list 
was used to identify symptoms included in current NICE guidelines on ovarian cancer 
detection.15 Women with ascites or a palpable pelvic mass recorded prior to CA125 testing 
were excluded, as these clinical signs have high positive predictive values for ovarian cancer 
and warrant urgent referral to a specialist.15,16 Where women had more than one CA125 
test during the study period, only the first was used in the analyses. 
 
Outcome definition 
The primary outcome was a diagnosis of ovarian cancer, as recorded using International 
Classification of Disease (ICD)-10 codes in NCRAS data, in the 12 months following initial 
CA125 testing. Ovarian cancer was defined as an ovarian malignancy (C56), a fallopian tube 
malignancy (C57.0), a peritoneal malignancy (C48.1, C48.2) or a neoplasm of uncertain 




From the literature, we identified a list of candidate variables which included: 1) established 
ovarian cancer risk/protective factors, 2) ovarian cancer symptoms and 3) blood tests. We 
focussed on variables which are well recorded within GP records. Routine blood tests were 
included as recent studies have shown that both having a test performed and the specific 
test level can be predictive of undiagnosed cancer in primary care.19 21 The final list of 
candidate variables taken forward into data-driven selection procedures was determined by 
the consensus of a multidisciplinary group consisting of GPs (GF, FMW, WH), a 
gynaecological oncologist (EJC) and a statistician (GA) (Table 1). Ethnicity was classified into 
5 categories (White, Mixed, Black, Asian, Other) in line with the 2001 census, using a pre-
developed code list.22 These were subsequently collapsed into 2 groups - White  and 
Other ethnicities  - as numbers in individual ethnic groups, other than White, were small 
and the risk of ovarian cancer is higher in people of White ethnicity than Black and Asian 
ethnicity.23 Recent research indicates that patients who have had routine blood tests 
performed in primary care are at greater risk of undiagnosed cancer (even if the test results 
are normal) when compared to those who have not had routine blood tests performed.21 
Therefore, we included each routine blood test as a categorical variable ith no test  
forming a category. Full details of variable preparation are included in the supplemental 
material (online supplemental appendix 2). 
  
 
Table 1. Candidate variables. 
Variable Data 
source 
Categorisation Variable inclusion time/period 
Risk / protective factors 






Most frequently recorded22 
Height26 29 CPRD Continuous (cm) Most recent on/prior to CA125 test 
date recorded when >18years old 
BMI26,30,31 CPRD Continuous (Kg/m2) Most recent on/in the 10 years 










CPRD Binary for each symptom. Presence/absence of: 
abdominal/pelvic pain, appetite loss, bloating, 
distension, change in bowel habit, fatigue, 
urinary frequency/urgency, new irritable bowel 
s ndrome  ears old), weight loss 
12 months prior to CA125 testing 
Blood biomarkers 
CA1258 CPRD Continuous First valid CA125 level in study 
period 




Most recent record on or in the 12 
months prior to the CA125 test 
date 




Most recent record on or in the 12 
months prior to the CA125 test 
date 





Most recent record on or in the 12 
months prior to the CA125 test 
date 





Most recent record on or in the 12 
months prior to the CA125 test 
date 
Abbreviations: BMI = body mass index, CRP = C-reactive protein, CPRD=Clinical Practice 
Research Datalink, CA125= cancer antigen 125, NCAS= National Cancer Registration and 
Analysis Service. Included citations provide further details on the association between 
candidate variables and cancer risk. The choice of categories for categorical blood tests was 






Model derivation and internal validation 
We developed two models. Model 1 was pre-specified and contained age and CA125 level 
alone. Model 2 contained the most predictive variables selected from the list of candidates.  
 
Prior to model derivation, continuous variables were mean centred. BMI and CA125 level 
were right skewed, so were log transformed. The relationships between log CA125 and age 
with ovarian cancer were non-linear. To account for this, we generated restricted cubic 
splines (5-knots) for log CA125 and for age and included these in place of age and log CA125 
within the models.36  
 
In order to derive Model 2, multivariate imputation by chained equation (MICE)37 was used 
to replace missing data on ethnicity, height and Body Mass Index (BMI). 20 imputations 
were performed. Following imputation, a logistic regression model, containing all candidate 
variables, was fitted to estimate variable coefficients. Rubin s rules ere used to combine 
the results across the imputed datasets.38 Possible interaction between age and log CA125 
level was examined through the inclusion of an interaction term. We examined 19 candidate 
variables with a total of 32 degrees of freedom (main effect and non-main effect), giving 9 
Events Per Parameter  (EPP). To select variables for Model 2, a backward elimination 
approach was used in which the full model was fitted, the least significant variable was 
removed, then the model was refitted and the process repeated until all variables had a p 
value of  Variable coefficients were used as model weights. 
 
To assess model discrimination i.e. the ability of a model to distinguish those who have a 
disease from those who do not have a disease, we calculated area under the receiver 
operating characteristic curve (AUC). 10-fold cross-validation was performed to assess for 
any optimism in model discrimination. To examine model calibration i.e. agreement 
between model estimated outcomes and observed outcomes, we calculated the calibration 
slope using 10-fold cross-validation. For Model 2, discrimination and calibration were 
calculated for each imputed dataset and Rubin s rules ere used to combine results across 




We devised thresholds to identify women with a ,  and  probability of 
undiagnosed ovarian cancer, based on our models. The lowest threshold -  - was 
selected as patients have reported that they would opt for cancer investigations at this risk 
level.39 The highest threshold -  - was chosen to match the risk threshold  at which NICE 
advocate urgent specialist cancer investigation or referral for symptomatic primary care 
patients.15 We applied these thresholds to the study cohort to calculate their diagnostic 
accuracy (sensitivity, specificity, positive predictive value [PPV] and negative predictive 
value [NPV]) for the detection of ovarian cancer within 12 months of CA125 testing. We 
compared these accuracy metrics with that of CA125 at its standard, NICE advocated, cut-
off U ml .7 We also compared the accuracy of model thresholds to that of CA125 cut-
offs with equivalent sensitivities, to determine whether using the models, rather than just 
CA125 based cut-offs, improved accuracy.  
 
All analysis was performed in Stata version 15.1. The user written cvAUROC command was 




29,962 women met inclusion criteria (Figure 1). Of these, 279 (0.9%) were diagnosed with 
ovarian cancer in the 12 months following CA125 testing.  
 
 
Figure 1. Application of study criteria.  
Invalid CA  entr   no CA  value  no or incorrect units  no upper threshold or 
spurious upper threshold.  
 
The baseline characteristics of the cohort are shown in Table 2. Missing data was noted for 
ethnicity (n=1,234, 4.1%), height (n=1,721, 5.7%) and BMI (n=2,986, 10%). The mean patient 
age was 55 years (range 18-101 years). The most common symptom was abdominal/pelvic 
pain, recorded for 58.5% of women. The proportion of women who had blood tests 







Table 2. Cohort baseline characteristics.  
Variable  N=29,962 
Risk / protective factors 
Age (years) Mean=55 (SD:15) 
Ethnicity: 
White n=26,511 (88.5%) 
Other ethnicities* n=2,217 (7.4%) 
Height (cm)  Mean=162 (SD:6.8) 
BMI (Kg/m2) Median=25.8 (IQR:22.8-29.7) 
Personal history breast cancer n=1,168 (3.9%) 
Symptoms 
Abdominal / pelvic pain n=17,538 (58.5%) 
Appetite loss n=203 (0.7%) 
Bloating n=5,649 (18.9%) 
Distension n=821 (2.7%) 
CIBH n=5,808 (19.4%) 
Fatigue n=3,968 (13.2%) 
Urinary frequency / urgency n=1,503 (5%) 
 years of age with new IBS n=286 (1%) 
Weight loss n=1,168 (3.9%) 
Blood biomarkers 
CA125  Median=12 (IQR:8-17) 
Albumin: 
Not tested n=3,723 (12.4%) 
<35 g/L n=834 (2.8%) 
≥35 g/L n=25,405 (84.8%) 
Haemoglobin: 
Not tested n=1,648 (5.5%) 
<12g/dl n=3,089 (10.3%) 
≥12g/dl n=25,225 (84.2%) 
Platelets: 
Not tested n=1,679 (5.6%) 
<300x109/L n=20,442 (68.2%) 
300-449x109/L n=7,314 (24.4%) 
≥450x109/L n=527 (1.8%) 
CRP: 
Not tested n=13,181 (44%) 
<3 mg/L n=6,907 (23.1%) 
3-9.99 mg/L n=7,370 (24.6%) 
≥10 mg/L n=2,504 (8.4%) 
            *Asian (n=1,117), Black (n=562), Mixed (n=160) and Other (n=378) 
Abbreviations: SD= standard deviation, IQR= interquartile range, IBS= irritable bowel 




The variables retained in Model 2 after backward elimination procedures were: age, 
ethnicity, BMI, height, abdominal/pelvic pain, distension, CA125 level, platelet level and 
albumin level. Coefficients and odds ratios for all variables are included in supplemental 
information (online supplemental appendix 3).  
 
Model discrimination and calibration 
The AUCs of Model 1 and 2, when directly calculated from the dataset (apparent 
performance), were similar (Table 3). On cross-validation the models had the same AUC 
(0.935). There was little difference between apparent and cross-validation AUCs, indicating 
that model overfitting/optimism was minimal. The AUC of CA125 alone, calculated directly 
from the study cohort, was 0.932. Models 1 and 2 had calibration slopes close to 1, 
indicating good calibration, but confidence intervals were wide. 
 
 
Table 3. Model discrimination and calibration. 
Model Apparent AUC Cross-validation AUC* Cross-validation 
calibration slope (95% CI) 
Model 1 0.938 0.935 1.01 (0.606-1.42) 
Model 2 0.938 0.935 1.05 (0.673-1.42) 
*Cross-validation ROC curves are included in online supplemental appendix 4. 
 
 
Thresholds for further investigation 
As the more parsimonious Model 1 exhibited the same AUC and similar calibration metrics 
to Model 2, the evaluation of thresholds for further investigation focussed on Model 1. The 
diagnostic accuracies of Model 1 thresholds, for the detection of ovarian cancer within 12 
months of CA125 testing, are shown in Table 4. These were compared against CA125 cut-
offs with equivalent sensitives for ovarian cancer. At the  probability threshold, the 
specificity of Model 1 was 3.1% higher than a CA125 cut-off with the same sensitivity  
U/ml), while there was a less marked difference at higher model probability thresholds. At 




Table 4. Diagnostic accuracy metrics for a range of Model 1 thresholds and for CA125 at 
equivalent sensitivities.  



























































The potential implications of applying different model threshold to the study cohort of 
29,962 women are illustrated in the schema provided in online supplemental appendix 5. In 
comparison to the current CA125 cut-off, applying a probability threshold of , would 
result in an additional 1,622 women being identified for further evaluation for ovarian 
cancer of whom 22 (1.4%) would have ovarian cancer i.e. an additional 1 in every 74 women 
identified for further evaluation would have ovarian cancer  Appl ing a  model 
probability threshold, instead of the current CA125 cut-off, would result in 706 fewer 
women being identified for further evaluation of whom 8 (1.1%) would have ovarian cancer. 
Applying a 2% model threshold, instead of the current CA125 threshold, would result in 58 





A model consisting of CA125 and age alone demonstrated excellent discrimination and 
calibration for the identification of ovarian cancer in women presenting to primary care with 
relevant symptoms. Including additional baseline risk factors, symptom type and routine 
blood test results did not improve model performance. While the model AUC was only 
slightly higher than that of CA125 alone, at a fixed sensitivity Model 1 showed superior 
specificity and PPV at a range of thresholds. When a  probabilit  threshold as applied 
to our cohort, rather than the current CA125 cut-off  U ml  one in 74 of the additional 
women identified by the model had ovarian cancer. 
 
Strengths and limitations 
The dataset used in this study was a key strength. Information on candidate variables was 
identified from a large routinely collected primary care data source, which is broadly 
representative of the UK general population, and outcome data was obtained from NCRAS 
(the English cancer registry), which is considered the gold standard source for cancer 
diagnostic information for epidemiological research.13 However, use of routinely collected 
data limited the candidate variables which we could include in our model. For example, 
family history of ovarian cancer is an established risk factor for the disease but was not 
included as a candidate variable as it is not routinely recorded in primary care records. 
Including family history may have introduced bias, as a GP might be more likely to ask about 
and record family history when there is a strong suspicion of ovarian cancer.   
 
While CA125 testing is only indicated in women with relevant symptoms in UK primary care, 
symptoms are not always coded within the GP notes; instead, they may be recorded within 
the free text which is not available for research purposes.41 In order to include symptoms as 
predictor variables we had to exclude 19,691 women who are likely to have had relevant 
symptoms which were simply not coded  this reduced sample size. Although CPRD is one of 
the largest primary care datasets in the world, our sample size was limited by available data 
on CA125 testing.  
 
We internally validated models  applying a cross-validation approach  to assess for model 
optimism and found that this was minimal. However, external validation in an independent 
dataset is warranted before the models are used in clinical practice. 
 
Comparison with existing literature 
In a recent systematic review, we did not identify any other diagnostic prediction models 
which combined CA125 with symptom variables.10 Existing primary care diagnostic 
prediction models, such as QCancer Ovarian,34 were developed in general primary care 
populations (which included both women with and without symptoms) with the aim of 
identifying higher risk women for tests, such as CA125, whereas the models in this study 
were developed within an entirely symptomatic CA125 tested population. Similarly, 
secondary care models such as the Risk of Ovarian Malignancy Algorithm (ROMA) and the 
Risk of Malignancy Index (RMI) are not comparable as they were developed in populations 
all of whom were known to have a pelvic mass, with the aim of distinguishing between 
benign and malignant masses.42,43 We have previously reported on the diagnostic accuracy 
of CA125, as used in the primary care population, and have estimated the probability of 
ovarian cancer based on patient age and CA125 level,8 but this is the first study to evaluate 
the diagnostic accuracy of CA125 predicated models within the symptomatic primary care 
population.  
 
Baseline patient risk factors, routine blood test results and the type of symptoms with which 
patients present have previously been found to be predictive of ovarian cancer in general 
practice,10 and so were included as candidate variables in this study. However, our results 
indicate that, in symptomatic women undergoing CA125 testing, the CA125 level is the 
dominant predictor  the inclusion of other variables, with the exception of age, does not 
materially improve model performance.   
 
Implications for research and practice 
In 2015, NICE recommended urgent cancer referral for symptomatic primary care patients 
when the risk of a particular cancer reached 3%.15 However, specific guidance on ovarian 
cancer investigation and referral was not brought into line with this threshold. NICE 
recommend that s mptomatic omen ith CA  levels  U ml should be referred b  
their GP for an ultrasound; only if the ultrasound shows evidence of possible cancer do they 
qualify for an urgent cancer pathway referral. As primary care ultrasound usually take 
several weeks to be performed in England,44 this could delay ovarian cancer diagnosis. The 
model developed in this study could be used to select women for urgent cancer pathway 
referral, in line with the NICE 3% threshold, thereby helping to ensure that those at higher 
risk of undiagnosed cancer receive prompt specialist investigation, diagnosis and treatment.  
 
We recently reported that women with false negative CA125 results in English primary care 
took twice as long, following testing, to be diagnosed with ovarian cancer as women with 
abnormal CA125 results.45 Such delays in diagnosis could have a detrimental effect on 
patient outcomes, including morbidity and survival. Model 1 would allow women with low 
risk but not no risk  of ovarian cancer to be identified and offered non-urgent evaluation or 
interval re-assessment. Applying a 1% probability threshold (instead of the current CA125 
cut-off) this approach could help detect one extra ovarian cancer for every 74 additional 
patients identified by the model for further evaluation. This evaluation could involve re-
testing for CA125, as most women who are retested in primary care prior to diagnosis have 
rising CA125 levels,45 or a referral for a non-urgent transvaginal ultrasound. An example of a 
risk-stratified approach using model thresholds is illustrated in online supplemental 
appendix 6. As Model 1 is based solely of CA125 level and age, it could readily be 
incorporated within laboratory computer systems, and the patient s cancer probability 
reported to the GP alongside the CA125 level. 
 
Implementing a two-tier risk-stratified approach is likely to result in more non-urgent 
investigation in primary care (‘low risk but not no risk’ women) and more urgent cancer 
referrals (higher risk women). Any such change in guidelines would require a full health 
economic evaluation, to assess the potential impact of such a strategy on the healthcare 
service and on patients, as most of those investigated would ultimately not be diagnosed 
with ovarian cancer. This evaluation would also be valuable in ensuring that the most 
appropriate model thresholds are chosen for use in clinical practice. The model thresholds 
evaluated within this study are of particular relevance to the healthcare system in England. 
However, following validation in appropriate local data-sets, our model could be used to 
select women for further investigation for ovarian cancer in line with any regional or 
national threshold. 
 
In the current study, we have focussed on optimising the initial testing step within the 
ovarian cancer diagnostic pathway. However, the timely diagnosis of cancer also depends 
on the accuracy of subsequent testing steps, most notably ultrasound. Further research is 
needed to ensure that use of model-based risk thresholds improves the accuracy of the 
diagnostic pathway as a whole.  
CONCLUSION 
A model consisting of age and CA125 level performs well for the detection of ovarian cancer 
in symptomatic women in English primary care. A risk-based triage system, informed by this 
model, has the potential to expedite the diagnosis of ovarian cancer in those at high risk of 
undiagnosed ovarian cancer (through urgent specialist investigation) and low risk but not 
no risk  of ovarian cancer (through interval retesting or routine ultrasound). Further 
research is needed to evaluate the practical impact of implementing such an approach on 
patients and the healthcare system.  
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Approved ISAC protocol 
 
Approved amendment to ISAC protocol 
  
ISAC APPLICATION FORM 
PROTOCOLS FOR RESEARCH USING THE CLINICAL PRACTICE RESEARCH DATALINK 
(CPRD) 
       











Please refer to the guidance for ‘Completing the ISAC application form’ 
found on the CPRD website (www.cprd.com/isac). If you have any 
queries, please contact the ISAC Secretariat at isac@cprd.com. 
  
SECTION A: GENERAL INFORMATION ABOUT THE PROPOSED RESEARCH STUDY 
 
1. Study Title§ (Please state the study title below) 
 
The role of CA125 in the detection of ovarian cancer in symptomatic primary care patients 
 
§Please note: This information will be published on the CPRD’s website as part of its transparency policy.  
2. Has any part of this research proposal or a related proposal been previously submitted to ISAC?  
Yes *   No   
 
*If yes, please provide the previous protocol number/s below. Please also state in your current submission how this/these 
are related or relevant to this study. 
       
 
3. Has this protocol been peer reviewed by another Committee? (e.g. grant award or ethics committee) 
Yes*    No   
 
*If Yes, please state the name of the reviewing Committee(s)  below and provide an outline of the review process and 
outcome as an Appendix to this protocol :  
 
4. Type of Study (please tick all the relevant boxes which apply) 
 
Adverse Drug Reaction/Drug Safety     Drug Effectiveness                               
Drug Utilisation                 Pharmacoeconomics       
Disease Epidemiology       Post-authorisation Safety                         
Health care resource utilisation      Methodological  Research                                     
Health/Public Health Services Research               Other*                                                                                   
  
*If Other, please specify the type of study here and in the lay summary below: 
Test diagnostic accuracy study 
5. Health Outcomes to be Measured§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy. 
 





• Ovarian cancer 
diagnosis 
 
    
Secondary outcomes: 
• Diagnosis of a cancer 
other than ovarian 
• Histological type and 
morphology, stage, size, 




• Death from ovarian cancer 
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6. Publication: This study is intended for (please tick all the relevant boxes which apply): 
 
Publication in peer-reviewed journals   Presentation at scientific conference  
Presentation at company/institutional meetings  Regulatory purposes    
Other*       
 
*If Other, please provide further information:       
SECTION B: INFORMATION ON INVESTIGATORS AND COLLABORATORS 
 
7. Chief Investigator§  
Please state the full name, job title, organisation name & e-mail address for correspondence - see guidance notes for 
eligibility. Please note that there can only be one Chief Investigator per protocol.  
 
Dr Fiona Walter, Principal Researcher in Primary Care Cancer Research, University of Cambridge, 
fmw22@medschl.cam.ac.uk 
 
§Please note: The name and  organisation of the Chief Investigator and  will be published on CPRD’s website as part of its transparency 
policy 
 
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
 
8. Affiliation of Chief Investigator (full address) 
Primary Care Unit 
Department of Public Health and Primary Care 
Strangeways Research Laboratory 
2 Worts’ Causeway 
Cambridge CB1 8RN 
9. Corresponding Applicant§ 
Please state the full name, affiliation(s) and e-mail address below: 
Dr Garth Funston, Department of Public Health and Primary Care, University of Cambridge, gf272@cam.ac.uk 
§Please note: The name and  organisation of the corresponding applicant and their organisation  name will be published on CPRD’s 
website as part of its transparency policy 
 
Same as chief investigator       
CV has been previously submitted to ISAC    CV number:  234_18 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
10. List of all investigators/collaborators§  
Please list the full name, affiliation(s) and e-mail address* of all collaborators, other than the Chief Investigator below: 
 
§Please note: The name of all investigators and their organisations/institutions will be published on CPRD’s website as part of its 
transparency policy 
 
Other investigator: Professor Willie Hamilton,  
Exeter Medical School, University of Exeter, w.hamilton@exter.ac.uk 
CV has been previously submitted to ISAC    CV number:  201_15CEPS 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
Other investigator: Dr Emma Crosbie 
Department of Gynaecological Oncology, University of Manchester, emma.crosbie@manchester.ac.uk 
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol                
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Other investigator: Dr Gary Abel 
Exeter Medical School, University of Exeter, g.a.abel@exeter.ac.uk 
CV has been previously submitted to ISAC    CV number: 149_18   
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
Other investigator:       
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
[Please add more investigators as necessary] 
 
*Please note that your ISAC application form and protocol must be copied to all e-mail addresses listed above at the time of submission of 
your application to the ISAC mailbox. Failure to do so will result in delays in the processing of your application. 
 
11. Conflict of interest statement*  
Please provide a draft of the conflict (or competing) of interest (COI) statement that you intend to include in any publication 
which might result from this work 
 
We have no conflicts of interest to declare. 
 
*Please refer to the International Committee of Medical Journal Editors (ICMJE) for guidance on what constitutes a COI. 
 
12. Experience/expertise available  
Please complete the following questions to indicate the experience/ expertise available within the team of 
investigators/collaborators actively involved in the proposed research, including the analysis of data and interpretation of 
results. 
 
 Previous GPRD/CPRD Studies Publications using GPRD/CPRD data 
None                        
1-3                         
> 3                         
 
Experience/Expertise available  Yes No 
Is statistical expertise available within the research team? 
If yes, please indicate the name(s) of the relevant investigator(s)   
 Dr Gary Abel  
  
Is experience of handling large data sets (>1 million records) available 
within the research team? 
If yes, please indicate the name(s) of the relevant investigator(s) 
 Professor Willie Hamilton, Dr Gary Abel 
  
Is experience of practising in UK primary care available to or within the 
research team? 
If yes, please indicate the name(s) of the relevant investigator(s)  
 Dr Garth Funston, Dr Fiona Walter, Professor Willie Hamilton 
  
13. References relating to your study 
Please list up to 3 references (most relevant) relating to your proposed study:  
 
1) National Institute of Clinical Excellence. Suspected cancer: recognition and referral. 
www.nice.org.uk/guidance/ng12. Accessed 26 Jul 2017. 
2) Hippisley-Cox J, Coupland C. Identifying women with suspected ovarian cancer in primary care: 
derivation and validation of an algorithm. BMJ. 2011;344:d8009–d8009. 
3) Usher-Smith JA, Sharp SJ, Griffin SJ. The spectrum effect in tests for risk prediction, screening, and 
diagnosis. BMJ. doi: 10.1136/bmj.i3139 
 








14. Financial Sponsor of study§ 
§Please note: The name of the source of funding will be published on CPRD’s website as part of its transparency policy 
 
Pharmaceutical Industry            Please specify name and country:      
Academia              Please specify name and country:      
Government / NHS             Please specify name and country:      
Charity              Please specify name and country: Cancer Research UK 
Other              Please specify name and country:      
None    
 
15. Type of Institution conducting the research 
 
Pharmaceutical Industry             Please specify name and country:      
Academia               Please specify name and country: University of Cambridge, UK 
Government Department             Please specify name and country:      
Research Service Provider             Please specify name and country:      
NHS               Please specify name and country:      
Other               Please specify name and country:      
16. Data access arrangements 
 
The financial sponsor/ collaborator* has a licence for CPRD GOLD and will extract the data                                
The institution carrying out the analysis has a licence for CPRD GOLD and will extract the data**         
A data set will be provided by the CPRD¥€             
CPRD has been commissioned to extract the data and perform the analyses€                                         
Other:           
If Other, please specify:       
 
*Collaborators supplying data for this study must be named on the protocol as co-applicants. 
**If data sources other than CPRD GOLD are required, these will be supplied by CPRD 
¥Please note that datasets provided by CPRD are limited in size; applicants should contact CPRD (enquiries@cprd.com) if a dataset of 
>300,000 patients is required. 
€Investigators must discuss their request with a member of the CPRD Research team before submitting an ISAC application. Please 
contact the CPRD Research Team on +44 (20) 3080 6383 or email (enquiries@cprd.com) to discuss your requirements. Please  also state 
the name of CPRD Research team with whom you have discussed this request (provide the date of discussion and any relevant reference 
information):   
 
 Name of CPRD Researcher   Helen Booth    Reference number (where available)            Date of contact 
1/3/18    
17. Primary care data  
Please specify which primary care data set(s) are required) 
Vision only (Default for CPRD studies                       Both Vision and EMIS®*            
EMIS® only*          
       
Note: Vision and EMIS are different practice management systems. CPRD has traditionally collected data from Vision practice. Data 
collected from EMIS is currently under evaluation prior to wider release.  
*Investigators requiring the use of EMIS data must discuss the study with a member of the CPRD Research team before submitting an 
ISAC application 
 
Please state the name of the CPRD Researcher with whom you have discussed your request for EMIS data: 
Name of CPRD Researcher           Reference number (where available)          Date of contact          
 
18. Site Location of Data 
a) Processing location(s): 
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Primary Care Unit 
Department of Public Health and Primary Care 
Strangeways Research Laboratory 
2 Worts’ Causeway 
Cambridge CB1 8RN 
Note: Please enter the location details of where the data for this study will be used (processed). 
b) Storage Location(s) 
 





Primary Care Unit 
Department of Public Health and Primary Care 
Strangeways Research Laboratory 
2 Worts’ Causeway 
Cambridge CB1 8RN 
Note: Please enter the location details of where the data for this study will be stored. 
c) Territory of analysis - UK / EEA / Worldwide: 
UK 
 
Primary Care Unit 
Department of Public Health and Primary Care 
Strangeways Research Laboratory 
2 Worts’ Causeway 
Cambridge CB1 8RN 
 
Note: Please enter the details of where the data for this study will be analysed. 
SECTION D: INFORMATION ON DATA LINKAGES 
 
19. Does this protocol seek access to linked data 
 
Yes*  No          If No, please move to section E. 
 
*Research groups which have not previously accessed CPRD linked data resources must discuss access to these resources with a 
member of the CPRD Research team, before submitting an ISAC application. Investigators requiring access to HES Accident and 
Emergency data, HES Diagnostic Imaging Dataset, PROMS data, the Pregnancy Register, Cancer Registration, SACT and CPES data 
and the Mental Health Services Data Set must also discuss this with a member of the CPRD Research team before submitting an ISAC 
application. Please contact the CPRD Research Team on +44 (20) 3080 6383 or email enquiries@cprd.comto discuss your requirements 
before submitting your application. 
 
Please state the name of the CPRD Researcher with whom you have discussed your linkage request.  
 
Name of CPRD Researcher Helen Booth      Reference number (where available)            Date of contact 
1/3/18    
 
Please note that as part of the ISAC review of linkages, your protocol may be shared - in confidence - with a representative of the 
requested linked data set(s) and summary details may be shared - in confidence - with the Confidentiality Advisory Group of the Health 
Research Authority.  
 
20. Please select the source(s) of linked data being requested§ 
§Please note: This information will be published on the CPRD’s website as part of its transparency policy.  
 
 ONS Death Registration Data                             
 HES Admitted Patient Care                  NCRAS (National Cancer Registration and Analysis Service) 
Cancer Registration Data * 
 HES Outpatient                                      NCRAS Cancer Patient Experience Survey (CPES) data* 
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 HES Diagnostic Imaging Dataset   
 HES PROMS (Patient Reported 
Outcomes Measure)** 
 Mental Health Services Data Set (MHDS) 
 CPRD Mother Baby Link  
 Pregnancy Register  
  
 Practice Level Index of Multiple Deprivation (Standard) 
 Practice Level Index of Multiple Deprivation (Bespoke) 
 Patient Level  Index of Multiple Deprivation*** 
 Patient Level Townsend Score *** 
 
*Applicants seeking access to NCRAS data must complete a Cancer Dataset Agreement form (available from CPRD). This should be 
submitted to the ISAC as an appendix to your protocol. Please also note that applicants seeking access to cancer registry data must 
provide consent for publication of their study title and study institution on the UK Cancer Registry website.  
**Assessment of the quality of care delivered to NHS patients in England undergoing four procedures: hip replacement, knee replacement, 
groin hernia and varicose veins. Please note that patient level PROMS data are only available for non-commercial purposes, such as 
academic research, or in connection with delivering services to the NHS. 
*** ‘Patient level IMD and Townsend scores will not be supplied for the same study 
****If “Other” is specified, please provide the name of the individual in the CPRD Research team with whom this linkage has been 
discussed.  
 
Name of CPRD Researcher           Reference number (where available)           Date of contact          
 
21. Total number of linked datasets requested including CPRD GOLD  
 
Number of linked datasets requested (practice/ ’patient’ level Index of Multiple Deprivation, Townsend Score, the CPRD 
Mother Baby Link and the Pregnancy Register should not be included in this count)  4 
 
Please note:  Where ≥5  linked datasets are requested, approval may be required from the Confidentiality Advisory Group (CAG) to 
access these data 
 
22. Is linkage to a local¥ dataset with <1 million patients being requested?  
 
 
Yes *   No   
 
 *If yes, please provide further details:       
¥ Data from defined geographical areas i.e. non-national datasets. 
 
23. If you have requested one or more linked data sets, please indicate whether the Chief Investigator 
or any of the collaborators listed in question 5 above, have access to these data in a patient 
identifiable form (e.g. full date of birth, NHS number, patient post code), or associated with an 
identifiable patient index. 
Yes*             No   
 
* If yes, please provide further details:       
 
24. Does this study involve linking to patient identifiable data (e.g. hold date of birth, NHS number, 
patient post code) from other sources? 
Yes   No   
 
SECTION E: VALIDATION/VERIFICATION 
 
25. Does this protocol describe a purely observational study using CPRD data? 
 
Yes*    No**   
 
 * Yes: If you will be using data obtained from the CPRD Group, this study does not require separate ethics approval from an NHS 
Research Ethics Committee. 
** No: You may need to seek separate ethics approval from an NHS Research Ethics Committee for this study. The ISAC will provide 








26. Does this protocol involve requesting any additional information from GPs?  
 
Yes*    No   
 
 * If yes, please indicate what will be required:  
 
  Completion of questionnaires by the GPy        Yes         No  
     Is the questionnaire a validated instrument?                                              Yes         No  
     If yes, has permission been obtained to use the instrument?                     Yes        No   
     Please provide further information:       
 
  Other (please describe)       
 
y Any questionnaire for completion by GPs or other health care professional must be approved by ISAC before circulation for completion.  
  
27. Does this study require contact with patients in order for them to complete a questionnaire? 
 
Yes*    No   
 
*Please note that any questionnaire for completion by patients must be approved by ISAC before circulation for completion.  
 
28. Does this study require contact with patients in order to collect a sample? 
 
Yes*    No   
 
* Please state what will be collected:         
 
SECTION F: DECLARATION 
 
29. Signature from the Chief Investigator 
 
§ I have read the guidance on ‘Completion of the ISAC application form’ and ‘Contents of CPRD ISAC Research 
Protocols’ and have understood these; 
§ I have read the submitted version of this research protocol, including all supporting documents, and confirm that these 
are accurate.  
§ I am suitably qualified and experienced to perform and/or supervise the research study proposed. 
§ I agree to conduct or supervise the study described in accordance with the relevant, current protocol  
§ I agree to abide by all ethical, legal and scientific guidelines that relate to access and use of CPRD data for research  
§ I understand that the details provided in sections marked with (§) in the application form and protocol will be published on 
the CPRD website in line with CPRD’s transparency policy. 
§ I agree to inform the CPRD of the final outcome of the research study: publication, prolonged delay, completion or 
termination of the study. 
 








PROTOCOL INFORMATION REQUIRED 
 
The following sections below must be included in the CPRD ISAC research protocol. Please refer to the guidance on 
‘Contents of CPRD ISAC Research Protocols’ (www.cprd.com/isac) for more information on how to complete the 




Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
 
A. Study Title§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
 
The role of CA125 in the detection of ovarian cancer in symptomatic primary care patients 
 
B. Lay Summary (Max. 200 words)§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
 
Ovarian cancer is the 5th most common cause of cancer related death in UK women. The majority of women are 
diagnosed late and only 46 out of every 100 UK women survive for 5 years after diagnosis. Early diagnosis is likely 
to result in better patient outcomes including survival.  
 
However, early diagnosis is challenging. The symptoms of ovarian cancer are vague and the same symptoms occur 
in non-worrying medical conditions, so it is can be difficult for GPs to decide which patients need to be sent to 
hospital urgently for more tests and which can be reassured. Simple blood tests, such as CA125, can be used to 
help GPs make these decisions. However, we don’t know how good CA125 is when used in primary care or what 
‘cut-off point’ to use for an abnormal result.  
 
In this study, we aim to determine how effective CA125 is at picking up cancer in women visiting their GP with 
symptoms which could be caused to ovarian cancer, and identify the most appropriate abnormal CA125 cut-off. 
This work will help GPs to make decisions regarding investigation and referral of symptomatic women. 
 
 
C. Technical Summary (Max. 200 words)§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
 
Ovarian cancer has the worst prognosis of any gynaecological cancer. Early diagnosis is likely to improve survival, 
and, while symptoms occur in all stages, they are also common in benign conditions. Tests are needed to help 
distinguish malignant from benign disease in symptomatic patients. 
 
The serum biomarker CA125 is frequently elevated in women with ovarian cancer. It is used as a first line 
investigation in primary care, in the UK and internationally, in patients presenting with symptoms that might be 
caused by ovarian cancer. Despite widespread use, the diagnostic accuracy of CA125 in the primary care 
population has not been established and the current ‘abnormal threshold’ (35u/ml) is not based on primary care 
data.  
 
In this prospective cohort study, we will determine the diagnostic accuracy (sensitivity, specificity, PPV, NPV) of 
CA125 in a symptomatic primary care population and identify CA125 thresholds that equate to a range of risk 
thresholds (PPVs). As CA125 levels and ovarian cancer risk are influenced by patient variables, we will produce 
stratified thresholds based on key variables e.g. age. This work will allow GPs to make decisions about further 








Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
D. Objectives, Specific Aims and Rationale 
Study objective: To evaluate the diagnostic accuracy of CA125 in a symptomatic primary care population and 
develop primary care evidenced thresholds to guide further investigation and referral. 
 
Aim 1: To determine the overall diagnostic accuracy of CA125 at the current threshold and identify a range of 
CA125 thresholds equating to different PPV’s  
Rationale: CA125 is advocated as the first line test in patients presenting to primary care in the UK (and several 
other countries) with symptoms suggestive of ovarian cancer. The National Institute of Clinical Excellence (NICE) 
has set a ‘risk threshold’ of 3% for investigation and cancer pathway referrals in symptomatic patients [1]. Research 
indicates that patients would opt for investigation at much lower risk thresholds [2]. We will determine the diagnostic 
accuracy (sensitivity, specificity, PPV, NPV) of CA125 in UK primary care at its current threshold and calculate 
thresholds that equate to a range of PPVs (including 1% and 3%). This will aid GPs to make informed decisions 
about further investigations and referrals. NICE guidance may be revised in 2019/2020, and our results would 
greatly facilitate guideline revision.  
 
Aim 2: To determine the diagnostic accuracy of CA125 at the current threshold and identify a range of primary care 
evidenced thresholds for patient subgroups 
Rationale: CA125 levels are affected by a number of patient variables such as age and co-morbidities. Further, 
some of the same factors affect the risk of ovarian cancer. Thus, the same CA125 level may equate to different 
PPVs in different patient subgroups e.g. <50 yrs old >50yrs old. As such, different CA125 thresholds may be 
required in different groups to reach the same ovarian cancer ‘risk threshold’. We will determine the diagnostic 
performance of CA125 in specific subgroups and calculate thresholds for these subgroups which equate to a range 
of PPVs (including 1% and 3%). This will aid GPs to make more individualised decisions about further 
investigations and referrals.  
 
 
Aim 3: To examine how CA125 testing, using the current threshold, impacts on the stage of diagnosis for women 
with values close to the current threshold 
Rationale: Current guidance advocates that women with CA125 levels above 35u/ml undergo further investigation. 
As the test is not perfect there will be women below the threshold who have, as yet undiagnosed, ovarian cancer. It 
is likely that these women will go on to be diagnosed, but in the intervening period the stage of disease may have 
advanced. It is hoped that by diagnosing women with an elevated CA125 level earlier than might have been done 
without the test, that they are diagnosed at an earlier stage which may allow curative treatment and better survival. 
Women just above and just below the threshold have no tangible difference in their risk of ovarian cancer. However, 
the timeliness of diagnosis is likely to be impacted by which side of the line they fall. We will exploit this arbitrary 
boundary, to establish the effect of initiating investigations and subsequent follow up on the basis of a positive test 
result using a regression discontinuity design. 
 
E. Study Background 
Ovarian cancer has the worst prognosis of any form of gynaecological cancer and accounts for over 4000 deaths in 
the UK each year. Survival is stage dependant and the majority of women are not diagnosed until the disease is 
advanced, which contributes to the UK’s poor 5-year survival rate of 46% [3, 4]. Most patients with ovarian cancer 
who present in primary care have common non-specific symptoms e.g. bloating. Testing in primary care can help 
determine which patients are at greatest risk of cancer and warrant referral, and which can be reassured.  
 
CA125 is a high molecular weight glycoprotein of unknown function expressed by several normal human tissues. 
Serum CA125 levels are raised in ovarian cancer and several other malignant and benign conditions [5–7]. Levels 
can also vary during the menstrual cycle and in pregnancy [7]. In 2011, NICE published guidelines advocating 
CA125 testing in primary care patients presenting with symptoms that might represent ovarian cancer [8]. Further 
investigation was recommended in patients with a CA125 level above 35u/ml. Following this guidance, there was a 
substantial increase in CA125 testing [9]. Several other countries also advocate CA125 as an initial test for ovarian 
cancer in primary care [10, 11].  
 
Despite its widespread use, the diagnostic performance of CA125 in patients presenting to primary care with 
symptoms suggestive of ovarian cancer has not been determined. The ‘abnormal threshold’ of 35u/ml, which is 
currently employed in both primary and secondary care throughout the world, is derived from a 1983 study in which 
 
 




Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
1% of 888 healthy patient and 82% (n=101) of patients with ovarian cancer had a CA125 level above 35u/ml [5]. 
CA125 has subsequently been studied extensively in secondary care, however, this research cannot readily be 
translated to the primary care setting as the characteristics of the population, including the incidence of ovarian 
cancer and other benign and malignant conditions which affect CA25 levels, is inherently different. These 
differences result in spectrum bias or spectrum effect, where the performance of a test varies depending on the 
population in which it is used [12].  
 
In addition, use of a single CA125 threshold may not be the optimal approach in primary care, as cancer risk and 
CA125 levels vary between patient groups. For example, CA125 levels are significantly higher in groups of 
apparently healthy women under the age of 50 years than groups 50 years and over [13], while the incidence of 
ovarian cancer is lower in women under the age of 50 years [14]. As such, a single threshold may equate to 
different PPVs for ovarian cancer in different patient groups. Thresholds stratified on the basis of key variables, 
such as age, can be more accurate in determining disease status [15].  
 
NICE recommends that in symptomatic patients presenting to primary care, a 3% risk (PPV) of ovarian cancer is 
sufficient to trigger urgent investigation or a cancer pathway referral. Patients have indicated that they would opt for 
investigation at lower risk thresholds e.g. 1%. In this study, we will determine what CA125 thresholds equate to 
different risk thresholds. The work will help guide GPs when making decisions about further investigations and 
referrals. 
 
Definitions and Terminology 
 
The term ovarian cancer can be used to encompass a number of distinct diseases which, while occurring in a 
similar anatomical region, differ in their tissue of origin, aetiology, molecular pathogenesis, clinical behaviour, 
presentation, treatment and prognosis. Ovarian cancer can be broadly divided into epithelial (>90%) and non-
epithelial in origin. Non-epithelial cancers are a heterogeneous group of rare cancers that present early, have a 
relatively good prognosis and generally do not cause elevation in serum CA125, while epithelial cancers present 
late, have a poor prognosis and usually result in elevated CA125. 
The term ovarian cancer is a misnomer. Epithelial ovarian cancer can arise from the epithelial lining of the ovary, 
fallopian tube (most common site) or the peritoneum [16]. Ovarian, fallopian tube and primary peritoneal cancers 
are now classified and staged using the same systems [17], and are treated collectively in current NICE guidance 
covering recognition and initial management.  
In this protocol, the term ‘ovarian cancer’ will be used to describe ovarian, fallopian tube and primary peritoneal 
cancer. 
 
F. Study Type 
This is a diagnostic accuracy study in which we seek to determine the diagnostic performance of CA125 in a 
symptomatic primary care population. We believe this falls into the ‘hypothesis testing’ category as outlined in the 
ISAC protocol guidance. 
 
G. Study Design 
We will use a prospective cohort design to determine the diagnostic accuracy of CA125 when used in UK general 
practice.  
 
H. Feasibility counts 
 
Patients with a CA125 result:  
We used the Define tool to estimate the numbers of patients with a new CA125 code and the number of patients 
with both a new CA125 code and a new code for ovarian cancer during our period of interest. We used Read codes 
for CA125 and epithelial ovarian cancer (Appendix). We applied the following restrictions- 
-Date- 1st May 2011 to 1st June 2016 
-Age at index date- >18 years at index date 
-Gender- Female 
-System- vision 
-CA125 first ever code in study period 
-Ovarian cancer first ever code in study period 
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This search identified 121,012 patients with a new code for CA125 and 1423 patients with a new code for CA125 
and a new code for ovarian cancer.  
 
Given the differences between epithelial and non-epithelial cancer (discussed in Definitions and Terminology) we 
will perform a sub analysis using diagnosis of epithelial ovarian cancer as the outcome. As codes for ovarian cancer 
within CPRD are non-specific, it is not possible to determine which CA125 tested patients have epithelial ovarian 
cancer on the basis of CPRD codes. As cancer registry data includes histological cancer type we will perform this 
subgroup analysis on patients with linked cancer registry data, which is around 57% of patients [18]. As 90% of 
ovarian cancer is epithelial in origin we anticipate that this analysis will include at least 68,977 CA125 tested 
patients of whom an estimated 730 patients will have a cancer registry documented epithelial ovarian cancer. 
 
 
I. Sample size considerations 
The principal objective of this study is to determine the diagnostic accuracy of CA125 when used within a 
symptomatic primary care population. As no study has evaluated the sensitivity and specificity of CA125 in primary 
care, we have used values from a large meta-analysis performed in secondary care in patients with a known pelvic 
mass (sensitivity 79%, specificity 78%) to perform the below calculations [19]. All calculations were performed using 
Stata 15.1. 
 
With a sample consisting of 121,012 CA125 tested patients and 1423 patients with ovarian cancer, we estimate 
95% confidence intervals of 76.8% to 81.1% around a sensitivity of 79%, 77.8% to 78.2% around a specificity of 
78% and 3.9% to 4.3% around a PPV of 4.1%.  
 
These confidence intervals are narrow and will allow for precision in our calculations of CA125 diagnostic accuracy 
for the overall population.  
 
The second objective of this study is to determine the diagnostic accuracy of CA125 in key patient subgroups. e.g. 
different age groups, different ethnicities and patients with specific ovarian cancer associated symptoms. The 
numbers of CA125 tested women and the number of patients with ovarian cancer within each of these groups is 
unknown but is likely to be small for some groups. For example, we are interested in evaluating the diagnostic 
performance of CA125 in patients of different ethnicities as baseline levels are believed to vary between different 
ethnic groups [20]. In the 2011 Census of England and Wales, 3.4% of the population were classified as Black [21]. 
Extrapolating this to our sample, we anticipate that 4,114 of the CA125 tested women will be of Black ethnicity. This 
will provide 80% power to see a difference in ovarian cancer diagnoses rates between 1.7% and 2.3% in non-
Black/Black women. We would also have 90% power to see a change in sensitivity from 79% to 92% in this group. 
Changes in either the prevalence of ovarian cancer in the tested population, the sensitivity or specificity of the test 
will lead to changes in the PPV. Restricting estimates of diagnostic accuracy to Black women will result in broader 
confidence intervals, which would be expected to be as follows if the test characteristics did not change: sensitivity 
(65.0-89.5%), specificity (76.7 -79.3%) and PPV (2.9-5.5%). In order to maximise our ability to evaluate test 
diagnostic accuracy in these subgroups we have requested data for all CA125 tested patients during our period of 
interest. 
J. Data Linkage Required (if applicable):§ 
§Please note that the data linkage/s requested in research protocols will be published by the CPRD as part of its 
transparency policy 
Cancer Registry- Diagnosis of ovarian cancer is the primary outcome in the study. Although concordance between 
CPRD and the cancer registry is high, additional cases can be identified from the registry data [22] and CPRD 
codes are frequently non-specific. The cancer registry contains information on cancer stage, grade and tumour size 
at diagnosis and histological cancer type, which will be included in the study as discussed below.  
 
HES Admitted Patient Care (integrated data)- ethnicity is a variable in the study. Ethnicity is more frequently 
recorded within HES than CPRD data [23]. 
 
Office of National Statistics (ONS) Deaths Registration data- Death due to ovarian cancer will be included as a 
secondary outcome. This linkage is required to cross validate the cause and date of death.  
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K. Study population 
The study population will consist of women who underwent a CA125 test between the 1st of May 2011 and a date 2 
years before the study commences (chosen to allow 2 years of follow-up for all patients). Read codes for CA125 
(listed in the appendix) will be used to define our cohort.  
 
Inclusion criteria:  
-Women >18 years of age at the time of the first CA125 test during the study period. 
-No recorded ovarian cancer diagnosis (either within the cancer registry or CPRD data) at the time of the first 
CA125 test. 
- > 1 year of up to standard CPRD records prior to first CA125 testing. 
 
Exclusion criteria:  
-Women < 18 years of age at the time of the first CA125 test during the study period. 
 -Women with a recorded ovarian cancer diagnosis (either within the cancer registry or CPRD data) at the time of 
CA125 testing during the study period. We will not exclude patients with other comorbidities known to affect CA125 
levels as we wish our study cohort to remain representative of the population in which the test is being performed.  
L. Selection of comparison group(s) or controls 
Internal comparison- we will compare the incidence of ovarian cancer in patients with / without an elevated CA125 
level. 
 
M. Exposures, Health Outcomes§ and Covariates  
§Please note: Summary information on health outcomes (as included on the ISAC application form  above )will be 
published on CPRD’s website as part of its transparency policy 
 
Primary outcome variable-  
A new diagnosis of ovarian cancer recorded within the clinical record / referral files or linked cancer registry data, 
within 2 years of a CA125 test.  
A code list for ovarian cancer (appendix), will be used to search the dataset. A follow-up period of two years from 
the date of initial CA125 testing has been chosen as a compromise between picking up all related cancers (which 
would be maximised by using a longer follow-up) and picking up unrelated cancers (which would be minimised by 
using a shorter follow-up). We will also stratify cancer diagnoses by the number of days the diagnosis occurred 
following CA125 testing.  
 
Secondary outcome variables-  
a) A new diagnosis of a cancer other than ovarian cancer, recorded within the clinical record / referral files or linked 
cancer registry data, within 2 years of a CA125 test. CA125 may be elevated in a number of other cancers e.g. 
endometrial and lung. Validated code lists for cancers developed by Professor Hamilton’s group will be used. 
b) Death, from 1) ovarian cancer, 2) any cancer, as recorded in CPRD data or ONS death registration data within 2 
years of a CA125 test. 
c) Stage of cancer as recorded in cancer registry data. It is acknowledged that this information will only be available 
for patients with linked cancer registry data. 
d) Tumour morphology and histology, as recorded in the cancer registry. CA125 levels are known to vary by 
histological type [7]. 
e) Tumour size, as recorded in cancer registry. 
f) Tumour grade as recorded in cancer registry. 
 
Principle explanatory variable-  
CA125 level. 
CA125 tests will be identified from CPRD data using Read codes (appendix). 
 
Other variables- 
CA125 level and / or ovarian cancer risk are affected by a number of variables such as symptoms, comorbidities, 
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Variable Source Comment / rationale 
Symptoms and signs   
Symptoms and signs within 1 
month of CA125 testing 
Validated code lists for symptoms 
related to ovarian cancer in CPRD 
Risk of ovarian cancer is greater in 
patients presenting to primary care 
with certain symptoms [24]. In 
addition, symptoms may be related 
to an underlying condition other 
than cancer e.g. endometriosis, 
which may affect CA125 level.  
Patient characteristics   
Age at time of CA125 testing CPRD data CA125 levels are thought to be 
higher in groups of younger women 
than older women [13]. Ovarian 
cancer risk is age related. 
Ethnicity CPRD data and, where available, 
HES data. Codes for the 16 ethnic 
groups recognised in the 2001 
census 
For analysis, these codes will be 
collapsed into 4 ethnic groups- 
‘white’, ‘mixed’, ‘Asian or Asian 
British’, ‘Chinese or other’. 
CA125 level is thought to vary 
between groups of women of 
different ethnicities [20]. 
Parity Relevant Read codes within CPRD CaA125 levels are thought to be 
lower in groups of parous vs 
nonporous women [25]. 
Tests   
Test results including FBC (platelet 
count, total white cell count, 
haemoglobin, platelet count), GFR, 
creatinine, CRP, albumin 
Read codes for test results within 
CPRD 
Some results e.g. GFR and CRP 
may indicate underlying conditions 
which affect CA125 levels. Other 
tests e.g. platelet count, may be 
predictive of ovarian cancer [26]. 
Comorbidities and operations   
Comorbidities (fibroids, 
endometriosis, ovarian cyst, renal 
failure, pre-existing cancer other 
than ovarian) recorded within 2 
years of CA125 testing 
Relevant Read codes within CPRD Comorbidities known to affect 
CA125 level will be included. The 
risk of ovarian cancer is greater in 
patients with endometriosis [27]. 
Personal and family history of cancer and cancer syndromes   
Personal history of breast, 
endometrial, stomach, colon, small 
intestine, hepatobiliary, urinary 
tract, brain or skin cancer 
Relevant Read codes within CPRD Risk of ovarian cancer is likely to 
be greater in women who have had 
a BRCA or Lynch syndrome related 
cancer 
Family history of breast, ovarian, 
endometrial, stomach, colon, small 
intestine, hepatobiliary, urinary 
tract, brain or skin cancer in first 
degree relatives 
Relevant Read codes within CPRD Risk of ovarian cancer may be 
greater in women with a family 
member who has had a BRCA or 
Lynch syndrome related cancer  
BRCA mutations or Lynch 
syndrome 
Relevant Read codes within CPRD Risk of ovarian cancer is greater in 
women with a BRCA mutation or 
Lynch syndrome 
BRCA mutations or Lynch 
syndrome in a first degree family 
member 
Relevant Read codes within CPRD Risk of ovarian cancer may be 
greater in women with a family 
member who has a BRCA mutation 










Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
N. Data/ Statistical Analysis 
Firstly, we will use descriptive statistics to summarise outcomes (e.g. numbers and proportions of patients 
diagnosed with ovarian cancer and other cancers) and variables (e.g. numbers and proportions of patients with 
symptom codes). All variables will be predefined prior to data analysis. An exploratory phase will assess the 
association between these pre-defined variables and CA125 level and predefined variables and primary outcome 
using regression analysis.  
 
The principal objective of this study is to determine the diagnostic accuracy of CA125 in symptomatic primary care 
patients. In order to do this we will calculate the number of true positive, false positive, true negative and false 
negative CA125 results. From this, we will calculate the diagnostic accuracy (sensitivity, specificity, PPV and NPV) 
of CA125. 95% confidence intervals will be calculated for the various measures of test accuracy. This analysis will 
be repeated for secondary outcomes.  
 
An important objective of the study is to determine what CA125 thresholds equate to different risk thresholds for 
ovarian cancer. As such, we will construct ROC curves to illustrate CA125 performance at a range of thresholds 
equating to various PPVs.  
 
We expect that the diagnostic accuracy of CA125 may differ between different patient groups e.g. >50/<50 years 
old. We will use logistic regression to establish which factors influence the risk of having cancer, and explore 
whether the association between having cancer and CA125 level varies between predefined patient groups. If there 
is evidence of either of these associations it will suggest different test characteristics. Once the important factors 
have been identified, we will repeat the ROC curve analysis for these key patient subgroups.   
 
As discussed above, CPRD codes for ovarian cancer are non-specific and will not allow us to distinguish epithelial 
ovarian cancer from non-epithelial types of ovarian cancer. A subgroup analysis will be performed using data for 
patients with linked CPRD-cancer registry data where histological cancer type can be accurately determined. We 
are including malignant and borderline tumours as our primary endpoint while excluding in situ lesions. Sensitivity 
analyses will be performed, using the morphology variable in the cancer registry, firstly excluding borderline 
tumours then including in situ and borderline tumours. 
 
Our study aims to determine the performance of CA125 in symptomatic patients. However, real world use of CA125 
in UK general practice may differ from intended use in symptomatic patients as set out in NICE guidelines. To test 
this, we will perform a sensitivity analysis using data from patients with CPRD codes for symptoms included in NICE 
guidance.  
 
Finally we will perform a regression discontinuity design analysis. Regression discontinuity designs exploit arbitrary 
thresholds at which a certain action is taken. This has recently been used to demonstrate that the use of PSA 
testing in a screening population leads to an overdiagnosis of early stage prostate cancers with no change in overall 
mortality [28]. In this study we will use a regression discontinuity design to examine changes in early stage (TNM 
stages 1 and 2) and in late stage (TNM stage 3 and 4) cancers as well as overall diagnosis rates at the currently 
used CA125 threshold. We do not expect to see evidence of overdiagnosis and thus no change in overall diagnosis 
rates, combined with increases in early stage diagnoses above the threshold would support the use of CA125 
testing to facilitate earlier diagnosis. Following the previous work on PSA testing we will use the user written 
regression discontinuity Stata module [29]. 
 
Analyses will be performed using STATA version 15.1. 
O. Plan for addressing confounding 
This study will assess the diagnostic accuracy of CA125 as it is used in real world UK general practice. CPRD data 
is largely representative of the UK general practice population. 
 
Nevertheless, we have endeavoured to identify variables that are associated with CA125 level and ovarian cancer 
risk, as outlined above. We will explore the relationship between each variable, CA125 level and cancer incidence 
using regression analysis. Wherever possible, we will produce variable specific ROC curves. 
 
P. Plans for addressing missing data 
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We will describe the extent of missing data and use appropriate approaches to evaluate its impact. 
 
Previous studies have found that the recording of blood results within CPRD data is excellent. Linkage to cancer 
registry data provides us with two sources from which we can identify cancer diagnoses. As such, we anticipate 
having relatively complete data for our principal explanatory variable and outcomes. As with any cohort or 
diagnostic accuracy study, there is a risk of loss to follow-up e.g. if a patient moves away. However, we do not 
anticipate that the loss to follow-up rate will be significantly different between CA125 positive/negative patients prior 
to diagnosis.  
 
For several of our variables and secondary outcomes we have identified more than one source of information e.g. 
mortality (CPRD, ONS). This will help reduce the impact of missing data. 
 
While we anticipate having relatively complete data for our principal explanatory variable and primary outcome, we 
recognise that data for several other variables, e.g. personal and family history of cancer may be less complete. 
Any such data will be interpreted with caution and the limitations of the data will be highlighted in any related 
publications. Some secondary outcomes e.g. stage at diagnosis, are also likely to have some missing data. 
However, missing outcome data will not result in bias in estimated associations under the Missing At Random 
(MAR) assumption. 
 
Q. Patient or user group involvement (if applicable) 
Our group has a patient and public involvement representative, Mrs Margaret Johnson. She has given valuable 
input into this proposal and the protocol and will continue to be involved throughout the study. 
R. Plans for disseminating and communicating study results, including the presence or absence of any 
restrictions on the extent and timing of publication  
 
We aim to publish this work in peer reviewed journals. In addition, it will be presented at national and 
international primary care and cancer conferences. This work will form an integral part of Garth Funston’s PhD 
thesis. 
Previous routine data studies have led to the development and dissemination of paper and online risk tools [30]. 
We will explore the possibility of converting our findings into an e-algorithm / tool which can be used by GPs in 
the assessment of patients. 
 
S. Limitations of the study design, data sources, and analytic methods  
Several minor limitations exist. 
 
One limitation is that we will be unable to conclusively identify the reasons for CA125 requests. However, we will be 
able to identify symptoms and signs recorded in CRPD data close to the time of CA125 testing, which may suggest 
a rationale for requests. As we cannot say for certain why CA125 tests were ordered, we will be unable to make 
firm judgements about the appropriateness of testing or whether it was conducted in line with NICE guidelines. 
Despite this, we will be able to demonstrate how CA125 performs as is it is currently used in UK general practice 
and a sensitivity analysis will be performed using data from patients with CPRD codes for symptoms included in 
NICE guidance.  
 
Reliance on Read codes to identify symptoms and the presence of other variables is a limitation, as coding may be 
incomplete. 
 
We have selected a 2 year follow up from the point of CA125 testing. While we believe that this is an appropriate 
period, it is possible that incidental ovarian cancers may occur and be diagnosed during this time or that patients 
with false negative CA125 results may not have re-presented and been diagnosed. 
 
We recognise that the number of cancer patients within some of the subgroups may be limited, which in turn will 
limit the precision of our estimates of diagnostic accuracy for these groups. In order to maximise our ability to 
evaluate test diagnostic accuracy in these subgroups we have requested data for all CA125 tested patients during 
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Dear ISAC Secretariat, 
 
RE: Protocol 18_184: “The role of CA125 in the detection of ovarian cancer in symptomatic primary 
care patients” 
 
We would like to request the following minor amendments to the above approved protocol: 
 
1) Amendment 1: Rather than accepting a code for ovarian cancer in CPRD or in NCRAS we will 
only accept an ovarian cancer record in NCRAS data. This will necessitate only using patients 
with NCRAS linkage for this aspect of the study. There are 2 reasons for this change: 
-Concordance between CPRD and NCRAS data is variable with regards to cancer 
recording [1]. A paper, published after our ISAC submission, highlights that solely 
relying on CPRD for cancer case identification could affect the results of diagnostic 
accuracy studies, such as ours, due to the potential for misclassification bias [1]. 
While compiling a list of Read codes for this study we found a number of nonspecific 
codes which may or may not indicate the presence of ovarian cancer- this could lead 
to misclassification bias. NCRAS reports a near 100% case ascertainment, collects 
data from multiple sources and is generally considered the gold standard for cancer 
recording in population cancer research and so we feel it is appropriate to use 
NCRAS to identify cancer cases in our study.  
-As noted in the protocol, we wish to perform a sensitivity analysis excluding 
borderline ovarian tumours- this is not possible using CPRD cancer codes due to 
their non-specific nature (morphology and topographical NCRAS codes are needed). 
 
The sample should still be adequate to determine diagnostic accuracy of CA125 with a high degree 
of precision: 72,182 patients have linkage in the dataset and, based on our feasibility count, we 
would assume that up to 849 women to have ovarian cancer. Using estimated sensitivity (79%) and 
specificity (78%) from the sample size considerations section of our protocol, we would anticipate 
narrow confidence intervals around measures of diagnostic accuracy (particularly our main measure 
which is PPV): PPV 4.1% (95% CI: 3.8-4.4), NPV 99.7% (95% CI:99.6-99.7), sensitivity 79% (95% CI: 
76.1-81.7), specificity 78% (95% CI: 77.7-78.3). These are very similar to the CI estimates in the 
approved ISAC protocol. 
 
2) Amendment 2: We will use a 1 year rather than a 2 year follow-up period post CA125 
testing. While some studies use a 2 year period the majority of similar recent studies 
(several of which have been published since we submitted our original ISAC protocol) have 
used a 1 year period [2-3]. We believe that a 1 year period will be sufficient for the majority 
of ovarian cancers to be diagnosed following CA125 testing and will minimise the number of 
incidental ovarian cancers included in our analysis. 
 
3) Amendment 3: In the protocol we state that we will exclude patients without 1 year of up-
to-standard follow-up prior to CA125 testing. We wish to change this to exclude patients 
whose practices are not up-to-standard at the point of CA125 testing (the focus of our study 
is activity post CA125 testing rather than prior to CA125 testing).  
 
4) Amendment 4: We wish to add the following exclusion criteria- “Patients with a CA125 
record prior to the study start date but within 12 months of the initial CA125 test during the 
study period”. This is because evidence has emerged since we submitted the ISAC protocol 
that the PPV of a repeat test may be different to that of an initial test [2]. 
These changes do not fundamentally alter the design or aim of the study and appear to fall under 
the minor amendment category in your document “Guidance on Resubmissions and Amendments of 
ISAC Research Protocols”. A protocol (with these amendments) will be submitted with the paper 
when we come to publish our results.   




Study Chief Investigator 
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Appendix C: Code lists 
 
 
This appendix comprises code lists used in this thesis. 
 
Contents: 
Supplementary Table C.1: Read codes and terms used to identify CA125 tested women. 
 
Supplementary Table C.2: Categorisation of ICD-O morphology and behaviour codes in the 
baseline dataset.  
 
Supplementary Table C.3: Ovarian cancer symptom Read code list. 
 
Supplementary Table C.4: BRCA mutation Read code list. 
 
Supplementary Table C.5: Family history of breast or ovarian cancer Read code list. 
 
Supplementary Table C.6: Bilateral oophorectomy codes. 
 
Supplementary Table C.7: Read codes and terms for platelet count. 
 
Supplementary Table C.8: Read codes and terms for haemoglobin level. 
 
Supplementary Table C.9: Read codes and terms for albumin level. 
 
Supplementary Table C.10: Read codes and terms for albumin level. 
 
Supplementary Table C.11: Read codes and terms for breast cancer. 
  
 322 
Supplementary Table C.1. Read codes and terms used to identify CA125 tested women. 
Medcode  Read code  Read term  
14565  44a6.00  CA125 level  
108230  44a6000  Serum CA 125 (cancer antigen 125) level  
9228  44a1.00  Carbohydrate antigen 125 level  
 
 
Supplementary Table C.2. Categorisation of ICD-O morphology and behaviour codes in the 







8000/1 Neoplasm, uncertain whether 
benign or malignant 
Unknown 0 1 
8000/3 Neoplasm, malignant Unknown 1 0 





8010/3 Carcinoma NOS Epithelial 
(unknown) 
1 0 





8041/3 Small cell carcinoma NOS Epithelial 
(other) 
1 0 
8070/3 Squamous cell carcinoma NOS Epithelial 
(other) 
1 0 
8140/3 Adenocarcinoma NOS Epithelial 
(unknown) 
1 0 
8240/3 Carcinoid tumor NOS Non-epithelial 1 0 
8246/3 Neuroendocrine carcinoma Epithelial 
(other) 
1 0 
8310/3 Clear cell adenocarcinoma 
NOS 
Clear cell 1 0 
8313/1 Clear cell adenofibroma of 
borderline malignancy 
Clear cell 0 1 
8323/3 Mixed cell adenocarcinoma Epithelial 
(other) 
1 0 
8380/3 Endometrioid carcinoma Endometrioid 1 0 
8440/3 Cystadenocarcinoma NOS Epithelial 
(unknown) 
1 0 
8441/1 Serous cystadenoma, 
borderline malignancy 
Serous 0 1 
8441/3 Serous cystadenocarcinoma 
NOS 
Serous 1 0 
8442/3 Serous cystadenoma, 
borderline malignancy 
Serous 0 1 
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8442/5 Serous cystadenoma, 
microinvasion 
Serous 0 1 
8460/3 Papillary serous 
cystadenocarcinoma 
Serous 1 0 
8461/3 Serous surface papillary 
carcinoma 
Serous 1 0 
8462/3 Papillary serous cystadenoma, 
borderline malignancy 
Serous 0 1 
8462/5 Papillary serous cystadenoa, 
microinvasion 
Serous 0 1 
8470/3 Mucinous 
cystadenocarcinoma NOS 
Mucinous 1 0 
8472/3 Mucinous cystadenoma, 
borderline malignancy 
Mucinous 0 1 
8472/5 Mucinous cystadenoma, 
microinvasive 
Mucinous 0 1 
8473/3 Papillary mucinous 
cystadenoma, borderline 
malignancy 
Mucinous 0 1 
8480/3 Mucinous adenocarcinoma Mucinous 1 0 
8620/1 Granulosa cell tumor NOS Non-epithelial 1 0 
8620/3 Granulosa cell tumor, 
malignant 
Non-epithelial 1 0 
8631/3 Sertoli-Leydig cell tumour, 
poorly differentiated 
Non-epithelial 1 0 
8890/3 Leiomyosarcoma NOS Non-epithelial 1 0 
8950/3 Mullerian mixed tumor Epithelial 
(other) 
1 0 
8980/3 Carcinosarcoma, NOS Epithelial 
(other) 
1 0 
9014/1 Serous adenofibroma of 
borderline malignancy 
Serous 0 1 
9014/3 Serous adenocarcinofibroma Serous 1 0 
9015/1 Mucinous adenofibroma of 
borderline malignancy 
Mucinous 0 1 
9071/3 Endodermal sinus tumour Non-epithelial 1 0 
9080/3 Teratoma, malignant NOS Non-epithelial 1 0 
9085/3 Mixed germ cell tumor Non-epithelial 1 0 




Supplementary Table C.3. Ovarian cancer symptom Read code list. 
Read code Read description Mapped NICE symptom 
25C..11 O/E - epigastric pain on palp. Abdo/pelvic pain 
R090A00 [D]Pain in left iliac fossa Abdo/pelvic pain 
R090600 [D]Umbilical pain Abdo/pelvic pain 
25CZ.00 O/E -abd.pain on palpation NOS Abdo/pelvic pain 
R090y00 [D]Other specified abdominal pain Abdo/pelvic pain 
197..14 Subcostal pain Abdo/pelvic pain 
R090M00 [D]Right lower quadrant pain Abdo/pelvic pain 
197A.00 Generalised abdominal pain Abdo/pelvic pain 
197Z.00 Site of GIT pain NOS Abdo/pelvic pain 
1973.00 Left subcostal pain Abdo/pelvic pain 
R090N00 [D]Nonspecific abdominal pain Abdo/pelvic pain 
25E..00 O/E - rebound tenderness Abdo/pelvic pain 
1963.00 Non-colicky abdominal pain Abdo/pelvic pain 
25D..11 O/E - guarding of abdomen Abdo/pelvic pain 
25DA.00 O/E - guarding - L.iliac Abdo/pelvic pain 
R090C00 [D]Loin pain Abdo/pelvic pain 
25C7.00 O/E - abd. pain - L.lumbar Abdo/pelvic pain 
N33A000 Bony pelvic pain Abdo/pelvic pain 
R090100 [D]Abdominal colic Abdo/pelvic pain 
R090K00 [D]Left upper quadrant pain Abdo/pelvic pain 
25C..15 O/E - abdomen tender Abdo/pelvic pain 
2I18100 Tenderness of epigastrium Abdo/pelvic pain 
Ryu1100 [X]Other and unspecified abdominal pain Abdo/pelvic pain 
197..12 Iliac fossa pain Abdo/pelvic pain 
25C8.00 O/E - abd. pain - R.iliac Abdo/pelvic pain 
196..12 Type of GIT pain - symptom Abdo/pelvic pain 
R090E00 [D]Recurrent acute abdominal pain Abdo/pelvic pain 
197..00 Site of GIT pain Abdo/pelvic pain 
196..11 Abdominal pain type Abdo/pelvic pain 
25D2.00 O/E - guarding-R.hypochondrium Abdo/pelvic pain 
R090.00 [D]Abdominal pain Abdo/pelvic pain 
25EZ.00 O/E - rebound tenderness NOS Abdo/pelvic pain 
25C..14 O/E - umbilical pain on palp. Abdo/pelvic pain 
1979.00 Suprapubic pain Abdo/pelvic pain 
1975.00 Left flank pain Abdo/pelvic pain 
25D3.00 O/E - guarding - epigastrium Abdo/pelvic pain 
Ryu1000 [X]Pain localized to other parts of lower 
abdomen 
Abdo/pelvic pain 
25C3.00 O/E - abd. pain - epigastrium Abdo/pelvic pain 
25C..12 O/E - iliac pain on palpation Abdo/pelvic pain 
R090G00 [D]Pelvic and perineal pain Abdo/pelvic pain 
25C5.00 O/E - abd. pain - R.lumbar Abdo/pelvic pain 
1A59.00 C/O pelvic pain Abdo/pelvic pain 
197B.00 Upper abdominal pain Abdo/pelvic pain 
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25D..00 O/E - guarding on palpation Abdo/pelvic pain 
25D9.00 O/E - guarding - hypogastrium Abdo/pelvic pain 
25C6.00 O/E - abd. pain - umbilical Abdo/pelvic pain 
1978.00 Left iliac fossa pain Abdo/pelvic pain 
2I18.00 O/E - tenderness/pain Abdo/pelvic pain 
1829.00 Retrosternal pain Abdo/pelvic pain 
R090000 [D]Abdominal tenderness Abdo/pelvic pain 
25D6.00 O/E - guarding - umbilical Abdo/pelvic pain 
R090L00 [D]Left lower quadrant pain Abdo/pelvic pain 
R090H00 [D]Upper abdominal pain Abdo/pelvic pain 
25C2.00 O/E - abd.pain-R.hypochondrium Abdo/pelvic pain 
2I18.12 O/E - tenderness Abdo/pelvic pain 
R090P00 [D]Functional abdominal pain syndrome Abdo/pelvic pain 
25C..13 O/E - lumbar pain on palpation Abdo/pelvic pain 
1969.00 Abdominal pain Abdo/pelvic pain 
1962.00 Colicky abdominal pain Abdo/pelvic pain 
1972.00 Epigastric pain Abdo/pelvic pain 
R090z00 [D]Abdominal pain NOS Abdo/pelvic pain 
197..13 Site of abdominal pain Abdo/pelvic pain 
1977.00 Right iliac fossa pain Abdo/pelvic pain 
197..11 Flank pain Abdo/pelvic pain 
25C9.00 O/E - abd. pain - hypogastrium Abdo/pelvic pain 
1969000 Abdominal wall pain Abdo/pelvic pain 
R090200 [D]Colic NOS Abdo/pelvic pain 
25CA.00 O/E - abd. pain - L.iliac Abdo/pelvic pain 
R090F00 [D]Acute abdomen Abdo/pelvic pain 
25DZ.00 O/E -guarding on palpation NOS Abdo/pelvic pain 
25D8.00 O/E - guarding - R.iliac Abdo/pelvic pain 
K58y000 Other pelvic pain - female Abdo/pelvic pain 
1976.00 Right flank pain Abdo/pelvic pain 
197D.00 Right upper quadrant pain Abdo/pelvic pain 
E278000 Psychogenic pain unspecified Abdo/pelvic pain 
1DC5.00 Griping pain Abdo/pelvic pain 
25C4.00 O/E - abd.pain-L.hypochondrium Abdo/pelvic pain 
R090B00 [D]Groin pain Abdo/pelvic pain 
R090J00 [D]Right upper quadrant pain Abdo/pelvic pain 
196..00 Type of GIT pain Abdo/pelvic pain 
R090G12 [D] Perineal pain Abdo/pelvic pain 
R090800 [D]Suprapubic pain Abdo/pelvic pain 
197A.11 General abdominal pain-symptom Abdo/pelvic pain 
25D4.00 O/E - guarding-L.hypochondrium Abdo/pelvic pain 
196Z.00 Type of GIT pain NOS Abdo/pelvic pain 
R090500 [D]Epigastric pain Abdo/pelvic pain 
197C.00 Lower abdominal pain Abdo/pelvic pain 
R090400 [D]Abdominal cramps Abdo/pelvic pain 
R090700 [D]Hypochondrial pain Abdo/pelvic pain 
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25F..00 O/E - abdominal rigidity Abdo/pelvic pain 
1968.00 Abdominal discomfort Abdo/pelvic pain 
1971.00 Central abdominal pain Abdo/pelvic pain 
R090900 [D]Pain in right iliac fossa Abdo/pelvic pain 
R096.00 [D]Acute abdomen Abdo/pelvic pain 
R073200 [D]Gas pain (abdominal) Abdo/pelvic pain 
R090G11 [D] Pelvic pain Abdo/pelvic pain 
25C..00 O/E - abdo. pain on palpation Abdo/pelvic pain 
25K2.00 O/E - abdominal mass - hard Abdo/pelvic mass 
2642.00 O/E - pelvic mass palpable-RIF Abdo/pelvic mass 
25J7.00 Right iliac fossa mass Abdo/pelvic mass 
7H2C500 Biopsy of abdominal mass Abdo/pelvic mass 
25J3.00 O/E -abd.mass fills 1 quadrant Abdo/pelvic mass 
R093100 [D]Abdominal mass Abdo/pelvic mass 
25L2.00 O/E -abd.mass -irregular shape Abdo/pelvic mass 
R093700 [D]Umbilical mass Abdo/pelvic mass 
25K..00 O/E-abdominal mass consistency Abdo/pelvic mass 
R093600 [D]Umbilical swelling Abdo/pelvic mass 
2641.00 O/E - pelvic mass palpable-LIF Abdo/pelvic mass 
2688.00 O/E - VE - pelvic mass NOS Abdo/pelvic mass 
R093A00 [D]Groin mass Abdo/pelvic mass 
25NZ.00 O/E -abd.mass -border def. NOS Abdo/pelvic mass 
25J9.00 Epigastric mass Abdo/pelvic mass 
R093800 [D]Umbilical lump Abdo/pelvic mass 
25N..00 O/E - abd.mass -border defined Abdo/pelvic mass 
25M1.00 O/E - abd.mass moves with resp Abdo/pelvic mass 
R093400 [D]Pelvic mass Abdo/pelvic mass 
25KZ.00 O/E - abd.mass consistency NOS Abdo/pelvic mass 
2643.00 O/E - central pelvic mass Abdo/pelvic mass 
25MZ.00 O/E - abd.mass + respn. NOS Abdo/pelvic mass 
R093.00 [D]Swelling, mass or lump within abdomen 
or pelvis 
Abdo/pelvic mass 
7H2C600 Biopsy of pelvic mass Abdo/pelvic mass 
25K1.00 O/E - abdominal mass - soft Abdo/pelvic mass 
25M..00 O/E - abd.mass movt.with resp. Abdo/pelvic mass 
R093200 [D]Abdominal lump Abdo/pelvic mass 
25N1.00 O/E -abd.mass-upper border def Abdo/pelvic mass 
25L..00 O/E - abdominal mass shape Abdo/pelvic mass 
R093500 [D]Pelvic lump Abdo/pelvic mass 
25N2.00 O/E -abd.mass-lower border def Abdo/pelvic mass 
264Z.00 O/E - pelvic mass palpable NOS Abdo/pelvic mass 
25J8.00 O/E left lower abdominal mass Abdo/pelvic mass 
25J..00 O/E - abdominal mass palpated Abdo/pelvic mass 
25J5.00 O/E - abd. mass fills abdomen Abdo/pelvic mass 
25K3.00 O/E - abdominal mass-very hard Abdo/pelvic mass 
 327 
R093z00 [D]Swelling, mass or lump within abdomen 
or pelvis NOS 
Abdo/pelvic mass 
R093000 [D]Abdominal swelling Abdo/pelvic mass 
25M2.00 O/E - abd.mass still with resp Abdo/pelvic mass 
R093111 [D]Lump stomach Abdo/pelvic mass 
264..00 O/E - pelvic mass palpated Abdo/pelvic mass 
R093B00 [D]Groin lump Abdo/pelvic mass 
R030000 [D]Appetite loss Appetite loss 
R030.00 [D]Anorexia Appetite loss 
ZC11.00 Restricting food intake Appetite loss 
E275600 Non-organic loss of appetite Appetite loss 
1612.12 Loss of appetite - symptom Appetite loss 
1615.00 Reduced appetite Appetite loss 
1612.00 Appetite loss - anorexia Appetite loss 
R030z00 [D]Anorexia NOS Appetite loss 
1612.11 Anorexia symptom Appetite loss 
Eu50y12 [X]Psychogenic loss of appetite Appetite loss 
25O3.00 O/E-ascites-fluid thrill shown Ascites 
4F32.00 Ascitic fluid: malignant cells Ascites 
7H2B100 Peritoneal to venous drainage for ascites Ascites 
J56y100 Chronic peritoneal effusion Ascites 
4JL5.00 Peritoneal fluid for organism Ascites 
4F12.00 Ascitic fluid exam. normal Ascites 
4JL4.00 Ascitic fluid for organism Ascites 
R095.00 [D]Ascites Ascites 
4F46.00 Ascitic fluid protein level Ascites 
4F5..00 Ascitic fluid cell count Ascites 
25O2.00 O/E - ascites - dipping shown Ascites 
B576200 Malignant ascites Ascites 
25O..00 O/E - ascites Ascites 
4F2..00 Ascitic fluid appearance Ascites 
7H2B000 Paracentesis abdominis for ascites Ascites 
4F1Z.00 Ascitic fluid gen. exam. NOS Ascites 
4F11.00 Ascitic fluid sent for exam. Ascites 
25O4.00 O/E -ascites-shifting dullness Ascites 
4F2Z.00 Ascitic fluid appearance NOS Ascites 
4F...00 Ascitic fluid examination Ascites 
G86y100 Chylous ascites Ascites 
R095z00 [D]Ascites NOS Ascites 
4F1..00 Ascitic fluid exam. - general Ascites 
4F3..00 Ascitic fluid microscopy Ascites 
25OZ.00 O/E - ascites NOS Ascites 
4JL4.11 Ascitic fluid for C/S Ascites 
4F45.00 Ascitic fluid glucose level Ascites 
R095000 [D]Fluid in peritoneal cavity Ascites 
R125.00 [D]Peritoneal fluid abnormal Ascites 
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4F4..00 Ascitic fluid chemistry Ascites 
7H2B200 Drainage of ascites NEC Ascites 
4FZ..00 Ascitic fluid exam. NOS Ascites 
4F43.00 Ascitic fluid lactate dehydrogenase level Ascites 
4F21.00 Ascitic fluid clear Ascites 
4F35.00 Ascitic fluid: organisms Ascites 
7H2B113 Insertion of peritoneal to venous shunt for 
ascites 
Ascites 
4F13.00 Ascitic fluid exam. abnormal Ascites 
J4zz.11 Diarrhoea - presumed non-infectious CIBH 
R076z00 [D]Incontinence of faeces NOS CIBH 
25Q6.00 O/E - PR-rectum full of faeces CIBH 
4745.00 Faeces consistency: hard CIBH 
19F..12 Loose stools CIBH 
J4...13 Noninfective diarrhoea CIBH 
19EA.11 Altered bowel habit CIBH 
J503100 Faecal impaction CIBH 
4746.00 Faeces consistency: dry CIBH 
J525.00 Functional diarrhoea CIBH 
19F3.00 Spurious (overflow) diarrhoea CIBH 
19F..00 Diarrhoea symptoms CIBH 
J521000 Irritable bowel syndrome with diarrhoea CIBH 
J520300 Drug induced constipation CIBH 
R078.00 [D]Change in bowel habit CIBH 
J43z.11 Chronic diarrhoea CIBH 
19FZ.00 Diarrhoea symptom NOS CIBH 
6643.00 GIT symptom changes CIBH 
R076.00 [D]Incontinence of faeces CIBH 
8138.00 Removal of impacted faeces CIBH 
J432.11 Allergic diarrhoea CIBH 
19E3.11 Incontinent of faeces symptom CIBH 
J433.11 Dietetic diarrhoea CIBH 
2AF2.00 O/E - defaec.ref.abn.-constip. CIBH 
4752.00 Faeces quantity: bulky CIBH 
19FZ.11 Diarrhoea & vomiting, symptom CIBH 
E264300 Psychogenic diarrhoea CIBH 
J52y100 Difficulty in ability to defaecate CIBH 
19C2.00 Constipated CIBH 
E264500 Psychogenic constipation CIBH 
19E3.00 Incontinent of faeces CIBH 
19G..00 Diarrhoea and vomiting CIBH 
J4z..11 Presumed noninfectious diarrhoea CIBH 
19C..11 Constipation symptom CIBH 
R079.00 [D] Defaecation painful CIBH 
19F2.00 Diarrhoea CIBH 
J520y00 Other specified constipation CIBH 
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19F..11 Diarrhoea CIBH 
J520z00 Constipation NOS CIBH 
J520000 Acute constipation CIBH 
7728100 Manual removal of impacted faeces from 
rectum 
CIBH 
J520400 Chronic constipation CIBH 
Eu45317 [X]Psychogenic diarrhoea CIBH 
J520200 Chronic constipation without overflow CIBH 
J520.00 Constipation - functional CIBH 
4743.00 Faeces consistency: semi-fluid CIBH 
19C..00 Constipation CIBH 
4744.00 Faeces consistency: fluid CIBH 
19EA.00 Change in bowel habit CIBH 
J520100 Chronic constipation with overflow CIBH 
R077100 [D] Stools loose CIBH 
19CZ.00 Constipation NOS CIBH 
19EC.00 Painful defaecation CIBH 
19A..00 Abdominal distension symptom Distension 
19A2.00 Abdomen feels bloated Distension 
19AZ.00 Abd. distension symptom NOS Distension 
19A3.00 Abdomen feels distended Distension 
19B..12 Bloating symptom Distension 
R073300 [D]Abdominal distension, gaseous Distension 
R073400 [D]Bloating Distension 
Eu46000 [X]Neurasthenia Fatigue 
1684.00 Malaise/lethargy Fatigue 
F286.14 Post-viral fatigue syndrome Fatigue 
2254.00 O/E - apathetic Fatigue 
F286.12 Postviral fatigue syndrome Fatigue 
E205.11 Nervous exhaustion Fatigue 
168Z.00 Tiredness symptom NOS Fatigue 
R007z00 [D]Malaise and fatigue NOS Fatigue 
F286.13 PVFS - Postviral fatigue syn Fatigue 
R007411 [D]Post viral debility Fatigue 
F286.00 Chronic fatigue syndrome Fatigue 
1682.00 Fatigue Fatigue 
1B32.00 Weakness present Fatigue 
168..00 Tiredness symptom Fatigue 
F286000 Mild chronic fatigue syndrome Fatigue 
R007000 [D]Malaise Fatigue 
E205.00 Neurasthenia - nervous debility Fatigue 
168..11 Fatigue - symptom Fatigue 
R007z11 [D]Lassitude Fatigue 
R204.00 [D]Senile exhaustion Fatigue 
F286100 Moderate chronic fatigue syndrome Fatigue 
E205.12 Tired all the time Fatigue 
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168..12 Lethargy - symptom Fatigue 
R007300 [D]Lethargy Fatigue 
F286200 Severe chronic fatigue syndrome Fatigue 
1684.11 C/O - debility - malaise Fatigue 
R2y3.00 [D]Debility, unspecified Fatigue 
R007211 [D]General weakness Fatigue 
1683.00 Tired all the time Fatigue 
1683.11 C/O - 'tired all the time' Fatigue 
1688.00 Exhaustion Fatigue 
F286.11 CFS - Chronic fatigue syndrome Fatigue 
R007200 [D]Asthenia NOS Fatigue 
R007500 [D]Tiredness Fatigue 
2832.12 O/E - weakness Fatigue 
R007400 [D]Postviral (asthenic) syndrome Fatigue 
1B3..12 Weakness symptoms Fatigue 
Eu46011 [X]Fatigue syndrome Fatigue 
R007.00 [D]Malaise and fatigue Fatigue 
R007100 [D]Fatigue Fatigue 
R084z00 [D]Frequency of micturition or polyuria NOS Urinary frequency 
1A1..00 Micturition frequency Urinary frequency 
1A1..11 Frequency of micturition Urinary frequency 
R084.00 [D]Micturition frequency and polyuria Urinary frequency 
R084000 [D]Frequency of micturition, unspecified Urinary frequency 
1A1..13 Urinary frequency Urinary frequency 
1A12.00 Frequency of micturition Urinary frequency 
1A1Z.00 Micturition frequency NOS Urinary frequency 
1A25.11 Urgency of micturition Urinary urgency 
1A25.00 Urgency Urinary urgency 
R086200 [D] Urgency of micturition Urinary urgency 
R032.00 [D]Abnormal loss of weight Weight loss 
1623.00 Weight decreasing Weight loss 
22A6.00 O/E - Underweight Weight loss 
1D1A.00 Complaining of weight loss Weight loss 
R034800 [D]Underweight Weight loss 
2287.00 Abnormally thin Weight loss 
1625.11 Abnormal weight loss - symptom Weight loss 
R2y4000 [D]Wasting disease Weight loss 
R2y4.00 [D]Cachexia Weight loss 
1625.00 Abnormal weight loss Weight loss 
R2y4z00 [D]Cachexia NOS Weight loss 
1627.00 Unintentional weight loss Weight loss 
2224.00 O/E - cachexic Weight loss 
 
E264311 Spurious diarrhoea CIBH 
3930.00 Bowels: incontinent CIBH 
19EE.00 Increased frequency of defaecation CIBH 
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19EF.00 Urgent desire for stool CIBH 
2AF3.00 O/E -defaec.ref-spurious diar. CIBH 
25J4.00 O/E - abd. mass fills half abd Abdo/pelvic mass 
25LZ.00 O/E - abd. mass shape NOS Abdo/pelvic mass 
25L1.00 O/E - abd. mass -regular shape Abdo/pelvic mass 
25JZ.00 O/E - abd. mass palpated NOS Abdo/pelvic mass 
25J2.00 O/E - abd. mass < 1 quadrant Abdo/pelvic mass 
25R3.00 O/E - dullness over abd. mass Abdo/pelvic mass 
25R2.00 O/E - tympany over abd. mass Abdo/pelvic mass 
J521.00 Irritable colon - Irritable bowel syndrome IBS 
J521.13 Spastic colon IBS 
J521.11 Irritable bowel syndrome IBS 
J521200 IBS characterised by alternating bowel habit IBS 
 
I identified and used these additional symptom terms while performing the research 
described in Chapter 6. 
 
 
Supplementary Table C.4. BRCA mutation Read code list. 
Read code Read term 
J521200 BRCA2 gene mutation positive 
4L44.00 BCRA1 gene mutation positive 
 
 
Supplementary Table C.5. Family history of breast or ovarian cancer Read code list. 
Read code Read term 
1243.11 FH: Breast cancer 
ZV16300 [V]Family history of malignant neoplasm of 
breast 
124C.00 FH: neoplasm of ovary 
1245.11 FH: Ovarian carcinoma 
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Supplementary Table C.6. Bilateral oophorectomy codes. 
Read code Read term 
7E04500 Abdominal hysterectomy and bilateral 
salpingoophorectomy 
7E04H00 Subtotl abdominal hysterectomy & bilat 
salpingo-oophorectomy 
7E04511 Abdominal hysterectomy & bilateral 
salpingoophorectomy (BSO) 
7E04512 TAH - total abdom hysterectomy & bilateral 
salpingoophorect 
7E10000 Bilateral salpingoophorectomy 
159B.00 H/O: bilateral oophorectomy 
7E10200 Bilateral oophorectomy NEC 
7E04P00 Radical hysterectomy with bilateral salpingo-
oophorectomy 
7E05600 Lap assist vag hysterectomy with bilat salpingo-
oophorectomy 
7E04900 TAH - Tot abdom hysterectomy and BSO - bilat 
salpingophorect 
7E11100 Salpingoophorectomy remaining solitary fallop 
tube and ovary 
7E04B00 Lapar total abdominal hysterect bilat salpingo-
oophorectomy 
7E11500 Oophorectomy of remaining solitary ovary NEC 
 
 
Supplementary Table C.7. Read codes and terms for platelet count. 
Read code Read term 
42P4.00 Platelet count abnormal 
42P1.00 Platelet count normal 
42PZ.00 Platelet count NOS 
42P..00 Platelet count 
 
 
Supplementary Table C.8. Read codes and terms for haemoglobin level. 
Read code Read term 
423..00 Haemoglobin estimation 
423B.00 Haemoglobin abnormal 
4238 Haemoglobin borderline high 
423A.00 Haemoglobin very high 
4234 Haemoglobin very low 
4236 Haemoglobin borderline low 
4239 Haemoglobin high 
423Z.00 Haemoglobin estimation NOS 
4232 Haemoglobin requested 
4235 Haemoglobin low 
4237 Haemoglobin normal 




Supplementary Table C.9. Read codes and terms for albumin level. 
Read code Read term 
44M4.00 Serum albumin 
44M4000 Serum albumin normal 
44MI.00 Plasma albumin level 
44M4100 Serum albumin low 
 
 
Supplementary Table C.10. Read codes and terms for albumin level. 
Read code Read term 
44CC000 C reactive protein normal 
44CC100 C reactive protein abnormal 
44CC.00 Plasma C reactive protein 
44CS.00 Serum C reactive protein level 
 
 
Supplementary Table C.11. Read codes and terms for breast cancer. 
Read code Read term 
B830100 Intraductal carcinoma in situ of breast 
Byu6.00 [X]Malignant neoplasm of breast 
B34yz00 
Malignant neoplasm of other site of female 
breast NOS 
B342.00 
Malignant neoplasm of upper-inner 
quadrant of female breast 
BB91.11 [M]Duct carcinoma NOS 
B34..00 Malignant neoplasm of female breast 
B830.00 Carcinoma in situ of breast 
B343.00 
Malignant neoplasm of lower-inner 
quadrant of female breast 
B341.00 
Malignant neoplasm of central part of 
female breast 
BB91100 [M]Infiltrating duct and lobular carcinoma 
B340100 
Malignant neoplasm of areola of female 
breast 
B83..00 
Carcinoma in situ of breast and 
genitourinary system 
BB9E000 
[M]Intraductal carcinoma and lobular 
carcinoma in situ 
B34y000 
Malignant neoplasm of ectopic site of 
female breast 
B34y.00 
Malignant neoplasm of other site of female 
breast 
BB9K.00 
[M]Paget's disease and infiltrating breast 
duct carcinoma 
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BB9J.00 [M]Paget's disease, mammary 
B344.00 
Malignant neoplasm of upper-outer 
quadrant of female breast 
B340000 
Malignant neoplasm of nipple of female 
breast 
BA03.00 Neoplasm of unspecified nature of breast 
ByuFG00 [X]Other carcinoma in situ of breast 
B345.00 
Malignant neoplasm of lower-outer 
quadrant of female breast 
BB94.00 [M]Juvenile breast carcinoma 
B3...11 
Carcinoma of bone, connective tissue, skin 
and breast 
B3y..00 
Malig neop of bone, connective tissue, skin 
and breast OS 
B830000 Lobular carcinoma in situ of breast 
B346.00 
Malignant neoplasm of axillary tail of 
female breast 
BB9K000 
[M]Paget's disease and intraductal 
carcinoma of breast 
B340z00 
Malignant neoplasm of nipple or areola of 
female breast NOS 
B34z.00 Malignant neoplasm of female breast NOS 
B347.00 
Malignant neoplasm, overlapping lesion of 
breast 
BB9E.00 [M]Lobular carcinoma in situ 
B3z..00 
Malig neop of bone, connective tissue, skin 
and breast NOS 
BB9J.11 [M]Paget's disease, breast 
BB90.00 
[M]Intraductal carcinoma, noninfiltrating 
NOS 
BB9F.00 [M]Lobular carcinoma NOS 
B340.00 
Malignant neoplasm of nipple and areola of 
female breast 
B3...00 
Malig neop of bone, connective tissue, skin 
and breast 
BB91.00 [M]Infiltrating duct carcinoma 
B34..11 Ca female breast 




Appendix D: Model specifications (RE 
Chapter 3) 
 
This Appendix contains details of the logistic regression model specifications used in the 
analyses in Chapter 3. The Odds ratios for terms included in each model and the location of 
knots in each model are described in order to aid interpretation and enable study 
replication. In all models, log CA125 was centred on a value of 3 prior to analysis. Where age 
was included, it was centred on a value of 55. 
 
Contents: 
Supplementary Table D.1: Knots included in the overall CA125 ovarian cancer model 
(women of all ages). Results displayed in Figure 3.5. 
 
Supplementary Table D.2: Odds ratios for terms included in the overall CA125 ovarian 
cancer model (women of all ages). Results displayed in Figure 3.5. 
 
Supplementary Table D.3: Knots included in the overall CA125 all cancer model (women of 
all ages). Results displayed in Figure 3.5. 
 
Supplementary Table D.4: Odds ratios for terms included in the overall CA125 all cancer 
model (women of all ages). Results displayed in Figure 3.5. 
 
Supplementary Table D.5: Knots included in the overall CA125 invasive ovarian cancer 
model (women of all ages). Results displayed in Figure 3.5. 
 
Supplementary Table D.6: Odds ratios for terms included in the overall CA125 invasive 
ovarian cancer model (women of all ages). Results displayed in Figure 3.5. 
 
Supplementary Table D.7: Knots included in the <50 years CA125 ovarian cancer model. 
Results displayed in Figure 3.6. 
 
Supplementary Table D.8: Odds ratios for terms included in the <50 years CA125 ovarian 
cancer model. Results displayed in Figure 3.6. 
 
Supplementary Table D.9: Knots included in the ≥50 years CA125 ovarian cancer model. 
Results displayed in Figure 3.6. 
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Supplementary Table D.10: Odds ratios for terms included in the ≥50 years CA125 ovarian 
cancer model. Results displayed in Figure 3.6. 
 
Supplementary Table D.11: Knots included in the age / CA125 ovarian cancer model. Results 
displayed in Figure 3.7. 
 
Supplementary Table D.12: Odds ratios for terms included in the age / CA125 ovarian 
cancer model. Results displayed in Figure 3.7. 
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Supplementary Table D.1. Knots included in the overall CA125 ovarian cancer model 
(women of all ages). Results displayed in Figure 3.5. 
Knot Placement on centred log CA125, (Quantile) 
k1 -1.390562 (0.05) 
k2 -0.8027754 (0.275) 
k3 -0.5150933 (0.5) 
k4 -0.1667867 (0.725) 
k5 0.7376696 (0.95) 
 
 
Supplementary Table D.2. Odds ratios for terms included in the overall CA125 ovarian 
cancer model (women of all ages). Results displayed in Figure 3.5. 
Variable OR (95% CI) 
CA125 spline 1 1.93881 (0.1789538 - 21.00534) 
CA125 spline 2 0.0105733 (6.00x10-09 - 18640.92) 
CA125 spline 3 3.08x1027 (0.0000101 - 9.42x1059) 
CA125 spline 4 7.66x10-50 (1.03x10-89 - 5.72x10-10) 
Constant 0.0018886 (0.0001076 - 0.033156) 
 
 
Supplementary Table D.3. Knots included in the overall CA125 all cancer model (women of 
all ages). Results displayed in Figure 3.5. 
Knot Placement on centred log CA125, (Quantile) 
k1 -1.208241 (0.10) 
k2 -0.5150933 (0.5) 
k3 0.3322045 (0.90) 
 
 
Supplementary Table D.4. Odds ratios for terms included in the overall CA125 all cancer 
model (women of all ages). Results displayed in Figure 3.5. 
Variable OR (95% CI) 
CA125 spline 1 1.506687 (1.205222 - 1.883559) 
CA125 spline 2 1.774489 (1.472288 - 2.138719) 




Supplementary Table D.5. Knots included in the overall CA125 invasive ovarian cancer 
model (women of all ages). Results displayed in Figure 3.5. 
Knot Placement on centred log CA125, (Quantile) 
k1 -1.390562 (0.05) 
k2 -0.8027754 (0.275) 
k3 -0.5150933 (0.5) 
k4 -0.1667867 (0.725) 
k5 0.7376696 (0.95) 
 
 
Supplementary Table D.6. Odds ratios for terms included in the overall CA125 invasive 
ovarian cancer model (women of all ages). Results displayed in Figure 3.5. 
Variable OR (95% CI) 
CA125 spline 1 0.918744 (0.085896 - 9.826892) 
CA125 spline 2 0.0015715 (8.94x10-11 - 27620.28) 
CA125 spline 3 2.05x1040 (0.9907357 - 4.23x1080) 




Supplementary Table D.7. Knots included in the <50 years CA125 ovarian cancer model. 
Results displayed in Figure 3.6. 
Knot Placement on centred log CA125, (Quantile) 
k1 -1.295252 (0.05) 
k2 -0.6021047 (0.35) 
k3 -0.1667867 (0.65) 
k4 0.7358818 (0.95) 
 
 
Supplementary Table D.8. Odds ratios for terms included in the <50 years CA125 ovarian 
cancer model. Results displayed in Figure 3.6. 
Variable OR (95% CI) 
CA125 spline 1 0.7911065 (0.0342347 - 18.28112) 
CA125 spline 2 801.5433 (0.2558281 - 2511342) 
CA125 spline 3 1.37x10-10 (1.86x10-21 - 10.16702) 
Constant 0.0003367 (0.0000169 - 0.0066908) 
 
 
Supplementary Table D.9. Knots included in the ≥50 years CA125 ovarian cancer model. 
Results displayed in Figure 3.6. 
Knot Placement on centred log CA125, (Quantile) 
k1 -1.410765 (0.05) 
k2 -0.9205585 (0.275) 
k3 -0.6021047 (0.5) 
k4 -0.2274113 (0.725) 
k5 0.7376696 (0.95) 
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Supplementary Table D.10. Odds ratios for terms included in the ≥50 years CA125 ovarian 
cancer model. Results displayed in Figure 3.6. 
Variable OR (95% CI) 
CA125 spline 1 1.930133 (0.1115593 - 33.39403) 
CA125 spline 2 0.0000447 4.05x10-15 - 492193.3) 
CA125 spline 3 3.49x1034 (0.000021 - 5.80x1073) 
CA125 spline 4 3.43x10-57 (1.2x10-100 - 9.73x10-14) 
Constant 0.0023171 (0.0000615 - 0.0872512) 
 
 
Supplementary Table D.11. Knots included in the age / CA125 ovarian cancer model. 
Results displayed in Figure 3.7. 
Knot Placement on centred age and centred log 
CA125, (Quantile) 
Age k1  -24 (0.05) 
Age k2  -9 (0.275) 
Age k3  -1 (0.5) 
Age k4  10 (0.725) 
Age k5  27 (0.95) 
CA125 k1 -1.390562 (0.05) 
CA125 k2 -0.8027754 (0.275) 
CA125 k3 -0.5150933 (0.5) 
CA125 k4 -0.1667867 (0.725) 
CA125 k5 0.7376696 (0.95) 
 
 
Supplementary Table D.12. Odds ratios for terms included in the age / CA125 ovarian 
cancer model. Results displayed in Figure 3.7. 
Variable OR (95% CI) 
Age spline 1 0.9263145 (0.8896194 - 0.9645232) 
Age spline 2 1.746288 (1.364622 - 2.234702) 
Age spline 3 0.1047997 (0.0284088 - 0.3866058) 
Age spline 4 7.06957 (1.294418 - 38.61104) 
CA125 spline 1 2.26625 (0.2010149 - 25.54979) 
CA125 spline 2 0.0046567 (2.28x10-09 - 9515.724) 
CA125 spline 3 1.25x1031 (0.0223821 - 6.99x1063) 
CA125 spline 4 3.40x10-56 (2.33x10-96 - 4.96x10-16) 




Appendix E: Supplementary figures (RE 
Chapter 3) 
 
This Appendix comprises supplementary figures relating to Chapter 3. 
 
Contents: 
Supplementary Figure E.1:  Estimated probabilities for ovarian cancer up to CA125 500 
U/ml.  
 
Supplementary Figure E.2: Estimated probabilities for invasive ovarian cancer up to CA125 
500 U/ml. 
 
Supplementary Figure E.3: Estimated probabilities for all cancers up to CA125 500 U/ml.  
 
Supplementary Figure E.4: Relationship between CA125 level and estimated probability of 
invasive ovarian cancer and all cancers in women <50 years and ≥50 years of age. 
 
Supplementary Figure E.5: Relationship between CA125 level and estimated probability of 





Supplementary Figure E.1. Estimated probabilities for ovarian cancer up to CA125 500 




















Supplementary Figure E.2. Estimated probabilities for invasive ovarian cancer up to CA125 






























Supplementary Figure E.3. Estimated probabilities for all cancers up to CA125 500 U/ml. 









Supplementary Figure E.4. Relationship between CA125 level and estimated probability of 




Supplementary Figure E.5. Relationship between CA125 level and estimated probability of 
all cancers for women of different ages.  
Probabilities are shown in relation to CA125 level for women of 30, 40, 50, 60, 70 and 80 
years of age. CA125 levels which correspond to the closest integer probabilities of 3% are 
indicated in red. 95% confidence intervals are displayed.  
Prof Gary Abel provided Stata code which was used to lay out this figure. 
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Appendix F: Supplementary tables (RE 
Chapter 4) 
 
This Appendix comprises supplementary results relating to Chapter 4. 
 
Contents: 
Supplementary Table F.1: Baseline characteristics of women with a recorded stage for 
ovarian cancer. 
 
Supplementary Table F.2: Association between CA125 test result, age, presence/absence of 






Supplementary Table F.1. Baseline characteristics of women with a recorded stage for 
ovarian cancer. 
 n Mean age at 
diagnosis 
[range] 
Patients with a 












Level 1:    71 (23.4) 
Level 2:    85 (28) 
Level 3:    66 (21.7) 
Level 4:    55 (18.1) 








Level 1:    15 (19.5) 
Level 2:    23 (29.9) 
Level 3:    19 (24.7) 
Level 4:    11 (14.3) 







Level 1:     86 (22.6) 
Level 2:    108 (28.4) 
Level 3:     85 (22.3) 
Level 4:     66 (17.3) 
Level 5:     36 (9.5) 




Supplementary Table F.2. Association between CA125 test result, age, presence/absence 
of a recorded symptom and Townsend score with early stage (I-II) at diagnosis for invasive 
tumours. 
 Unadjusted Adjusted 
 OR 95% CI (p value) OR 95% CI (p value) 
Abnormal 
CA125 
Reference - Reference - 



















- (0.39)* - (0.77)* 
Townsend 1 Reference - - - 






















Appendix G: PRISMA checklist (RE Chapter 5) 
 
This appendix comprises the PRISMA checklist completed for the systematic review presented in Chapter 5. 
 
 
Section/topic  # Checklist item  Location  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Chapter Title 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
N/A (no study 
abstract) 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Section 5.1 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
Section 5.1 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
Section 5.2.2 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
Sections 5.2.3 and 
5.2.4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
Section 5.2.3 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated.  
Appendix H 
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
Section 5.2.5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
Section 5.2.6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
Section 5.2.6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in 
any data synthesis.  
Section 5.2.8 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Section 5.2.7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
Section 5.2.7 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
Section 5.3.1 and 
Fig 5.1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
Section 5.3.2 and 
table 5.1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see 
item 12).  
Section 5.3.3 and 
Figure 5.2 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot.  
Sections 5.3.4-
5.3.6 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta- N/A 
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regression [see Item 16]).  
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Section 5.4.1 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
5.4.2 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications 
for future research.  
5.5 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review.  
Acknowledgements 
section of thesis 
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Appendix H: Supplementrary inforation (RE 
Chapter 5) 
 
Supplementary Box H.1: MEDLINE search strategy.  
 
Supplementary Table H.1: Specific study exclusions. 
 
Supplementary Table H.2: Tool specifications. 
 







Supplementary Box H.1. MEDLINE search strategy.  
 
 
Supplementary Table H.1. Specific study exclusions. 
Author, Date Specific exclusions 
Lurie, 2009 Controls: Hx OC, no intact ovaries 
Rossing, 2010 Non-English speakers, no residential telephone 
Controls: Hx OC, no intact ovaries 
Jordan, 2010 Cases: language difficulties, mental incapacity, illness 
Controls: language difficulties, illness, previous ovarian cancer or 
previous bilateral oophorectomy 252 
Hamilton, 2009 No entry in the records ≤1 year pre-diagnosis (cases), previous OC 
or bilateral oophorectomy, lived outside study area at time of 
diagnosis (cases) 91 
Hippisley-Cox, 2012  Hx bilateral oophorectomy or OC, ‘red flag symptom’ ≤12 months 
before study entry datea, no postcode related Townsend score 
Hippisley-Cox, 2013 ‘Red flag symptom’ ≤12 months before study entry date, no 
postcode-related Townsend score 
Grewal, 2013, UK No entry in the records ≤1 year pre-diagnosis (cases), previous OC 
or bilateral oophorectomy, lived outside study area at time of 
diagnosis (cases) 91 
Collins, 2013 As per Hippisley-Cox, 2011 
Goff, 2006 Screening control criteria as outlined in OCEDS 254 
Anderson, 2008 Screening control criteria as outlined in OCEDS 254 
Anderson, 2010 Screening control criteria as outlined in OCEDS 254b 
1. ((ovar* or fallopian or peritone*) and (cancer* or neoplas* or tumour* or 
tumor* or malignan*)).ti,ab.  
2. exp Ovarian Neoplasms/ or exp Fallopian Tube Neoplasms/ or exp Peritoneal 
Neoplasms/  
3. 1 or 2  
4. symptom*.ti,ab.  
5. exp symptom assessment/  
6. 4 or 5  
7. (risk* or probabilit* or likelihood* or chance*).ti,ab.  
8. exp Risk/ or exp Risk factors/ or exp Probability/  
9. predict*.ti,ab.  
10. exp "Early Detection of Cancer"/  
11. diagnos*.ti,ab.  
12. 7 or 8 or 9 or 10 or 11 (5845128) 
13. (model* or algorithm* or tool* or index* or score* or rule*).ti,ab.  
14. exp models, statistical/ or exp algorithms/  
15. 13 or 14  
16. 3 and 6 and 12 and 15  
17. limit 16 to yr="2000 -Current"  
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Lim, 2012 Controls: Hx of bilateral oophorectomy or OC, active malignancy, 
increased risk of familial OC, not post menopause (as per UKCTOCS 
trial criteria) 154 
Kim, 2009 Pap smear controls: Hx of gynaecological malignancy, no intact 
ovaries or uterus 
Macuks, 2011 Severe co-morbidities, previous or other coexisting malignancies  
Shetty, 2015 Controls (gynae check-up group): no ovaries, no intact uterus 
Jain, 2018 Cases: Hx of ovarian cancer, Hx bilateral oophorectomy, recall 
difficulty, inoperable 
a Loss of appetite, weight loss, abdominal pain, abdominal distension, rectal bleeding, or postmenopausal 
bleeding 
b Patients with known BRCA mutations excluded during study 
 
 
Supplementary Table H.2. Tool specifications. 




Goff SI Goff, 2007 Tool positive if any of pelvic/abdominal pain, increased 
abdominal size/bloating, and difficulty eating/feeling full 
occurred >12 times per month but were present for <1 year 
Modified Goff SI 1 Kim, 2009 Tool positive if any of pelvic/abdominal pain, urinary 
urgency/frequency, increased abdominal size/bloating, 
difficulty eating/feeling full present for <1 year that occurred 
>12 times per month 
Lurie 7-SI Lurie, 2009 Tool positive if any of distended abdomen (defined as 
“persistent distended and hard abdomen”), abnormal vaginal 
bleeding (defined as “vaginal bleeding not associated with 
periods”), palpable abdominal mass (defined as “a palpable 
abdominal mass that woman herself had noticed”), abdominal 
pain (defined as “persistent abdominal or pelvic pain or 
discomfort”), urinary symptoms (defined as “urinary frequency, 
difficulty emptying urinary bladder, or dysuria”), bowel 
symptoms (defined as “unusual bowel irregularity such as 
diarrhoea or constipation, flatulence, or bloating”), and 
fatigue/appetite loss (defined as “persistent fatigue or loss of 
appetite”), present in previous 12 months 
Lurie 5-SI Lurie, 2009 Tool positive if any of distended abdomen (defined as 
“persistent distended and hard abdomen”), abnormal vaginal 
bleeding (defined as “vaginal bleeding not associated with 
periods”), palpable abdominal mass (defined as “a palpable 
abdominal mass that woman herself had noticed”), abdominal 
pain (defined as “persistent abdominal or pelvic pain or 
discomfort”), and urinary symptoms (defined as “urinary 
frequency, difficulty emptying urinary bladder, or dysuria”), 
present in previous 12 months 
Lurie 4-SI Lurie, 2009 Tool positive if any of distended abdomen (defined as 
“persistent distended and hard abdomen”), abnormal vaginal 
bleeding (defined as “vaginal bleeding not associated with 
periods”), palpable abdominal mass (defined as “a palpable 
abdominal mass that woman herself had noticed”), and 
abdominal pain (defined as “persistent abdominal or pelvic 
pain or discomfort”), present in previous 12 months 
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Lurie 3-SI Lurie, 2009 Tool positive if any of distended abdomen (defined as 
“persistent distended and hard abdomen”), abnormal vaginal 
bleeding (defined as “vaginal bleeding not associated with 
periods”), and palpable abdominal mass (defined as “a 
palpable abdominal mass that woman herself had noticed”), 
present in previous 12 months 
Hamilton SI Hamilton, 2009 Tool positive if any of bloating, urinary frequency, rectal 
bleeding, postmenopausal bleeding, loss of appetite, 




Rossing, 2010 Tool positive if any of bloating or feeling full, pelvic or 
abdominal pain, or urinary urgency or frequency, present for at 
least 1 month, with an onset of less than 12 months 
Lim SI 1 Lim, 2012 Tool positive if any of pelvic/abdominal pain or discomfort, loss 
of appetite or feeling full quickly, weight loss, increase in 
abdominal size, abdomen feels bloated, and able to feel a lump 
in the abdomen in previous 12 months 
Lim SI 2 Lim, 2012 Tool positive if any of pelvic abdominal pain or discomfort, loss 
of appetite, increase in abdominal size, able to feel a lump in 
the abdomen, and vaginal discharge in previous 12 months 
Hippisley-Cox SI Hippisley-Cox, 2012 Tool positive if currently consulting general practitioner with 
first onset of any of abdominal pain, abdominal distension, 
appetite loss, rectal bleeding, postmenopausal bleeding, 
weight loss.  
Modified Goff SI 2 Shetty, 2015 Tool positive if any of abdominal/pelvic pain, increased 
abdominal size/bloating, difficulty in eating/feeling full and 
urinary frequency/urgency, loss of appetite/weight, occurred 
>12 times per month and time since onset was <1 year 
Augmented symptom checklist 
Goff SI + CA125 Anderson, 2008 The threshold for a positive CA125 test was determined by 
dichotomizing CA 125 at the 95th percentile in the control 
group (threshold approx. 30 u/ml).  
Goff SI + HE4 Anderson, 2010 The threshold for a positive HE4 test was determined by 
dichotomizing HE4 at the 95th percentile in the control group.   
Goff SI + HE4 + 
CA125 
Anderson, 2010 The threshold for a positive HE4 and CA125 tests were 
determined by dichotomizing HE4 at the 95th percentile in the 
control group.  Study evaluated several thresholds for a 
positive tool (Table 4). 
Goff SI + CA125 + 
menopause  
 
Macuks, 2011 CA125 thresholds: 25 U/ml, 35 U/ml and 65 U/ml examined. 
Definition of menopause not specified. 
Prediction models 
QCancer Ovarian  Hippisley-Cox, 2012 The prediction model included age, family history of ovarian 
cancer, haemoglobin <110 g/L in past year, currently consulting 
general practitioner with first onset of any of abdominal pain, 
abdominal distension, appetite loss, rectal bleeding, 
postmenopausal bleeding, weight loss. Tool threshold was set 
based on risk level e.g. 10% of women at highest risk deemed 
tool positive. 
QCancer Female Hippisley-Cox, 2013 The prediction model included age, BMI, Townsend score, 
smoking status, alcohol status, family history of gastrointestinal 
cancer, family history of breast cancer, family history of ovarian 
cancer, type 2 diabetes, COPD, endometrial hyperplasia or 
polyp, chronic pancreatitis. Current: loss of appetite, 
unintentional weight loss, abdominal pain, abdominal swelling, 
difficulty swallowing, heartburn or indigestion, rectal bleeding, 
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blood in urine, blood in vomit, blood when cough, 
postmenopausal bleeding, irregular menstrual bleeding, 
vaginal bleeding after sex, a breast lump, breast skin tethering 
or nipple discharge, breast pain, a lump in your neck, night 
sweats, a venous thromboembolism. In the last year seen GP 
with: change in bowel habit, constipation, cough, unexplained 
bruising, anaemia (haemoglobin <11g/dL). Tool threshold was 
set based on risk level e.g. 10% of women at highest risk 
deemed tool positive. 
OC Scores A 
 
Grewal, 2013 Variables: bloating, urinary frequency, rectal bleeding, 
postmenopausal bleeding, loss of appetite, abdominal pain, 
abdominal distension, present in the previous 12 months. 
Model used conditional logistic logarithmic odds ratio of each 
symptom, to three significant figures. Various threshold 
reported (Table 4). 
OC Scores B 
 
Grewal, 2013 Variables: bloating, urinary frequency, rectal bleeding, 
postmenopausal bleeding, loss of appetite, abdominal pain, 
abdominal distension, present in the previous 12 months. 
Model used the conditional logarithmic odds ratio of each 
variable rounded to the nearest integer. Various threshold 
reported (Table 4). 
OC Scores C 
 
Grewal, 2013 Variables: Age (≥50 years / < 50 years), bloating, urinary 
frequency, rectal bleeding, postmenopausal bleeding, loss of 
appetite, abdominal pain, abdominal distension, present in the 
previous 12 months. Various threshold reported (Table 4). 
 
 
Supplementary Table H.3. Deviations from the original Goff SI in validation studies. 
Study Deviation 
Rossing, 2010 1) Symptom criteria listed as “bloating or feeling 
full”, whereas original Goff SI includes “Increased 
abdominal size/bloating” and “difficulty 
eating/feeling full”.  
2) Duration/frequency of symptoms criteria was 
“present at least daily for at least 1 week”, whereas 
the original Goff SI criteria is >12x/month. 
Jordan, 2010 Duration/frequency of symptoms criteria was “>2 
weeks in previous 12 months” whereas the original 
Goff SI criteria is >12x/month. 
Lim, 2012 Duration/frequency of symptoms criteria was 
“occurred 16-31 days per month” for interview and 
questionnaire study components, and no frequency 
criteria was applied in the GP notes study 









Appendix I: Excluded variables (RE Chapter 
6). 
 
This appendix lists the variables considered but ultimately not taken forwards into data 
driven selection procedures in Chapter 6. The rationale for exclusion is also detailed for 
each variable.  
 











HE4  •  Identified in the ovarian cancer 
tool review but not in routine use 
in GP (no Read code). 
Erythrocyte 
Sedimentation 
Rate (ESR) and 
Plasma 
Viscosity (PV) 
   
• 
Recognised predictors for cancer in 
primary care, unknown association 
with ovarian cancer.175 CRP 
included in preference to ESR  and 
PV as more common in the 
baseline cohort. 
Risk / protective factors 
Family history 




 Risk of ovarian cancer is greater in 
women with family history of 
breast or ovarian cancers.25,26 
However, preliminary searches in 
the dataset showed that the 
prevalence of relevant codes for 
family history of these cancers in 
the CPRD is much lower in our 
cohort  than in published studies - 
likely significant missing data. 
Potential for bias. 
Known 
germline BRCA 




 BRCA mutations and family history 
of BRCA associated cancers are a 
strong risk factor for ovarian 
cancer.25 Preliminary searches 
within CPRD records of the 
baseline cohort showed that these 






 Evidence from systematic reviews 
and meta-analyses indicates that 
asbestos exposure is associated 
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with an increased risk of ovarian 
cancer.39,41 Consensus group - 
concerns over likely missing data 






 Evidence from systematic reviews 
and meta-analyses indicate that 
breastfeeding is a protective factor 
for ovarian cancer.25,274,316 
However, 2018 World Cancer 
Research Fund report only found 
“limited- suggestive evidence” for 
an association.274 Consensus group 
- concerns over likely missing data 
(particularly historically) pertaining 
to breastfeeding in the CPRD. 
Parity  •  There is evidence that increasing 
parity is associated with reduced 
ovarian cancer risk.25,274,317,318 
Consensus group - concerns over 






 There is evidence that early 
menarche is associated with an 
increased risk of ovarian 
cancer.25,28,274 But, date of 
menarche is unlikely to be 
routinely recorded by GPs (<13,000 
entries relating to menarche in the 
whole of the CPRD GOLD) - likely 
significant missing data. Practical 
issues foreseen by consensus group 
with patient recall if data entered 






 There is evidence that late 
menopause is associated with an 
increased risk of ovarian 
cancer.25,29,274 Consensus group - 
concerns over likely missing data 
pertaining to menopause in the 
CPRD. Also, concern over possible 
inaccuracy of date of menopause 
even if codes recorded in the 
CPRD.   
Diet / nutrition    Multiple dietary factors have been 
implicated in ovarian cancer 
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• • development/risk.319 However, the 
World Cancer Research Fund 
Report did not find enough 
evidence to draw conclusions on 
any dietary factor.274 Consensus 
group - data on diet not routinely 










 Some studies indicate that a 
sedentary lifestyle is associated 
with increased ovarian cancer risk. 
But, a meta-analysis of prospective 
studies in 2014 did not support 
that,320 and insufficient evidence to 
draw a conclusion in World Cancer 
Research Fund report.274  
Consensus group - data not 
routinely collected by GPs and 
likely to be highly inconsistent.  




 Listed as a risk factor for ovarian 
cancer by IARC but a recent meta-
analysis did not find evidence that 
talc exposure increased the risk of 
ovarian cancer. 41,42 Consensus 
group - data not routinely recorded 
by GPs/likely bias. 
Deprivation  
• 
  Considered by models identified in 
the ovarian cancer tool review 
(Chapter 5), but not included in any 
of the final models. No studies 
identified which report an 
association between deprivation 






  Older reports indicated that 
hysterectomy was a protective 
factor for ovarian cancer.25,319 
Multiple recent large studies found 
no evidence that hysterectomy 
reduces the overall risk of ovarian 






  Some studies have found an 
association between PID and 
ovarian cancer but the evidence 
has been inconsistent and 
contradictory.319 A pooled analysis 
of 13 studies found no significant 
association between PID and 
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•   Previously thought to increase 
ovarian cancer risk. Recent 
prospective studies and a meta-
analysis found no significant 
increase in the risk of ovarian 
cancer in PCOS.324,325 




 Smoking is associated with an 
increased risk of the mucinous 
subtype of ovarian cancer.40 
Smoking is classified as an ovarian 
cancer carcinogenic agent by 
IARC.41 However, no association 
between smoking and ovarian 
cancer overall was identified in a 
large pooled analysis study.40 
Smoking was not included in the 
final QCancer prediction model for 
ovarian cancer.54 Consensus group 
- some concern about the accuracy 
of smoking status data in CPRD. 
Alcohol •   While an association was once 
postulated, recent studies, 
including a large pooled analysis, 
have found no association between 






  Some large population-based 
studies have not found any 
significant association while other 
studies and meta-analyses report 
an increased risk of ovarian cancer 
in women with diabetes.327–330 
Diabetes was dropped from final 
EPIC model (predicts future risk of 
ovarian cancer) as not 










 Some research indicates that 
NSAID use is inversely proportional 
to ovarian cancer risk.25,332 
However, two meta-analyses 
(2012, 2013) did not demonstrate a 
significant association between 
NSAID use and ovarian cancer 
risk.333,334 NSAIDs are not noted as 
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a protective factor for ovarian 
cancer by IARC.41 In adition, NSAIDs 
can be bought over the counter so 
CPRD is unlikely to capture the true 






 There is evidence from systematic 
reviews and meta-analyses that 
COC use is associated with lower 
risk of ovarian cancer.25,30,274,335 
Importantly, risk reduction is 
strongly related to duration of 
use.30 Examination of the data in 
my cohort indicated that 
approaches to determine duration 
of use likely to be inaccurate due 
to limited information on number 
of tablets, prescription use and 
length. In addition, COC can be 
obtained from other locations e.g. 
sexual health centres, so GP 




 •  There is evidence from large 
prospective studies, systematic 
reviews and meta-analyses that 
HRT use is associated with 
increased ovarian cancer 
risk.25,33,274,336 Duration of use is 





Appendix J. ROC Curves (RE Chapter 6) 
 
Contents:  
Supplementary Figure J.1: Receiver operating characteristic curve for CA125. 
 
Supplementary Figure J.2: Tenfold cross-validation receiver operating characteristic curve 
for Model 1.  
 
Supplementary Figure J.3: Tenfold cross-validation receiver operating characteristic curve 
for Model 2, prepared using imputation set 20 as an example. 
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Supplementary Figure J.2. Tenfold cross-validation receiver operating characteristic curve 








Supplementary Figure J.3. Tenfold cross-validation receiver operating characteristic curve 
for Model 2, prepared using imputation set 20 as an example.  
Note: To calculate the overall cross-validation AUC for Model 2, the cross-validation AUC 
was calculated for each of the 20 imputed datasets and Rubin’s rules were used to combine 
results across the imputed datasets. 
 
